Download Eligibility Criteria - American Society of Transplantation

EligibilityCriteria
Lastupdated:11/30/2015
Page1
Pleaserevieweacheligibilitycriteriabelow.Pleasechecktheboxifyouareincompliancewitheachcriteria.
Ineligibleapplicantswillnotbereviewed.
ResponsesSelected:
Nomineehasmadesignificantcontributionstothefieldofsolidorgantransplantation.
Nomineeisrecognizedasanexpertinhis/herfield.
NomineeandnominatorareactivemembersoftheAST.Membershipduesarepaidtodate(by1/1/2015);otherwisethenominationwillbe
disqualifiedandnotconsidered.
1of1
PersonalInformationForm
Lastupdated:11/30/2015
PersonalInformation
NomineeInformation
Pleaseenterinallinformationfornominee.
FirstName
Jon
LastName
Kobashigawa
Degree
MD
Title
AssociateDirectorofClinicalAffairs
Institution
Cedars-Sinai
Department
Medicine
Address
127S.SanVicenteBlvd.
ThirdFloorCardiologyA3107
City
LosAngeles
State/Province
California
Zip/PostalCode
90048
Country
US
Phonenumber
(310)248-8300
Email
[email protected]
NominatorInformation
Pleaseenterinallinformationfornominator.
FirstName
Jeffrey
LastName
Teuteberg
Degree
MD
Title
MedicalDirector,AdvancedHeartFailurer
Institution
UPMC
Department
HeartandVascularInstitute
Address
ScaifeHall,Suite556
200LothropStreet
City
Pittsburgh
State/Province
Pennsylvania
Zip/PostalCode
15213
Country
US
Phonenumber
4126477168
1of2
Email
[email protected]
IsthisnominationmadeonbehalfofanASTadvisorycouncil,committee,orcommunityofpractice?
Yes
Ifyes,pleaselistadvisorycouncil/committee/communityofpracticename:
TCCCOP
2of2
7/ 27/2015
JON KOBASHIGAWA, MD
Business Address:
Cedars-Sinai Heart Institute
127 S. San Vicente Blvd.
Third Floor Cardiology A3107
Los Angeles, CA 90048
Phone:
Fax:
Email:
(310) 248-8300
(310) 248-8333
[email protected]
E D U CA T I O N
1972 - 1976
B.S., Stanford University, Stanford, CA
1976 - 1980
M.D., Mount Sinai School of Medicine, New York, NY
1980 - 1981
Internship in Internal Medicine
UCLA Medical Center, Los Angeles, CA
1981 - 1983
Residency in Internal Medicine
UCLA Medical Center, Los Angeles, CA
1984 - 1986
Fellowship in Cardiology
UCLA Medical Center, Los Angeles, CA
A P PO I N T M E N T S
1986 - 1988
Clinical Instructor of Medicine
The David Geffen School of Medicine,
University of California at Los Angeles
Los Angeles, CA
1988 - 1994
Assistant Clinical Professor of Medicine,
The David Geffen School of Medicine,
University of California at Los Angeles
Los Angeles, CA
1994 - 1999
Associate Clinical Professor of Medicine
The David Geffen School of Medicine,
University of California at Los Angeles
Los Angeles, CA
1994 - 2009
Medical Director, UCLA Heart Transplant Program
UCLA Medical Center, Los Angeles, CA
1998 - 2009
Chief, Division of Clinical Faculty Medicine,
Department of Medicine,
The David Geffen School of Medicine,
University of California at Los Angeles
Los Angeles, CA
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
1999 - Present
Clinical Professor of Medicine
The David Geffen School of Medicine,
University of California at Los Angeles
Los Angeles, CA
1999-Present
Chief Medical Officer,
California Heart Center Foundation
Los Angeles, CA
2005-Present
Board of Directors,
California Heart Center Foundation
Los Angeles, CA
2003-Present
President, University Cardiovascular Medical Group
Los Angeles, CA
2010-Present
DSL/Thomas D. Gordon Chair in Heart Transplantation Medicine
Cedars-Sinai Medical Center
Los Angeles, CA
2010-Present
Associate Director for Clinical Affairs
Director for Advanced Heart Disease
Director, Heart Transplant Program
Cedars-Sinai Heart Institute
Los Angeles, CA
2015-Present
Professor of Medicine
Cedars-Sinai Medical Center
Los Angeles, CA
M E M BE R S H I P S



















Alpha Omega Alpha
American Association for the Advancement of Science
American College of Cardiology
American College of Physicians
American Heart Association
American Medical Association
American Society of Transplant Physicians
California Medical Association
Council of Clinical Cardiology (American Heart Association)
International Society for Heart and Lung Transplantation
Internship Selection Committee of the UCLA School of Medicine
Los Angeles Medical Association
Medical Staff Credentials Committee of the UCLA Hospital
NIH Training Grant Cardiovascular Scientist Training Program Faculty
UCLA Clinical Faculty Association
UCLA Clinical Faculty Association Board of Directors
UCLA Clinical Faculty Association (Vice President 1998-1999)
Working Group of Transplant Cardiologists (national organization)
Member, Search Committee for UCLA Chief of the Division of Cardiac Surgery
2
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
A P PO I N T M E N T S I N NA T I O NA L CO M M I T T E E S























Clinical Practice Committee, American Society of Transplant Physicians 1996-1998
Transplantation Committee, American College of Cardiology 1997-1999
Training and Manpower Committee, American Society of Transplant Physicians 1998
Practice Guidelines Committee, American Society of Transplant Physicians 1998
Board of Directors, International Society for Heart and Lung Transplantation 1997-2004
Program Chair, International Society for Heart and Lung Transplantation Scientific Sessions, Osaka, Japan 2000
President, International Society for Heart and Lung Transplantation 2003-2004
Board of Directors, American Heart Association Western States Affiliate 1998-1999
Medical Director, Gift of Heart Foundation, Los Angeles, CA 2000
At-Large Member, UNOS National Thoracic Organ Committee 2000
Clinical Cardiology Council, Scientific Council, American Heart Association 2000-2003
Chairman, Heart Failure and Transplant Committee, American College of Cardiology 2000-2004
Heart Transplant Advisory Board for CIGNA Healthcare’s Lifesource Transplant Network 2002-Present
Consultant, Foundation for the Accreditation of Cellular Therapy for the Hematopoietic Stem Cell
Transplantation Program 2002-Present
Advisory Board, Ventura County West Valley Transplant Recipients International Organization (TRIO) April
2005
Advisory Board, MedscapeCME Transplantation 2010-2012
Member, Study Scientific Committee for RAD trial A2310, 2009-Present
Invited Participant, NHLBI Workshop, “Cardiac Transplantation Research for the Next Decade: A Goal to
Evidence Based Outcomes.” Bethesda, MD, 2010
American Transplant Congress Program Committee 2011-2015
Clinical Trials in Organ Transplant (CTOT) Steering Committee 2012-present
Member of Executive Committee, AST Thoracic and Critical Care Community of Practice 2013-2014
Member, International Society for Heart and Lung Transplantation Education Taskforce 2013-2014
Executive Program Committee for the World Transplant Congress 2012-2014
C E RT I F I CA T I O N S / L I CE N S E S

California Medical License #G45447

DEA License #AK 1274149

Diplomate American Board of Internal Medicine (September 14, 1983)

Diplomate American Board of Cardiovascular Disease (November 11, 1987)

Certified for Special Competency - Cardiac Pacing (NASPE)

Fellow - American College of Cardiology

Fellow – American Heart Association

Fellow – American Society of Transplantation
AWA R D S / H O N O R S

Alpha Omega Alpha Honor Medical Society (September 1979)

Upjohn Clinical Scholar Award (June 1980)

UCLA Clinical Faculty Teaching Award (June 1987, June 1990, June 1991, June 2004)
3
CURRICULUM VITAE

JON KOB ASHIGAWA, MD
Member of the American College of Cardiology Task Force on Cardiac Transplantation: The 24th Bethesda
Conference. Author on sections on Cardiac Rejection, Osteoporosis, Obesity, Surgical complications, and
Psychosocial issues in cardiac Transplantation. Nov 1992, Bethesda, MD.

Program Director: An International Symposium on Heart Failure and Heart Transplantation 1995. Lectures
given: Diagnosis and treatment of rejection, Steroid-free immunosuppression, Treatment of transplant coronary
artery disease. The Disneyland Hotel, Anaheim, CA, November 9-11, 1995.

Plenary Session: Invited lecture, International Society for Heart and Lung Transplantation Scientific Sessions.
Results of randomized trial of mycophenolate mofetil vs. azathioprine in heart transplantation. London,
England, April 3, 1997.

FDA Advisory Board Meeting: Use of mycophenolate mofetil for indication in heart transplantation.
Washington, DC, January 14, 1998.

Program Chair, International Society for Heart and Lung Transplantation Scientific Sessions, Osaka,
Japan 2000

Chair, Novartis Lunch Symposium: “TCAD: IVUS, Surrogate Markers & Treatments.” International Society for
Heart and Lung Transplantation, 23rd Annual Meeting and Scientific Sessions, Vienna, Austria April 7-13, 2003

President, International Society for Heart and Lung Transplantation 2003-2004

Chairman, Heart Failure and Transplant Committee, American College of Cardiology 2000-2004

At-Large Member, United Network for Organ Sharing National Thoracic Organ Committee 2000

Millennium Edition of Strathmore’s Who’s Who (2000-2001)

Los Angeles Times Dr.’s Dr. Recognition in Cardiology (2000 - Present)

Marquis Who’s Who in America / Medicine and Healthcare (2000 - Present)

Wall Street Journal Businessman of the Year (2001)

Best Doctors in America (2001 - Present)

Who’s Who in the 21st Century, 1st Edition (2001)

Co-Chair, Work Group Sessions: Diagnosis of Humoral Rejection. A Conference to Analyze Humoral Rejection
in Solid Organ Transplantation, Bethesda, MD, April 23-24, 2003.

Co-Chair: Clinical Science Symposium: Pre-Transplant Risk Factors and Effect on Post-Transplantation
Outcomes. American Transplant Congress 2004 Meeting. John B. Haynes Convention Center, Boston, MA.
May 17, 2004.

United States National Leader, AQUARIUS Trial (2009)

Chairman, An International Consensus Conference on the Sensitized Patient Awaiting Heart Transplantation.
California Heart Center Foundation and the International Society for Heart and Lung Transplantation. Boston,
MA, April 8, 2008

Invited Keynote Speaker, The 6th Biennial Psychiatric, Psychosocial and Ethical Issues in Organ Transplantation
Conference. Keynote Address: Cardiac Transplantation: Advances and Ethical Dilemmas. Doubletree Hotel,
Santa Monica, CA. February 4-6, 2005.

Pfizer Visiting Professorship, Northwestern University Cardiology Grand Rounds: “Advances in
Immunossuppression in Heart Transplantation.” Northwestern University Feinberg School of Medicine,
Chicago, IL, September 14-15, 2006.

Discussant, Late-Breaking Clinical Trials II: CORONA trial. American Heart Association Scientific Sessions
2007, Orlando, FL, November 5, 2007.
4
CURRICULUM VITAE
JON KOB ASHIGAWA, MD

Cambridge Who’s Who Among Executives and Professionals in Healthcare, Honors Edition (2007-2008)

Co-chairman, 72nd Annual Scientific Meeting of the Japanese Circulation Society. Lecture given: “Current Status
in Cardiac Transplantation in the United States.” Fukuoka, Japan, March 28, 2008.

Distinguished Service Award from the California Heart Center Foundation (2009)

International Association of Cardiologists’ Top Cardiologist (2009-2010)

Invited Participant, NHLBI Workshop, “Cardiac Transplantation Research for the Next Decade: A Goal to
Evidence Based Outcomes.” Bethesda, MD, August 5-6, 2010.

Member of the Clinical Trials in Organ Transplantation (CTOT) steering committee (2011-present)

Member of the Novartis Data Safety Monitoring Board, CRAD001A2429 Trial (2011-present)

Reviewer for the Health Research Council of New Zealand 2011 Annual Contestable Funding Round

Reviewer for the Medical Research Council Industrial Collaboration Award (September 2011)

Director of RAD-B253 8-Year Follow Up Investigator’s Meeting Prague, Czech Republic. April 17, 2012.

Member of Special Review Committee for Program Project Grant Application (NIH/NHLBI): Cardiac allograft
tolerance through kidney co-transplantation, P01HL116266-01. May 9, 2012.

Reviewer for Heart Research United Kingdom Translational Research Project Grant, UK national charity (2012)

Visiting Lecturer for the Servier Canada Endowed Lectureship in Heart Function, University of Ottawa Heart
Institute, November 18-19, 2012.

Invited Ad Hoc Reviewer for NIH Program Grant: Cardiac allograft tolerance through kidney co-transplantation,
1 P01HL116266-01. February 18, 2013.

Course Co-Director of the 24th Annual Meeting of the California ACC: Controversies & Advances in the
Treatment of Cardiovascular Disease. November 21 & 22, 2013.

Executive Program Committee for the World Transplant Congress 2012-2014

Featured Guest, Heart to Heart Community Conversation with Larry Mantle, SLS Hotel, Los Angeles, California,
February 25, 2014

Top Doctors in L.A., The Hollywood Reporter, September 2014.

Visiting Professorship, Queens Hospital, Honolulu, Hawaii. October 10, 2014.

Member of the Transmedics the PROCEED II Trial Steering Committee (2011-2013).

Member of the Organ Care System EXPAND Heart Steering Committee (2014-present)

Visiting Professorship, Cleveland Clinic, Philadelphia, Pennsylvania May 7th, 2014.

Chairman of the Outcomes AlloMap Registry and Diagnostic and Prognostic Utility of Cell-free DNA in
association with Gene-Expression Profiling (AlloMap®) in Heart Transplant Recipients Steering Committee
(August 2015).
E D I TO R I A L BOA R D S

Editorial Board, Cardiology Today (1998 - present)

Associate Editor, American Society of Transplantation Primer for Heart Transplantation (1999)

Guest Editor, Heart Transplant Section in Graft, AST Winter Symposium (1999)
5
CURRICULUM VITAE
JON KOB ASHIGAWA, MD

Editorial Board, Journal of Heart and Lung Transplantation (1999-present)

Associate Editor, American Journal of Transplantation (2000-2002)

Editorial Board, the heart.org for Heart Failure & Cardiac Transplant Medicine (2000-present)

Editorial Board, Medscape Transplantation (2000-present)

Associate Editor, AST Newsletter (2000)

Editorial Board, Journal of Cardiac Failure (2002)

Editorial Board, Reviews on Clinical Transplantation (2006-Present)

Editorial Board, Trends in Transplantation (2007, 2011)

Senior Consultant, Editorial Board, Journal of Heart & Lung Transplantation (2009)

International Editorial Board, European Heart Journal (2012)

Section Editor, Thoracic Transplantation, Current Transplantation Reports (2013)

Guest Editor, Thoracic Transplantation, Current Transplantation Reports (2015)
A B S T R A CT G R A D E R














Scientific Sessions of the American College of Cardiology 1989, 1990, 2001, 2006, 2007.
Scientific Sessions of the American Heart Association 1994.
Scientific Sessions of the International Society of Heart and Lung Transplantation 1995-2003, 2005,
2006, 2008, 2009, 2010, 2011
Co-Chairman, Clinical Heart Transplant Section, ISHLT Program Committee 1995.
Program Chairman, ISHLT Scientific Sessions in Osaka, Japan 2000.
Scientific Sessions of the American Society of Transplant Physicians 1996, 1999, 2001, 2002, 2003, 2006,
2007.
Joint American Transplant Meeting 2001.
Co-Chairman, Immunosuppression Section, ISHLT Program Committee 2001.
Co-Chairman, Thoracic Organ Transplant Section, International Symposium on Immunosuppression,
San Diego, CA. 2001 and 2004.
Co-Chairman, Clinical Heart Section, American Transplant Congress, Seattle, WA. 2005.
World Transplant Congress 2006.
American Transplant Congress 2007, 2008, 2009, 2010, 2011
Abstract Panel Review International Congress of the Transplantation Society 2008, 2009, 2010
American College of Cardiology Abstract Reviewer 2015
S TA N D I N G M A N U S CR I P T R E V I E W E R













American Journal of Cardiology
American Journal of Kidney Diseases
American Journal of Transplantation
Annals of Transplantation
Atherosclerosis
Collegium Antropologicum
European Heart Journal
Expert Opinion On Drug Safety
Circulation
Circulation: Heart Failure
Circulation: Research
Clinical Transplantation
Future of Medicine
6
CURRICULUM VITAE















JON KOB ASHIGAWA, MD
Human Immunology
International Journal of Cardiology
Journal of Heart and Lung Transplantation
Journal of the American College of Cardiology
Journal of the American College of Cardiology: Heart Failure
Nature Reviews Cardiology
New England Journal of Medicine
Pediatric Transplantation
Science Translational Medicine
Therapeutic Advances in Cardiovascular Disease
Translational Research
Transplantation
Transplant Immunology
Transplant International
World Journal of Surgery
P R E S E N TA T IO N S / S Y MP O S I U M S
American Heart Association, Los Angeles Chapter. Luncheon panel on: Cardiac Transplantation. October 1989.
Heart Failure and Transplantation: 1990. (January 19-20, Doubletree Marina Beach Hotel, Marina del Rey,
California). Sponsor, UCLA School of Medicine. Lectures given: Selection for heart Transplantation, diagnosis
and treatment of rejection, accelerated atherosclerosis and other late complications. Panel discussant on How to
manage immunosuppression.
Family Practice Refresher Course: Treatment strategies in congestive heart failure. May 28, 1991. Sponsored by
the UCLA Extension, Division of Family Medicine UCLA School of Medicine, Family Practice residency program
at Santa Monica Hospital Medical Center.
Current Concepts in Cardiovascular Disease: Managing the mature and elderly patient. September 21, 1991.
Sponsored by UCLA Extension. Lecture given: Diagnosis and management of hypertensive urgencies and
emergencies.
Family Medicine Grand Rounds: Modem therapy of congestive heart failure. October 18, 1991.
Symposium on Transplant Coronary Artery Disease and Steroid Weaning. Guest speaker on: Weaning of steroid
maintenance late after cardiac Transplantation, relation to HLA-DR matching. St. Louis, MO, October 25, 1991.
Sponsored by International Society for Heart and Lung Transplantation.
Symposium:
Current Controversies in Cardiac Transplantation - Panel Speaker. International Society for
Heart and Lung Transplantation Scientific Sessions. April 1, 1992 in San Diego, CA.
Family Medicine Refresher Course. Lectures given: Approach to the patient with syncope; Clinical approach to
hypertensive urgency/emergency. May 28, 1992.
Medical Grand Rounds: Recent advances in the treatment of congestive heart failure. Hollywood Community
Hospital, August 21, 1992.
Medicine Staff Rounds: -Congestive heart failure. Monrovia Community Hospital. September 17, 1992.
Medicine Grand Rounds: Cardiac Transplantation. Wadsworth VA Medical Center. October 14, 1992.
Medicine Staff Rounds: Current evaluation and management of cardiac failure, including cardiac Transplantation.
Temple Community Hospital, October 27, 1992.
Member of the American College of Cardiology Task Force on Cardiac Transplantation: The 24th Bethesda
Conference. Author on sections on Cardiac Rejection, Osteoporosis, Obesity, Surgical complications, and
Psychosocial issues in cardiac transplantation. Nov 1992, Bethesda, MD.
7
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
Heart transplant monitor expert panel, sponsored by Medtronics. Westin La Paloma Resort.Tucson, AZ. Dec l013, 1992
Heart Failure and Heart & Lung Transplantation. 1993. January 7-9, 1993, Ritz Carlton Hotel, Marina Del Rey,
CA. Lectures given: Contraindications to cardiac transplantation, Diagnosis and treatment of rejection, New
immunosuppressive therapies, Accelerated graft atherosclerosis. Panel discussant on medical management after
transplantation.
Moderator: Post transplant complications.
Transplant Recipients International Organization (TRIO).
immunosuppressive therapies. January 11, 1993.
Lecture on heart transplant rejection and new
Regional Transplant Coordinators Meeting. Lecture on mycophenolate mofetil in cardiac transplantation. Loews
Hotel, Santa Monica, CA. February 17, 1993.
Sandoz Sponsored Cardiac Transplant Expert Panel on cyclosporine dosing, steroid-free immunosuppression,
transplant coronary artery disease and long-term renal function. Boca Raton, FL. March 29,30, 1993.
Symposium: Recent Advances in Cardiology. Lecture on frontiers in cardiac transplantation. Sponsored by
Western Medical Center. Anaheim Marriott, May 1, 1993.
Cardiology Rounds Lecture on: Heart Transplantation. Sierra Vista Regional Medical Center. San Luis Obispo,
CA. June 2, 1993
Family Practice Refresher Course: Treatment of congestive heart failure. Approach to the patient with syncope.
Miramar Sheraton Hotel. Santa Monica, CA. June 3, 1993.
Heart and Lung Transplantation. Delta Medical Center, Visalia, CA. September 7, 1993. The use of pravastatin
in heart transplant recipients. Division of Adult Cardiology monthly conference. UCLA Medical Center. October
26, 1993.
Selected Topics in Cardiology. Family Medicine Symposium: Approach to the patient with chest pain. Sheraton
Miramar Hotel, Santa Monica, CA. October 30, 1993.
Heart Transplantation. Henry Mayo Newhall Memorial Hospital. Valencia, CA. November 4, 1993.
ROPA Donor Presentation. Holy Cross Medical Center, Mission Hills, CA. November 17, 1993.
Pravastatin in Heart Transplantation. Lipid Education Faculty Program, Pazzia Restaurant, Los Angeles, CA.
Sponsored by E.R. Squibb. November 18, 1993.
Southern California Lipid Conference. Pravastatin in cardiac transplant atherosclerosis. Hyatt Newport, Newport
Beach, CA. November 20, 1993. Sponsored by Bristol Myers Squibb.
Cardiology Rounds: Advances in Heart Transplantation. Queen of the Valley Medical Center, West Covina, CA.
February 8, 1994.
Medicine Grand Rounds: Care of the Heart Transplant Recipient. Daniel Freeman Memorial Hospital, Los
Angeles, CA. February 10, 1994
Overview of Heart Transplantation. Thousand Oaks Rotary Club, Howard Johnson Hotel, Thousand Oaks, CA.
February 17, 1994.
Invited speaker: Natural History of Grade 1 B, 2 and 3A Rejection Symposium.
Doubletree Hotel Post Oak, Houston, TX. February 26, 1994.
Texas Heart Institute.
Medicine Grand Rounds: Update in heart transplantation. Kaiser West Los Angeles Medical Center. Los Angeles,
CA, March 1, 1994.
8
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
Moderator, International Society Heart and Lung Transplantation Scientific Sessions, March 26, 1994, Venice,
Italy.
Cardiothoracic Surgery Grand Rounds: Impact of pravastatin in heart transplant recipients. UCLA Medical
Center, March 29, 1994.
Invited Speaker: HMG CoA reductase inhibitors and immunosuppressive agents. Issues in lipid education in the
1990s: Therapeutic considerations. April 8 & 9, 1994, Orlando, Florida.
UCLA Division of Cardiology Seminar: Advances in cardiac transplantation. UCLA Medical Center, May 13,
1994.
Medicine Grand Rounds: Impact of pravastatin in cardiac transplantation. UCLA Medical Center, May 18, 1994.
Invited Speaker, Cardiology Rounds: Research in cardiac transplantation. Barnes Hospital, Washington University
School of Medicine, St. Louis, Mo., May 27, 1994.
Family Practice Refresher Course: Approach to the patient with congestive heart failure. Miramar Sheraton Hotel.
Santa Monica, CA. June 2, 1994.
Endocrine Grand Rounds: The treatment of hyperlipidemia in solid organ transplantation.
Wadsworth VA Medical Center, Los Angeles, CA.
June 3, 1994,
American College of Physicians, Internal Medicine Board Review Faculty, UCLA School of Medicine. Lecture:
Preoperative evaluation, prophylaxis, and imaging. July 10, 1994, Los Angeles, CA.
Invited Speaker, Cardiology Grand Rounds: Early hospital discharge, working with managed care. July 25, 1994,
Texas Heart Institute, Houston, TX.
Medicine Grand Rounds: Heart Transplantation.
Torrance, CA.
September 7, 1994, Torrance Memorial Medical Center,
Invited Speaker for the integrated West Los Angeles VAMC / San Fernando Valley Cardiology Program: Heart
Transplantation. September 12, 1994.
Invited Speaker, Medicine Grand Rounds: Cardiac Transplantation. Kaiser-Permanente Medical Center, Los
Angeles, CA, September 22, 1994.
Invited Speaker, Medicine Grand Rounds: Lipid Disorders in Heart Transplantation. Ochsner Clinic, New
Orleans, LA, November 2, 1994.
Invited Speaker, Lipid Research Faculty Symposium: Treatment of hyperlipidemia in high risk populations,
Anthony Gotto, MD, Chairman. Dallas, TX, November 12, 1994.
Moderator: Cardiac Transplant Coronary Artery Disease Section. American Heart Association Scientific Sessions,
Dallas, TX, November 14, 1994.
Chairman, Symposium: Hyperlipidemia and Atherosclerosis in Organ Transplantation: Can We Alter the Natural
History? Dallas, TX, December 8, 1994.
UCLA Sports Medicine Conference: Management of Syncope in the Athlete. Division of Family Medicine.
UCLA Medical Center, Los Angeles, CA. January 18, 1995.
Invited Speaker, Medicine Grand Rounds: Immunosuppressive effects of hypolipidemic therapy in Heart
Transplantation. St Paul's Medical Center - University of Texas Southwestern, Dallas, TX, January 20, 1995.
UCLA Division of Cardiology Seminar: Update in heart transplantation. UCLA Medical Center, Los Angeles, CA,
January 27, 1995.
9
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
Invited Speaker, Second Symposium on Cardiac Allograft Vasculopathy. Lectures on "Does rejection correlate
with development of ACAD: Results of a multicenter study using ICUS", "Use of bypassed donor hearts", and
"Impact of lipid lowering therapy on ACAD". Ritz-Carlton Hotel, St. Louis, MO., January 31 - February 1, 1995.
UCLA Cardiothoracic Grand Rounds: Advances in cardiac transplantation.
CA, February 14, 1995.
UCLA Medical Center, Los Angeles,
Symposium - Lung Transplantation: An International Dialogue. Lecture on "Immunosuppression: Current
Protocols, What’s Ahead?" Ritz-Carlton Hotel, Laguna Niguel, CA, February 17, 1995.
Invited Speaker: Update on heart transplantation- Saint Joseph Medical Center, Burbank, CA, February 23, 1995.
Invited Speaker: Optimal immunosuppression in heart transplantation. Texas Heart Institute Symposium, Double
Tree Hotel, Houston TX, February 25, 1995.
UCLA Medicine Grand Rounds: Advances in Cardiac Transplantation- UCLA Medical Center / School of
Medicine, Los Angeles, CA, March 3, 1995.
Invited Speaker. Lipid Research Faculty Symposium: Hyperlipidemia in organ transplantation. Anthony Gotto,
MD, Chairman. New Orleans, LA, March 18, 1995.
Invited Speaker: Management of hyperlipidemia. Stouffer Hotel, Los Angeles, CA, March 26, 1995.
Case Presentations: Heart Transplantation. Invited Speaker/Discussant. International Society for Heart and Lung
Transplantation Scientific Sessions, San Francisco, CA, April 5, 1995.
Moderator: Clinical Heart Transplantation: Outcome and risk factors. International Society for Heart and Lung
Transplantation Scientific Sessions, San Francisco, CA, April 5, 1995.
Invited Speaker: Modern therapy for congestive heart failure. Little Company of Mary Hospital, Torrance, CA,
April 27, 1995.
Invited Speaker: Hyperlipidemia in solid organ transplantation. Loma Linda Medical Center, Loma Linda, CA,
May 8, 1995.
UCLA Family Medicine Refresher Course. Lecture: Medical versus surgical management of coronary artery
disease. Miramar Sheraton Hotel, Santa Monica, CA, June 1, 1995.
Invited Speaker, Medicine Grand Rounds: Cardiac transplantation. Kaiser Regional Medical Center, Los Angeles,
CA, June 23, 1995.
Invited Speaker, UCLA Family Medicine Grand Rounds: Medical versus surgical treatment of coronary artery
disease. UCLA Medical Center, Los Angeles, CA, June 29, 1995.
American College of Physicians, Internal Medicine Board Review Faculty, UCLA School of Medicine. Lecture:
Preoperative evaluation, prophylaxis, and imaging. July 16, 1995, Los Angeles, CA.
Invited Speaker, Medicine Grand Rounds: Cardiac Transplantation. Kaiser Permanente Regional Medical Center,
Los Angeles, CA, August 8, 1995.
Invited Speaker, Cardiology Grand Rounds: Hyperlipidemia and atherosclerosis in organ transplantation.
University of Minnesota, Minneapolis, MN, September 19, 1995.
Invited Speaker, Transplant Grand Rounds: Hyperlipidemia and atherosclerosis in organ transplantation: Can we
alter the natural history? Mayo Clinic, Rochester, MN, September 19, 1995.
Invited Speaker, Association of Clinical Scientists: Applied seminar and workshop on immunologic techniques for
diagnosis, transplantation and therapy. Effects of pravastatin on rejection, survival, and transplant coronary
vasculopathy. Holiday Inn Crown Plaza, Redondo Beach, CA, October 26, 1995.
Invited Speaker, American Heart Association Scientific Sessions 1995, Council on Clinical Cardiology:
Hyperlipidemia in cardiac transplantation. Anaheim Hilton Hotel, CA, November 13, 1995.
10
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
Program Director: An International Symposium on Heart Failure and Heart Transplantation 1995. Lectures given:
Diagnosis and treatment of rejection, Steroid-free immunosuppression, Treatment of transplant coronary artery
disease. CME, UCLA School of Medicine, Los Angeles, CA. The Disneyland Hotel, Anaheim, CA, November 911, 1995.
Invited Speaker, Australian Satellite Symposium - Hyperlipidemia in heart transplantation. December 1, 1995
from LA9 Studios, Los Angeles, CA.
UCLA General Surgery Conference: The perioperative management of cardiac disease. UCLA Medical Center,
Los Angeles, CA, December 9, 1995.
Invited Speaker, Medicine Grand Rounds: Hyperlipidemia and atherosclerosis in heart transplantation.
Wadsworth VA Regional Medical Center, Los Angeles, CA, December 13, 1995.
Invited Speaker, Cardiology Grand Rounds: Hyperlipidemia in cardiac transplantation.
Medical Center, St. Louis, MO, December 19, 1995.
St Louis University
Invited Speaker, Medicine Grand Rounds: Hyperlipidemia in the general population and in organ transplantation.
Christ Hospital, Oaklawn, IL, January 25, 1996.
Invited Speaker, Cardiology Grand Rounds: Hyperlipidemia and atherosclerosis in solid organ transplantation.
Rush-Presbyterian-St. Luke's Medical Center, Chicago, IL, January 25, 1996.
UCLA Medical Residents Conference: The diagnosis and treatment of Syncope. UCLA Medical Center, Los
Angeles, Ca, January 19, 1996.
UCLA Medicine Grand Rounds: Hyperlipidemia in solid organ transplantation, can we alter the natural history?
UCLA Medical Center, Los Angeles, Ca, January 31, 1996.
Invited Speaker, Scientific Conference on Exercise Testing and Training in Patients With Left Ventricular
Dysfunction and After Cardiac Transplantation (American Heart Association): Pathophysiology of the
transplanted heart and its influence on exercise tolerance. Belleview Mido Resort Hotel, Clearwater, Florida,
February 16, 1996.
Invited Speaker. Lipid Research Faculty Symposium: Hyperlipidemia in organ transplantation. Anthony Gotto,
MD, Chairman. Scottsdale, Arizona, February 24, 1996.
Invited Speaker, Medicine Noon Conference: Hyperlipidemia and atherosclerosis after organ transplantation.
Cedars-Sinai Medical Center, Los Angeles, Ca, March 7, 1996.
Member on Expert Panel on Recurrent Rejection, Breakfast Symposia at the International Society of Heart and
Lung Transplantation Scientific Sessions. New York City, New York, March 17, 1996.
Moderator, Clinical Heart Transplantation. International Society of Heart and Lung transplantation Scientific
Sessions. New York City, New York, March 18, 1996.
Invited Speaker, Cardiology Grand Rounds: Hyperlipidemia and atherosclerosis in organ transplantation. Mount
Sinai School of Medicine, New York City, New York, March 19, 1996.
Invited Speaker, Cardiology Grand Rounds: Hyperlipidemia in solid organ transplantation.
California at San Diego, San Diego, CA, March 20, 1996.
University of
Invited Speaker, Follow-up care of the heart transplant recipient. Cardiology Directors Annual Meeting at the
American College of Cardiology Scientific Sessions, Orlando, Florida, March 24, 1996.
Invited Speaker and Moderator, The Pd-Med Conference (Harvard Medical School and UCLA School of
Medicine): Cardiology for primary care clinicians - Management of congestive heart failure. Long Beach
Convention Center, Long Beach, CA, March 30, 1996.
Invited Speaker, Cardiology Rounds: The use of pravastatin in post cardiac transplant patients. St. Michael's
Hospital, Toronto, Canada, April 15, 1996.
11
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
Invited Speaker, Cardiology Rounds: Pravastatin benefits in heart transplantation. Toronto General Hospital,
Toronto, Canada, April 15, 1996.
Invited Speaker, Dinner Symposium (The Granite Club): Cardiac transplantation. West Hill Country Club,
Toronto, Canada, April 15, 1996.
Invited Speaker, Medicine Grand Rounds: Hyperlipidemia and atherosclerosis in organ transplantation. NotreDame's Hospital, Montreal, Canada, April 16, 1996.
Invited Speaker, Cardiology Transplant Rounds: Hyperlipidemia and atherosclerosis in organ transplantation.
Ottawa Heart Institute, Ottawa, Canada, April 16, 1996.
Invited Speaker, Cardiology Rounds: Hyperlipidemia and atherosclerosis in organ transplantation. The St. Luc's
Hospital, Montreal, Canada, April 17, 1996.
Invited Speaker, Cardiology Transplant Rounds: Hyperlipidemia and atherosclerosis in organ transplantation.
Montreal Heart Institute, Montreal, Canada, April 17, 1996.
Invited Speaker, Transplantation Grand Rounds: Hyperlipidemia and atherosclerosis in organ transplantation.
Oregon Health Sciences University, Portland, OR, April 25, 1996.
Invited Speaker, Medicine CME: Advanced heart failure: Medical therapy, devices, surgery. Holy Cross Medical
Center, Mission Hills, CA, April 30, 1996.
Invited Speaker, Transplant Forum and Clinical Research Conference: Hyperlipidemia and vasculopathy in solid
organ transplantation; HMG's and adjunctive therapy with immunosuppressive drugs. Stanford University,
Stanford, CA, May 9, 1996.
Invited Speaker, UCLA Family Practice Refresher Course: Current concepts in the management of congestive
heart failure. Miramar Sheraton Hotel, Santa Monica, CA, May 30, 1996.
Invited Speaker, Specialty Laboratories, Inc: Hyperlipidemia and atherosclerosis in solid organ transplantation.
Santa Monica, CA, June 27, 1996.
Invited Speaker, American Society of Transplant Physicians - Fellows Symposium: Transplant coronary artery
disease. Ritz-Carlton Hotel, St. Louis, MO, July 28, 1996.
Invited Speaker, Lipid Conference: Hyperlipidemia in solid organ transplantation. University of Iowa, October 16,
1996.
Invited Speaker, Symposium. Individualizing immunosuppression: Strategies for the next decade. Lectures on
Treatment of asymptomatic cardiac rejection “and Non-alloimmune factors in the treatment of transplant
vasculopathy" Tucson, AZ, October 25-26, 1996.
Invited Speaker, Working group of transplant cardiologist. Panel reactive antibodies and cardiac transplantation.
Ochsner Medical Center, New Orleans, LA, November 9, 1996.
Invited Speaker, American Heart Association Scientific Sessions:
transplantation. New Orleans, LA, November 10, 1996.
Accelerated atherosclerosis in cardiac
Invited Speaker, Cardiology Grand Rounds, Harbor-UCLA Medical Center. Update in cardiac transplantation.
Torrance, CA, December 20, 1996.
Invited Speaker, American Society of Transplant Physicians' Winter Symposium. Management of post-transplant
lipid disorders: Impact on graft outcome. The Pointe Hilton Resort, Phoenix, AZ, February 15, 1997.
Invited Speaker, Texas Heart Institute Symposium.
Houston, TX, March 1. 1997.
Pravastatin and the future in cardiac transplantation.
Invited Speaker, American College of Cardiology Scientific Sessions:
transplantation. Anaheim, CA, March 18, 1997.
12
New developments in cardiac
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
Plenary Session: Invited lecture, International Society for Heart and Lung Transplantation Scientific Sessions.
Results of randomized trial of mycophenolate mofetil vs. azathioprine in heart transplantation. London, England,
April 3, 1997.
Moderator, Clinical heart transplantation: Allograft vasculopathy - predictors and risk factors. International
Society Heart and Lung Transplantation Scientific Sessions, London, England, April 3, 1997.
Moderator, Roche Luncheon Symposium on Mycophenolate Mofetil. International Society Heart and Lung
Transplantation Scientific Sessions, London, England, April 3, 1997.
UCLA Medicine Grand Rounds: The results of the Mycophenolate Mofetil study and other advances in cardiac
transplantation. UCLA Medical Center and School of Medicine, Los Angeles, CA, May 7, 1997.
Family Practice Refresher Course: Medical versus surgical approach to the patient with coronary artery disease.
Miramar Sheraton Hotel, Santa Monica, CA, May 29, 1997.
Invited Speaker, Endocrine Grand Rounds: Hyperlipidemia in solid organ transplantation. Cedars-Sinai Medical
Center, Los Angeles, CA, June 2, 1997
Invited Speaker, Family Medicine Medical Rounds: Management of congestive heart failure. UCLA Medical
Center, Los Angeles, CA, July 2, 1997.
Invited Speaker, Medicine Grand Rounds: Current management of congestive heart failure. Sherman Oaks
Medical Center, Sherman Oaks, CA, August 14, 1997.
Invited Speaker, Surgical Teaching Rounds: Perioperative arrhythmias and heart failure. UCLA Medical Center,
Los Angeles, CA, September 13, 1997.
Invited Speaker, Hyperlipidemia in organ transplantation.
September 24, 1997.
Balboa Naval Medical Center, San Diego, CA,
Invited Speaker, Family Medicine Grand Rounds: Congestive heart failure. UCLA Medical Center, Los Angeles,
CA, October 3, 1997.
Invited Speaker, Cardiothoracic Surgery Grand Rounds: Advances in Immunosuppression. UCLA Medical
Center, Los Angeles, CA, October 7, 1997.
Program Co-Chair, Advanced Heart Failure and Transplantation for the Primary Care Physician. Lecture given:
Medical management of the post transplant patient: what the primary care physician needs to know. Miramar
Sheraton, Santa Monica, CA, October 18, 1997.
Invited Speaker, Transplantation Grand Rounds: Pravastatin in heart transplantation. University of Minnesota
Medical Center, Minneapolis, MN, October 24, 1997.
Chairperson, Bristol-Myers Squibb Symposium: Advanced Heart Failure and Transplantation.
Cardiovascular Medical Group/UCLA Medical Center, Los Angeles, CA, November 6, 1997.
University
Invited Speaker, Transplant Grand Rounds: Results of MMF in heart transplantation. Stanford University, Palo
Alto, CA, December 4, 1997.
Invited Speaker, Cardiology Research Rounds: Update on statins in transplant coronary artery disease, Stanford
University, Palo Alto, CA December 4, 1997.
Invited Speaker, International Congress on Immunosuppression. Tacrolimus versus cyclosporine. The argument
in favor of cyclosporine. Renaissance Resort Hotel, Orlando, FL, December 12, 1997.
FDA Advisory Board Meeting: Use of mycophenolate mofetil for indication in heart transplantation. Medical
Consultant on behalf of Roche Pharmaceuticals. Washington, DC, January 14, 1998.
Invited Speaker, Cardiology Grand Rounds: Hyperlipidemia in heart transplantation. University of Washington
Medical Center, Seattle, WA, January 23, 1998.
13
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
Invited Speaker: Cardiac transplantation and the medical management of the post transplant patient. Holiday Inn,
Bakersfield, CA, March 6, 1998.
Invited Speaker, National Association of Transplant Coordinators: Use of the alternate waiting list for organ
transplantation. Hilton Hotel, La Jolla, CA, March 12, 1998.
Invited Speaker, Medicine Grand Rounds: Treatment of hyperlipidemia, St. Bernadine Medical Center, San
Bernardino, CA, March 19, 1998.
Invited Guest, Radio Talk Show “Partners In Health”: Cardiac transplantation. San Luis Obispo, CA, March 27,
1998.
Invited Speaker, American College of Cardiology Symposium: Prevention of nonimmune factors. Georgia World
Congress Center, Atlanta, GA, April 1, 1998.
Invited Speaker, UCLA Cardiology Update: Treatment of hyperlipidemia and medical versus surgical treatment of
coronary artery disease. Flamingo Hilton Hotel, Las Vegas, NV, April 3, 1998.
Invited Speaker, Opening Plenary Session: Management of the highly sensitized patient pretransplant.
International Society for Heart and Lung Transplantation Scientific Sessions, Sheraton Chicago Hotel, Chicago,
IL, April 16, 1998.
Chairman, Breakfast Symposium: Difficult heart transplant cases. International Society for Heart and Lung
Transplantation Scientific Sessions, Sheraton Chicago Hotel, Chicago, IL, April 17, 1998.
Invited Speaker, Luncheon workshop: Use of plasmapheresis for the sensitized VAD patient awaiting heart
transplantation. International Society for Heart and Lung Transplantation Scientific Sessions, Sheraton Chicago
Hotel, Chicago, IL, April 17, 1998.
Invited Speaker, Breakfast symposium: When to substitute mycophenolate. International Society for Heart and
Lung Transplantation Scientific Sessions, Sheraton Chicago Hotel, Chicago, IL, April 18, 1998.
Moderator: In vitro and in vivo mechanisms of immunosuppression. International Society for Heart and Lung
Transplantation Scientific Sessions, Sheraton Chicago Hotel, Chicago, IL, April 18, 1998.
Invited Speaker, Cardiology Grand Rounds. Advances in heart transplantation. Harbor General-UCLA Medical
Center, Los Angeles, CA, April 28, 1998.
Invited Speaker for Family Medicine Refresher Course. Medical versus surgical approach to the patient with
coronary artery disease. Miramar Sheraton Hotel, Santa Monica, CA. May 28, 1998.
Invited Speaker, Cardiology Grand Rounds: Heart transplantation. UCLA Medical Center, Los Angeles, CA May
29, 1998.
Invited Speaker, Division of Family Medicine, Advances in Congestive Heart Failure. UCLA Medical Center, Los
Angeles, CA, July 7, 1998.
Program Director, Advanced Heart Failure and Heart Transplantation for Roche Representatives. UCLA Medical
Center. 100 Medical Plaza Building, Los Angeles, CA, August 6, 1998. Lectures: Overview of heart
transplantation; Mycophenolate mofetil in heart transplantation, newer immunosuppressive agents.
Invited Speaker, UCLA Department of Medicine Grand Rounds: Heart transplants in the next millennium.
UCLA Medical Center, Los Angeles, CA, August 19, 1998.
Invited Speaker, Family Medicine Grand Rounds. Medical versus surgical management of patients with coronary
artery disease. UCLA Medical Center, Los Angeles, CA, August 28, 1998.
Invited Speaker, Department of Surgery House Staff Rounds: Perioperative cardiac complications of arrhythmia,
myocardial infarction, and congestive heart failure. UCLA Medical Center, Los Angeles, CA August 29, 1998.
14
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
Invited Speaker, Symposium on transplant vasculopathy in heart transplantation sponsored by the International
Society of Heart and Lung Transplantation. Lectures on the use of HMG-CoA reductase inhibitors in
transplantation; vascular remodeling of transplant coronary arteries. Sheraton Hotel, Washington DC, September
25, 1998.
Invited Speaker for Plenary talk on the postoperative management of transplant recipients. Japan Society for
Transplantation. Kokeio Plaza Hotel, Tokyo, Japan. December 1, 1998.
Invited Speaker, Luncheon Symposium. Hyperlipidemia in Heart Transplantation. Sponsored by Novartis at the
Japan Society for Transplantation. Kokeio Plaza Hotel, Tokyo, Japan. Dec. 1, 1998.
Invited Speaker, Cardiac transplantation module. Lecture on cardiac transplantation for second year medical
students. UCLA Medical Center, Los Angeles, CA, January 4, 1999.
Program Director, UCLA Symposium: Heart Failure and Transplantation: New Concepts and Therapies. Lectures
given: Post transplant management, Advances in immunosuppressive therapy. Sheraton Miramar Hotel, Santa
Monica, CA, January 16, 1999.
Invited speaker, Cardiology Grand Rounds. Advances in Immunosuppression in Cardiac Transplantation. Sharp
Memorial Hospital, San Diego, CA, January 22, 1999.
Invited Speaker, Medicine Grand Rounds. HMG-CoA Reductase Inhibitors in Transplantation: Clinical to Basic
Science Research. Ochsner Medical Center, New Orleans, LA, March 10, 1999.
Invited Speaker, Pri-Med Conference. Debate: Statin Treatment for Normal Cholesterol Values – CON. Long
Beach, CA, April 9, 1999.
Invited Speaker, Sunrise Symposium. Advances in Immunosuppression: Mycophenolate and Beyond. American
Society of Transplantation, Hilton Hotel, Chicago, IL, May 16, 1999
Moderator, Luncheon Session. Coronary Artery Disease in the Transplant Population. American Society of
Transplantation, Hilton Hotel, Chicago, IL, May 18, 1999
Invited Speaker, Medicine Grand Rounds. The Use of HMG Reductase Inhibitors in Clinical Heart
Transplantation. University of Minnesota, Minneapolis, MN, May 20, 1999.
Invited Speaker, Family Medicine Refresher Course. Medical Versus Surgical Management of the Patient with
Coronary Artery Disease. Sheraton Miramar Hotel, Santa Monica, CA, May 27, 1999.
Invited Speaker, Cardiology Grand Rounds. Advances in Heart Transplantation and the Denervated Heart.
UCLA Medical Center, Los Angeles, CA, May 28, 1999.
Program Director, UCLA Symposium: Heart Failure and Transplantation: New Concepts and Therapies. Lectures
given: Post transplant management, Advances in immunosuppressive therapy. Hyatt Newport, Newport Beach,
CA, October 16, 1999.
Invited Speaker, “Reducing Cardiovascular Risk in the New Millennium: One Heart at a Time” Staples Center, Los
Angeles, CA, January 7, 2000.
Invited Speaker, Grand Rounds. Novel Risk Markers for Cardiovascular Disease. Huntington Memorial Hospital
(Braun Auditorium), Pasadena, CA, Friday, February 25, 2000.
Invited Speaker, American College of Cardiology Scientific Sessions. Symposium: Transplant Vasculopathy:
Etiologic Factors and Prevention. Anaheim Convention Center, Anaheim, CA, March 13, 2000.
Invited Speaker, International Society for Heart and Lung Transplantation. Satellite Symposium 1: Introduction to
Clinical Heart Transplantation: Pre-Operative Issues. “Physiology of the Transplanted Heart and Pacing Needs
Convention Hall,” Osaka International Convention Center, Osaka, Japan, April 5, 2000.
15
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
Moderator, International Society for Heart and Lung Transplantation Opening Plenary Session.
Convention Hall, Osaka International Convention Cent er, Osaka, Japan, Thursday, April 6, 2000.
Invited Speaker, International Society for Heart and Lung Transplantation Plenary Session. Scientific Program
Report, Convention Hall, Osaka International Convention Center, Osaka, Japan, Thursday, April 6, 2000.
Moderator, International Society for Heart and Lung Transplantation Closing Plenary Session.
Convention Hall, Osaka International Convention Center, Osaka, Japan, Saturday, April 8, 2000.
Invited Speaker, Nuclear Medicine Journal Club and Lecture Series, Evaluation and Management of Heart
Transplant Patients. Nuclear Medicine Clinic Conference Room, CHS-AR-277, Friday, May 5, 2000.
Invited Speaker, UCLA Heart Failure and Transplantation: New Concepts and Therapies, Post Transplant
Management for the Primary Care Physician. The Embassy Suites at Mandalay Beach Resort, Oxnard, CA,
Saturday, May 6, 2000.
Invited Speaker, Educational Talk: Heart Transplant Program Update. Board of Advisors Executive Committee
Meeting, Administrative Conference Room, 14-214 U, UCLA Medical Center, May 11, 2000.
Co-Chair, Session: Clinical Immunosuppression. AST Chicago, Chicago Sheraton Hotel, May 15, 2000.
Medicine Grand Rounds. Lecture: Reducing Cardiovascular Risk in the New Millennium: One Heart at a Time.
University of California at San Diego Medical Center, San Diego, CA, May 19, 2000.
Medicine Grand Rounds. Lecture: Update on Cardiac Transplantation. Harbor-UCLA Medical Center, Torrance,
CA, May 23, 2000.
Invited Speaker, Mini-Course, Cardiology for the Primary Care Physician: Management of Congestive Heart
Failure. 27th Annual UCLA Family Practice Refresher Course. Fairmont Miramar Hotel, Santa Monica, CA, May
30-June 3, 2000.
Invited Speaker, “IVUS Assessment of Cyclosporine vs. Tacrolimus. Current Perspectives in Cardiac Transplant
Immunosuppression. The New York Palace Hotel, New York, NY, June 23, 2000.
Invited Speaker, “Cardiac Transplantation”. Grand Rounds Educational Meeting, Kaiser Hospital Conference
Rooms 2A and 2B, Fontana, CA, August 15, 2000.
Invited Speaker, “Cardiovascular Disability”. Los Angeles County Bar Association’s Social Security Section,
McCormick and Schmick’s Restaurant, Los Angeles, CA, September 5, 2000.
Invited Speaker, Grand Rounds “Hyperlipidemia in Solid Organ Transplantation”.
Medical Center, Ann Arbor, MI, September 15, 2000.
University of Michigan
Invited Speaker, Plenary Session: “Current Aspects on Cardiac Allograft Vasculopathy”. The Gifu Renaissance
Hotel, Gifu, Japan, October 12, 2000.
Invited Speaker, Japan Society for Transplantation. Heart Transplantation in the New Millennium, Main
Symposium, “Transplantation: At the Start of a New Century”. The Gifu Renaissance Hotel, Gifu, Japan,
October 12, 2000.
Invited Speaker, Commentary on “Immunological Monitoring and Pre-term Diagnosis of Rejection Response”.
The Gifu Renaissance Hotel, Gifu, Japan, October 13, 2000.
16
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
Invited Speaker, “Statins as Immunosuppressive Agents”. University of Minnesota CME Symposium: Late
Complications after Solid Organ Transplantation. Royal Palms Hotel & Casitas, Phoenix, AZ, November 1-3,
2000.
Medicine Grand Rounds. Advances in Heart Transplantation. UCLA Medical Center, 43-105 CHS, Los Angeles,
CA November 22, 2000.
Doctoring Lecture- Second year UCLA Medical Students, UCLA Medical Center, 73-105 CHS, Los Angeles, CA.
January 12, 2001.
Invited Speaker, “Cardiovascular Risks.” Fraternity of Friends. UCLA Covel Commons, January 23, 2001.
Invited Speaker, “Heart Transplantation.” Pfizer Symposium, UCLA Medical Center, February 12, 2001.
Invited Speaker, “Treatment of a Highly Sensitized Patient Prior to Heart Transplant.” Texas Heart Institute,
Houston, TX, February 16, 2001.
Invited Speaker, National Institute of Health Grand Rounds: “Statins as immunosuppression agents in organ
transplantation.” March 14, 2001.
Invited Speaker, “Hyperlipidemia Management Update: Diabetes, Low HDL, and More.” 1 st Annual UCLA
Department of Medicine Clinical Faculty Association CME Symposium: Cardiovascular Medicine: 2001. The
Century Plaza Hotel, Century City, CA Saturday, March 31, 2001.
Moderator, “Immunosuppressive Protocols and Drug Monitoring: Defend or Deny.” International Society for
Heart and Lung Transplantation Scientific Sessions, Vancouver, BC Canada. April 26, 2001.
Moderator, “Immunosuppression 1: Clinical Outcome Measurements and Side Effects.” International Society for
Heart and Lung Transplantation Scientific Sessions, Vancouver, BC Canada. April 26, 2001.
Moderator, Luncheon Session. “Selected Posters on Heart and Lung.” American Society of Transplantation,
Sheraton Hotel, Chicago, IL. May 14, 2001.
Invited Speaker, Mini-Course, Cardiology for the Primary Care Physician: Approach to the Patient with Syncope.
28th Annual UCLA Family Practice Refresher Course. Fairmont Miramar Hotel, Santa Monica, CA, May 29-June
2, 2001.
Invited Speaker, Cardiopulmonary Exercise Testing: A Case Study Approach Presentation 4: “Post-Transplant
Assessment and Follow-Up.” AHA Scientific Sessions 2001, Anaheim Convention Center, Room 303 C-D.
November 12, 2001.
Moderator, Heart & Lung, “Meet the Experts” The 2 nd International Congress on Immunosuppression. San
Diego, CA. December 7, 2001.
Invited Speaker, Doctoring Course, Second-Year UCLA Medical Students. "Heart Transplantation". UCLA
Medical Center, Los Angeles, CA. January 7, 2002.
Invited Speaker, Cardiology Fellows Grand Rounds: “Transplant Coronary Artery Disease.”
Presbyterian Hospital/Columbia University, New York, NY January 8-9, 2002
Invited Speaker, Cardiology Grand Rounds: “High Risk Program at UCLA.”
Hospital/Columbia University, New York, NY January 8-9, 2002
17
New York
New York Presbyterian
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
Moderator and Invited Speaker, Fujisawa Roundtable: Managing Cardiovascular and Immunologic Risk Factors
Post-Heart Transplant: “Role of Statins.” Key West, FL February 7-8, 2002
Moderator and Participant, Group Discussion Regarding Retrospective Analysis Project: “Project Objectives” and
“Publication Plans.” Key West, FL February 7-8, 2002
Invited Speaker, Transplant Coronary Artery Disease Evening Session. “Impact of Lipid Lowering”. American
College of Cardiology Conference 2002. Atlanta, GA. March 17-20, 2002.
Invited Speaker and Moderator, Mid-Day Workshop 4: “Cardiovascular Risk Factors Post Heart Transplant: Do
They Matter and Can They be Treated?” International Society for Heart and Lung Transplantation, 22 nd Annual
Meeting and Scientific Sessions. Washington D.C. April 10-13, 2002.
Invited Speaker, Novartis Satellite Symposium: The Immunosuppressive Regimen: Redefining the Path to
Improved Patient Outcomes. “Promising Approaches to Chronic Rejection” American Transplant Conference
2002. Washington, D.C. April 27, 2002.
Invited Speaker, Mini-Course, Cardiology for the Primary Care Physician: Modern Management of Congestive
Heart Failure. 29th Annual UCLA Family Practice Refresher Course. Fairmont Miramar Hotel, Santa Monica, CA,
May 28-June 1, 2002.
Invited Speaker, Cardiology Grand Rounds. 2002: The New Heart Transplant Odyssey – Advances in the Field.
UCLA Medical Center, Los Angeles, CA, June 14, 2002.
Invited Speaker, “Advances in Heart Transplantation.” Grand Rounds, Harbor-UCLA Medical Center, Los
Angeles, CA. August 27, 2002.
Invited Speaker, UCLA Noon Conference. “Cardiac Transplant Basics”. UCLA Medical Center, Los Angeles,
CA. August 29, 2002.
Invited Speaker, “Advances in Transplantation” Conference. “Cardiac Biopsies: Today’s Uses and Tomorrow’s
Methods of Non-Invasive Techniques to Detect Rejection”. La Jolla, CA. October 27-30, 2002.
Invited Speaker, “Advances in Transplantation” Conference.
Transplant Population”. La Jolla, CA. October 27-30, 2002.
“Chronic Disease Management in the Post
Moderator, “Management Issues In Cardiac Transplantation”.
November 17-19, 2002.
AHA Scientific Session 2002. Chicago, IL.
Invited Speaker, Immunosuppression in Heart Transplant: State of the Art. “The Effect of Everolimus/Sirolimus
on the Development of Allograft Vasculopathy:” AHA Scientific Session 2002. Chicago, IL. November 17-19,
2002.
Guest Lecturer, Doctoring II Cardiac Module, “Cardiac Transplantation.” UCLA Medical Center, Los Angeles,
CA January 6, 2003.
Invited Speaker, Postoperative Management: “Clinical Approach to the Treatment of Coronary Graft
Vasculopathy.” 4th Vail Conference: Cardiothoracic Transplantation 2003. Vail, Colorado. February 22-26, 2003.
Invited Speaker, Postoperative Management: “Rapamycin in Heart Transplantation.”
Cardiothoracic Transplantation 2003. Vail, Colorado. February 22-26, 2003.
18
4 th Vail Conference
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
Invited Speaker, Postoperative Management: “Cardiac Biopsies: Current Uses and Noninvasive Techniques for
Rejection Monitoring.” 4th Vail Conference Cardiothoracic Transplantation 2003. Vail, Colorado. February 2226, 2003.
Program Chair, Roundtable: “Heart Transplantation and Recent Advances in mTOR Inhibitors.” Boca Raton,
Florida. March 17-18, 2003.
Moderator, Heart Failure Press Conference. American College of Cardiology, 52 nd Annual Scientific Sessions,
Hyatt Regency McCormick Place, Chicago, IL March 30-April 1, 2003
Invited Speaker, Cardiac Transplantation: “Allograft Vasculopathy.” American College of Cardiology, 52 nd Annual
Scientific Sessions, Hyatt Regency McCormick Place, Chicago, IL March 30-April 1, 2003
Chair, Novartis Lunch Symposium: “TCAD: IVUS, Surrogate Markers & Treatments.” International Society for
Heart and Lung Transplantation, 23rd Annual Meeting and Scientific Sessions, Vienna, Austria April 7-13, 2003
Invited Speaker, “Results of Multi-Center Study of Metabolic and Renal Factors Influencing Survival in Heart
Transplantation.” International Society for Heart and Lung Transplantation, 23 rd Annual Meeting and Scientific
Sessions, Vienna, Austria April 7-13, 2003
Co-Moderator, Closing Plenary Session. International Society for Heart and Lung Transplantation, 23rd Annual
Meeting and Scientific Sessions, Vienna, Austria April 7-13, 2003
Co-Chair, Work Group Sessions: Diagnosis of Humoral Rejection. A Conference to Analyze Humoral Rejection
in Solid Organ Transplantation, Bethesda, MD, April 23-24, 2003.
Co-Chair, Plenary Session: Work Group 2: Presentation of Consensus Recommendations. A Conference to
Analyze Humoral Rejection in Solid Organ Transplantation, Bethesda, MD, April 23-24, 2003.
Program Co-Chair, UCLA Symposium: Cutting Edge Therapy in Heart Failure Treatment: New Concepts and
Therapies. Lectures given: Advances in Heart Transplantation. Four Seasons Resort Santa Barbara, CA. May 3,
2003.
Invited Speaker, “Cardiovascular Risk Factors in Transplant Recipients.” Cardiology Grand Rounds, New York
Presbyterian Hospital/Columbia University, New York, NY, May 5-7, 2003.
Invited Speaker, “The Immunosuppressive Effects of Statins.” General Transplant Grand Rounds, New York
Presbyterian Hospital/Columbia University. May 5-7, 2003.
Invited Speaker, “UCLA Heart Transplant Program.” Dinner Meeting with Heart Transplant Medical Staff. New
York Presbyterian Hospital/Columbia University. May 5-7, 2003.
Invited Speaker, Mini-Course: Cardiology for the Primary Care Physician: “Approach to the Patient with
Syncope.” 30th Annual UCLA Family Practice Refresher Course. The Beverly Hilton, CA, May 27-May 31, 2003.
Invited Speaker, Clinical Science Symposium: “Who Should Not be Transplanted/Retransplanted.” American
Transplant Congress 2003, Washington D.C. May 30-June 4, 2003.
Invited Speaker, Thoracic Mini-Oral Session: “Improved Survival of Heart Transplant Patients with Severe TCAD
in Era of Percutaneous Coronary Intervention and Statin Therapy.” American Transplant Congress 2003,
Washington D.C. May 30-June 4, 2003.
Co-Chair, Heart Transplantation: Immunosuppression Protocols.
Washington D.C. May 30-June 4, 2003.
American Transplant Congress 2003,
Invited Speaker, Thoracic: Recipient and Donor Outcomes: “Impact of On-Going Post Cardiac Transplant Risk
Factors on Outcomes: A Multi-Center Study.” American Transplant Congress 2003, Washington D.C. May 30June 4, 2003.
Co-Moderator, Congestive Heart Failure. American Heart Association 2 nd Asia-Pacific Scientific Forum, June 810, 2003.
19
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
Invited Speaker, “Heart Failure as it Affects Persons of Asian Descent in North America.” American Heart
Association 2nd Asia-Pacific Scientific Forum, June 8-10, 2003.
Invited Speaker, “Hyperlipidemia in Solid Organ Transplantation.” Kidney Transplant Grand Rounds, University
of Southern California. July 14, 2003.
Invited Speaker, “Adult Heart Transplant Rejection and Immunosuppression Therapy.” 4 East ICU Nursing
Symposium, UCLA. September, 18, 2003.
Invited Speaker, “Post-Transplant Patient Care: New Challenges.” Symposium XV: Surgery and Device Therapy
in Heart Failure, 7th Annual Scientific Meeting 2003 Heart Failure Society of America, Las Vegas, NV. September
23, 2003.
Invited Speaker, “Current Immunosuppression at UCLA.” Fujisawa Preceptorship, UCLA. October 15, 2003.
Invited Speaker, “New Immunosuppression Therapy.” Fujisawa Preceptorship, UCLA. October 16, 2003.
Invited Speaker, “Present Status and Future Trends of Immunosuppression in Heart Transplantation.” 39 th
Annual Meeting of Japan Society for Transplantation, Osaka, Japan. October 27, 2003.
Invited Speaker, “Current Immunosuppression Strategies in Heart Transplantation.” American Heart Association
Scientific Sessions 2003, Orlando, FL. November 10, 2003.
Invited Speaker, “Advanced Heart Failure, Transplantation and Devices and Heart
Immunosuppression.” Cardiothoracic Grand Rounds, University of Arizona. December 4, 2003.
Transplant
Invited Speaker, “Current Immunosuppression at UCLA’s Heart Transplant Program.” Cardiac Transplant Grand
Rounds, University of Arizona. December 5, 2003.
Invited Speaker, “Advances in Heart Transplantation.” UCLA Medical School lecture Series to Second Year
Medical Students, UCLA. January 20, 2004.
Invited Speaker, “Exercise Capacity in Heart Transplant Patients.”
Inservice, UCLA. February 18, 2004.
UCLA Physical Therapy Department
Program Co-Chair, UCLA Symposium: Cutting Edge Therapy in Heart Failure Treatment: New Concepts and
Therapies. Lectures given: Advances in Heart Transplantation. Four Seasons Resort, Las Vegas, NV. February
21, 2004.
Invited Speaker, “Advances in Heart Transplantation.” Multidisciplinary Cardiovascular Conference, Hoag
Hospital Heart and Vascular Institute. Newport Beach, CA. February 25, 2004.
Invited Speaker, “Transplantation 2004.” Management of End-Stage Heart Failure Symposium, American College
of Cardiology 52nd Annual Scientific Sessions, New Orleans, LA. March 8, 2004.
Invited Speaker, “Heart Transplantation; A Life Sustaining Organ Transplant.” Pathology 240, UCLA. April 27,
2004.
Invited Speaker, “Diagnostic Approach to the Patient with Syncope.” Harvard/UCLA Pri-Med Conference.
Current Clinical Issues in Primary Care. Anaheim Convention Center, Anaheim, CA. May 14, 2004.
Co-Chair: Clinical Science Symposium: Pre-Transplant Risk Factors and Effect on Post-Transplantation
Outcomes. American Transplant Congress 2004 Meeting. John B. Haynes Convention Center, Boston, MA. May
17, 2004.
Co-Chair: Pediatric Cardiac Transplant and Post-Transplant Complications. American Transplant Congress 2004
Meeting. John B. Haynes Convention Center, Boston, MA. May 17, 2004.
Invited Speaker, “Modern Management of Congestive Heart Failure.” 31 st Annual UCLA Family Practice
Refresher Course. Minicourse: Cardiology for the Primary Care Physician. The Beverly Hilton Hotel. June 3,
2004.
20
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
Program Co-Chair, UCLA Symposium: Cutting Edge Therapy in Heart Failure Treatment: Newest Concepts and
Treatments. Presentations: Welcome and Introductory Remarks and Update on Heart Transplantation
Management. Marriott Hotel, Newport Beach, CA. October 9, 2004.
Invited Speaker, Heart Failure University: Transplant Evaluation and Post-Transplant Treatment. Los Angeles
Airport Marriot, Los Angeles, CA. November 12-14, 2004.
Invited Speaker, Individualization of Immunosuppression, Heart and Lung: Short-Term. Manchester Grand Hyatt
San Diego, San Diego, CA. December 8-11, 2004.
Invited Speaker, Roche National Cardiac Transplant Advisory Board. Presentation: The Cellcept Cardiac
Registration Trial and Data Reanalysis. Chicago, IL. December 16-17, 2004.
Invited Speaker, Brigham and Women’s Hospital, Transplant Grand Rounds. Presentation: Immunosuppression
in Heart Transplantation. Brigham and Women’s Hospital, Boston, MA. January 11, 2005.
Invited Speaker, Massachusetts General Hospital, Cardiology Grand Rounds. Presentation: Immunosuppression
in Heart Transplantation. Massachusetts General Hospital, Boston, MA. January 12, 2005.
Invited Speaker, Tufts-New England Medical Center, Cardiology Grand Rounds.
Presentation:
Immunosuppression in Heart Transplantation. Tufts-New England Medical Center, Boston, MA. January 13,
2005.
Invited Keynote Speaker, The 6th Biennial Psychiatric, Psychosocial and Ethical Issues in Organ Transplantation
Conference. Keynote Address: Cardiac Transplantation: Advances and Ethical Dilemmas. Doubletree Hotel,
Santa Monica, CA. February 4-6, 2005.
Invited Speaker, American College of Cardiology. Meet the Experts Session: Heart Transplant 2005. Orange
County Convention Center, Orlando, FL. March 8, 2005.
Invited Speaker, Johns Hopkins Comprehensive Transplant Center, Research Lectures: Tough Cases for the
Expert. Johns Hopkins - Cardiology Library, Baltimore, MD. March 25, 2005.
Invited Speaker, Johns Hopkins Comprehensive Transplant Center, Research Lecture. Transplant Lecture:
Advances in Immunosuppression & Cardiac Allograft Vasculopathy After Heart Transplantation. Johns Hopkins
- Cader Room, Baltimore, MD. March 25, 2005.
Co-Moderator, International Society for Heart and Lung Transplantation Plenary Session. Philadelphia Marriot,
Philadelphia, PA. April 9, 2005.
Co-Chair: Welcome and Introductory Remarks. New Advances in Heart Failure Treatment: Newest Concepts and
Therapies. Hilton Los Angeles North/Glendate & Executive Meeting Center, CA. April 16, 2005.
Lecturer, The David Geffen School of Medicine at UCLA - Pathology 240 Course Spring 2005 Immunobiology of
Transplantation: From Bench to Bedside, “Heart Transplantation; A Life Sustaining Organ Transplant” UCLA
Center for Health Sciences, Los Angeles, CA April 26, 2005.
Moderator, American Transplant Congress, Contemporary Outcomes in Immunosuppression Session.
Washington State Convention and Trade Center, Seattle, WA, May 20-25, 2005.
Invited Speaker, VA Greater Los Angeles Health Care System, Cardiology Grand Rounds Medical Educational
Conference – Cardiology Division, James Wadsworth Building, Los Angeles, CA. June 15, 2005.
Presenter, Australian Transplant Symposium. Lectures: Coronary Artery Vasculopathy and Humoral Rejection—A
Historical Review. Park Hyatt Melbourne, Melbourne, Australia, July 22-23, 2005.
Invited Speaker, Department of Medicine Noon Conference. Lecture: Basics in Cardiac Transplantation. UCLA,
Los Angeles, CA. July 29, 2005.
Invited Speaker, Cellcept Heart STN Investigators Meeting, Hyatt Regency Chicago, Chicago, IL. August 10-12,
2005.
21
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
Invited Speaker, Certican Mock “B” Meeting, Westminster Hotel. Livingston, NJ. September 26-27, 2005.
Invited Speaker, Advances in Transplantation--Contemporary Forums Symposium. Lectures: “Revisiting Criteria
for Heart Transplantation” and “Advanced Case Studies in Thoracic Transplantation.” Las Vegas Hilton, Las
Vegas, NV. September 29-30, 2005.
Invited Speaker, Montreal Heart Institute. Lecture: “Advances in Immunosuppression After Heart
Transplantation.” Montreal Heart Institute and Hospital Laval, Quebec City, Canada. October 4-7, 2005.
Faculty Moderator, Clinical Challenges in Heart Transplantation. Four Seasons Hotel, Los Angeles, CA. October
20, 2005.
Invited Speaker, Transplant Summit 2005. Lecture: “Update on the Classification of Heart Transplant Rejection."
Roundtable Leader: “Transplant Cardiology and Heart Failure Roundtable.” The Westin St. Francis Hotel, San
Francisco, CA October 26-28, 2005.
Invited Speaker, Heart Failure University. Lecture: “Heart Transplant Evaluation and Post-Transplant Treatment.”
Los Angeles Airport Marriott, Los Angeles, CA December 3-4, 2005.
Facilitator, Clinical Challenges in Heart Transplantation. Seattle, WA, March 6, 2006.
Invited Speaker, Roche Satellite Symposium: “Looking Beyond Cellular Rejection in Cardiac Transplantation.”
International Society for Heart and Lung Transplantation, 26th Annual Meeting and Scientific Sessions,
Auditorium Hotel, Madrid, Spain. April 5-8, 2006.
Presenter, XDx CARGO Steering Committee breakfast meeting: “Mild Rejection/Steroid Weaning.”
International Society for Heart and Lung Transplantation, 26th Annual Meeting and Scientific Sessions,
Auditorium Hotel, Madrid, Spain. April 5-8, 2006.
Moderator, Concurrent Session 13: CAV: A Never-ending Story. International Society for Heart and Lung
Transplantation, 26th Annual Meeting and Scientific Sessions, Auditorium Hotel, Madrid, Spain. April 5-8, 2006.
Presenter, Concurrent Session 17: The Cells Versus the Humors: “Flow-cytometry positive, cytotoxicity-negative
donor-specific crossmatch: To transplant or not to transplant, that is the question” and “Adequate cyclosporine
(CsA) microemulsion (Neoral®) C2-levels critical within the first 30 days to prevent rejection after cardiac
transplant.” International Society for Heart and Lung Transplantation, 26th Annual Meeting and Scientific
Sessions, Auditorium Hotel, Madrid, Spain. April 5-8, 2006.
Invited Speaker, Astellas Heart Transplant Panel. Grand Hyatt Seattle, Seattle, WA. May 18, 2006.
UCLA Medicine Grand Rounds: “Advances in Heart Transplantation: Where Will We Be Tomorrow?” UCLA
Medical Center and School of Medicine, Los Angeles, CA, May 24, 2006.
Invited Speaker, Immunosuppression Minimization in Cardiac Transplantation: “Update on Clinical Trials in
Cardiac Transplantation”. World Transplant Congress Meeting 2006, Hynes Convention Center, Boston, MA, July
25, 2006.
Chairman, Heart Transplant Roundtable: “Process of Care.” Hilton O’ Hare, Chicago, IL, July 14, 2006.
Pfizer Visiting Professorship, Northwestern University Cardiology Grand Rounds: “Advances in
Immunosuppression in Heart Transplantation.” Northwestern University Feinberg School of Medicine, Chicago,
IL, September 14-15, 2006.
Invited Speaker, Cleveland Clinic Grand Rounds: “Advances in Immunosuppression in Heart Transplantation.”
The Cleveland Clinic Lerner Research Building, Cleveland, OH, September 24-25, 2006.
Co-Chairman, New Advances in Heart Failure Treatment: Newest Concepts and Therapies: “Update on Heart
Transplantation Management.” California Heart Center Continuing Medical Education Symposium, Marriott
Oxnard, Ventura, CA, October 7, 2006.
22
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
Invited Speaker, Pennsylvania State University Cardiology Grand Rounds: “Advances in Immunosuppression in
Heart Transplantation.” Pennsylvania State University Medical Center, Hershey, PA, October 15, 2006.
Invited Speaker, Drexel University Cardiology Grand Rounds: “Advances in Immunosuppression in Heart
Transplantation.” Drexel University Medical Center, Philadelphia, PA, October 16, 2006.
Clinical Advisor for XDx, MediCal Board of California. The Hyatt Sacramento, Sacramento CA, November 16,
2006.
Invited Speaker, The Second International Conference on Heart Failure in Children and Young Adults--New
Strategies for Diagnosis and Treatment of Heart Failure: “Lessons Learned from Adult Randomized Controlled
Trials,” “Challenging Case Session (My Worst Nightmare),” “Roundtable: Is There a Role for Primary
Transplantation for Hypopolastic Left Heart Syndrome?” The Ritz-Carlton, Laguna Niguel, CA, November 28December 2, 2006.
Invited Speaker, Heart Failure University 2006: “Heart Transplant Evaluation and Post-Transplant Treatment.”
Sheraton Gateway Hotel, Los Angeles, CA, December 1-3, 2006.
Invited Speaker, XDx AlloMap Clinical Advisory Board Meeting: “Allograft Dysfunction and Survival.” The Oval
Room Restaurant, Washington, DC, December 4-5, 2006.
Moderator and Invited Speaker, NewEra Cardiac Care 2007 Meeting: “Heart Failure and Biventricular Pacing,”
Heart Failure Session. The Hyatt Regency Resort & Spa, Huntington Beach, CA, January 4-7, 2007.
Lecturer, The David Geffen School of Medicine at UCLA - Pathology 240 Course Spring 2006 Immunobiology of
Transplantation: From Bench to Bedside, “Heart Transplantation; A Life Sustaining Organ Transplant.” UCLA
Center for Health Sciences 43-130, Los Angeles, CA, April 23, 2007.
Invited Speaker, Satellite Symposium 5—The Evolving Problem of Antibodies in Thoracic Transplantation:
“Clinical Therapies Currently in Use: Do Any of Them Work?” International Society for Heart and Lung
Transplantation, 27th Annual Meeting and Scientific Sessions, San Francisco, CA, April 24-27, 2007.
Invited Speaker, Cylex Symposium: “Immune Monitoring in Heart & Lung Transplant Patients.” International
Society for Heart and Lung Transplantation, 27th Annual Meeting and Scientific Sessions, San Francisco, CA,
April 24-27, 2007.
Invited Speaker, Immunosuppressive strategies for Transplantation in the Next Decade Advisory Board Meeting.
San Francisco Marriot, San Francisco, CA, May 4, 2007.
Invited Speaker, Pri-Med Conference: “Approach to the Patient with Chest Pain.” Anaheim Convention Center,
Anaheim, CA, May 10, 2007.
Invited Speaker, 34th Annual UCLA Family Practice Refresher Course: “Current Concepts in Atrial Fibrillation.”
Hyatt Regency Centery Plaza, Los Angeles, CA, May 30, 2007.
Invited Speaker, Contemporary Forums Advances in Transplantation: “Right Sided Heart Failure” and “Immune
Monitoring.” La Jolla, CA, September 9-12, 2007.
Invited Speaker, UCLA Heart Failure and Transplantation: New Advances in Heart Failure Treatment. The
Doubletree Hotel, Santa Monica, CA, Saturday, October 12, 2007.
Invited Speaker/Participant, XDx Clinical Advisory Board Meeting: “Optimizing Clinical Outcomes Study
Design.” Sonoma, CA, October 10-11, 2007.
Speaker/Participant, United Resource Network Site Visit with UCLA Transplant Services Programs: “Heart
Transplant.” UCLA NPI Building, Los Angeles, CA, November 1, 2007.
Moderator, Advances in Immunosuppression after Cardiac Transplantation. American Heart Association
Scientific Sessions 2007, Orlando, FL, November 4, 2007.
Discussant, Late-Breaking Clinical Trials II: CORONA trial. American Heart Association Scientific Sessions 2007,
Orlando, FL, November 5, 2007.
23
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
Quoted source, CORONA: Rosuvastatin can reduce hospitalization, some adverse events. Eric Raible, Cardiology
Today, December 2007.
Invited Speaker, The David Geffen School of Medicine at UCLA Cardiology Rounds: “Treatment of the
sensitized patient before and after heart transplantation.” The David Geffen School of Medicine, CHS, Los
Angeles, CA, November 16, 2007.
Participant, Novartis EveroCAV Protocol Design Meeting. The Westin New York at Times Square, Nederlander
Room, New York, NY, December 5, 2007.
Invited Speaker, Heart Transplant Clinical and Scientific Updates: Improving Long Term Outcomes: “Improving
Long-Term Graft Survival: Cardiac Allograft Vasculopathy.” John Hopkins University, Baltimore, MD, February
8, 2008. Webcast: http://www.jhasim.com/heart/web/site/index.cfm.
Invited Speaker, Cleveland Clinic Transplantation Grand Rounds: “Management of the Highly Sensitized PreTransplant Patient.” Cleveland Clinic, Cleveland, OH, February 11, 2008.
Invited Speaker, Comprehensive Transplant Center Presentation: “What all cardiologists should know about heart
transplantation now and in the near future.” Ohio State University, Ross Auditorium, Columbus, OH, February
13, 2008.
Invited Speaker, Comprehensive Transplant Center Presentation: “Cardiac Transplantation at the leading edge and
future.” Ohio State University, Ross Auditorium, Columbus, OH, February 13, 2008.
Invited Speaker, Grand Rounds: “Immune Monitoring in Heart Transplantation.” St. Luke’s Mid America Heart
Institute, Crockett Center, Kansas City, MO, February 14, 2008.
Medscape CME Activity Author: “Immunosuppressive Strategies for Long-term Success in Heart
Transplantation.” Medscape, http://cme.medscape.com/viewprogram/8819, February 28, 2008.
Invited Guest Participant, Transplant Histocompatibility Conference. Hyatt Regency O’Hare, Chicago, IL, March
2-4, 2008.
Co-chairman, 72nd Annual Scientific Meeting of the Japanese Circulation Society. Lecture given: “Current Status in
Cardiac Transplantation in the United States.” Fukuoka, Japan, March 28, 2008.
Invited Speaker, Pathology 240 Course: “Immunobiology of Transplantation.” David Geffen School of Medicine
at UCLA, 16-154 CHS, Los Angeles, CA, April 16, 2008.
Invited Speaker, Harvard/UCLA Pri-Med Conference: Current Clinical Issues in Primary Care. “Management of
Congestive Heart Failure.” Anaheim Convention Center, Anaheim, CA, May 15, 2008.
Invited Speaker, American Transplant Congress Satellite Symposium: Extending Patient and Graft Survival,
Current Barriers and Future Solutions. “Insights form Heart Transplantation.” Royal York Fairmont, Toronto,
Ontario, Canada, June 2, 2008.
Invited Speaker, American Transplant Congress Sunrise Symposium: Randomized Clinical Trials in Heart
Transplantation. “What have Randomized Clinical Trials Taught Us So Far?” Metropolitan Toronto Convention
Center, Toronto, Ontario, Canada, June 4, 2008.
Invited Speaker, 35th Annual UCLA Family Practice Refresher Course: “Current Concepts in Atrial Fibrillation.”
David Geffen School of Medicine at UCLA, Los Angeles, CA, May 21, 2008.
Invited Speaker, CBS Television Show “The Doctors.” Los Angeles, CA, September 12, 2008.
Invited Speaker, Lecture at National Cheng-Kung University Hospital: “What Have RCT’s Taught Us So Far.”
Tainan, Taiwan, September 26, 2008.
Invited Speaker, Lecture at National Taiwan University Hospital: “Should the Patients with Right Ventricular
Failure Undergo Heart Transplantation?- Review of the Indication for Heart Transplantation.” Taipei, Taiwan,
September 27, 2008.
24
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
Invited Speaker, Prograf Launching 10th Anniversary Symposium: Sharing organ Transplantation, Lighting New
Life. “Current Immunosuppressive Strategies in Heart Transplantation and Future Trend.” The Westin Taipei,
Taipei, Taiwan, September 27, 2008.
Invited Speaker, Joint Transplant Histocompatibility Conference: A Progress Report. “Report from a Consensus
Conference on the Sensitized Patient Awaiting Heart Transplantation.” December 9, 2008.
Invited Speaker, Cardiology Interest Group, Second Year UCLA Medical Students: “Heart Transplantation.”
David Geffen School of Medicine at UCLA. April 6, 2009.
Invited Speaker, Harbor-UCLA Cardiology Grand Rounds: “Advances in Heart Transplantation.” Saint John’s
Cardiovascular Research Center, Torrance, CA, May 4, 2009.
Invited Speaker, PRI-Med West: Current Clinical Issues in Primary Care, “Management of Atrial Fibrillation.”
Anaheim Convention Center, Anaheim, CA, May 7, 2009.
Featured Speaker, UCLA Department of Medicine Clinical Faculty Annual General Dinner Meeting: “Advances in
Heart Transplantation.” UCLA Faculty Center, Los Angeles, CA, May 27, 2009.
Invited Speaker, 36th Annual UCLA Family Practice Refresher Course: Cardiology: “Approach to the Patient with
Atrial Fibrillation.” Hyatt Regency Century Plaza, Los Angeles, CA, May 29, 2009.
Invited Lecturer, Internal Medicine Resident Lecture: “Basics in Heart Transplantation.” UCLA Medical Center,
July 27, 2009.
Invited Speaker, UCLA Cardiology Grand Rounds: “Advances in Heart Transplantation/Antibody Mediated
Rejection.” UCLA Medical Center, September 4, 2009.
Invited Speaker, Surgical Core Curriculum Conference: “Arrhythmia Management for Surgeons.” UCLA Medical
Center, September 30, 2009.
Invited Speaker, Heart Failure and Transplant Symposium: “Advances in Heart Transplantation.” Pelican Hill
Resort, Newport Beach, CA, October 3, 2009.
Invited Speaker, Venice Family Clinic: “Cardiac Arrhythmias.” Venice, CA, October 20, 2009.
Invited Speaker, American Society of Transplantation Audioconference Series: “Cardiothoracic Transplantation: Diagnosis
and Treatment of Antibody Mediated Rejection.” December 9, 2009; January 19, 2010.
Invited Speaker, American College of Cardiology Symposium: “Venous Thromboembolism in Patients with Heart Failure –
Assessing Risk and Optimizing Prophylaxis of VTE in HF Patients in the Hospital and Out.” Atlanta, GA, March 13, 2010.
Invited Speaker, Berdie Justice Memorial Lectureship: “Advances in Heart Failure and Heart Transplantation.” Cedars-Sinai
Medical Center, Los Angeles, CA, May 4, 2010.
Invited Speaker, Pri-Med West: “Approach to the Patient with Syncope.” Anaheim, CA, May 6, 2010.
Invited Speaker, 34th Annual Blood Donor Recognition: “Why One Blood Donation Goes A Long Way.” Cedars-Sinai
Medical Center, Los Angeles, CA, June 24, 2010.
Lecturer, Cedars-Sinai Department of Anesthesiology Grand Rounds: “Sensitization.” Cedars-Sinai Medical Center, Los
Angeles, CA, July 28, 2010.
Invited Speaker, American Society for Histocompatibility and Immunogenetics: “ASHI-Antibody Mediated Rejection in
Heart Transplantation.” Hollywood, Florida, September 29, 2010.
Invited Speaker, Brano Heart Failure Forum: “The future of heart transplantation.” Portoroz, Slovenia, October 2, 2010.
Program Chair, Board Review Course: “Management of the Sensitized Patient Awaiting Heart Transplantation.” Los
Angeles, CA, October 15, 2010.
25
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
Invited Speaker, Heart Institute Cardiology Grand Rounds Presentation at Cedars-Sinai Medical Center. “State of the Art –
Antibody Mediated Rejection in Heart Transplantation.” Los Angeles, CA, Jan 4, 2011.
Invited Speaker, Donor/Recipient Issues: “Management of the Donor Specific HLA and non-HLA Antibodies
Pre- and Post-Heart Transplantation.” Division of Cardiothoracic Surgery, University of Colorado School of
Medicine. 8th Vail Cardiothoracic Transplantation: An International Update. Vail, CO, Jan 22-26, 2011.
Invited Speaker, Post Transplant Issues: “Immune Monitoring Post-Heart Transplantation.” Division of
Cardiothoracic Surgery, University of Colorado School of Medicine. 8th Vail Cardiothoracic Transplantation: An
International Update. Vail, CO, Jan 22-26, 2011.
Invited Speaker, Post Transplant Issues: “Prevention and Management of Coronary Graft Vasculopathy.” Division
of Cardiothoracic Surgery, University of Colorado School of Medicine. 8th Vail Cardiothoracic Transplantation:
An International Update. Vail, CO, Jan 22-26, 2011.
Invited Speaker, 2011 Western Regional Meeting of the American Federation for Medical Research. “Mentor Talk:
Experiences in Heart Transplant Research.” Carmel, CA, January 28, 2011.
Invited Speaker, Methodist Transplant Center Grand Rounds, Methodist Hospital. “State of the Art – Antibody Mediated
Rejection in Heart Transplantation.” Houston, TX, Feb 9, 2011.
Invited Speaker, Legacy Society Palm Springs hosted by Cedars-Sinai Medical Center. “Advancements in Heart
Transplantation.” Palm Springs Air Museum Palm Springs, CA, Mar 15, 2011.
Invited Speaker, Division of Cardiology Grand Rounds Presentation at Harbor-UCLA Medical Center. “State of the Art –
Antibody Mediated Rejection in Heart Transplantation.” Los Angeles, CA, March 22, 2011.
Invited Speaker, American College of Cardiology Symposium: “Lipid Management in the Transplant Population.” New
Orleans, LA, April 4, 2011.
Invited Speaker, American College of Cardiology Symposium: “Does Gender Mismatch Increase the Risk of AntibodyMediated Rejection?” New Orleans, LA, April 4, 2011.
Invited Speaker, Division of Cardiology Grand Rounds Presentation at California Pacific Medical Center. “Advances in
Heart Transplantation.” San Francisco, CA, April 6th, 2011.
Satellite Session CoChair, International Society of Heart and Lung Transplantation 31st Scientific Annual Meeting and
Scientific Sessions. Satellite symposium 07: “Coronary Artery Vasculopathy: Form Consensus to Controversy.” San Diego,
CA, April 13th, 2011.
Invited speaker, International Society of Heart and Lung Transplantation 31st Scientific Annual Meeting and Scientific
Sessions. “Reduction of Cardiac Allograft Vasculopathy with Everolimus over Mycophenolate Mofetil: Intravascular
Ultrasound Results of a Randomized Multicenter Trial.” San Diego, CA, April 14 th, 2011.
Plenary Session Co Chair, International Society of Heart and Lung Transplantation 31st Scientific Annual Meeting and
Scientific Sessions. San Diego, CA, April 16th, 2011.
Invited Speaker, Pri-Med Symposium: Current Clinical Issues in Primary Care “Management of Heart Failure.” Anaheim,
CA, April 28th, 2011.
Invited Presenter, American Transplant Congress. “Male Donor to Female Recipient in Heart Transplantation Increases the
Risk of Antibody-Mediated Rejection.” Philadelphia, PA, April 30th, 2011.
Invited Presenter, American Transplant Congress. “Primary Graft Dysfunction and Autopsy Findings.” Philadelphia, PA,
April 30th, 2011.
Invited Presenter, American Transplant Congress. “Virtual Crosshatch and Desensitization Therapy Has Reduced Time to
Transplant for Sensitized Patients.” Philadelphia, PA, April 30th, 2011.
Invited Presenter, American Transplant Congress. “The Category of Biopsy-Negative Rejection in Heart Transplantation.”
Philadelphia, PA, April 30, 2011.
26
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
Invited Presenter, American Transplant Congress. “Screening Nuclear Stress Testing as a Prognostic Maker after Heart
Transplantation.” Philadelphia, PA, May 1, 2011.
Invited Speaker, American Transplant Congress Symposium: Improving Long-Term Survival in Thoracic Transplantation.
“How to Stop Chronic Heart and Lung Graft Injury from Antibody Medicated Rejection” Philadelphia, PA, May 2, 2011.
Invited Speaker, American Transplant Congress Symposium: Out with the Old? Novel Immunosuppression in Cardiac
Transplantation. “CMV Infections Are Less Frequent in De Novo Heart Transplant Recipients Receiving
Immunosuppression with Everolimus Plus Reduced CsA Compared to MMF and Standard CsA.”
Philadelphia, PA, May 2, 2011.
Invited Speaker, 13th Annual Board of Governors Healthcare College at Cedars-Sinai Medical Center. “The Future of
Cardiology: From Heart Transplantation to the Total Artificial Heart.” Los Angeles, CA, May 3, 2011.
Program Director and Speaker, Optimal Care and New Therapies for Advanced Heart Disease. “Heart Transplantation:
State of the Art Management.” California Heart Center at the Cedars-Sinai Heart Institute Continuing Medical Education
Symposium, Hyatt Regency, Bakersfield, CA, May 21, 2011.
Invited Speaker, UCLA Family Practice Refresher Course. “Management of Atrial Fibrillation.” Hyatt Regency Century
Plaza, Century City, CA, May 23, 2011.
Invited Speaker, The AMIRA Fibrosis Taskforce Meeting: Fibrosis Symposium. “Roadblocks for the Research and
Development of New Compounds in Fibrosis.” La Jolla, CA, July 14, 2011.
Program Director and Speaker, Optimal Care and New Therapies for Advanced Heart Disease. “Heart Transplantation:
State of the Art Management.” California Heart Center at the Cedars-Sinai Heart Institute Continuing Medical Education
Symposium, Hyatt Regency, Newport Beach, CA, September 17, 2011.
Invited Speaker, 15th Annual Scientific Meeting 2011 Heart Failure Society of America: Continuing Medical
Education Symposium. Before and After Cardiac Transplantation “Double-Organ Transplantation: Who and
Why?” Hynes Convention Center, Boston, MA. September 20, 2011.
Invited Panel Member, International Heart Failure Forum: Innovations and New Treatment Strategies in Heart
Failure. “Acute Heart Failure Patients.” Portoroz, Slovenia. September 23, 2011.
Invited Speaker, International Heart Failure Forum: Innovations and New Treatment Strategies in Heart Failure.
Advanced Heart Failure Patient: “Candidate Selection for Heart Transplantation.” Portoroz, Slovenia. September
23, 2011.
Invited Chair, Fourth International Branislav “Brano” Randovancevic Heart Failure Forum “End Stage Heart
Failure Treatment: Historical and Future Perspective.” Belgrade, Serbia. September 29, 2011.
Invited Speaker, Fourth International Branislav “Brano” Randovancevic Heart Failure Forum “Humoral Rejection
in Heart Transplantation.” Belgrade, Serbia. October 1, 2011.
Invited Speaker, French Heart Transplantation Congress: Coronary Graft Disease: Current Status and
Perspectives. Graft Coronary Disease: Different Mechanisms and the Challenge of Early Detection “Methods of
Investigation of Coronary Graft Disease” and “Local Practices of Detection in the United States.” Paris, France.
October 12, 2011.
Invited Speaker, French Heart Transplantation Congress: Coronary Graft Disease: Current Status and
Perspectives. Management of Coronary Graft disease: “Therapeutic Approaches of Coronary Graft Disease: News
and Perspectives—What Treatments, When to Intervene” and “Local Practices in the United States.” Paris,
France. October 12, 2011.
Invited Speaker, French Heart Transplantation Congress. Coronary Graft Disease: Current Status and
Perspectives. Immunosuppression: “Results of Multicenter Study Certican vs. Cellcept in de Novo Heart
Transplantation, IVUS Analysis.” Paris, France. October 13, 2011.
Course Chair and Speaker, Optimal Care and New Therapies for Advanced Heart Disease. “Heart Transplantation: State of
the Art Management.” California Heart Center at the Cedars-Sinai Heart Institute Continuing Medical Education
Symposium, Platinum Hotel, Las Vegas, NV, October 22, 2011.
27
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
Invited Speaker, Core Curriculum Lecture for General Cardiology Fellows—Introduction to Transplant Cardiology.
Cedars-Sinai Medical Center, Los Angeles, CA, November 22, 2011.
Invited Speaker, Cedars-Sinai Emergency Department Symmposium “Caring for the Patient Post-Heart Transplant.” Four
Seasons Hotel, Los Angeles, CA, Dec 2, 2011.
Keynote Speaker, Cedars-Sinai Board of Directors Annual Meeting “The Total Artificial Heart and Other Innovations in
Advanced Heart Disease.” Four Seasons Hotel, Los Angeles, CA, Dec 13, 2011.
Invited Speaker, Core Curriculum Lecture for General Cardiology Fellows “Research in Progress Lecture.” Cedars-Sinai
Medical Center, Los Angeles, CA, Dec 15, 2011.
Invited Speaker, Personalized Medicine World Conference (PMWC) conference. “Genomics and the Detection of Heart
Transplant Rejection.” Silicon Valley, CA, Jan 23, 2012.
Invited Speaker, Cedars-Sinai Psychiatry Grand Rounds. “Heart Transplantation: Advances and Ethical Dilemmas.”
Cedars-Sinai Medical Center, Los Angeles, CA, Feb 9, 2012.
Invited Speaker, Medicine in Motion 5th Annual Speaker Series, “Innovations at Work Targeting Advanced Heart Disease.”
Santa Barbara, CA, Mar 15, 2012.
Session Co-Chair, American College of Cardiology 2012, “Heart Transplantation Challenges in 2012.” McCormick Place,
Chicago, IL, Mar 25, 2012.
Invited Speaker, Pri-Med Symposium: Current Clinical Issues in Primary Care “Approach to the Patient with Syncope.”
UCLA, Anaheim, CA, April 13, 2012.
Invited Co-Chair, International Society of Heart and Lung Transplantation 32st Scientific Annual Meeting and Scientific
Sessions Pre-meeting Symposium 14: “The DEFs of AMR: Detecting the Antibodies, Evaluating the Biopsy, and Finally
the Patient.” Prague, Czech Republic, April 18, 2012.
Invited Moderator, One Lambda Symposium. Clinical Relevance of DSA in Thoracic Transplantation. “The Clinical Impact
of DSA: Management of Sensitized Heart Transplant Recipient.” Prague, Czech Republic, April 18, 2012.
Invited Speaker, International Society of Heart and Lung Transplantation 32st Scientific Annual Meeting and Scientific
Sessions Concurrent Abstract Session 26: Heart Transplant Immunosuppression: What Can We Learn from Clinical Trials.
“Multi-Center Randomized Trial of Eveorlimus vs. Mycophenolate Mofetil in Heart Transplantation: Final 24-Month
Analysis of Efficacy and Safety.” Prague, Czech Republic, April 19, 2012.
Invited Co-Chair, International Society of Heart and Lung Transplantation 32st Scientific Annual Meeting and Scientific
Sessions Concurrent Abstract Session 42: Featured Abstracts. Prague, Czech Republic, April 20, 2012.
Invited Speaker, Cedar-Sinai Medical Grand Rounds, “Advances in Heart Transplantation.” Cedars-Sinai Medical Center,
Los Angeles, CA, May 4, 2012.
Course Director and Speaker, Optimal Care and New Therapies for Advanced Heart Disease. “Heart Transplantation: State
of the Art Management.” California Heart Center at the Cedars-Sinai Heart Institute Continuing Medical Education
Symposium, Crown Plaza Hotel, Ventura, CA, May 12, 2012.
Invited Speaker, American Transplant Congress 2012. Joint Plenary Session II: Heart Transplant Immunosuppression:
“Effect of Everolimus Based Immunosuppression on De Novo Heart Transplant Recipient: 24-Months Efficacy and Safety
Results from A2310 Study” John B. Hynes Convention Center, Boston, MA, June 4, 2012.
Invited Speaker, American Transplant Congress 2012. Luncheon Workshop: Meet the Experts: Practical Approach to
Circulating Antibodies for Patients Awaiting Heart Transplantation…or Making Sense of the Sensitized Patient. John B.
Hynes Convention Center, Boston, MA, June 5, 2012.
Invited Speaker, American Transplant Congress 2012. Concurrent Session 44: Heart: Post-Operative Outcomes and
Allosensitization. “Are Sensitized VAD Patients Similar to Sensitized Non-VAD Patients in Terms of Outcomes” John B.
Hynes Convention Center, Boston, MA, June 5, 2012.
28
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
Course Chair and Moderator, Success with Failure: The Nursing Perspective of Heart Failure, Mechanical Circulatory
Support and Cardiac Transplantation. Opening Plenary Session. California Heart Center Foundation at the Cedars-Sinai
Heart Institute Continuing Medical Education Symposium, Universal Hilton, Los Angeles, CA, June 7, 2012.
Course Chair and Speaker, Success with Failure: The Nursing Perspective of Heart Failure, Mechanical Circulatory Support
and Cardiac Transplantation, “Heart Transplantation: Then and Now.” California Heart Center Foundation at the CedarsSinai Heart Institute Continuing Medical Education Symposium, Universal Hilton, Los Angeles, CA, June 7, 2012.
Invited Speaker, Current Clinical Issues in Primary Care. Session 7: Common Problems in Ambulatory Care. “Approach to
the Patient with Syncope.” Anaheim Convention Center, Anaheim, CA, April 13, 2012.
Moderator, Immunosuppression in Heart Transplantation. 24th International Congress of the Transplantation
Society. International Congress Center, Berlin, Germany, July 17, 2012.
Invited Speaker, Immunotherapy after Heart and Lung Transplantation. “Sensitized Patients, Diagnosis and
Therapy of Antibody-Mediated Rejection.” International Congress Center, Berlin, Germany, July 18, 2012
Invited Speaker. Clinical Fundamentals: Options for Advanced Heart Failure and Clinical Pearls. “Cardiac Transplantation:
Individualizing Immune Suppression.” Heart Failure Society of America Annual Scientific Meeting, Washington State
Convention Center, Seattle, WA, September 12, 2012.
Course Director and Speaker. Optimal Care and New Therapies for Advanced Heart Disease. “Heart Transplantation: State
of the Art Management.” California Heart Center at the Cedars-Sinai Heart Institute Continuing Medical Education
Symposium, Riverside Marriott, Riverside, CA, September 15, 2012.
Invited Speaker. 2012 Louis Eni Visiting Professorship. “Advances in Heart Transplantation: Promises of Tomorrow.”
Drexel University, Philadelphia, PA, October 3, 2012.
Invited Interviewee. “Selecting Options For The Patient with Advanced Heart Failure: Is Transplant Still An Option?”
ACCEL Interview at the American College of Cardiology Conference, Los Angeles, CA, November 6, 2012.
Invited Speaker. “Selecting Options For The Patient with Advanced Heart Failure: Is Transplant Still An Option?”
American Heart Association Annual Scientific Meeting, Los Angeles Convention Center, Los Angeles, CA, November 6,
2012.
Planning Committee Member. American Transplant Congress 2013 Planning Meeting. New Orleans, LA, January 16-18,
2013.
Invited Speaker. American Society of Transplantation: Cutting Edge of Transplantation Meeting. Speed Roundtable
Discussions and Dinner: “Best Treatments for AMR.” Phoenix, AZ, February 15, 2013.
Invited Speaker. American Society of Transplantation: Cutting Edge of Transplantation Meeting. Controversies in
Antibodies in Transplantation: “What Is the Importance of Antibodies and AMR in Heart Transplantation?” Phoenix, AZ,
February 16, 2013.
Presenter. American Society of Transplantation: Cutting Edge of Transplantation Meeting. Controversies in Antibodies in
Transplantation: “ATG Induction Improves Outcome for Sensitized Patients Who Have Undergone Heart
Transplantation.” Phoenix, AZ, February 16, 2013.
Invited Speaker, “Don’t Forget the Science! How to Balance a Career in Investigation and Clinical Heart Failure.” American
College of Cardiology 2013 Symposium: Careers in Heart Failure and Transplant, San Francisco, CA, March 9, 2013.
Cardiology Grand Rounds: Advances in Heart Transplantation. UT Southwestern Medical Center, March 27, 2013.
Chair. International Society for Heart and Lung Transplantation: 33rd Annual Meeting and Scientific Sessions.
Primary Graft Dysfunction Consensus Conference. Palais des Congres, Montreal, Canada, April 23, 2013.
Presenter. International Society for Heart and Lung Transplantation: 33 rd Annual Meeting and Scientific Sessions.
Concurrent Session 8: Heart 3: Coronary Artery Vasculopathy in 2013- Diagnosis, Prognosis and Treatment.
“Change in Maximum Intimal Thickness with Everolimus-Based Immunosuppression after Heart Transplantation
in Patients at Increased Risk of Cardiac Allograft Vasculopathy.” Palais des Congres, Montreal, Canada, April 25,
2013.
29
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
Presenter. International Society for Heart and Lung Transplantation: 33 rd Annual Meeting and Scientific Sessions.
Poster Session 2: Heart Diagnostics/Therapeutics. “Results of a Randomized Trial of Allomap vs. Heart Biopsy in
the 1st Year after Heart Transplant: Early Invasive Monitoring Attenuation through Gene Expression Trial.” Palais
des Congres, Montreal, Canada, April 25, 2013.
Presenter. International Society for Heart and Lung Transplantation: 33rd Annual Meeting and Scientific Sessions.
Concurrent Session 20: Heart 5: Advances in Interpretation of Cardiac Allograft Immune Activation. “Cylex
Scores May Predict Risk for Infection in the First Year Following Heart Transplantation.” Palais des Congres,
Montreal, Canada, April 26, 2013.
Invited Speaker. International Society for Heart and Lung Transplantation: 33 rd Annual Meeting and Scientific
Sessions. ISHLT and AST Joint Session II: Antibody-Mediated Rejection: State of the “Current” Art. “Treatment
Strategies in AMR in Thoracic Transplantation.” Palais des Congres, Montreal, Canada, April 26, 2013.
Invited Speaker. International Society for Heart and Lung Transplantation: 33 rd Annual Meeting and Scientific
Sessions. Plenary Session: From Bench to Bedside. “ISHLT Consensus Conference Report: Primary Graft Failure
in Heart Transplantation.” Palais des Congres, Montreal, Canada, April 27, 2013.
Invited Speaker, Pri-Med West 2013. “A Clinical Approach to Heart Failure Treatments”. Anaheim, CA, May 7,
2013.
Invited Speaker, Optimal Care and New Therapies for Advanced Heart Disease. “Heart Transplantation: State of
the Art Management”. Hyatt Regency, Long Beach, CA, May 11, 2013
Moderator: Optimal Care and New Therapies for Advanced Heart Disease. “Morning Session”. Hyatt Regency,
Long Beach, CA, May 11, 2013.
Invited Speaker, 6th Greater Milwaukee Heart Failure Society Lecture Series. “Surveillance and Treatment for
Rejection after Heart Transplantation”. Milwaukee, Wisconsin.
Moderator. Advances in Cardiac Transplantation. American Transplant Congress. Seattle, Washington, May 19,
2013.
Presenter. American Transplant Congress. Concurrent Session 19: Predicting Rejection and Outcomes: Cells and
Antibodies. “Poor Outcomes in Non-Sensitized Patients Developing de Novo Circulating Antibodies after Heart
Transplantation.” Washington State Convention Center, Seattle, Washington, May 19, 2013.
Presenter. American Transplant Congress. Concurrent Session 28: Medications and Outcomes in Heart
Transplantation. “North American Results from the Multicenter Randomized Trial of Everolimus vs.
Mycopheonlate Mofetil in Heart Transplantation.” Washington State Convention Center, Seattle, Washington,
May 20, 2013.
Presenter. American Transplant Congress. Concurrent Poster Session D: Late Breaking. “Intravascular Ultrasound
(IVUS) Results of a Randomized Trial of Allomap vs. Heart Biopsy in the First Year After Heart Transplant.”
Washington State Convention Center, Seattle, Washington, May 21, 2013.
Invited Speaker, 40th Annual UCLA Family Practice Refresher Course. “Atrial Fibrillation Update: 2013.” Hyatt
Regency, Los Angeles, California, May 24, 2013.
Invited Speaker, Medical Grand Rounds. “ Advances in Heart Transplantation”. Cedars-Sinai Medical Center.
Los Angeles, CA, June 28, 2013.
Invited Speaker, 6th International Symposium for Innovations and New Treatment Strategies in Heart Failure.
“Improving Survival During Heart Transplantation: Diagnosis of AMR and Techniques for the Prevention of
Graft Injury”. Split, Croatia, September 10 & 11, 2013.
Chair, 6th International Symposium for Innovations and New Treatment Strategies in Heart Failure. “Elderly
Heart Failure Population”. Krakow, Poland, September 13th, 2013.
Chair, 6th International Symposium for Innovations and New Treatment Strategies in Heart Failure. “Acute
Rejection”. Krakow, Poland, September 14th, 2013.
30
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
Invited Speaker, Heart Failure Society of America 17th Annual Scientific Meeting. “Desensitization Strategies for
Allosensitized Patients”. Orlando, Florida, September 24, 2013.
Course Director, Experts in MCS Therapy: Current State of the Art. Century City, CA, September 2, 2013.
Invited Speaker, Experts in MCS Therapy: Current State of the Art. “Management of Sensitized MCS Patients
Awaiting Heart Transplantation”. Century City, CA, September 2, 2013.
Conference Chair, Forum on U.S. Heart Allocation Policy. Dallas, Texas, November 15, 2013.
Invited Speaker, American Heart Association Scientific Sessions 2013. “Don’t Be So Sensitive: Is Desensitization
Therapy Necessary”. Dallas Convention Center, Dallas, Texas, November 17, 2013.
Moderator, Controversies in Heart Failure Therapy Section. 24th Annual Meeting of the California ACC:
Controversies & Advances in the Treatment of Cardiovascular Disease. Beverly Hills Hotel, Beverly Hills, CA,
November 21 & 22, 2013.
Invited Speaker, Advances in Heart Failure Therapy: Where Are We Now? 24th Annual Meeting of the California
ACC: Controversies & Advances in the Treatment of Cardiovascular Disease. Beverly Hills Hotel, Beverly Hills,
CA, November 21 & 22, 2013.
Speaker, “Current Update in Heart Transplant” Patient Education Series, Los Angeles, California, December 5th,
2013.
Invited Speaker, Cardiology Grand Rounds. Advances in Heart Transplant. University of California – Los
Angeles Harbor Medical Center, Torrance, CA, February 4, 2014.
Invited Speaker, Cedars-Sinai Surgical Grand Rounds. Current State of Heart Transplant. Cedars-Sinai Medical
Center, Los Angeles, CA, February 12, 2014.
Invited Speaker, Primary Graft Dysfunction. AlloMap® Medical Advisory Board Meeting, Los Angeles Airport
Marriot, Los Angeles, CA, February 17, 2014.
Invited Speaker, Review of eIMAGE. AlloMap® Medical Advisory Board Meeting, Los Angeles Airport Marriot,
Los Angeles, CA, February 17, 2014.
Invited Interviewee, Heart to Heart Conversation. SLS Hotel, Beverly Hills, CA, February 25, 2014.
Invited Speaker, Pri-Med Symposium: Current Clinical Issues in Primary Care “Approach to the Patient with Syncope.”
UCLA, Anaheim, CA, March 28, 2014.
Co-Chair, Cardiorenal Syndrome: Tip of an Iceberg? American College of Cardiology 63 rd Annual Scientific
Sessions & Expo, Washington, DC, March 29-31, 2014.
Participant, When to Consider other Organ Transplantations with Cardiac Transplantations? American College of
Cardiology 63rd Annual Scientific Sessions & Expo, Washington, DC, March 29-31, 2014.
Invited Speaker, Heart Failure and Transplant: Where will We Be in 2024? International Society of Heart and
Lung Transplantation 34th annual Meeting & Scientific Sessions, San Diego, CA, April 10-13, 2014
Invited Speaker, Sensitized VAD Patients Awaiting Heart Transplantation: Are They Different? International
Society of Heart and Lung Transplantation 34th annual Meeting & Scientific Sessions, San Diego, CA, April 10-13,
2014
Invited Speaker, Long-term Care of Heart Transplant Recipients. International Society of Heart and Lung
Transplantation 34th annual Meeting & Scientific Sessions, San Diego, CA, April 10-13, 2014
Invited Speaker, “Management of Heart Failure”. UCLA Family Practice Refresher Course, Hyatt Hotel, Century
City, May 20, 2014.
Speaker, “Current Update in Heart Transplant” Patient Education Series, Los Angeles, California, May 29th, 2014.
31
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
Speaker, Welcome and Introductory Remarks. Bakersfield Heart Hospital – Heart Failure Preceptorship, CedarsSinai Medical Center, Los Angeles, California, May 30, 2014.
Course Director, Bakersfield Heart Hospital – Heart Failure Preceptorship, Cedars-Sinai Medical Center, Los
Angeles, California, May 30, 2014
Invited Speaker, Advances in Heart Failure Treatment: Looking to the Future. Bakersfield Heart Hospital – Heart
Failure Preceptorship, Cedars-Sinai Medical Center, Los Angeles, California, May 30, 2014.
Invited Speaker, eIMAGE data; AlloMap/AMR patients. Intermountain Med Center. University of Utah/VA;
Primary Children’s Hospital, Salt Lake City, Utah, June 2, 2014.
Invited Speaker, “The Future of Organ Transplantation”. 3rd National Congress of Spanish Society of
Transplantation, Valencia, Spain, June 8, 2014.
Invited Speaker, “Statins in Organ Transplantation”. 3rd National Congress of Spanish Society of Transplantation,
Valencia, Spain, June 8, 2014.
Invited Speaker, “Hear Transplantation and the Cedars-Sinai Medical Center”. Trade Commissioners Networking
Group. Cedars-Sinai Medical Center, Los Angeles, California, July 23, 2014.
Invited Speaker, “MCS Total Artificial Support”. 10th Annual Conference of American Association of Heart
Failure Nurses, Los Angeles, California, June 27, 2014.
Invited Speaker, “Heart Transplantation Multidisciplinary Panel: When to Refer, Patient/Donor Selection,
Immunosuppression Overview”. 10th Annual Conference of American Association of Heart Failure Nurses, Los
Angeles, California, June 27, 2014.
Invited Speaker, “Looking Forward, Understanding, and Limiting the Long-term Consequences of Cardiac
Antibody Mediated Rejection”. World Transplant Congress, San Francisco, California, July 27, 2014.
Invited Speaker, “State of the Art Symposium - Primary Graft Dysfunction: Definition and Clinical Overview”.
World Transplant Congress, San Francisco, California, July 29, 2014.
Invited Speaker, “Fellows Conference: Advances in Heart Transplantation”. Grand Rounds, Queens Hospital,
Honolulu, Hawaii, October 10, 2014.
Invited Speaker, “Advances in Heart Transplantation”. Surgical Alternatives in Advanced Heart Failure.
Honolulu, HI. October 11, 2014, Honolulu, Hawaii.
Course Chair, Visiting Professorship, Queens Hospital, Honolulu, Hawaii. October 10, 2014
Invited Speaker, “Management of Primary Graft Dysfunction Following Transplant”. 16th Annual Heart Failure
Summit. Cleveland Clinic, Cleveland, Ohio, October 17, 2014
Invited Speaker, “Advances in Heart Transplantation”. Grand Rounds, University of Pittsburg Medical Center,
Pittsburg, Pennsylvania. November 4, 2014.
Moderator, Don’t Go Rejecting My Heart: Management Considerations in Heart Transplantation. American
Heart Association Scientific Sessions 2014. November 18, 2014
Invited Speaker, “Immune Monitoring: Thinking Outside the Box”. American Heart Association Scientific
Sessions 2014. November 18, 2014.
Program Director, Controversies & Advances in the Treatment of Cardiovascular Disease. Montage Beverly Hills,
Beverly Hills, California. November, 20-21, 2014.
Invited Discussant, “HeartMate II vs. HeartWare: Which is Better?”. Controversies & Advances in the Treatment
of Cardiovascular Disease. Montage Beverly Hills, Beverly Hills, California. November, 20, 2014.
32
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
Invited Speaker, “Recreational Marijuana is Not a Contraindication for Heart Transplantation”. Controversies &
Advances in the Treatment of Cardiovascular Disease. Montage Beverly Hills, Beverly Hills, California.
November, 20, 2014.
Invited Speaker, “Advances in Heart Transplantation”. Surgery Grand Rounds, Cedars-Sinai Medical Center, Los
Angeles, California. November 26, 2014.
Chairman, Heart Allocation Policies: The Times They Are A-Changin', International Society for Heart and Lung
Transplantation. Nice, France, April 15th, 2015.
Invited Speaker, “Use of AlloMap in the AMR Era: Application of EIMAGE Results and Cedars-Sinai
Experience”. International Society for Heart and Lung Transplantation. Nice, France, April 16th, 2015.
Invited Speaker, “Use of Cell-free DNA in the Detection of Heart Transplant Rejection (and New Findings with
AlloMap)”. International Society for Heart and Lung Transplantation. Nice, France, April 16 th, 2015.
Chairman, Allomap Scientific Symposium, International Society for Heart and Lung Transplantation. Nice,
France, April 16th, 2015.
Discussant, Heart Transplantation Poster Session, International Society for Heart and Lung Transplantation.
Nice, France, April 16th, 2015.
Invited Speaker, “The Timecourse Development of Anti-HLA Antibodies Following Heart Transplantation”. International
Society for Heart and Lung Transplantation. Nice, France, April 17th, 2015.
Chairman, Consensus Conference on Donor Heart Selection and Management, American Transplant Congress,
Philadelphia, Pennsylvania, May 1st, 2015.
Chairman, Discussion Forum on US Heart Allocation Policy, American Transplant Congress. Philadelphia,
Pennsylvania, May 4th, 2015.
Invited Speaker, “Current Immune Monitoring in Heart Transplantation: Allomap, ImmuneKnow, Others (BNP,
CRP, Troponin) - Advantages and Limitation”. American Transplant Congress. Philadelphia, Pennsylvania, May
2nd, 2015.
Invited Speaker, “Plasma Levels of Donor-Derived Cell-Free DNA Increase With Rejection and Often Decrease
After Treatment in Organ Transplant Recipients”. American Transplant Congress, Plenary Session II.
Philadelphia, Pennsylvania, May 4th, 2015.
Invited Speaker, “Natural History of Anti- Human Leukocyte Antigen Antibodies After Hear Transplant”.
American Transplant Congress. Philadelphia, Pennsylvania, May 4th, 2015.
Moderator, When Transplanting a Heart is Not Enough - The Role of Dual Organ Transplantation
American Transplant Congress. Philadelphia, Pennsylvania, May 4th, 2015.
Moderator, Antibodies in Thoracic Transplantation - Shedding New Light on the Subject . Philadelphia, Pennsylvania,
May 4th, 2015.
Invited Speaker, “Leading edge science and technology in advanced heart disease”. 2015 Health Seminar Lecture sponsored
by the Joint Chinese University Alumni Association, El Monte, CA, August 18th, 2015.
P U B L I CA T I O N S : J O U R NA L S
1.
Stevenson LW, Dadourian BJ, Kobashigawa J, Child JS, Clark SH, Laks H. Mitral regurgitation after
cardiac transplantation. Am J Cardiol 1987;60:119-22.
33
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
2.
Kobashigawa J, Stevenson LW, Moriguchi J, Westlake C, Wilmarth J, Kawata N, Chuck C, Lewis W,
Drinkwater D, Laks H. Randomized study of high dose oral cyclosporine therapy for mild acute cardiac
rejection. J Heart Lung Transplant 1989;8:53-8.
3.
Walden JA, Stevenson LW, Dracup K, Wilmarth J, Kobashigawa J, Moriguchi J. Heart transplantation
may not improve quality of life for patients with stable heart failure. Heart Lung 1989;18:497-506.
4.
Stevenson LW, Sietsema K, Tillisch JH, Lem V, Walden J, Kobashigawa JA, Moriguchi J. Exercise
capacity for survivors of cardiac transplantation or sustained medical therapy for stable heart failure.
Circulation 1990;81:78-85.
5.
Martin SM, Laks H, Drinkwater DC, Warner-Stevenson L, Kawata N, Kobashigawa JA, Moriguchi JD,
Hamilton MA. Cardiac transplantation: the UCLA experience 1984 to 1990. Clin Transpl 1990;103-14.
6.
Kobashigawa JA, Murphy FL, Stevenson LW, Moriguchi JD, Kawata N, Kamjoo P, Brownfield E,
Wilmarth J, Leonard L, Chuck C, Drinkwater DC, Laks H. Low-dose lovastatin safely lowers
cholesterol after cardiac transplantation. Circulation 1990;82:281-3.
7.
Stevenson LW, Tillisch JH, Hamilton MA, Luu M, Chelimsky-Fallick C, Moriguchi J, Kobashigawa J,
Walden J. Importance of hemodynamic response to therapy in predicting survival with ejection fraction
less than or equal to 20% secondary to ischemic or nonischemic dilated cardiomyopathy. Am J Cardiol
1990; 66:1348-54.
8.
Stevenson LW, Hamilton MA, Tillisch JH, Moriguchi JD, Kobashigawa JA, Creaser JA, Drinkwater
DC, Laks H. Decreasing survival benefit from cardiac transplantation for outpatients as the waiting list
lengthens. J Am Coll Cardiol 1991;18:919-25.
9.
Cates J, Chavez M, Laks H, Drinkwater D, Stevenson L, Kobashigawa J, Saunders K, Abedin M,
Roslyn J. Gastrointestinal complications after cardiac transplantation: a spectrum of diseases. Am J
Gastroenterol 1991;86:412-16.
10.
Krivokapich J, Stevenson LW, Kobashigawa J, Huang SC, Schelbert HR. Quantification of absolute
myocardial perfusion at rest and during exercise with positron emission tomography after human cardiac
transplantation. J Am Coll Cardiol 1991;18:512-17.
11.
Kobashigawa JA, Stevenson LW, Brownfield ED, Moriguchi JD, Kawata N, Fandrich R, Drinkwater
DC, Laks H. Initial success of steroid weaning late after heart transplantation. J Heart Lung Transplant
1992;11:428-30.
12.
Stevenson LW, Warner SL, Hamilton MA, Moriguchi JD, Chelimsky-Fallick C, Fonarow GC,
Kobashigawa J, Drinkwater DC, Laks H. Modeling distribution of donor heart to maximize early
candidate survival. Circulation 1992;86:224-30.
13.
Stevenson LW, Warner SL, Kobashigawa JA, Drinkwater DC, Laks H. Modeling a solution to the
waiting list crisis. J Heart Lung Transplant 1992; in press.
14.
Chelimsky-Fallick C, Stevenson LW, Middlekauff HR, Stevenson WG, Kobashigawa J, Saxon LA,
Moriguchi J, Brownfield ED, Hamilton MA, Drinkwater D, Laks H, et al. Amiodarone therapy does not
compromise subsequent heart transplantation. J Am Coll Cardiol 1992;20:1556-61.
15.
Ardehali A, Laks H, Drinkwater DC, Ziv ET, Sorensen TJ, Hamilton MA, Warner-Stevenson L,
Moriguchi JD, Kobashigawa JA. Cardiac transplantation at UCLA. Clin Transp 1993:119-27.
16.
Kobashigawa JA, Stevenson LW, Brownfield ED, Moriguchi JD, Kawata N, Hamilton M, Minkley R,
Drinkwater D, Laks H. Does short-course induction with OKT3 improve outcome after heart
transplantation? A randomized trial. J Heart Lung Transplant 1993;12:205-8.
17.
Kobashigawa JA, Stevenson LW, Moriguchi JD, Kawata N, Brownfield E, Drinkwater DC, Laks H. Is
intravenous glucocorticoid therapy better than an oral regimen for asymptomatic cardiac rejection? A
randomized trial. J Am Coll Cardiol 1993;21:1142-4.
34
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
18.
Kobashigawa JA, Kirklin JK, Naftel DC, Bourge RC, Ventura HO, Mohanty PK, Cintron GB, Bhat G.
Pretransplantation risk factors for acute rejection after heart transplantation: a multi-institutional study.
The Transplant Cardiologists Research Database Group. J Heart Lung Transplant 1993;12:355-66.
19.
Kobashigawa JA, Warner-Stevenson L, Johnson BL, Moriguchi JD, Kawata N, Drinkwater DC, Laks
H. Influenza vaccine does not cause rejection after cardiac transplantation. Transplant Proc 1993;25:27389.
20.
Kobashigawa JA, Stevenson LW. Postoperative treatment of heart transplant recipients. (Review
article). J Crit Illness 1993;8:607-15.
21.
Kobashigawa JA, Stevenson LW. Managing complications in heart transplant recipients. Improve
techniques and medications increase survival rates. J Crit Illness 1993;8:678-9 (review).
22.
Laks H, Gates RN, Ardehali A, Capouya ER, Moriguchi JD, Kobashigawa JA, Stevenson LW.
Orthotopic heart transplantation and concurrent coronary bypass. J Heart Lung Transplant 1993;12:81015.
23.
Miller LW, Schlant RC, Kobashigawa J, Kubo S, Renlund DG. 24th Bethesda Conference: Cardiac
Transplantation. Task Force Complications. J Am Coll Cardiol 1993;22:41-54.
24.
Stevenson LW, Warner SL, Steimle AE, Fonarow GC, Hamilton MA, Moriguchi JD, Kobashigawa JA,
Tillisch JH, Drinkwater DC, Laks H. The impending crisis awaiting cardiac transplantation. Modeling
solution based on selection. Circulation 1994;89:450-7.
25.
Chan SY, Kobashigawa J, Stevenson LW, Brownfield E, Brunken RC, Schelbert HR. Myocardial
blood flow at rest and during pharmacological vasodilation in cardiac transplants during and after
successful treatment of rejection. Circulation 1994;90:204-12.
26.
Kobashigawa JA. Can we prevent CMV disease after heart transplantation? J Critical Illness 1994;9:907.
27.
Ardehali A, Laks H, Drinkwater DC, Kobashigawa JA, Moriguchi JD, Drake TA. Vascular cell
adhesion molecule-1 (VCAM-1) up-regulation precedes and predicts cellular rejection of human cardiac
allografts. Am Coll Surgeons 1994;45:312-14.
28.
Kobashigawa JA, Stevenson LW, Brownfield ED, Gleeson MP, Moriguchi JD, Kawata N, Minkley R,
Drinkwater DC, Laks H. Corticosteroid weaning late after cardiac transplantation: relation to HLA-DR
mismatching and long-term metabolic benefits. J Heart Lung Transplant 1995;14:963-7.
29.
Kobashigawa JA, Katznelson S, Laks H, Johnson JA, Yeatman L, Wang XM, Chia D, Terasaki PI,
Sabad A, Cogert GA, Trosian K, Hamilton MA, Moriguchi JD, Kawata N, Hage A, Drinkwater DC,
Stevenson LW. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med
1995;333:621-7.
30.
Katznelson S, Kobashigawa JA. Dual roles of HMG-CoA reductase inhibitors in solid organ
transplantation: lipid lowering and immunosuppression. Kidney Int Suppl 1995;52:S112-5 (review).
31.
Kobashigawa JA. Invited Commentary: Optimal timing and indications for cholecystectomy in cardiac
transplant patients. World J Surg 1995 Jul-Aug;19(4):661-7.
32.
Johnson JA, Kobashigawa JA. Quantitative analysis of transplant coronary artery disease with use of
intracoronary ultrasound. J Heart Lung Transplant 1995;14:S198-202.
33.
Kobashigawa JA, Miller L, Yeung A, Hauptman P, Ventura H, Wilensky R, Valantine H, Weidermann
J. Does acute rejection correlate with the development of transplant coronary artery disease? A
multicenter study using intravascular ultrasound. Sandoz/CVIS Investigators. J Heart Lung Transplant
1995;14:S221-6.
34.
Yeung AC, Davis SF, Hauptman P, Kobashigawa JA, Miller LW, Valantine HA, Ventura HO,
Wiedermann J, Wilensky R. Incidence and progression of transplant coronary artery disease over 1 year:
results of a multicenter trial with use of intravascular ultrasound. Multicenter Intravascular Ultrasound
Transplant Study Group. J Heart Lung Transplant 1995;14:S215-20.
35
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
35.
Johnson JA, Kobashigawa JA. Methodology of quantitating intracoronary ultrasound. J Am Coll
Cardiol 1995;26:303-4.
36.
Miller L, Kobashigawa J, Valantine H, Ventura H, Hauptman P, O'Donnell J, Wiedermann J, Yeung A.
The impact of cyclosporine dose and level on the development and progression of allograft coronary
disease. Sandoz/CVIS Investigators. J Heart Lung Transplant 1995;14:S227-34.
37.
Johnson JA, Kobashigawa JA. Quantitating serial intracoronary ultrasound. Circulation 1995;92:3363-4.
38.
Drinkwater DC, Rudis E, Laks H, Ziv E, Marino J, Stein D, Ardehali A, Aharon A, Moriguchi J,
Kobashigawa J. University of Wisconsin solution versus Stanford cardioplegic solution and the
development of cardiac allograft vasculopathy. J Heart Lung Transplant 1995;14:891-6.
39.
Kobashigawa JA, Laks H, Drinkwater DC, Hamilton MA, Moriguchi JD, Fonarow G, Blitz A, Hage A,
Kawata N. The University of California at Los Angeles experience in heart transplantation. Clin Transpl
1995;129-35.
40.
Kobashigawa JA. Letter to the Editor: Drugs in Cardiac Transplantation. N Engl J Med 1996.
41.
Kobashigawa JA. Early and late complications in the elderly heart transplant recipient. (Review article).
Cardiology in the Elderly 1996;4:15-21.
42.
Kobashigawa JA. Coronary artery disease in the transplanted heart: What causes it and what can we do
about it? Cardiology in Review 1996;4:216-25.
43.
Kobashigawa JA, Sabad A, Drinkwater DC, Cogert GA, Moriguchi JD, Kawata N, Hamilton MA,
Hage A, Terasaki P, Laks H. Pretransplant panel reactive-antibody screens: Are they truly a marker for
poor outcome after cardiac transplantation? Circulation 1996;94:II294-7.
44.
Drinkwater DC, Laks H, Blitz A, Kobashigawa J, Sabad A, Moriguchi J, Hamilton M. Outcomes of
patients undergoing transplantation with older donor hearts. J Heart Lung Transplant 1996;15:684-91.
45.
Katznelson S, Wilkinson AH, Kobashigawa JA, Wang XM, Chia D, Ozawa M, Zhong HP, Hirata M,
Cohen AH, Terasaki PI, Danovitch G. The effect of pravastatin on acute rejection after kidney
transplantation--a pilot study. Transplantation 1996;61:1469-74.
46.
Johnson C, Takemoto SK, Cecka JM, Kobashigawa JA, Terasaki PI. Detection of cardiac allograft
rejection for Flow Cytometry. Hum Immunology 1997;55:suppl 67.
47.
Kofoed KF, Czernin J, Johnson J, Kobashigawa J, Phelps ME, Laks H, Schelbert HR. Effects of
cardiac allograft vasculopathy on myocardial blood flow, vasodilator capacity, and coronary vasomotion.
Circulation 1997;95:600-6.
48.
Kobashigawa JA, Kasiske BL.
1997;63:331-8 (review).
49.
Leaf DA, Kobashigawa J, Gleeson M, Laks H. Defining obesity in patients undergoing orthotopic
heart transplantation: body mass index versus percent body fat. J Heart Lung Transplant 1997; 16:563-5.
50.
Kobashigawa JA. Targeting non-alloimmune dependent pathways. Transplant Proc 1997;29(8A):47S-50S
(review).
51.
Kobashigawa JA. Treatment of non-hemodynamic compromising rejection: conventional approaches
vs. individualization/new immunosuppressive drugs. Transplant Proc 1997;29(8A):37S-39S (review).
52.
Laks H, Scholl FG, Drinkwater DC, Blitz A, Hamilton M, Moriguchi J, Fonarow GC, Kobashigawa J.
The alternate recipient list for heart transplantation: does it work? J Heart Lung Transplant 1997;16:73542.
53.
Johnson MR, Naftel DC, Hobbs RE, Kobashigawa JA, Pitts DE, Levine TB, Tolman D, Bhat G,
Kirklin JK, Bourge RC. The incremental risk of female sex in heart transplantation: a multi-institutional
Hyperlipidemia in solid organ transplantation.
36
Transplantation
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
study of peripartum cardiomyopathy and pregnancy. Cardiac Transplant Research Database Group. J
Heart Lung Transplant 1997;16:801-12.
54.
Wang XM, Zhong HP, Takemoto SK, Kobashigawa J, Cecka JM, Terasaki PI. A bioassay that
measures sensitivity of resistance to immunosuppression. Hum Immunology 1998;59:suppl 113.
55.
Kobashigawa JA, Miller L, Renlund DG, Mentzer R, Alderman E, Bourge R, Costanzo M, Eisen H,
Dureau G, Ratkovec R, Hummel M, Ipe D, Johnson J, Keogh A, Mamelok R, Mancini D, Smart F,
Valantine H. A randomized active-controlled trial of mycophenolate mofetil in heart transplant
recipients. Mycophenolate Mofetil Investigators. Transplantation 1998;66(4):507-15.
56.
Kobashigawa JA, Laks H, Marelli D, Moriguchi JD, Hamilton MA, Fonarow G, Hage A, Kawata N.
The University of California at Los Angeles experience in heart transplantation. Clin Transpl 1998;:30310.
57.
Katznelson S, Wang XM, Chia D, Ozawa M, Zhong HP, Hirata M, Terasaki PI, Kobashigawa JA.
The inhibitory effects of pravastatin on natural killer cell activity in vivo and on cytotoxic T lymphocyte
activity in vivo. J Heart Lung Transplant 1998;17:335-40.
58.
Kobashigawa JA. Mycophenolate mofetil in cardiac transplantation. Curr Opin Cardiol 1998;13:117-21.
59.
Navab M, Hama SY, Van Lenten BJ, Hough GP, Hedrick CC, Sorenson R, La Du BN, Kobashigawa
JA, Fonarow GC, Berliner JA, Laks H, Fogelman AM. High density associated enzymes: their role in
vascular biology. Curr Opin Cardiol 1998;9:449-56.
60.
Kobashigawa JA.
1998;10:155-74.
61.
Kobashigawa JA. Controversies in heart and lung transplantation immunosuppression: tacrolimus
versus cyclosporine. Transplant Proc 1998;30:1095-7.
62.
Gebel HM, Takemoto SK, Mancini M, Costanzo MR, Kobashigawa JA, Roggero AL, Ortegal JW,
Cecka JM, Tambur AR. Pre and post-transplant detection of class I and class II antibodies to predict
cardiac allograft rejection. Hum Immunology 1999;60:s14.
63.
Kobashigawa JA, Leaf DA, Lee N, Gleeson M, Liu H, Hamilton MA, Moriguchi JD, Kawata N,
Einhorn K, Herlihy E, Laks H. A controlled trial of exercise rehabilitation after heart transplantation.
N Engl J Med 1999 Jan;340:272-7.
64.
Allen-Auerbach M, Schoder H, Johnson J, Kofoed K, Einhorn K, Phelps ME, Kobashigawa J, Czernin
J. Relationship between coronary function by positron emission tomography and temporal changes in
morphology by intravascular ultrasound (IVUS) in transplant recipients. J Heart Lung Transplant
1999;18:211-19.
65.
Kobashigawa JA. Postoperative management following heart transplantation. Transpl Proc
1999;31:2038-46.
66.
Son R, Tobis JM, Yeatman LA, Johnson JA, Wener LS, Kobashigawa JA. Does use of intravascular
ultrasound accelerate arteriopathy in heart transplant recipients? Am Heart J 1999;138:358-63.
67.
Dulai G, Higa L, Kobashigawa J, Martin P. Successful use of lamivudine for severe acute hepatitis B
virus infection in a cardiac transplant recipient. Transplantation 1999;67:1288-9.
68.
Skotzko CE, Rudis R, Kobashigawa JA, Laks H. Psychiatric disorders and outcome following cardiac
transplantation. J Heart Lung Transplant 1999;18:952-6.
69.
Kobashigawa JA. Treatment of Hyperlipidemia for the Primary Care Physician. Family Practice
Recertification 2000;23:69-88.
70.
Hillel Laks, MD, Daniel Marelli, MD, Daniel Fazio, DS, Jon Kobashigawa, MD. Expanding the heart
donor base. Curr Opin Organ Transplant 2000;5:134-38.
Advances in immunosuppression for heart transplantation.
37
Adv Card Surg
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
71.
Marelli D, Laks H, Fazio D, Moore S, Moriguchi J, Kobashigawa J. The use of donor hearts with left
ventricular hypertrophy. J Heart Lung Transplant 2000;19:496-503.
72.
Michaels PJ, Kobashigawa JA, Child JS, Fishbein MC. Chronic right-sided myocarditis mimicking
arrhythmogenic right ventricular dysplasia. Hum Pathol 2000;31:618-21.
73.
Kobashigawa J, Wener L, Johnson J, Currier JW, Yeatman L, Cassem J, Tobis J. Longitudinal Study of
Vascular Remodeling in Coronary Arteries After Heart Transplantation. J Heart Lung Transplant
2000;19:546-50.
74.
Cui G, Kobashigawa J, Chung T, Sen L. Atrial conduction disturbance as an indicator of rejection
after cardiac transplantation. Transplantation 2000;70:223-7.
75.
Tambur R, Bray RA, Takemoto SK, Mancini M, Costanzo MR, Kobashigawa JA, D'Amico CL, Kanter
KR, Berg A, Vega, JD, Smith AL, Roggero AL, Ortegel JW, Hosey LW, Cecka JM, Gebel HM. Flow
cytometric detection of class I and class II antibodies as a predictor of heart allograft rejection.
Transplantation 2000;70:1055-59.
76.
Marelli D, Laks H, Bresson J, Houston E, Fazio D, Tsai FC, Hamilton M, Moriguchi J, Fonarow GC,
Ardehali A, Camara R, Burch C, Alejos JC, George B, Kawata N, Kobashigawa J. Sixteen-year
experience with 1,000 heart transplants at UCLA. Clin Transpl. 2000; 297-310.
77.
Kobashigawa J. What is the optimal prophylaxis for treatment of cardiac allograft vasculopathy? Curr
Control Trials Cardiovasc Med 2000;1(3):166-171.
78.
Ardehali A, Hughes K, Sadeghi A, Esmailian F, Marelli D, Moriguchi J, Hamilton MA, Kobashigawa J,
Laks H. Inhaled nitric oxide for pulmonary hypertension after heart transplantation. Transplantation
2001; 4: 638-641.
79.
Wong C, Ganz P, Miller L, Kobashigawa J, Schwarzkopf A, Valantine von Kaeper H, Wilensky R,
Ventura H, Yeung AC. Role of vascular remodeling in the pathogenesis of early transplant coronary
artery disease: A multicenter prospective intravascular ultrasound study. J Heart Lung Transplant. 2001
Apr;20(4):385-92.
80.
Michaels PJ, Kobashigawa J, Laks H, Azarbal A, Espejo ML, Chen L, Fishbein MC. Differential
expression of RANTES chemokine, TGF- and leukocyte phenotype in acute cellular rejection and
Quality B lesions. J Heart Lung Transplant 2001 Apr;20(4):407-16.
81.
Kobashigawa J. Research under the United Network for Organ Sharing in the United States. The
Circulation Frontier 2001; 5:45.
82.
Kobashigawa JA. Statins as Immunosuppressive Agents. Liver Transpl 2001 Jun;7(6):559-61.
83.
Cui G, Tung T, Kobashigawa J, Laks J, Sen L. Increased incidence of atrial flutter associated with the
rejection of heart transplantation. Am J Cardiol. 2001 Aug 1:88(3):280-4.
84.
Rose ML, Smith J, Dureau G, Keogh A, Kobashigawa J. Mycophenolate mofetil decreases antibody
production after cardiac transplantation. J Heart Lung Transplant 2002 Feb;21(2):282-5.
85.
Marelli D, Bresson J, Laks H, Kubak B, Fonarow G, Tsai FC, Tran J, Weston SR, Kobashigawa J.
Hepatitis C-positive donors in heart transplantation. Am J Transplant. 2002 May;2(5):443-7.
86.
Fairhurst RM, Kubak BM, Pegues DA, Moriguchi JD, Ha KF, Haley JC, Kobashigawa JA.
Mycobacterium haemophilum infections in heart transplant recipients: case report and review of the
literature. Am J Transplant. 2002 May;2(5);476-9.
87.
Tsai FC, Marelli D, Bresson J, Gjertson D, Kermani R, Patel J, Kobashigawa JA, Laks H. Use of
hearts transplanted from donors with atraumatic intracranial bleeds. J Heart Lung Transplant. 2002 Jun;
21(6):623-8.
88.
Boston AD, Brown RS Jr., Chavers BM, Coffman TM, Cosio FG, Colver K, Cutis JJ, Danovitch GM,
Everson GT, First MR, Garvey C, Grimm R, Hertz MI, Hricik DE, Hunsicker LG, Ibrahim H, Kasiske
38
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
BL, Kennedy M, Klag M, Knatterrud ME, Kobashigawa J, Lake JR, Light JA, Matas AJ, McDiarmid
SV, Miller LW, Payne WD, Rosenson R, Sutherland DE, Tejani A, Textor S, Valantine HA, Wiesner
RH. Prevention of post-transplant cardiovascular disease—report and recommendations of an ad hoc
group. Am J Transplant. 2002 Jul;2(6):491-500.
89.
Tsai FC, Marelli D, Bresson J, Gjertson D, Kermani R, Ardehali A, Esmailiam F, Hamilton M, Fonarow
GC, Moriguchi J, Plunkett M, Hage A, Tran J, Kobashigawa JA, Laks H. Recent trends in early
outcome of adult patients after heart transplantation: a single-institution review of 251 transplants using
standard donor organs. Am J Transplant. 2002 Jul;2(6):539-45.
90.
Pinderski LJ, Fonarow GC, Hamilton M, Fishbein MC, Marelli D, Moriguchi J, Cohen B, Kobashigawa
JA. Giant cell myocarditis in a young man responsive to T-lymphocyte cytolytic therapy. J Heart Lung
Transplant. 2002 Jun;21(6):818-21.
91.
Takano Y, Currier J, Yeatman L, Kobashigawa JA, Rogers A, Cianfichi L, Fishbein MC, Tobis JM.
Cutting Balloon Angioplasty for Cardiac Transplant Vasculopathy. J Heart Lung Transplant 2002
Aug;21(8) 910-913.
92.
Tsai FC, Marelli D, Laks H, Moriguchi J, Sohper M, Bresson J, Moghaddam S, Kubak B, Esmailian F,
Ardehali A, Plunkett M, Litwin P, Kobashigawa J. Short-term bridge to heart transplant using the BVS
5000 external ventricular assist device. Am J Transplant. 2002 Aug;2(7):646-51.
93.
Marelli D, Laks H, Kobashigawa JA, Bresson J, Ardehali A, Esmailian F, Plunkett MD, Kubak B.
Seventeen-Year Experience with 1,083 Heart Transplants at a Single Institution. Society Thorac Surg.
2002;74:1558-67.
94.
Michaels PJ, Espejo ML, Kobashigawa J, Alejos JC, Burch C, Takemoto S, Reed EF, Fishbein MC.
Humoral Rejection in Cardiac Transplantation: Risk Factors, Hemodynamic Consequences and
Relationship to Transplant Coronary Artery Disease. J Heart Lung Transplant. 2003 Jan; 22(1): 58-69.
95.
Deng MC, Young JB, Stevenson LW, Oz MC, Rose EA, Hunt SA, Kirklin JK, Kobashigawa J, Miller
L, Saltzberg M, Konstam M, Portner PM, Kormos R. Destination mechanical circulatory support:
proposal for clinical standards. J Heart Lung Transplant. 2003 Apr; 22(4):365-9.
96.
Gajjar N, Kobashigawa JA, Laks H, Espejo-Vassilakis M, Fishbein MC. FK506 versus cyclosporin:
Pathologic findings in 1067 endomyocardial biopsies. Cardiovasc Pathol. 2003 Apr; 12:73-76.
97.
Marelli D, Kermani R, Bresson, J, Fishbein MC, Hamilton M, Moriguchi J, Fonarow GC, Cohen B,
Kobashigawa JA, Laks H. Support with the BVS 5000 Assist Device during Treatment of Acute
Giant-Cell Myocarditis. Tex Heart Inst J. 2003;30(1):50-6.
98.
Laks H, Marelli D, Fonarow GC, Hamilton MA, Ardehali A, Moriguchi JD, Bresson J, Gjertson D,
Kobashigawa JA. Use of two recipient lists for adults requiring heart transplantation. J Thorac
Cardiovasc Surg 2003;125(1):49-59.
99.
Eisen HJ, Tuzcu EM, Dorent R, Kobashigawa JA, Mancici D, Valentine-von Kaeppler HA, Starling
RC, Sorensen K, Hummel M, Lind JM, Abeywickrama KH, Bernhardt, P. Everolimus for the
Prevention of Allograft Rejection and Vasculopathy in Cardiac Transplant Recipients. N Engl J Med
2003; 349:847-58.
100.
Kao J, Kobashigawa J, Fishbein MC, MacLellan WR, Burdick MD, Belperio JA, Strieter RM. Elevated
serum levels of the CXCR3 chemokine ITAC are associated with the development of transplant
coronary artery disease. Circulation 2003;107(15):1958-61. Epub 2003 Apr 14.
101.
Evangelista LS, Doering LV, Dracup K, Vassilakis ME, Kobashigawa J. Hope, mood states and
quality of life in female heart transplant recipients. J Heart Lung Transplant 2003;22(6):681-6.
102.
Cui G, Kobashigawa J, Margarian A, Sen L. Cause of atrioventricular block in patients after heart
transplantation. Transplantation 2003;76(1):137-42.
103.
Kobashigawa JA. First-year intravascular ultrasound results as a surrogate marker for outcomes after
heart transplantation. J Heart Lung Transplant 2003;22(7):711-4. Review.
39
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
104.
Radovancevic B, McGiffin DC, Kobashigawa JA, Cintron GB, Mullen GM, Pitts DE, O'Donnell J,
Thomas C, Bourge RC, Naftel DC. Retransplantation in 7,290 primary transplant patients: a 10-year
multi-institutional study. J Heart Lung Transplant 2003;22(8):862-8.
105.
Grise MA, Reilly JP, Tobis JM, Takano Y, Currier JW, Kobashigawa JA, Weisz G, Moses JW, Leon
MB, Yeung A, Teirstein PS. Intracoronary radiation to treat in-stent restenosis in six cardiac transplant
patients. Catheter Cardiovasc Interv 2003;60(1):41-4.
106.
Marelli D, Laks H, Patel B, Kermani R, Marmureanu A, Patel J, Kobashigawa J; University of
California at Los Angeles Heart Transplant Group. Heart transplantation in patients with diabetes
mellitus in the current era. J Heart Lung Transplant 2003;22(10):1091-7.
107.
Marelli D, Laks H, Bresson S, Ardehali A, Bresson J, Esmailian F, Plunkett M, Moriguchi J,
Kobashigawa J. Results after transplantation using donor hearts with preexisting coronary artery
disease. J Thorac Cardiovasc Surg 2003;126(3):821-5.
108.
Evangelista LS, Moser D, Dracup K, Doering L, Kobashigawa J. Functional status and perceived
control influence quality of life in female heart transplant recipients. J Heart Lung Transplant
2004;23(3):360-7.
109.
Sung EC, Friedlander AH, Kobashigawa JA. The prevalence of calcified carotid atheromas on the
panoramic radiographs of patients with dilated cardiomyopathy. Oral Surg Oral Med Oral Pathol Oral
Radiol Endod 2004;97(3):404-7.
110.
Patel JK, Kobashigawa JA. Cardiac transplant experience with cyclosporine. Transplant Proc 2004;36(2
Suppl):323S-330S.
111.
Patel JK, Kobashigawa JA. Cardiac transplantation: the alternate list and expansion of the donor pool.
Curr Opin Cardiol 2004;19(2):162-5.
112.
Fishbein MC, Kobashigawa J. Biopsy-negative cardiac transplant rejection: etiology, diagnosis, and
therapy. Curr Opin Cardiol 2004;19(2):166-9.
113.
Reyes CJ, Evangelista LS, Doering L, Dracup K, Cesario DA, Kobashigawa J. Physical and
psychological attributes of fatigue in female heart transplant recipients. J Heart Lung Transplant
2004;23(5):614-9.
114.
Kobashigawa JA. Statins in solid organ transplantation: is there an immunosuppressive effect? Am J
Transplant 2004;4(7):1013-8.
115.
Takemoto SK, Zeevi A, Feng S, Colvin RB, Jordan S, Kobashigawa J, Kupiec-Weglinski J, Matas A,
Montgomery RA, Nickerson P, Platt JL, Rabb H, Thistlethwaite R, Tyan D, Delmonico FL. National
conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant
2004;4(7):1033-41.
116.
Chantranuwat C, Blakey JD, Kobashigawa JA, Moriguchi JD, Laks H, Espejo Vassilakis M, Fishbein
MC. Sudden, unexpected death in cardiac transplant recipients: An autopsy study. J Heart Lung
Transplant 2004;23:683-9.
117.
Phillips M, Boehmer JP, Cataneo RN, Cheema T, Eisen HJ, Fallon JT, Fisher PE, Gass A, Greenberg J,
Kobashigawa J, Mancini D, Rayburn B, Zucker MJ. Heart allograft rejection: detection with breath
alkanes in low levels (the HARDBALL Study). J Heart Lung Transplant 2004;23:701-8.
118.
Mehra MR, Kobashigawa JA. Advances in heart and lung transplantation 2004: report from the 24th
International Society for Heart and Lung Transplantation annual meeting, San Francisco, April 21-24,
2004. J Heart Lung Transplant 2004;23(8):925-30.
119.
Kobashigawa JA. Presidential Address: “International Camaraderie”—Excerpts from the ISHLT 2004
presidential address. J Heart Lung Transplant 2004;23(8):931-2.
40
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
120.
Lindenfeld J, Miller GG, Shakar SF, Zoltry R, Lowes BD, Wolfel EE, Mestroni L, Page RL,
Kobashigawa, J. Drug therapy in the heart transplant recipient. Part I: cardiac rejection and
immunosuppressive drugs. Circulation 2004;110(24):3734-3740.
121.
Phillips M, Boehmer JP, Cataneo RN, Cheema T, Eisen HJ, Fallon JT, Fisher PE, Gass AG, Greenberg
J, Kobashigawa J, Mancini D, Rayburn B, Zucker MJ. Prediction of heart transplant rejection with a
breath test for markers of oxidative stress. Am J Cardiol 2004;1593-4.
122.
Kobashigawa JA. Editorial Overview: Is it time for a noninvasive test to detect cardiac allograft
rejection? Curr Opin Organ Transplant 2004, 9:441-2.
123.
Lindenfeld J, Miller GG, Shakar SF, Zoltry R, Lowes BD, Wolfel EE, Mestroni L, Page RL,
Kobashigawa, J. Drug therapy in the heart transplant recipient. Part II: common medical problems
and drug-drug interactions. Circulation 2004;111(25):3858-65.
124.
Patel J and Kobashigawa JA. Immunosuppression, Diagnosis and Treatment of Cardiac Allograft
Rejection. Semin Thorac Cardiovasc Surg 2004;16(4):378-385.
125.
Subherwal S, Kobashigawa JA, Cogert G, Patel J, Espejo M, Oeser B. Incidence of acute cellular
rejection and non-cellular rejection. Transplant Proc 2004;36(10):3171-2.
126.
Kobashigawa JA. Statins and cardiac allograft vasculopathy
Semin Vasc Med. 2004 Nov;4(4):401-6.
127.
Eisen H, Kobashigawa J, Starling RC, Valantine H, Mancini D. Improving outcomes in heart
transplantation – the potential of proliferation signal inhibitors. Transplant Proc 2005;37(Suppl 4S):4S17S.
128.
Kobashigawa JA, Tobis JM, Starling RC, Tuzcu EM, Smith AL, Valantine HA, Yeung AC, Mehra MR,
Anzai H, Oeser BT, Abeywickrama KH, Murphy J, Cretin N. Multicenter Intravascular Ultrasound
(IVUS) Validation Study Among Heart Transplant Recipients: Outcomes After 5 Years. J Am College of
Cardiology 2005 May 3;45(9):1532-1537.
129.
Kobashigawa J, David K, Morris J, Chu AH, Steffen BJ, Gotz VP, Gordon RD. Daclizumab is
associated with decreased rejection and no increased mortality in cardiac transplant patients receiving
MMF, cyclosporine and corticosteroids. Transplant Proc 2005;37:1333-39.
130.
Evans RW, Willaims GE, Baron HM, Deng MC, Eisen HJ, Hunt SA, Khan MM, Kobashigawa JA,
Marton EN, Mehra MR, Mital SR. The economic implication of noninvasive molecular testing for
cardiac allograft rejection. Am J Transplant 2005;5:1553-1558.
131.
Eisen HJ, Kobashigawa J, Keogh A, Bourge R, Renlund D, Mentzer R, Alderman E, Valantine H,
Dureau G, Mancinin D, Mamelok R, Gordon R, Wang W, Mehra M, Constanzo MR, Hummel M,
Johnson J, Mycophenolate Mofetil Cardiac Study Investigators. Three-year results of a randomized,
double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant
recipients. J Heart Lung Transplant. 2005;24(5):517-25.
132.
Patel JK, Kobashigawa JA. Immunosuppressants in cardiac transplantation. Hosp Pharm Europe 2005
May/June.
133.
Mitropoulos FA, Odim J, Marelli D, Karandikar K, Gjertson D, Ardehali A, Kobashigawa J, Laks H.
Outcome of hearts with cold ischemic time greater than 300 minutes. A case-matched study. Eur J
Cardiothorac Surg. 2005 Jul;28(1):143-8.
134.
Grady K, Naftel D, White-Williams C, Bellg A, Young J, Pelegrin D, Patton-Schroeder K,
Kobashigawa J, Chait J, Kirklin J, Piccione Jr. W, McLeod M, Heroux A. Predictors of Quality of Life
at 5 to 6 Years after Heart Transplantation. J Heart Lung Transplant 2005. 2005 Sep;24(9):1431-9.
135.
Evangelista LS, Dracup K, Doering L, Moser DK, Kobashigawa J. Physical Activity Patterns in Heart
Transplant Women. J Cardiovasc Nurs. 2005 September/October;20(5):334-339.
41
after heart transplantation.
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
136.
Kobashigawa JA, Meiser BM. Review of major clinical trials with mycophenolate mofetil in cardiac
transplantation. Transplantation. 2005 Oct 15;80(2 Suppl):S235-43.
137.
Kobashigawa JA, Moriguchi JD, Laks H, Wener L, Hage A, Hamilton MA, Cogert G, Marguez A,
Vassilakis ME, Patel J, Yeatman L. Ten-Year Follow-up of a Randomized Trial of Pravastatin in Heart
Transplant Patients. J Heart Lung Transplant 2005. Nov;24(11):1736-40.
138.
Stewart S, Winters GL, Fishbein MC, Tazelaar HD, Kobashigawa J, Abrams J, Andersen CB, Angelini
A, Berry GJ, Burke MM, Demetris AJ, Hammond E, Itescu S, Marboe CC, McManus B, Reed EF,
Reinsmoen NL, Rodriguez ER, Rose AG, Rose M, Suciu-Focia N, Zeevi A, Billingham ME. Revision of
the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart
rejection. J Heart Lung Transplant. 2005 Nov;24(11):1710-20.
139.
Billingham M, Kobashigawa J. Editorial: The revised ISHLT Heart Biopsy Grading Scale. J Heart
Lung Transplant 2005. J Heart Lung Transplant. 2005 Nov;24(11):1709.
140.
Grady KL, Naftel DC, Kirklin J, White-Williams C, Kobashigawa J, Chait J, Young J, Pelegrd,
Rybarczyk B, Heroux A. Predictors of physical functional disability at 5-6 years after heart
transplantation. J Heart Lung Transplant 2005 Dec;24(12):2279-85.
141.
Deng MC, Eisen HJ, Mehra MR, Billingham M, Marboe CC, Berry G, Kobashigawa J, Johnson FL,
Starling RC, Murali S, Pauly DF, Baron H, Wohlgemuth JG, Woodward RN, Klingler TM, Walther D,
Lal PG, Rosenberg S, Hunt S; CARGO Investigators. Noninvasive discrimination of rejection in cardiac
allograft recipients using gene expression profiling. Am J Transplant. 2006 Jan;6(1):150-60.
142.
Reed EF, Demetris AJ, Hammond E, Itescu S, Kobashigawa JA, Reinsmoen NL, Rodriguez E R,
Rose M, Stewart S, Suciu-Foca N, Zeevi A, Fishbein MC. Acute Antibody-mediated Rejection of
Cardiac Transplants. J Heart Lung Transplant. 2006 Feb;25(2):153-159.
143.
Odim J, Wheat J, Laks H, Kobashigawa J, Gjertson D, Osugi A, Mukherjee K, Saleh S. Peri-operative
Renal Function and Outcome after Orthotopic Heart Transplantation. J Heart Lung Transplant. 2006
Feb;25(2):162-66.
144.
Patel JK, Kobashigawa JA. Should we be doing routine biopsy after heart transplantation in a new era
of anti-rejection? Curr Opin Cardiol. 2006 Mar;21(2):127-31.
145.
Kobashigawa JA, Patel J. Review: Immunosuppression for heart transplantation: where are we now?
Nat Clin Pract Cardiovasc Med. 2006;3(4):203-12.
146.
Kobashigawa JA, Patel J, Furukawa H, Moriguchi JD, Yeatman L, Takemoto S, Marquez A, Shaw J,
Oeser BT, Subherwal S, Wu GW, Kawano J, Laks H. Five-Year Results of a Randomized Single Center
Study of Tacrolimus Versus Micoremulsion Cyclosporine in Heart Transplant Patients. J Heart and Lung
Transplant 2006;25(4):434-9.
147.
Li HY, Tanaka K, Oeser B, Wertman B, Kobashigawa JA, Tobis JM. Compensatory enlargement in
transplant coronary artery disease: an intravascular ultrasound study. Chin Med J (Engl). 2006 Apr
5;119(7):564-9.
148.
Tanaka K, Li H, Curran PJ, Takano Y, Arbit B, Currier JW, Yeatman LA, Kobashigawa JA, Tobis JM.
Usefulness and Safety of Percutaneous Coronary Interventions for Cardiac Transplant Vasculopathy.
Am J Cardiol. 2006 Apr 15;97(8):1192-7.
149.
Kobashigawa JA, Tobis JM, Mentzer RM, Valantine HA, Bourge RC, Mehra R, Smart FW, Miller LW,
Tanaka K, Haiyan L, Gjertson DW, and Gordon RD. Mycophenolate mofetil reduces intimal thickness
by intravascular ultrasound after heart transplantation: reanalysis of the multicenter trial. Am J Transplant
2006;6(5 Pt. 1):993-7.
150.
Kobashigawa JA, Miller LW, Russell SD, Ewald GA, Zucker M, Goldberg LR, Eisen HJ, Salm K,
Tolzman D, Gao J, Fitzsimmons WE, First R.. Tacrolimus with Mycophenolate Mofetil (MMF) or
Sirolimus vs. Cyclosporine with MMF in Cardiac Transplant Patients: 1-Year Report. Am J Transplant
2006;6(6):1377-86.
42
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
151.
Li H, Tanaka K, Anzai H, Oeser B, Lai D, Kobashigawa JA, Tobis JM. Influence of pre-existing donor
atherosclerosis on the development of cardiac allograft vasculopathy and outcomes in heart transplant
recipients. J Am Coll Cardiol 2006;47(12):2470-6.
152.
Patel JK, Kobashigawa JA. Everolimus: an immunosuppressive agent in transplantation. Expert Opin
Pharmacother 2006;7(10):1347-55.
153.
Lepin EJ, Zhang Q, Zhang X, Jindra PT, Hong LS, Ayele P, Peralta MV, Gjertson DW, Kobashigawa
JA, Wallace WD, Fishbein MC, Reed EF. Phosphorylated S6 Ribosomal Protein: A Novel Biomarker of
Antibody Mediated Rejection in Heart Allografts. Am J Transplant 2006;6(7):1560-71.
154.
Kobashigawa, JA. Cardiac Allograft Vasculopathy in Heart Transplant Patients: Pathologic and Clinical
Aspects for Angioplasty/Stenting. Editorial Comment. J Am Coll Cardiol 2006 Aug;48(3):462-3.
155.
Kobashigawa JA, Renlund DG, Gerosa G, Almenar, Eisen HJ, Keogh AM, Lehmkuhl HB, Livi U,
Ross H, Segovia J, Yonan, Novartis Reps. A 12 month, single blind, randomized, parallel group,
multicenter study, to investigate the efficacy and safety of enteric coated mycophenolate sodium (ECMPS) compared with mycophenolate mofetil (MMF) in de novo heart recipients: 12 month results. J
Heart Lung Transplant 2006; 25(8):935-41.
156.
Li H, Tanaka K, Oeser B, Lai D, Kobashigawa JA, Tobis JM. Vascular remodeling after cardiac
transplantation: a 3-year serial intravascular ultrasound study. Eur Heart J 2006; 27(14):1671-7.
157.
Mehra MR, Kobashigawa J, Starling R, Russell S, Uber PA, Parameshwar J, Mohacsi P, Augustine S,
Aaronson K, Barr M. Listing criteria for heart transplantation: International Society for Heart and Lung
Transplantation guidelines for the care of cardiac transplant candidates--2006. J Heart Lung Transplant.
2006;25(9):1024-42.
158.
Kobashigawa JA, Starling R, Mehra M, Kormos R, Bhat G, Barr M. Multi-center Retrospective
Analysis of Cardiovascular Risk Factors Affecting Outcome of De Novo Cardiac Transplant Recipients.
J Heart Lung Transplant. 2006 Sep;25(9):1063-9.
159.
Starling RC, Pham M, Valantine H, Miller L, Eisen H, Rodriguez ER, Taylor DO, Yamani MH,
Kobashigawa J, McCurry K, Marboe C, Mehra MR, Zuckerman A, Deng MC; Working Group on
Molecular Testing in Cardiac Transplantation. Molecular testing in the management of cardiac transplant
recipients: initial clinical experience. J Heart Lung Transplant. 2006;25(12):1389-95.
160.
Li H, Tanaka K, Chhabra A, Oeser B, Kobashigawa JA, Tobis JM.Vascular Remodeling 1 Year After
Cardiac Transplantation. J Heart Lung Transplant. 2007 Jan;26(1):56-62.
161.
Patel JK, Kobashigawa JA. Tacrolimus in Cardiac Transplantation. Expert Review of Clinical Immunology
2007:3(2):131-8.
162.
Grady KL, Naftel DC, Kobashigawa J, Chait J, Young JB, Pelegrin D, Czerr J, McLeod M, Heroux A,
Higgins R, White-Williams C, Kirklin JK. Patterns and predictors of quality of life at 5–10 years after
heart transplantation. J Heart Lung Transplant. 2007 May;26(5):535-43.
163.
Rybarczyk B, Grady KL, Naftel DC, Kirklin JK, White-Williams C, Kobashigawa J, Chait J, Young JB,
Pelegrin D, Czerr J, McLeod J, Rissinger M, Higgins R, Heroux A. Emotional Adjustment Five Years
after Heart Transplant: A Multi-Site Study. Rehab Psych 2006;52:206-14.
164.
Barr ML, Kobashigawa JA. Improving Long-term Outcomes of Heart Transplantation:
Cardiac Allograft Vasculopathy, Malignancy, and Treatment Options. Clinical Updates 2006
165.
Kobashigawa JA. Contemporary Concepts in Noncellular Rejection. Heart Failure Clin 2007
Jan:3(1):11-15.
166.
Patel JK, Kobashigawa JA. Tacrolimus in Heart Transplant Recipients: an overview. Biodrugs
2007:21(3):139-143.
167.
De La Zerda DJ, Cohen O, Beygui RE, Kobashigawa J, Hekmat D, Laks H. Alcohol use in donors is a
protective factor on recipients' outcome after heart transplantation. Transplantation. 2007;83(9):1214-8.
43
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
168.
Hill JA, Hummel M, Starling RC, Kobashigawa JA, Perrone SV, Arizon JM, Simonsen S,
Abeywickrama KH, Bara C. A Lower Incidence of Cytomegalovirus Infection in De Novo Heart
Transplant Recipients Randomized to Everolimus. Transplantation 2007 Dec 15;84(11):1436-42.
169.
Mehra MR, Kobashigawa JA, Deng MC, Fang KC, Klinger TM, Lal PG, Rosenberg S, Uber PA,
Starling RC, Murali S, Pauly DF, Dedrick R, Walker MG, Zeevi A, Eisen HJ, CARGO Investigators.
Transcriptional signals of T-cell and corticosteroids sensitive genes are associated with future acute
cellular rejection in cardiac allografts. 2007 Dec;26(12):1255-63.
170.
Bernstein D, Williams GE, Eisen H, Mital S, Wohlgemuth JG, Klinger TM, Fang KC, Deng MC,
Kobashigawa J. Gene expression profiling distinguishes a molecular signature for grade 1B mild acute
cellular rejection in cardiac allograft recipients. J Heart Lung Transplant 2007 Dec;26(12):1270-80.
171.
Flechner SM, Kobashigawa J, Klintmalm G. Calcineurin Inhibitor-Sparing Regimens in Solid Organ
Transplantation: Focus on Improving Renal Function and Nephrotoxicity. Clin Transplant 2008;22:1-15.
172.
Kobashigawa JA and Patel JK. Pathophysiology for Coronary Artery Vasculopathy. Transplant Index and
Reviews 2008.
173.
Lieberman JR, Roth KM, Elsissy P, Dorey FJ, Kobashigawa JA. Symptomatic Osteonecrosis of the
Hip and Knee After Cardiac Transplantation. J Arthroplasty 2008 Jan; 23(1):90-6.
174.
Flechner SM, Kobashigawa J, Klintmalm G. Calcineurin Inhibitor Sparing Regimens in Solid Organ
Transplantation: Focus on Improving Renal Function and Nephrotoxicity. Clin Transplant 2008 JanFeb;22(1):1-15.
175.
Mehra MR, Kobashigawa JA, Deng MC, Fang KC, Klinger TM, Lal PG, Rosenberg S, Uber PA,
Starling RC, Murali S, Pauly DF, Dedrick R, Walker MG, Zeevi A, Eisen HJ, CARGO Investigators.
Clinical Implications and Longitudinal Alteration of Peripheral Blood Transcriptional Signals Indicative
of Future Cardiac Allograft Rejection. J Heart Lung Transplant 2008 Mar; 27(3):297-301.
176.
Lee MS, Kobashigawa J, Tobis J. Comparison of Percutaneous Coronary Intervention With BareMetal and Drug-Eluting Stents for Cardiac Allograft Vasculopathy J Am Coll Cardiol Intv 2008;1:710-715
177.
Lehmkuhl H, Hummel M, Kobashigawa J, Ladenburger S, Rothenburger M, Sack F, Dengler T, Hetzer
R. Enteric-coated mycophenolate-sodium in heart transplantation: efficacy, safety, and pharmacokinetic
compared with mycophenolate mofetil. Transplantation Proceedings 2008 May;40(4):953-5.
178.
Vaseghi M, Boyle NG, Kedia R et al. Supraventricular tachycardia after orthotopic cardiac
transplantation. J Am Coll Cardiol 2008 Jun 10;51(23):2241-9.
179.
Segovia J, Gerosa G, Almenar L, Livi U, Vigano M, Arizon JM, Yonan N, Di Salvo TG, Renlund DG,
Kobashigawa JA, ERL 2401 Study Group. Impact of Dose Reductions on Efficacy Outcome in Heart
Transplant Patients Receiving Enteric-Coated Mycophenolate Sodium or Mycophenolate Mofetil at 12
Months Post-Transplantation. Clin Transplant 2008 Nov-Dec;22(6):809-14.
180.
Kubak BM, Gregson AL, Pegues DA, Leibowitz MR, Carlson M, Marelli D, Patel J, Laks H,
Kobashigawa JA. Use of Hearts Transplanted from Donors with Severe Sepsis and Infectious Deaths.
J Heart Lung Transplant 2009 Mar;28(3):260-5.
181.
Kobashigawa J, Mehra M, West L, Kerman K, George J, Rose M, Zeevi A, Reinsmoen N, Patel J, Reed
E, Consensus Conference Participants. Report from a Consensus Conference on the Sensitized Patient
Awaiting Heart Transplantation. J Heart Lung Transplant 2009 Mar;28(3):213-25.
182.
Vaseghi M, Lellouche N, Ritter H, Fonarow GC, Patel JK, Moriguchi J, Fishbein MC, Kobashigawa
JA, Shivkumar K. Mode and Mechanisms of Death Following Orthotopic Heart Transplantation. Heart
Rhythm 2009 Apr;6(4):503-9.
183.
Wu GW, Kobashigawa JA, Fishbein MC, Patel JK, Kittleson MM, Reed EF, Kiyosaki KK, Ardehali A.
Asymptomatic Antibody-Mediated Rejection After Heart Transplantation Predicts Poor Outcomes. J
Heart Lung Transplant 2009 May;28(5):417-22.
44
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
184.
Marelli D, Esmailian F, Wong SY, Kobashigawa JA, Kwon MH, Beygui RE, Laks H, Plunkett MD,
Ardehali A, Shemin RJ. Tricuspid Valve Regurgitation After Heart Transplantation. J Thorac Cardiovasc
Surg 2009 Jun; 137(6):1557-9.
185.
Yang HM, Lai CK, Gjertson DW, Baruch-Oren T, Ra SH, Watts W, Wallace WD, Shintaku P,
Kobashigawa JA, Fishbein MC. Has the 2004 Revision of the International Society of Heart and Lung
Transplantation Grading System Improved the Reproducibility of the Diagnosis and Grading of Cardiac
Transplant Rejection? Cardiovasc Pathol 2009 Jul-Aug;18(4):198-204.
186.
Grady KL, Wang E, Higgins R, Heroux A, Rybarczyk B, Young JB, Pelegrin D, Czerr J, Kobashigawa
J, Chait J, Naftel DC, White Williams C, Myers S, Kirklin JK. Symptom Frequency and Distress from 5
to 10 years after Heart Transplantation. J Heart Lung Transplant 2009 Aug;28(8):759-68.
187.
Baran DA, Taylor DO, Kobashigawa JA. Immunosuppression and Heart Transplantation: How Do
We Define Success? Editorial. Am J Transplant. 2010 Feb;10(2):205-6.
188.
Kobashigawa JA, Kiyosaki KK, Patel JK, Kittleson MM, Kubak BM, Davis SN, Kawano MA, Ardehali
AA. The Benefit of Immune Monitoring in Heart Transplant Patients Using ATP Production in
Activated Lymphocytes. J Heart Lung Transplant. 2010 May;29(5):504-8.
189.
Kobashigawa JA. Non-Invasive Blood Tests Hold Promise for Transplant Outcomes. Cedars-Sinai
Advances in Heart & Heart Surgery. 2010 June; 1.
190.
Mehra MR, Crespo-Leiro MG, Dipchand A, Ensminger SM, Hiemann NE, Kobashigawa JA, Madsen
J, Parameshwar J, Starling RC, Uber PA. International Society for Heart and Lung Transplant Working
Formulation of a Standardized Nomenclature for Cardiac Allograft Vasculopathy—2010. J Heart and
Lung Transplant. 2010 June;29(6): 717-27.
191.
Costanzo MR, Dipchand A, Starling R, Anderson A, Chan M, Desai S, Fedson S, Fisher P, GonzalesStawinski G, Martinelli L, McGiffin D, Smith J, Taylor D, Meiser B, Webber S, Baran D, Carboni M,
Dengler T, Feldman D, Frigerio M, Kfoury A, Kim D, Kobashigawa J, Shullo M, Stehlik J, Teuteberg
J, Uber P, Zuckermann A, Hunt S, Burch M, Bhat G, Canter C, Chinnock R, Crespo-Leiro M, Delgado
R, Dobbels F, Grady K, Kao W, Lamour J, Parry G, Patel J, Pini D, Towbin J, Wolfel G, Delgado D,
Eisen H, Goldberg L, Hosenpud J, Johnson M, Keogh A, Lewis C, O'Connell J, Rogers J, Ross H,
Russell S, Vanhaecke J; International Society of Heart and Lung Transplantation Guidelines. The
International society of Heart and Lung Transplantation Guidelines for the care of heart transplant
recipients. J Heart Lung Transplant. 2010 Aug; 29(8):914-56
192.
Oda N, Kato TS, Komamura K, Patel J, Kobashigawa JA. Retrospective Review of Japanese Heart
Transplant Recipients Transplanted in Japan and Transplanted in the U.S. J Heart Lung Transplant. . 2010
Sep;29(9):1076-8.
193.
Kobashigawa JA, Patel JK, Kittleson MM, Kawano MA, Kiyosaki KK, Davis SN, Moriguchi JD, Reed
EF, Ardehali AA. The long-term outcome of treated sensitized patients who undergo heart
transplantation. Clin Transplant. 2010 Oct; E-pub.
194.
Taylor D, Meiser B, Webber S, Baran DA, Carboni M, Dengler T, Feldman D, Frigerio M, Kfoury A,
Kim D, Kobashigawa J, Shullo M, Stehlik J, Teuteberg J, Uber PA, West L, Zuckermann A. ISHLT
HT Guidelines Task Force 2: Immunosuppression and Rejection. J Heart Lung Transplant. 2010 Nov, Epub.
195.
Kobashigawa JA. Strategies in immunosuppression after heart transplantation: is less better? Circ Heart
Fail. 2011 Mar; 4(2): 111-3.
196.
Kobashigawa J, Crespo-Leiro MG, Ensminger SM, Reichenspurner H, Angelini A, Berry G, Burke M,
Czer L, Hiemann N, Kfoury AG, Mancini D, Mohacsi P, Patel J, Pereira N, Platt JL, Reed EF,
Reinsmoen N, Rodriguez ER, Rose ML, Russell SD, Starling R, Suciu-Foca N, Tallaj J, Taylor DO, Van
Bakel A, West L, Zeevi A, Zuckermann, A. Report from a consensus conference on antibody-mediated
rejection in heart transplantation. J Heart Lung Transplant. 2011 Mar; 30(3): 252-69.
45
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
197.
Lockhart D, Kittleson MM, Velleca A, Patel JK, Kobashigawa JA. Homeless donors and heart
transplantation outcomes. J Heart Lung Transplant. 2011 Mar; 30(3): 355-6.
198.
Kittleson MM, Kobashigawa JA. Management of advanced heart failure: the role of heart
transplantation. Circulation. 2011 Apr; 123(14): 1569-74.
199.
Zhang Q, Cecka JM, Gjertson DW, Ge P, Rose ML, Patel JK, Ardehali A, Kobashigawa JA, Fishbein
MC, Reed EF. HLA and MICA: targets of antibody-mediated rejection in heart transplantation.
Transplantation. 2011 May; 91(10): 1153-1158. ***“Editor’s Pick”
200.
Patel J, Kobashigawa J. Quest for lower immunosuppression in cardiac transplantation: an analysis of
the TICTAC trial. Future Cardiol. 2011 May;7(3):293-7.
201.
Liu T, Shehata M, Chang D, Patel J, Kittleson M, Kobashigawa J, Chugh SS, Wang X. Prolonged QT
and cardiac arrest post heart transplantation: inherited or acquired? J Electrocardiol. 2011 May-Jun; 44(3):
350-2.
202.
Patel JK, Kittleson M, Kobashigawa JA. Cardiac Allograft Rejection. Surgeon. 2011 Jun; 9 (3): 160-167.
203.
Berry GJ, Angelini A, Burke MM, Bruneval P, Fishbein MC, Hammond E, Miller D, Neil D, Revelo
MP, Rodriguez ER, Stewart S, Tan C, Winters G, Kobashigawa J, Mehra MR. The ISHLT working
formulation for pathological diagnosis Of antibody-mediated rejection in heart transplantation:
evolution and current status (2005-2011). J Heart Lung Transplant. 2011 Jun; 30(6):601-11.
204.
Patel J, Kobashigawa J. Everolimus for Cardiac Allograft Vasculopathy – Every Patient, at any Time?
Transplantation. 2011 Jul 27; 92(2): 127-128.
205.
Patel JK, Kobashigawa JA. Cardiology patient page: Heart transplantation. Circulation. 2011 Jul 26;
124(4):e132-4.
206.
Kittleson M, Shemin R, Patel J, Ardehali A, Kawano M, Davis S, Moriguchi J, Kobashigawa J. Donorrecipient sex mismatch portends poor 10-year outcomes in a single-center experience. J Heart Lung
Transplant. 2011 Sept; 30(9): 1018-1022.
207.
Lu WH, Palatnik K, Fishbein GA, Lai C, Levi DS, Perens G, Alejos J, Kobashigawa J, Fishbein MC.
Diverse morphologic manifestations of cardiac allograft vasculopathy: A pathologic study of 64 allograft
hearts. J Heart Lung Transplant. 2011 Sept; 30(9): 1044-1050.
208.
Moriguchi J, Davis S, Jocson R, Esmailian F, Ardehali A, Laks H, Kwon M, Kittleson M, Kobashigawa
J, Patel J, Marelli D, Plunkett M, Beygui R, Shemin R. Successful use of a pneumatic biventricular assist
device as a bridge to transplantation in cardiogenic shock. J Heart Lung Transplant. 2011 Oct; 30(10):
1143-7.
209.
Kittleson MM, Patel JK, Moriguchi JD, Kawano M, Davis S, Hage A, Hamilton MA, Esmailian F,
Kobashigawa JA. Heart Transplant recipients supported with extracorporeal membrane oxygenation:
outcomes from a single-center experience. J Heart Lung Transplant. 2011 Nov; 30(11):1250-6.
210.
Yanagida R, Czer LSC, Reinsmoen N, Cao K, Rafiei M, De Robertis MA, Mirocha J, Kass RM,
Kobashigawa JA, Trento A. Impact of virtual cross match on waiting times for heart transplantation.
Ann Thorac Surg: 2011 Dec; 92(6):2104-10.
211.
Zuckermann A, Arizon JM, Dong G, Eisen HJ, Kobashigawa J, Lehmkuhl H, Ross H, Pelligrini C,
Wang S-S, Barten MJ. Impact of De-Novo Everolimus-Based Immunosuppression on Incisional
Complications in Heart Transplantation. Transplantation. 2011 Sep 15; 92(5):594-600.
212.
Patel J, Everly M, Chang D, Kittleson M, Reed E, Kobashigawa J. Reduction of alloantibodies via
proteasome inhibition in cardiac transplantation. J Heart Lung Transplant. 2011 Dec; 30(12): 1320-6.
213.
Shah MR, Starling RC, Longacre LS, Mehra MR, Working Group Participants (Kobashigawa J). Heart
Transplantation Research in the Next Decade – A Goal to Achieving Evidence-Based Outcomes. J Am
Coll Cardiol. 2012 Apr 3; 59(14):1263-9.
46
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
214.
Thajudeen A, Stecker EC, Shehata M, Patel J, Wang X, McAnulty JH Jr, Kobashigawa J, Chugh SS.
Arrhythmias after Heart Transplantation: Mechanisms and management. J Am Heart Ass. 2012 Apr;
1(2):e001461.
215.
Kfoury A, Kobashigawa JA. Prioritizing sensitized heart transplant candidates. A sensitize affair. J
Heart Lung Transplant. 2012 Jul; 31(7):677-8.
216.
Kobashigawa J, Ross H, Bara C, Delgado JF, Dengler T, Lehmkuhl HB, Wang S, Dong G, Witte S,
Junge G, Potena L. Everolimus is associated with a reduced incidence of cytomegalovirus infection
following de novo cardiac transplantation. Transplant Infectious Disease. 2012; 0:1-13.
217.
Kobashigawa JA. The Future of Heart Transplantation. Am J of Transplant. 2012 Aug 17; Epub.
218.
Shah AB, Morrissey RP, Baraghoush A, Bharadwaj P, Phan A, Hamilton M, Kobashigawa J, Schwarz
ER. Failing the Failing Heart: A review of Palliative Care in Heart Failure. Rev Cardiovasc Med. 2013;
14(1): 41-48.
219.
Shah AB, Patel JK, Rafiei M, Morrissey RP, Kittleson MM, Kobashigawa JA. The impact of mean firstyear heart rate on outcomes after heart transplantation: does it make a difference? Clin Transplant. 2013
Aug 8; Epub.
220.
Kobashigawa J, Pauly D, Starling R, Eisen H, Ross H, Wang S, Cantin B, Hill J, Lopez, P, Dong G,
Nichols S. Cardiac Allograft Vasculopathy by Intravascular Ultrasound in Heart Transplant Patients:
Substudy from the Everolimus or Mycophenolate Mofetil Randomized, Multicenter Trial. J Am Coll
Cardiol 2013; 1(5):389-399.
221.
Azarbal B, Arbit B, Ramaraj R, Kittleson M, Young A, Czer L, Rafiei M, Currier J, Makkar R,
Kobashigawa J. Clinical and Angiographic Outcomes with Everolimus Eluting Stents for the
Treatment of Cardiac Allograft Vasculopathy. J Interv Cadiol. 2013 Sep 30; Epub.
222.
Kobashigawa J, Itagaki B, Razi R, Patel J, Chai W, Kawano M, Goldstein Z, Kittleson M, Fishbein M.
Correlation between Myocardial Fibrosis and Restrictive Cardiac Physiology in Patients Undergoing
Retransplantation. Clinical Transplantation. 2013 Nov; 27(6):E679-84.
223.
Kransdorf E, Czer L, Luthringer D, Patel, J, Montgomery S, Velleca A, Mirocha J, Zakowski P, Zabner
R, Gaultier C, Qvarnstrom Y, Benedict T, Steurer F, Bosserman E, Paddock C, Rafiei M, Kobashigawa
J. Heart Transplantation for Chagas Cardiomyopathy in the United States. Am J Transplant. 2013 Dec;
13(12):3262-8.
224.
White M, Cantin B, Haddad H, Kobashigawa J, Ross H, Carrier M, Pflugfelder P, Isaac D, Cecere R,
Whittom L, Ali I, Wang SH, He Y, Groulx A, Touyz R. Cardiac signaling Molecules and Plasma
Biomarkers Following Cardiac Transplantation: Impact of Tacrolimus vs. Cyclosporine. J Heart Lung
Transplant. 2013 Dec; 32(12):1222-32.
225.
Tang Z, Kobashigawa J, Rafiei M, Stern LK, Hamilton M. The Natural History of Biopsy-Negative
Rejection after Heart Transplantation. Journal of Transplantation. 2013. Vol. 2013, Article ID 236720.
226.
Kansara P, Czer L, Awad M, Arabia F, Mirocha J, De Robertis M, Moriguchi J, Ramzy D, Kass RM,
Esmailian F, Trento A, Kobashigawa J. Heart Transplantation With and Without Prior Sternotomy:
Analysis of the United Network for Organ Sharing Database. Transplantation Proceedings. 2014 Jan; 46(1):
249-255.
227.
Murray K, Wong S, Kittleson M, Ardehali A, Laks H, Shemin R, Kobashigawa J. Selecting Oversized
Donor Cardiac Allografts for Patients with Pulmonary Hypertension May Be Unnecessary.
Transplantation Proceedings. 2014 Jun; 46(5): 1497-1501
228.
Kransdorf E, Kittleson M, Kobashigawa J. Atypical hemolytic-uremic syndrome immediately after
heart transplantation. J Heart Lung Transplant. 2014 Jun; 33(6): 664-5.
229.
Kittleson M, Kobashigawa J. Management of the ACC/AHA Stage D Patient: Cardiac
Transplantation. Cardiol Clin. 2014 Feb;32(1):95
47
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
230.
Kittleson M, Kobashigawa J. Terasaki Festschrift Report: Statins in Heart Transplantation. Clinical
Transplants. 2014 Jul.
231.
Kransdorf E, Zakowski P, Kobashigawa J. Chagas Disease in Solid Organ and Heart Transplantation.
Curr Opin Infectious Disease. 2014 Oct; 27(5): 418-24.
232.
Kittleson M, Kobashigawa J. Long-term care of the heart transplant recipient.
Transplant. 2014, 19:515-524.
233.
Kwon M, Wong S, Kittleson M, Ardehali A, Laks H, Shemin J, Kobashigawa J. Selecting
Oversized Donor Cardiac Allografts for Patients With Pulmonary Hypertension May Be
Unnecessary. Transplantation Proceedings. 2014; 46(5): 1497-1501
234.
Lee MS, Zimmer R, Kobashigawa J. Long-term Outcomes of Orthotopic Heart
Transplantation for Hypertrophic Cardiomyopathy.
Transplantation Proceedings. 2014;
46(5):1502-1505.
235.
Kobashigawa J. Editorial: Time for Change in US Donor Heart Allocation Policy. J Am Coll Cardiol.
2014;2(2):178-179
236.
Kobashigawa J. Editorial: Coronary Computed Tomography Angiography: Is it time to replace the
conventional coronary angiogram in heart transplant patients? J Am Coll Cardiol. 2014;63(19):2005-2006
237.
Cohen B, Rafiei M, Osborne A, Kobashigawa J. Characteristics of Primary Graft Dysfunction: A
Single Center Experience. J Exp Clin Cardiol. 2014; 20(1): 2890-2896
238.
Kobashigawa J, Zuckermann A. Everolimus in Heart Transplantation: Does It Finally Have a Home?
Am J Transplant. 2014;14(8):1719-1720
239.
Rafiei M, Kittleson M, Patel J, Osborne A, Chang D, Czer L, Reinsmoen N, Esmailian F,
Kobashigawa J. Anti-thymocyte Gammaglobulin May Prevent Antibody Production after Heart
Transplantation. Transplant Proc. 2014;(10):3570-4
240.
Kransdorf E, Kittleson M, Kobashigawa J: Atypical hemolytic-uremic syndrome immediately after
heart transplantation. J Heart Lung Transplant; 2014 Jun;33(6):664-5
241.
Colvin-Adams M, Peura J, Chang P, Fedson S, Francis G, Hsu D, Kiernan M, Kobashigawa J,
Lindenfeld J, Masri SC, Miller D, O’Connell J, Rodriguez R, Rosengard B, Self S, Williams CW, Zeevi A.
Antibody-Mediated Rejection in Cardiac Transplantation: Emerging Knowledge in Diagnosis and
Management. Circulation, Circulation. 2015 May; 131 (18): 1608-39
242.
Patel J, Klapper E, Shafi H, Kobashigawa J. Extracorporeal photopheresis in heart transplant
rejection. Trans Sci. 2015, Apr; 52(2): 167-170
243.
Awad M, Czer L, Mirocha J, Ruzza A, Rafiei M, Reich H, De Robertis M, Rihbany K, Pinzas J, Ramzy
D, Arabia F, Trento A, Kobashigawa J, Esmailian F. Prior Sternotomy Increases the Mortality and
Morbidity of Adult Heart Transplantation. Transplant Proc. 2015 Mar; 47(2): 485-97
244.
Awad M, Czer L, Soliman C, Mirocha J, Ruzza A, Pinzas J, Rihbany K, Chang D, Moriguchi J, Ramzy
D, Esmailian F, Kobashigawa J, Arabia F. High Prevalence of Warfarin Genotype Polymorphisms in
Patients with Mechanical Circulatory Support. J Heart Lung Transplant. 2015. Jul-Aug; 61(4): 391-6.
245.
Ardehali A, Esmailian F, Deng M, Soltesz E, Hsich E, Naka Y, Mancini D, Camacho M, Zucker M,
Leprince P, Padera R, Kobashigawa J. A Prospective, Randomized, Multi-center Trial of ex-vivo
Donor Heart Perfusion for Human Heart Transplantation: The PROCEED II Trial. Lancet.. 2015 Jun;
385(9987):2577-84
48
Curr Opin Organ
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
P U B L I C A T I O N S : J O U R NA L S – I N P R E S S
1.
Kransdorf E, Chang D, Ro R, Reznik R, Yu R, Gordon O, Patel J, Kittleson M, Kobashigawa J. Sympathetic
Paraganglioma- Induced Cardiomyopathy Requiring Heart Transplantation. J Heart Lung Transplant. (Pending
Publication).
2.
Li F, Wei J, Valenzuela N, Lai C, Zhang Q, Gjertson D, Fishbein M, Kobashigawa J, Deng M, Reed E.
Phosphorylated S6 Kinase and S6 Ribosomal Protein are Biomarkers of Antibody Mediated Rejection in Heart
Allografts. J Heart Lung Transplant. (Pending Publication)
3.
Kobashigawa J. Cardiac transplantation in the modern era. N Engl J Med. 2014 (Pending Publication)
4.
Kittleson MM, Kobashigawa JA. Management of the Highly Sensitized Patient Awaiting Heart Transplant.
http://www.acc.org. January 8, 2015. http://www.acc.org/latest-incardiology/articles/2014/12/22/17/07/management-of-the-highly-sensitized-patient-awaiting-heart-transplantexpert-analysis.
5.
Esmailian F, Kittleson M, Kobashigawa J. Human Immunodeficiency Virus in Orthotopic Heart Transplant Case
Report. Texas Heart Institute Journal. (In Press)
P U B L I C A T I O N S : B O O K C H A P T E R S / M ON O G R A P H S
1.
Kobashigawa JA, Stevenson LW. Noninvasive Detection of Acute Cardiac Allograft Rejection. In:
Kapoor AS, Laks H, Schroeder JS, Jacoub MH, eds. Cardiomyopathies and Heart-Lung Transplantation. New
York: McGraw-Hill, 1991:293-303.
2.
Kobashigawa JA, Stevenson LW. Endomyocardial Biopsy. In: Kulich DL, Rahimtoola SH, eds.
Techniques and Applications in Interventional Cardiology. St. Louis, Mo: Mosby Year Book, 1991:489-99.
3.
Martin SM, Laks H, Drinkwater DC, Stevenson LW, Kawata N, Kobashigawa JA, Moriguchi JD,
Hamilton MA. Cardiac Transplantation: The UCLA Experience 1984 to 1990. In: Terasaki P, ed. Clinical
Transplantation 1990. Los Angeles, CA: The Regents of the University of California, 1991:103-114
4.
Ardehali A, Laks H, Drinkwater DC, Ziv ET, Sorensen TJ, Hamilton MA, Stevenson LW, Moriguchi
JD, Kobashigawa JA. Cardiac Transplantation at UCLA. In: Terasaki P, Cecka JM, eds. Clinical
Transplants 1993. Los Angeles, CA: The Regents of the University of California, 1994:119-128.
4.
Kobashigawa JA. Cardiac Allograft Rejection. In: Kapoor AS, Laks H eds. Atlas of Heart-Lung
Transplantation. New York: McGraw-Hill, 1994:95-102.
5.
Kobashigawa JA, Kasiske B, Katznelson S, Miller LW, Weisner R. Interdisciplinary perspectives on
solid organ transplantation: Focus on hyperlipidemia. Medical Education (monograph), Continuing
Medical Education, UCLA School of Medicine, August 1996.
6.
Kobashigawa JA, Laks H, Drinkwater DC, Moriguchi JD, Hamilton MA, Hage A, Blitz A, Kawata N.
The University of California at Los Angeles Experience in Heart Transplantation. In: Terasaki P, Cecka
JM, eds. Clinical Transplants 1995. Los Angeles, CA: The Regents of the University of California, 1996.
7.
Kobashigawa JA. Modifications in immunosuppression. In: Cooper DKC, Miller LW, Patterson GA
eds. The Transplantation and Replacement of Thoracic Organs. United Kingdom: Kluwer Academic Publishers,
1996.
8.
Kobashigawa JA. Pathophysiology of the transplanted heart and its influence on exercise tolerance. In:
Balady GJ, Pina IL (eds.) Exercise and Heart Failure. Armonk, NY: Futura Publishing Company, Inc.,
1997.
49
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
9.
Katznelson S, Kobashigawa JA. The effects of HMG-CoA reductase inhibitors after kidney and heart
transplantation: lipid lowering and immunosuppression. In: Touraine JL, ed. Late Graft Loss. 1997
Kluwer Academic Publishers, Great Britain.
10.
Nonoyama M, Laks H, Drinkwater DC, Brauner R, Ruzevich S, Kobashigawa JA. The UCLA
experience with assist devices as a bridge to transplantation in end-stage heart failure. In Akutsu T.,
Koyanagi H. eds. Heart replacement- Artificial Heart 6. 1998, Springer-Verlag, Tokyo.
11.
Kobashigawa JA. Advances in immunosuppression for heart transplantation. In: Advances in Cardiac
Surgery, Volume 10. St. Louis, MO: Mosby, Inc. 1998.
12.
Kobashigawa JA, Laks H, Marelli D, Moriguchi JD, Hamilton MA, Fonarow G, Hage A, Kawata N.
The University of California at Los Angeles Experience in Heart Transplantation. In: Terasaki P, Cecka
JM, eds. Clinical Transplants 1998. Los Angeles, CA: The Regents of the University of California, 1998.
13.
Kobashigawa JA. Dyslipidemias in heart transplant recipients. American Heart Association
Monograph. In: Costanzo MR ed. Longitudinal follow-up and treatment of heart transplant recipients 1999, in
press.
14.
Kobashigawa JA. Cardiac Complications of Urologic Surgery. In: SS Taneja, RB Smith, RM Ehrlich,
eds. Complications of Urologic Surgery: Prevention and Management, Third Edition. Saunders, Inc., 2000.
15.
Daniel Marelli, Hillel Laks, Jessica Bresson, Emily Houston, Daniel Fazio, Feng-Chun Tsai, Michele
Hamilton, Jaime Moriguchi, Gregg C. Fonarow, Abbas Ardehali, Rocky Camara, Caron Burch, Juan C.
Alejos, Barbara George, Nobuyuki Kawata, and Jon Kobashigawa. Chapter 26: Sixteen-Year
Experience with 1,000 Heart Transplants at UCLA. Clinical Transplants 2000. Los Angeles, CA: UCLA
Immunogenetics Center, Los Angeles, California.
16.
Kobashigawa JA. Physiology of the Transplanted Heart. AST Primer on Transplantation, Second Edition,
2001.
17.
Kobashigawa JA. Lipids and Lipid Lowering Therapy. Transplant-Associated Coronary Artery Vasculopathy,
Eurekah, 2001: 181-188.
18.
Patel JK and Kobashigawa JA. Chapter 57: Allograft Coronary Artery Disease. Advanced Therapy in
Cardiac Surgery (Second Edition). 2003.
19.
Kobashigawa JA. Special Supplement. CNIs in Heart Transplantation: Minimizing the Cardiovascular
Risk. Guest editor’s Introduction. J Heart Lung Transplant 2004 May; 23(5 Suppl):S185-6.
20.
Kobashigawa JA, Laks H, Wu G, Patel J, Moriguchi J, Hamilton M, Fonarow G, Fishbein M, Ardehali
A. The University of California at Los Angeles heart transplantation experience. Clin Transpl. 2005;17385.
21.
Patel JK, Kobashigawa JA, Hamilton M. Cardiac, Lipid, and Atherosclerotic Complications Among
Lung and Heart-Lung Recipients. Lynch III JP and Ross DJ, eds. Lung and Heart-Lung
Transplantation. New York, NY: Taylor & Francis Group, 2006: 881-894.
22.
Kobashigawa JA. Congenital Heart Disease in Adults, 3rd Edition. Edited by Dr. Jospeh Perloff.
23.
Kobashigawa JA. Transplant in Congenital Heart Disease Patients. Congenital Heart Disease in Adults
Book 2006.
24.
Kobashigawa JA. Lipids Book Chapter. 2006
25.
Patel JK, Kobashigawa JA. Cardiac Allograft Vasculopathy. Book Chapter. Chronic Allograft Failure:
Natural History, Pathogenesis, Diagnosis and Management. 2007.
26.
Kobashigawa JA. Chapter 40: Hyperlipidemia in Heart Transplantation. Clinical Lipidology: A
companion to Braunwald’s Heart Disease. Edited by Dr. Ballantyne. 2008: 490-493.
50
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
27.
Patel JK, Everly MJ, Kittleson M, Kobashigawa JA. Chapter 25C: Use of Bortezomib as Adjunctive
Therapy for Desensitization in Combined Heart and Kidney Transplantation – A Case Report. Clinical
Transplants. 2009;347-349.
28.
Kobashigawa JA. ISHLT President 2003-2004. 2009.
29.
Kobashigawa JA. ISHLT in the 1990’s Decade. 2009.
30.
Kittleson M, Kobashigawa JA. Chapter 64: Heart Transplantation. Baliga-McGraw-Hill Specialty Board
Review: Cardiology. 2010.
31.
Patel JK, Kobashigawa JA. Thoracic Organ Transplantation: Laboratory Methods. Book Chapter.
Methods in Molecular Biology: Transplantation Immunology. 2012.
32.
Holdaas H, Kobashigawa JA, Fellstrom B, Jardine A. Chapter 40: Special Patient Populations:
Transplant Recipients. Clinical Lipidology: A companion to Braunwald’s Heart Disease. 2013
P U B L I C A T I O N S : A BS T R A CT S
1.
Kobashigawa JA, Stevenson LW, Moriguchi JD, et al. Randomized trial of oral cyclosporine for
the treatment of mild acute cardiac rejection. Abstract presented at the Scientific Session of the
International Society of Heart Transplantation in April 1988.
2.
Moriguchi JD, Stevenson LW, Kobashigawa JA, Westlake C, Laks H, Child J. Decrease
in
2-dimensional echocardiographic ejection fraction during transplant rejection: A study of 400
biopsies. (Abstract) J Am Coll Cardiol:121A,1988
3.
Krivokapich J, Kobashigawa JA, Stevenson LW. Positron Emission Tomography Reveals
Decreased Coronary Flow Response to Exercise after Cardiac Transplantation. Presented at the
American College of Cardiology Scientific Session in March 1989.
4.
Kobashigawa JA, Murphy F, Stevenson LW, et al. Low dose lovastatin safely lowers cholesterol in
cardiac transplant patients. Abstract presented at the American Heart Association Scientific Session
in November 1989.
5.
Stevenson LW, Moriguchi JD, Kobashigawa JA, Tillisch J, Walden J, Drinkwater DC, Laks H.
Decreasing Survival Benefit of Cardiac Transplantation as Waiting List Lengthens. (Abstract)
Circulation 1989:80(4);11-671.
6.
Kobashigawa JA, Stevenson LW, Moriguchi JD, et al. Is an Intravenous Glucocorticoid Pulse
Better than Oral Taper for Asymptomatic Cardiac Rejection? A Randomized Trial. Abstract
presented at the American College of Cardiology Scientific Session in March 1990.
7.
Kobashigawa JA, Stevenson LW, Moriguchi JD, et al. Influenza Vaccine Does Not Cause
Rejection After Cardiac Transplantation. Abstract presented at the American College of Cardiology
Scientific Session in March 1990.
8.
Holt C, Fandrich R, Kobashigawa JA, et al. Nursing Strategy to Allow Early Discharge after
Cardiac Transplantation: Is it Safe? Abstract presented at the International Society for Heart
Transplantation Scientific Session in April 1990.
9.
Kobashigawa JA, Stevenson LW, Moriguchi JD, et al. A randomized trial of short course OKT3
induction vs. initial triple therapy: Impact on rejection and renal function after cardiac
transplantation. (Abstract) J Heart Transplant, 1991;10:163.
10.
Kobashigawa JA, Stevenson LW, Moriguchi JD, et al. Lack of appropriate erythropoietin
response in anemia after cardiac transplantation. (Abstract) J Heart Lung Transplant, 1991;10:178.
51
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
11.
Chan S, Kobashigawa JA, Stevenson LW, et al. Changes in basal and maximal blood flow during
acute cardiac transplant rejection: A non-invasive quantitative study with positron emission
tomography. (Abstract) J Heart Lung Transplant 1991;10:174.
12.
Kobashigawa JA, Stevenson LW Brownfield E, et al. Outcome of ABO compatible versus
identical blood type matching in cardiac transplant recipients on triple immunotherapy. (Abstract) J
Am Coll Cardiol 1991;17:309A.
13.
Kobashigawa JA, Stevenson LW, Moriguchi JD, et al. Inadequate erythropoietin production in
cardiac transplant patients with anemia. (Abstract) J Am Coll Cardiol 1991;17:364A.
14.
Kobashigawa JA, Stevenson LW, Louie H, et al. Elevated serum tumor necrosis factor is not
useful for monitoring cardiac transplant rejection. Abstract presented at the American College of
Cardiology Scientific Session in March 1991.
15.
Chelimsky C, Kobashigawa JA, Stevenson LW, et al. Chronic amiodarone therapy poor to cardiac
transplantation does not increase the perioperative risk. (Abstract) J Am Coll Cardiol 1991;17:290A.
16.
Chan S, Kobashigawa JA, Stevenson LW, et al. Basal myocardial blood flow is increased but
maximal flow is decreased during acute cardiac transplant rejection: A non-invasive study.
(Abstract) J Am Coll Cardiol 1991:17:58A.
17.
Stevenson LW, Warner SL, Hamilton MA, Kobashigawa JA. Distribution of donor hearts to
maximize transplant candidate survival. Circulation 1991;84(suppl 11);11-352.
18.
Kobashigawa JA, Brownfield E, Shaked A, Busuttil R. Review of Cardiac Complications in 300
liver transplant recipients. (Abstract) Transplantation 1992.
19.
Kobashigawa JA, Brownfield E, Shaked A, Busuttil R. Risk factors for cardiac complications
following liver transplantation. (Abstract) Transplantation 1992.
20.
Brownfield E, Kobashigawa JA, Stevenson LW, et al. B blood type cardiac transplant patients
have increased immune related mortality. (Abstract) Transplantation 1992.
21.
Brownfield E, Kobashigawa JA, Stevenson LW, et al. Does hemodynamic compromise during
cardiac rejection require listing for urgent retransplantation? (Abstract) Transplantation 1992.
22.
Brownfield E, Kobashigawa JA, Stevenson LW, et al. Cholesterol lowering with lovastatin after
one year does not appear to decrease the risk of transplant coronary artery disease in cardiac
transplant recipients. (Abstract) Transplantation 1992.
23.
Kobashigawa JA, Naftel D, Bourge R, Kirklin JK, Ventura H, and the Transplant Cardiologists'
Research Database Group. Acute rejection after cardiac transplantation: A Multi-Institutional
analysis. (Abstract) J Heart Lung Transplant l992;11:192.
24.
Kobashigawa JA, Stevenson LW, Albanese E, et al. Initial results of RS-61443 for refractory
moderate cardiac rejection. (Abstract) J Heart Lung Transplant 1992;11:200.
25.
Stevenson LW, Warner S, Kobashigawa JA, Drinkwater DC, Laks H. All donor hearts will soon
be required for urgent candidates. (Abstract) J Heart Lung Transplant 1992;11:191.
26.
Kobashigawa JA, Stevenson LW, Brownfield E, et al. Success of steroid weaning late after cardiac
transplantation: Relation to HLA-DR Matching. (Abstract) J Am Coll Cardiol 1992;19:204A.
27.
Kobashigawa JA, Renlund D, Olsen S, et al. Initial results of RS-61443 for refractory cardiac
rejection. (Abstract) J Am Coll Cardiol 1992;19:203A.
28.
Brownfield E, Kobashigawa JA, Stevenson LW. B-Antigen confers higher risk of immune related
mortality after cardiac transplantation. (Abstract) Clinical Research 1992;40:19A.
29.
Brownfield E, Kobashigawa JA, Stevenson LW. Partial matching at HLA DR locus improves late
cardiac graft acceptance despite frequent early rejection. (Abstract) Clinical Research 1992;40:33A.
52
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
30.
Fyfe A, Brownfield E, Kobashigawa JA, Drinkwater DC, Laks H. Rh Incompatible cardiac
transplantation is associated with increased early rejection and transplant atherosclerosis. (Abstract)
Circulation, November 1992.
31.
Fyfe A, Brownfield E, Kobashigawa JA, Stevenson LW. Blood group B endothelia and serum
induce high affinity binding of cardiac transplant recipient monocytes. (Abstract) Circulation,
November 1992.
32.
Fonarow GC, Chelimsky-Fallick C, Hamilton MA, Moriguchi JD, Kobashigawa JA, Walden JA,
Tillisch JH, Stevenson LW. Medical therapy has improved to rival cardiac transplantation for
advanced heart failure (Abstract) Circulation, November 1992.
33.
Kobashigawa JA, Brownfield ED, Stevenson LW, Gleeson MP, Moriguchi JD, Kawata N,
Hamilton MA, Hage AS, Minkley R, Salamandra J, Ruzevich. Effects of pravastatin in cardiac
transplant recipients. (Abstract) J Am Coll Cardiol 1993;21:141A.
34.
Kobashigawa JA, Gleeson MP, Stevenson LW, Moriguchi JD, Kawata N, Hage AS, Hamilton
MA, Drinkwater DC, Laks H. Significance of mild rejection late after cardiac transplant in patients
with and without steroid maintenance. (Abstract) J Am Coll Cardiol 1993;21:36A.
35.
Kobashigawa JA, Brownfield ED, Stevenson LW, Moriguchi JD, Hamilton MA, Hage AS,
Kawata N, Minkley R, Salamandra J, Ruzevich S, Drinkwater DC, Laks H. Hypercholesterolemia in
the first year post cardiac transplant is related to transplant coronary arteriopathy despite
subsequent lowering. (Abstract) J Am Coll Cardiol 1993;21:169A.
36.
FyfeA, Mojibi N, Kobashigawa JA, Demer LL, Drinkwater DC, Laks H, Stevenson LW.
Antibodies to vascular smooth muscle and endothelium after cardiac transplantation. (Abstract) J
Am Coll Cardiol 1993;21:334A.
37.
Kobashigawa JA, Ogura K, Stevenson LW, Ardehali A, Gleeson MD, Drinkwater DC, Laks H,
Terasaki PI. The use of flow cytometry to detect cardiac transplant recipients at risk for early
humoral rejection. (Abstract) Transplantation 1993, in press.
38.
Fyfe A, Elsayegh A, Kobashigawa JA, Lusis AJ. Anti-chlamydia antibodies after cardiac
transplantation are associated with transplant coronary disease. (Abstract) Circulation 1993.
39.
Kobashigawa JA, Gleeson MP, Stevenson LW, Brownfield ED, Moriguchi JD, Kawata N, Hage
AS, Hamilton MA, Drinkwater DC, Laks H. Benefit of steroid weaning late after cardiac
transplant: Relationship to transplant coronary artery disease. J Am Coll Cardiol, February,
1994:230A.
40.
Kobashigawa JA, Leaf DA, Gleeson MP, Hamilton MA, Chelimsky-Fallick C, Moriguchi JD,
Kawata N, Skotzko C, Herlihy E, Lee N, Stevenson LW. A randomized study of cardiac
rehabilitation in heart transplant recipients. J Am Coll Cardiol, February, 1994:356A.
41.
Gleeson MP, Kobashigawa JA, Stevenson LW, Moriguchi JD, Kawata N, Hamilton MA, Hage
AS, Drinkwater DC, Laks H. The natural history of focal moderate rejection in orthotopic heart
transplant recipients. J Am Coll Cardiol, February, 1994:483A.
42.
Kobashigawa JA, Gleeson MP, Stevenson LW, Carr JG, Moriguchi JD, Kawata N, Hamilton MA,
Hage AS, Drinkwater DC, Laks H. Prevention of severe cardiac allograft rejection with pravastatin:
a randomized trial. J Am Coll Cardiol 1994:483A.
43.
Carr JG, Johnson JA, Kobashigawa JA, Sack JB, Yeatman LA. Does the vasodilator response to
nitroglycerin over time affect quantitative assessment of coronary artery lesion dimensions using
intravascular ultrasound? J Am Coll Cardiol 1994:243A.
44.
Kobashigawa JA, Gleeson MP, Stevenson LW. Late steroid weaning in cardiac transplant patients
is not associated with an increase in transplant coronary artery disease. J Heart Lung Transplant
1994:13;S48.
53
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
45.
Kobashigawa JA, Leaf D, Gleeson MP. Benefit of cardiac rehabilitation in heart transplant
patients. J Heart Lung Transplant 1994:13;S77.
46.
Kobashigawa JA, Gleeson MP, Stevenson LW. Pravastatin lowers cholesterol and may prevent
severe cardiac transplant rejection. J Heart Lung Transplant 1994:13;S75.
47.
Ruzevich SA, Gleeson MP, Kobashigawa JA, et al. Early hospital discharge despite pre-operative
status following cardiac transplant surgery. J Heart Lung Transplant 1994:13;S44.
48.
Kobashigawa JA, Gleeson MP, Hamilton MA, Moriguchi JD, Kawata N, Hage AS, Drinkwater
DC, Laks H. Survivors of cardiac transplant rejection with hemodynamic compromise appears to
be at increased risk to develop transplant coronary artery disease. American Society of Transplant
Physicians Scientific Sessions, May 16, 1994 in Chicago, IL.
49.
Kobashigawa JA, Gleeson MP, Hamilton MA, Moriguchi JD, Kawata N, Hage AS, Drinkwater
DC, Laks H. When to consider cardiac retransplantation in patients who develop transplant
coronary artery disease. American Society of Transplant Physicians Scientific Sessions, May 16,
1994 in Chicago, IL.
50.
Katznelson S, Kobashigawa JA, Terasaki P, et al. Natural killer cell cytotoxicity is inhibited by
pravastatin in heart transplant patients. American Society of Transplant Physicians Scientific
Sessions, May 17, 1994 in Chicago, IL.
51.
Ardehali A, Laks H, Drinkwater DC, Kobashigawa JA, Moriguchi JD, Drake TA. Vascular cell
adhesion molecule-I upregulation precedes and predicts cellular rejection of human cardiac
allografts. American College of Surgeons, October 12, 1994 in Chicago, IL.
52.
Kobashigawa JA, Carr JG, Moriguchi JD, et al. Pravastatin lowers cholesterol and appears to
decrease transplant coronary artery disease: a randomized trial. Circulation 1994;90:1-94.
53.
Katznelson S, Kobashigawa JA, Wang XM et al. Pravastatin use in heart transplant patients
suppresses natural killer cell (NKC) cytotoxicity and may be associated with reduced allograft
rejection. Circulation 1994;90:1-200.
54.
Yeung AC, Miller L, Kobashigawa JA, et al. Does induction therapy influence the degree of
intimal thickening early after heart transplantation? Circulation 1994;90:1-638.
55.
Bourge RC, Naftel DC, Kirklin JK, Spears J, Kobashigawa JA, Young JB, Jarcho J, Kubo S, Smart
F. Computerization of the application of parametric multi-variable risk factor analysis to estimate
the risk of events after cardiac transplantation. J Am Coll Cardiol February 1995:328A.
56.
Laks H, Drinkwater DC, Kobashigawa JA, Gleeson MP. Outcome of patients transplanted with
bypassed donor hearts. J Am Coll Cardiol February 1995:142A.
57.
Kobashigawa JA, Gleeson MP, Laks H, Moriguchi JD, Kawata N, Hamilton MA, Hage AS,
Drinkwater DC. Long term outcome of mono-immunosuppression in cardiac transplant recipients.
J Am Coll Cardiol February 1995:242A.
58.
Laks H, Drinkwater DC, Kobashigawa JA. Long term outcome in cardiac transplant patients
transplanted with older donor hearts. J Heart Lung Transplant 1995;14:S41.
59.
Johnson M, Naftel D, Hobbs R, Kobashigawa JA, Pitts D, Levine T, Tolman D, Bhat G, Kirklin
J, Bourge R. The incremental risk of female gender in cardiac transplantation: a multi-institutional
study of pregnancy and peripartum cardiomyopathy. J Heart Lung Transplant 1995;14:S41.
60.
Johnson JA, Trosian KD, Yeatman LA, Carr JG, Kobashigawa JA. Morphometric analysis of
intracoronary ultrasound: A new method to quantitate transplant coronary disease. J Heart Lung
Transplant 1995;14:S49.
61.
Ruzevich SA, Sabad A, Kobashigawa JA. Pre-transplant cardiac cachexia does not cause increase
in post transplant morbidity or mortality. J Heart Lung Transplant 1995;14:S74.
54
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
62.
Sabad A, Kobashigawa JA, Minkley R. Is pre-operative obesity a relative contraindication to heart
transplantation?: The controversy revisited. J Heart Lung Transplant 1995;14:S74.
63.
Kobashigawa JA, Johnson J, Trosian K. Cellular rejection does not appear to be associated with
intimal thickening after one year post cardiac transplant: A longitudinal intravascular ultrasound
study using qualitative morphometric analysis. American Society of Transplant Physicians, May 1995:106.
64.
Katznelson S, Wilkinson AH, Danovitch GM, Wang XM, Chia D, Ozawa, Hirata M, Zhong HP,
Kobashigawa JA, Terasaki PI. The impact of pravastatin on the incidence of acute rejection after
renal transplantation and on cellular immune function. American Society of Transplant Physicians, May
1995:115.
65.
Kobashigawa JA, Sabad A, Cogert GA, Kawata N, Moriguchi JD, Hamilton MA, Hage AS,
Drinkwater DC, Laks H. Mild-moderate obesity after cardiac transplant is not associated with
transplant coronary artery disease or poor outcome. American Society of Transplant Physicians, May
1995:142.
66.
Kofoed KF, Czemin J, Kobashigawa JA, Johnson J, Phelps ME, Schelbert HR. Transplant
vasculopathy by intravascular ultrasound is correlated with abnormal microcirculation and
vasomotion by PET. Circulation 1995;92:1-244.
67.
Westlake CA, Walden JA, Minkley R, Fonarow GC, Hamilton MA, Shpiner RB, Levine MS, Sabad
A, Cogert GA, Kobashigawa JA. Smoking and abnormal pulmonary function tests: Are they risk
factors for poor outcome after cardiac transplantation? The controversy revisited. Circulation
1995;92:1-178.
68.
Miller L, Kobashigawa JA, Hauptman P, Valantine H, Ventura H, O'Donnell J, Yeung A,
Wiedermann J, Greenwalt T. Definition of critical cyclosporine level for preventing rejection in
heart transplant patients. J Heart and Lung Transplant 1996;15:S77.
69.
Laks H, Drinkwater DC, Kobashigawa JA. Alternate heart transplant waiting list: Does it work? J
Heart Lung Transplant l996;15:S41.
70.
Johnson JA, Kobashigawa JA, Yeatman LA, Carr JG, Trosian KD, Sabad A, Wener LS,
Drinkwater DC, Laks H. Does preexisting donor heart atherosclerosis lead to more transplant
coronary artery disease? A prospective study using morphometric analysis of intracoronary
ultrasound. J Am Coll Cardiol March 1996.
71.
Johnson JA, Kobashigawa JA, Yeatman LA, Carr JG, Trosian KD, Sabad A, Wener LS,
Drinkwater DC, Laks H. The distribution and characteristics of transplant coronary disease in a
prospective morphometric analysis of intracoronary ultrasound. J Am Coll Cardiol March 1996.
72.
Salamandra J, Kobashigawa JA, Mansukhani P, Medkiff K, Ruzevich S, Minkley R, Chait J, Utley
C, Wagner A, Sabad A, Cogert GA, Drinkwater DC, Laks H. The impact on survival of managed
care transplant patients under the care of transplant specialists. American Society of Transplant
Physicians, May 1996.
73.
Wong CK, Schwarzkopf, Kobashigawa JA, Miller L, Valantine H, Ventura H, Ganz P, Yeung AC.
Role of vascular remodeling in the pathogenesis of early transplant coronary artery disease: A
multicenter prospective intravascular ultrasound study. Circulation 1996;94(8):I-290.
74.
Kobashigawa JA, Moriguchi JD, Laks H, Hamilton MA, Hage AS, Kawata N, Sabad A, Cogert
GA, Muhlmeister HF, Drinkwater DC. Successful therapy for cardiac transplant recipients with
hemodynamic compromising rejection. Circulation 1996;94(8):I-479.
75.
Kobashigawa JA, Sabad A, Cogert GA, Moriguchi JD, Kawata N, Hamilton MA, Hage AS,
Drinkwater DC, Laks H. Panel reactive antibodies: Are they truly a marker for poor outcome after
cardiac transplantation? Circulation 1996;94(9):II:294-297.
76.
Kobashigawa JA, Laks H, Fonarow GC, Hamilton MA, Moriguchi JD, Hage AS, Kawata N,
Drinkwater DC, Sabad A, Cogert GA, Muhlmeister HF, Schiller GJ. Circulation 1996:94(8):I-479.
55
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
77.
Czernin J, Johnson JA, Kofoed K, Wener LS, Stepanian C, Laks H, Schelbert HR, Phelps ME,
Kobashigawa JA. Quantitative blood flow imaging with PET for predicting progression of
transplant vasculopathy. Circulation 1996;94(8):I-649.
78.
Kobashigawa JA, Cogert GA, Sabad A, Muhlmeister H, Cassem JD, Moriguchi JD, Kawata N,
Hamilton MA, Hage AS, Drinkwater DC, Laks H. Naturally occurring leukopenia as a marker for
good outcome after cardiac transplantation. J Am Coll Cardiol 1997;29(2A):28A.
79.
Kobashigawa JA, Johnson J, Moriguchi JD, Sabad A, Wener LS, Cogert GA, Hage AS, Hamilton
MA, Kawata N, Drinkwater DC, Laks H. Obesity as a risk factor for transplant coronary artery
disease: The IVUS truth. J Am Coll Cardiol 1997;29(2A):291A.
80.
Kubo S, Stevenson L, Miller L, Kobashigawa JA, Kenzora J, Torre G, Tolman D, Naftel D,
Bourge R, Kirklin J. Outcomes in non-urgent patients (status II) awaiting transplantation: Risk
factors for death or deterioration to status I (urgent status). J Heart and Lung Transplant 1997,16:42.
81.
Czemin J, Johnson J, Sabad A, Schelbert H, Kobashigawa JA. Quantitative blood flow imaging
with PET for predicting progression of transplant vasculopathy. J Heart and Lung Transplant
1997,16:67.
82.
Kobashigawa JA, Czemin J, Laks H, Sabad A, Cogert GA, Cassem JD, Schelbert H. Pravastatin
preserves coronary endothelial-dependent vasodilation determined by positron emission
tomography in cardiac transplant patients. J Heart and Lung Transplant 1997.16:47.
83.
Johnson JA, Kobashigawa JA, Wener LS, Stepanian C, Sabad A, Cogert GA, Yeatman L,
Drinkwater D, Laks H. Histologic validation of morphometric analysis of intravascular ultrasound
in quantitative coronary artery disease. J Heart and Lung Transplant 1997,16:48.
84.
Kobashigawa JA, Moriguchi JD, Sabad A, Albanese E, Cogert GA, Hamilton MA, Hage A,
Kawata N, Cassem JD, Liu H, Drinkwater D, Laks H. Cyclosporine and pravastatin
pharmacokinetics in cardiac transplant recipients. J Heart and Lung Transplant 1997;16:84.
85.
Moriguchi JD, Kobashigawa JA, Sabad A, Hamilton MA, Hage A, Kawata N, Cogert GA,
Cassem JD, Muhlmeister H, Drinkwater D, Laks H. Estrogen therapy in postmenopausal heart
transplant women may be effective in cholesterol lowering. J Heart and Lung Transplant 1997,16:84.
86.
Katznelson S, Kobashigawa JA, Wang XM Chia D, Ozawa M, Zhong HP, Terasaki PI The
inhibitory effects of pravastatin on cytotoxic T-lymphocyte and natural killer cell activity. J Heart
and Lung Transplant 1997,16:108
87.
Kobashigawa JA, Moriguchi JD, Russell SD, Einhorn K, Ro TK, Inglish JA, Cassem JD, Kawata
N, Laks H. Early results of FK506 versus Neoral: a randomized trial. The International Congress on
Immunosuppression, Orlando, FL, December 13, 1997.
88.
Takemoto S, Johnson C, Terasaki PI, Cecka M, Inglish JA, Cassem JD, Einhorn K, Kobashigawa
JA. Flow cytometry panel reactive antibody: a possible tool to detect rejection after cardiac
transplant. Circulation 1997,96(8):I-369.
89.
Wener LS, Moriguchi JD, Kawata N, Hage A, Hamilton MA, Einhorn K, Inglish JA, Cassem JD,
Kobashigawa JA. Redo heart transplant patients are at risk for first year increased intimal
thickening by coronary ultrasound. Circulation 1997,96(8):I-369.
90.
Guanuggen C, Sen L, Ma XY, Laks H, Kobashigawa JA. Atrial conduction disturbance as an
indicator of rejection after cardiac transplantation. Circulation 1997,96(8):I-428.
91.
Wong CK, Ganz P, Kobashigawa JA, Miller LW, Valantine-von Kaeppler HA, Ventura HO,
Yeung AC. Donor coronary disease serves as a nidus for intimal thickening and prevent adequate
remodeling during the first year after transplant: a multicenter transplant intravascular ultrasound
study. Circulation 1997,96(8):I-429.
56
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
92.
Wener LS, Johnson JA, Tobis JM, Einhorn K, Inglish JA, Cassem JD, Curier JW, Kobashigawa
JA. Longitudinal study of vascular remodeling in coronary arteries after heart transplantation.
Circulation 1997,96(8): I-429.
93.
Takemoto SK, Johnson C, Kobashigawa JA, Cecka JM, Gjertson DW, Terasaki PI. Detection of
HLA antibody to diagnose cardiac allograft rejection. XVII International Congress of the
Transplantation Society Abstracts 1998: 245.
94.
Kobashigawa JA, Moriguchi JD, Ro TK, Einhorn K, Cassem JD, Hamilton MA, Hage A, Kawata
N, Laks H. Atorvastatin for refractory hypercholesterolemia in heart transplant patients. J Am
Coll Cardiol 1998;31: 157A.
95.
Kobashigawa JA, Einhorn K, Ro TK, Cassem JD, Moriguchi JD, Hamilton MA, Hage A, Kawata
N, Laks H. The meaning of mild rejection in steroid-free heart transplant recipients. J Am Coll
Cardiol 1998;31: 35A.
96.
Cui G, Ma XY, Kobashigawa JA, Sen L. Atrial conduction disturbance in the post heart
transplantation: atrial fibrillation. J Am Coll Cardiol 1998; 31:471A.
97.
Wang XM, Kobashigawa JA, Terasaki PI, Moriguchi JD, Einhorn K, Laks H. Pravastatin reduces
natural killer cell cytotoxicity in heart transplant patients on FK506. J Heart Lung Transplant
1998;17: 57.
98.
Kobashigawa JA, Einhorn K, Ro TK, Cassem J, Moriguchi JD, Hamilton MA, Hage A, Kawata
N, Laks H. Mild rejection in steroid-free heart transplant recipients: Is it of concern? J Heart Lung
Transplant 1998;17:84.
99.
Kobashigawa JA, Moriguchi JD, Ro TK, Einhorn K, Cassem J, Hamilton MA, Hage A, Kawata
N, Laks H. Refractory hypercholesterolemia in heart transplant patients: response to atorvastatin.
J Heart Lung Transplant 1998;17:107.
100.
Kobashigawa JA, Ro TK, Einhorn K, Moriguchi JD, Hamilton MA, Hage A, Kawata N, Laks H.
Increased morbidity in insulin-dependent diabetic patients long-term after heart transplantation.
ASTP Scientific Sessions, Chicago Sheraton Hotel, May 9-13, 1998.
101.
Kobashigawa JA, Ro TK, Einhorn K, Cogert GA, Cassem JD, Moriguchi JD, Kawata N,
Hamilton MA, Hage A, Laks H. Risk factors for malignancies in heart transplant recipients. ASTP
Scientific Sessions, Chicago Sheraton Hotel, May 9-13, 1998.
102.
Kobashigawa JA, Einhorn K, Moriguchi JD, Cassem JD, Ro TK, Hamilton MA, Hage A, Kawata
N, Laks H. The meaning of mild rejection during corticosteroid weaning in heart transplant
recipients. ASTP Scientific Sessions, Chicago Sheraton Hotel, May 9-13, 1998.
103.
Kobashigawa JA, Fishbein M, Inglish JA, Moriguchi JD, Hamilton MA, Hage A, Kawata N, Laks
H. Quilty B lesions on endomyocardial biopsies: are they associated with subsequent histologic
rejection in cardiac transplant patients? ASTP Scientific Sessions, Chicago Sheraton Hotel, May 9-13,
1998.
104.
Moriguchi JD, Kobashigawa JA, Ro TK, Einhorn K, Cassem JD, Hamilton MA, Hage A, Kawata
N, Laks H. At what creatinine level is angiographic dye safe for coronary angiography in cardiac
transplant recipients? ASTP Scientific Sessions, Chicago Sheraton Hotel, May 9-13, 1998.
105.
Kobashigawa JA, Ro TK, Moriguchi JD, Cassem JD, Inglish JA, Einhorn K, Cogert GA,
Hamilton MA, Hage A, Kawata N, Laks H. Cholesterol lowering after heart transplantation is
associated with a lower incidence of transplant coronary artery disease. ASTP Scientific Sessions,
Chicago Sheraton Hotel, May 9-13, 1998.
106.
Kobashigawa JA, Ro TK, Einhorn K, Moriguchi JD, Hamilton MA, Hage A, Kawata N,
Cassem JD, Laks H. Redo heart transplants have increased incidence of transplant coronary artery
disease: impact on long-term survival. J Am Coll Cardiol, 1999.
57
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
107.
Marelli D, Laks H, Fazio D, Moore S, Moriguchi J, Kobashigawa J. The Use of Donor Hearts
with Left Ventricular Hypertrophy. J Heart Lung Transplant 1999.
108.
Kobashigawa JA, Moriguchi JD, Laks H, Ro TK, Hamilton MA, Hage A, Wener L, Kawata N.
Five-year follow-up of a randomized trial of pravastatin in heart transplant patients. J Heart Lung
Transplant 1999.
109.
Moriguchi JD, Kobashigawa JA, Ro TK, Hamilton MA, Hage A, Kawata N, Laks H.
Pretransplant panel reactive antibodies are associated with increased risk of transplant coronary
artery disease (TCAD) in cardiac transplant recipients. J Heart Lung Transplant 1999.
110.
Chait J, Kobashigawa JA, Chuang J, Moriguchi J, Kawata N, Laks H. Efficacy and safety of
sildenafil citrate (Viagra) in male heart transplant patients. J Heart Lung Transplant 1999.
111.
Eisenring EM, Canobbio MN, Chait J, Kobashigawa JA, Alejos JC, Rapkin A, Laks H. Does
cardiac transplantation affect gynecologic and reproductive outcomes? J Heart Lung Transplant
1999.
112.
Kobashigawa JA, Ro TK, Moriguchi JD, Lee R, Cassem JD, Hamilton MA, Hage A, Kawata N,
Laks H. Hemodynamic compromising rejection is associated with increased incidence of
transplant coronary artery disease in cardiac transplant recipients. J Heart Lung Transplant 1999.
113.
Keogh A, St. Vincent’s Hospital, Sydney, Australia. Steering Committee: Bourge R, Costanzo M,
Dureau G, Eisen H, Kobashigawa JA, Mehra M, Mentzer R, Miller L, Renlund D, Smart F,
Valantine H, on behalf of the Mycophenolate Mofetil Study Investigators. Three year results of the
double-blind randomized multicenter trial of mycophenolate mofetil in heart transplant patients. J
Heart Lung Transplant 1999.
114.
Wang XM, Zhong HP, Takemoto SK, Chuang J, Kobashigawa JA, Terasaki PI, Cecka JM.
Immunologic assessment of risk for rejections after heart transplantation. J Heart Lung Transplant
1999.
115.
Takemoto SK, Tambur AR, Roggero AL, Ortegal JW, Mancini M, Costanzo MR, Kobashigawa
JA, Cecka JM, Gebel HM. Flow cytometric detection of class I and class II antibodies is a
predictor if heart allograft rejection. Sixth Congress of the Asian Society of Transplantation 1999;:74.
116.
Kobashigawa JA, Lin P, Moriguchi JD, Ro TK, Cassem JD, Hamilton MA, Hage A, Kawata N.
Do Heart Transplant Patients on Corticosteroid –Free Immunosuppression Have Less Rejection?
Circulation 1999;100(18):I-525.
117.
Kobashigawa JA, Ro TK, Chuang J, Moriguchi JD, Schiller G, Kawata N. The Use of
Photopheresis for the Treatment of Chronic Humoral Rejection in Heart Transplant Patients.
Circulation 1999;100(18):I-526.
118.
Kobashigawa JA, Laks H, UCLA Med Ctr. Los Angeles, CA; Admon D, Hadassah University
Hospital, Jerusalem, Israel; Hachida M, Koyanagi H, Heart Inst of Japan, Tokyo, Japan. LongTerm Success of Foreign Nationals Undergoing Heart Transplantation in the United States.
Circulation 1999;100(18):I-529.
119.
Cui G, Kobashigawa J, Sen L. Increased incidence of atrial flutter associated with the rejection of
heart transplantation. J Am Coll Cardiol 2000;35:221A.
120.
Kobashigawa JA, Moriguchi JD, Chuang JM, et al. A randomized trial of tacrolimus versus neoral
cyclosporine in heart transplant recipients. J Am Coll Cardiol 2000;35:222A.
121.
Kobashigawa JA, Devereaux D, Moriguchi JD, et al. Effect of race in outcomes after heart
transplantation. J Am Coll Cardiol 2000;35:167A.
122.
Kobashigawa JA, Moriguchi JD, Takemoto S, Chuang JM, Wener L, Yeatman L, Ro T,
Devereaux D, Kawata N, Laks H. First Year Results of a Randomized Trial of Tacrolimus vs.
Neoral Cyclosporine in Heart Transplant Patients. J Heart Lung Transplant 2000.
58
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
123.
Laks H, Marelli D, Fazio D, Sadeghi A, Ardehali A, Hamilton M, Moriguchi J, Fonarow G, Hage
A, Esmailian F, Kawata N, Kobashigawa J. Intermediate Term Results of the Alternate Recipient
List for Heart Transplantation. J Heart Lung Transplant 2000.
124.
Camara R, Kobashigawa JA, Lackey S, Chuang JM, Moriguchi JD, Kawata N, Laks H. Concern
Regarding the Use of Orlistat (Xenical) For the Treatment of Obesity in Cardiac Transplant
Recipients. J Heart Lung Transplant 2000.
125.
Marelli D, Laks H, Fazio D, Sadeghi A, Ardehali A, Moriguchi J, Houston E, Talamo M,
Esmailian F, Hage A, Hamilton M, Fonarow G, Kawata N, Kobashigawa J. The Use of Marginal
Donor Hearts. J Heart Lung Transplant 2000.
126.
Moriguchi JD, Kobashigawa JA, Takemoto S, Wener L, Tobis J, Lee R, Kumar N, Chuang JM,
Kawata N, Laks H. Development of Circulating IgG Class I Antibodies is Associated With
Increase in Intimal Thickness by Intravascular Ultrasound (IVUS) After Heart Transplant. J Heart
Lung Transplant 2000.
127.
Moriguchi JD, Bueno P, Kobashigawa JA, Chuang JM, Lackey S, Camara R, Kawata N, Laks H.
A Pilot Study of L-Arginine for Renal Insufficiency in Heart Transplant Recipients. J Heart Lung
Transplant 2000.
128.
Chuang JM, Kobashigawa JA, Mui M, Lackey S, Camara R, Moriguchi JD, Kawata N, Marks M,
Velleca A, Brown M, Laks H. What are the Infectious Risks of Pets Immediately After Heart
Transplant? J Heart Lung Transplant 2000.
129.
Moriguchi JD, Devereaux D, Kobashigawa JA, Lackey S, Camara R, Velleca A, Marks M, Brown
M, Chuang JM, Kawata N, Laks H. Long Term Effects of Medical Insurance on Heart Transplant
Recipients. J Heart Lung Transplant 2000.
130.
Michaels PJ, Fishbein MC, Azarbal A, Espejo ML, Chen L, Laks H, Kobashigawa J. Rantes
Expression and Leukocyte Phenotype Distinguish Acute Cellular Rejection (ACR) From Quilty B
Lesions (QB). J Heart Lung Transplant 2000.
131.
Kobashigawa J. Deleterious Effects of Systemic Hypertension on the Donor Heart after Heart
Transplantation. AST Chicago, Chicago Sheraton Hotel, May 15, 2000.
132.
Kubak B, Kobashigawa J, et al. Is Cytomegalovirus (CMV) Prophylaxis with Ganciclovir in Heart
Transplant Patients Effective? AST Chicago, Chicago Sheraton Hotel, May 15, 2000.
133.
Buljubasic N, Kobashigawa J, et al. Comparison of QID and BID Regimen for Initiation of
Cyclosporine Treatment Following Heart Transplantation. AST Chicago, Chicago Sheraton Hotel,
May 15, 2000.
134.
Marelli D, Laks H, Moriguchi J, Fazio D, Hamilton M, Fonarow G, Hage A, Salehmoghaddam S,
Kubak B, Meehan D, Talamo M, Sadeghi A, Esmailian F, Ardehali A, Plunkett M, Kobashigawa
J. Single Institution Outcome Analysis of 344 Consecutive Patients Receiving Donor Hearts
Preserved Using University of Wisconsin Solution. AST Chicago, Chicago Sheraton Hotel, May 15,
2000.
135.
Marelli D, Hamilton MA, Laks H, Fonarow GC, Fazio D, Moriguchi JD, Salehmoghaddam S,
Kubak B, Ardehali A, Esmailian F, Hage A, Kobashigawa JA. Heart Transplantation in the
Elderly. Scientific Sessions 2000, New Orleans, Louisiana, November 12-15, 2000. Circulation
2000;102:II-490.
136.
Marelli D, Laks H, Fazio D, Moriguchi JD, Fonarow GC, Salehmoghaddam S, Kubak B, Alejos JC,
Galindo A, Kobashigawa JA. Clinical and Laboratory Studies in Thoracic Organ Transplantation.
Scientific Sessions 2000, New Orleans, Louisiana, November 12-15, 2000. Circulation 2000;102:II763.
59
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
137.
Rose ML, Danskine A, Smith JD, Keogh AM, Dureau G, Kobashigawa JA, Dunn MJ,
Mycophenolate Mofetil (MMF) Depresses Antibody Production after Cardiac Transplantation.
Scientific Sessions 2000, New Orleans, Louisiana, November 12-15, 2000. Circulation 2000;102:II-.
138.
Tran TD, Han S, Saab S, Hage A, Kobashigawa J, Lassman C, Martin P. Outcome After
Orthotopic Heart Transplantation of Patients with Underlying Liver Disease. International
Transplantation Society, Scientific Session 2000, Rome, Italy, August 2000.
139.
Rose M, Smith J, Dureau G, Keogh A, Kobashigawa J. Mycophenolate Mofetil (MMF)
Decreases Antibody Production After Cardiac Transplantation. International Transplantation
Society, Scientific Session 2000, Rome, Italy, August 2000.
140.
Boles J, Fonarow G, Kobashigawa J, Hamilton M, Laks H, Feliciano Z. The Role of Implantable
Cardioverter-Defibrillators in Advanced Graft Failure Patients Awaiting Orthotopic Heart
Transplantation. J Am Coll Cardiol 2001; 37:108A.
141.
Cui G, Kobashigawa J, Sen L. Etiology of Atrioventricular Conduction Block in Patient
Following Heart Transplantation. J Am Coll Caridiol 2001; 37:189A.
142.
Gass A, Eisen H, Griffith B, Kobashigawa J, Koerner M, Mancini D, Mehra M, Meiser B,
Webber S. Immunosuppression Induction, Maintenance and Rejection Regimens in 213
Consecutive Transplant Recipients. J Heart Lung Transplant 2001; 20: 121.
143.
Tsai F, Marelli D, Laks H, Bresson J, Houston E, Friend L, Kobashigawa J, Lackey S, Camara R.
Outcome of Hepatitis C Positive Donors in Cardiac Transplant Recipients in Triple Drug
Immunosuppression (TDI). J Heart Lung Transplant 2001; 20: 177.
144.
Giesler G, Espejo M, Kubak B, Moriguchi J, Patel J, Laks H, Kobashigawa J. Increased Risk of
CMV Infection in Heart Transplant Patient on Mycophenolate Mofetil. J Heart Lung Transplant
2001; 20: 178.
145.
Shivkumar K, Espejo M, Kobashigawa J, Watanabe M, Ikeda M, Chuang J, Patel J, Moriguchi J,
Hamilton M, Kawata N, Laks H. Sudden Death After Heart Transplantation: The Major Mode of
Death. J Heart Lung Transplant 2001; 20: 180.
146.
Radovancevic B, McGiffin DC, Kobashigawa JA, Cintron GB, Mullen GM, Pitts DE, O’Donnell
J, Thomas C, Bourge RC, Naftel DC. A Multi-Institutional Study of Cardiac Retransplantation:
Incidence, Risk Factors for Mortality, and Outcome. J Heart Lung Transplant 2001; 20: 181.
147.
Tsai F, Marelli D, Laks H, Houston E, Sykes A, Bresson J, Friend L, Vellaca A, Burch C,
Kobashigawa J. Cardiac Allografts with Ischemic Time Over 300 Minutes. J Heart Lung Transplant
2001; 20: 182.
148.
Blakey JD, Kobashigawa J, Laks H, Espejo ML, Fishbein M. Sudden, Unexpected Death in
Cardiac Transplant Recipients: An Autopsy Study. J Heart Lung Transplant 2001; 20: 229.
149.
Gajjar NA, Kobashigawa J, Laks H, Fishbein M. FK506 vs. Cyclosporin: Pathologic Findings in
1067 Endomyocardial Biopsies. J Heart Lung Transplant 2001; 20: 229.
150.
Espejo M, Kobashigawa J, Moriguchi J, Patel J, Kumar N, Hamilton M, Hage A, Kawata N, Laks
H. The Dilemma of Disability After Heart Transplantation. J Heart Lung Transplant 2001; 20: 244.
151.
Marelli D, Tsai F, Laks H, Houston E, Bresson J, Friend L, Gjertson D, Sykes A, Ardehali A,
Esmailian F, Hamilton M, Fonarow G, Moriguchi J, Plunkett M, Hage A, Brown M, Mark M,
Kobashigawa J. Use of Heart Transplanted from Donors with Atraumatic Intracranial Bleeds. J
Heart Lung Transplant 2001; 20: 256.
152.
Gass A, Eisen H, Griffith B, Kobashigawa J, Koerner M, Mancini D, Mehra M, Meiser B,
Webber S, Young J, Gilb E, Tuteja S. Current practices: immunosuppression induction,
maintenance and rejection regimens in 213 consecutive transplant recipients. J Heart Lung
Transplant. 2001 Feb;20(2):162
60
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
153.
Cogert G, Kobashigawa J, Espejo M, Patel J, Moriguchi J, Laks H. Plasmapheresis Lowers the
Incidence of Transplant Coronary Artery Disease following Hemodynamic Transplant Rejection.
AST Chicago, Chicago Sheraton Hotel, May 15, 2001.
154.
Incidence of Biopsy-Proven Cardiac Transplant Rejection Through the 90’s Decade. The 2nd
International Congress on Immunosuppression. San Diego, CA. Dec. 6, 2001.
155.
The Growing Threat of Malignancies Under Various Heart Transplant Immunosuppressive
Regimens From a Single Institution. The 2nd International Congress on Immunosuppression. San Diego,
CA. Dec. 6, 2001.
156.
Espejo ML, Subherwal S, Hamilton M, Go S, Almeda P, Kobashigawa JA. Is donor heart rejection
truly a risk factor for the development of transplant coronary artery disease after heart
transplantation [abstract]. J Investig Med 2002;50(1):39A.
157.
Subherwal S, Espejo ML, Hamilton M, Kobashigawa JA. The decreasing incidence of cardiac
allograft rejection and its impact on clinical trials [abstract]. J Investig Med 2002;50(1):39A.
158.
Is donor heart rejection truly a risk factor for the development of transplant coronary artery disease
after heart transplantation? American Transplant Congress. Washington, D.C. April 29, 2002.
159.
Takemoto S, Gjertson D, Cecka J, Espejo M, Kobashigawa J, Fishbein M, Reed E. Association
between post-transplant HLA antibody and histopathologic diagnosis of humoral rejection. ASHI
Meeting - Hum. Immunol. 2002 Oct;63(10 Suppl):S84
160.
Evangelista L, Dracup K, Doering, Kobashigawa J. Health Risks and Quality of Life of Female
Heart Transplant Recipients. American Heart Association Scientific Sessions 2002. Chicago, IL. Nov.
17-20, 2002.
161.
Gerard I, Doering L, Evangelista L, Dracup K, Kobashigawa J. What Factors Contribute to
Emotional Distress in Women after Heart Transplant? American Heart Association Scientific Sessions
2002. Chicago, IL. Nov. 17-20, 2002.
162.
Reyes C, Evangelista L, Doering L, Dracup K, Kobashigawa J. What Predicts Fatigue in Women
after Heart Transplant? American Heart Association Scientific Sessions 2002. Chicago, IL. Nov.
17-20, 2002.
163.
Cogert GA, Shivkumar K, Hamilton M, Espejo-Vassilakis M, Almeda NP, Kobashigawa JA. The
use of implantable cardioverter defibrillators in heart transplant patients at risk for sudden death
[abstract]. J Investig Med 2003;51(1):S115.
164.
Subherwal S, Cogert GA, Hamilton M, Wu G, Patel JK, Espejo Vassilakis M, Fishbein MC,
Kobashigawa JA. Incidence of non-cellular (humoral) rejection unchanged in the 1990 decade
despite a decrease in cellular rejection [abstract]. J Investig Med 2003;51(1):S115-6.
165.
Go SE, Lee P, Almeda NP, Subherwal S, Cogert G, Cole B, Vassilakis ME, Wang E, Hamilton M,
and Kobashigawa JA. The effects of immunosenescence on biopsy proven rejection in older
heart transplant recipients [abstract]. J Investig Med 2003;51(1):S116.
166.
Wheat J, Odim J, Laks H, Osugi A, Mukherjee K, Alikhani A, Saleh S, Kobashigawa J.
Preoperative renal function and outcomes following orthotopic heart transplantation [abstract]. J
Investig Med 2003;51(1):S170-171.
167.
Zaia B, Gleason BS, Laks H, Mulder D, Kobashigawa JA, Alikhani A, Odim J. Outcomes of
heart transplantation using refurbished allografts [abstract]. J Investig Med 2003;51(1):S171.
168.
Patel JP, Espejo Vassilakis M, Cole B, Kessler L, Kubak B, Kobashigawa JA, Patel JK. Outcomes
Following Cardiac Transplantation in Patients Receiving Allografts from Hepatitis C Positive
Donors – The UCLA Experience. Presented at American College of Cardiology Scientific Session,
Chicago, IL, Apr 2003.
61
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
169.
Cruz D, Espejo Vassilakis M, Garfinkel A, Moriguchi J, Fonarow G, Fishbein M, Kobashigawa J,
Patel J. The vagrancy of B-type natriuretic peptide (BNP) levels in orthotopic heart transplant
(OHT) recipients. Presented at American College of Cardiology Scientific Session, Chicago, IL, April 2003.
170.
Odim J, Gleason C, Zaia B, Mulder D, Kobashigawa J, Alikhani A, Laks H. Outcome of heart
transplantation using refurbished allografts [abstract]. J Heart Lung Transplant 2003;22(1S):S87.
171.
Kao J, Fishbein MC, Kobashigawa JA, Patel JK, McLellan RC, Burdick M, Belperio J, Strieter RM.
Elevated levels of the CXCR3 chemokine ligand ITAC is associated with the development of
severe transplant coronary artery disease in humans [abstract]. J Heart Lung Transplant
2003;22(1S):S97-98.
172.
Cogert GA Subherwal S, Wu G, Patel JK, Vassilakis ME, Fishbein MC, Moriguchi J, Laks H, and
Kobashigawa JA. Incidence of non-cellular (humoral) rejection unchanged in the 1990 decade
despite a decrease in cellular rejection [abstract]. J Heart Lung Transplant 2003;22(1S):S119-120.
173.
Bellg AJ, Grady KL, Naftel DC, Rybarczyk B, Young J, Pelegrin D, Patton-Schroeder K,
Kobashigawa J, Chait J, Kirklin J, White-Williams C, Heroux A, Piccione Jr W. Patient adherence
at 5 to 6 years after heart transplantation [abstract]. J Heart Lung Transplant 2003;22(1S):S127.
174.
Gerard I, Doering LV, Evangelista L, Dracup K, Kobashigawa J. What contributes to emotional
distress in female heart transplant recipients? [abstract]. J Heart Lung Transplant 2003;22(1S):S131S132.
175.
Baird BL, Velleca AW Erickson VS, Woo MA, Patel JK, Hamilton MA, Kobashigawa JA, and
Dracup KA. Rapid assessment of quality of life in patients with advanced heart failure [abstract]. J
Heart Lung Transplant 2003;22(1S):S132.
176.
Espejo Vassilakis M, Kobashigawa JA, Subherwal S, Fishbein MC, Patel JK, Moriguchi J, Go S,
Almeda P and Laks H. Scoring of 2.788 endomyocardial biopsies correlate rejection to the
development of transplant coronary artery disease after heart transplantation [abstract]. J Heart
Lung Transplant 2003;22(1S):S139.
177.
Takemoto SK, Gelbard A, Yuan GW, Vassilakis ME, Michaels PJ, Gjertson DW, Fishbein MC,
Reed EF, Kobashigawa JA. Impact of post-transplant antibody in a re-examination of humoral
rejection diagnosis [abstract]. J Heart Lung Transplant 2003;22(1S):S170-S171.
178.
Odim JNK, Wheat J, Osugi A, Mukherjee K, Alikhani A, Salehi-Rad R, Kobashigawa J, Laks H.
Pre-operative renal function and outcomes following orthotopic heart transplantation [abstract]. J
Heart Lung Transplant 2003;22(1S):S176.
179.
Cogert GA, Shivkumar K, Patel JK, Weiner I, Moriguchi J, Espejo Vassilakis M, Laks H, and
Kobashigawa JA. Implantable cardioverter defibrillators in heart transplant patients at risk for
sudden death: shocking news? [abstract]. J Heart Lung Transplant 2003;22(1S):S178-179.
180.
Grady, KL, Naftel DC, White-Williams C, Belig AJ, Young J, Pelegrin D, Patton-Schroeder K,
Kobashigawa J, Chait J, Kirklin J, Piccione Jr W, McLeod M, Heroux A. Predictors of quality of
life at 5 to 6 years after heart transplantation [abstract]. J Heart Lung Transplant 2003;22(1S):S220.
181.
Evangelista LS, Doering LV, Dracup K, Kobashigawa J. Measuring physical activity among
female heart transplant recipients [abstract]. J Heart Lung Transplant 2003;22(1S):S220.
182.
Cole BT, Kobashigawa JA, Patel JP, Moriguchi J, Espejo Vassilakis M, Go SE, Chait J, Laks H.
Perception is deceiving; the real gender specific exercise capacity of heart transplant recipients
[abstract]. J Heart Lung Transplant 2003;22(1S):S220-221.
183.
Kobashigawa JA, ML Barr, G Bhat, RL Kormos, MR Mehra and RC Starling. Multi-Center
Retrospective Analysis of Cardiovascular and Immunologic Risk Factors Affecting Survival of de
Novo Cardiac Transplant Recipients. Accepted for presentation at International Society for Heart and
Lung Transplantation Annual Meeting, Vienna, Austria, April 2003.
62
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
184.
Kobashigawa JA, Takano Y, Tobis JM, Cogert, G, Espejo Vassilakis M, Moriguchi J, Laks H. A
randomized trial switching from azathioprine to mycophenolate mofetil in cardiac transplant
patients with newly diagnosed angiographic transplant coronary artery disease. Accepted for
presentation at American Transplant Congress, Washington DC, June 2003.
185.
Kobashigawa JA, Starling RC, Mehra MR, Bhat G, Kormos RL, and Barr ML. Impact of ongoing
post cardiac transplant risk factors on outcomes: A multi-center study. Accepted for presentation
at American Transplant Congress, Washington DC, June 2003.
186.
Kobashigawa JA, Cogert GA, Tobis JM, Currier J, Espejo Vassilakis M, Patel JK, Moriguchi JD,
Laks H. Improved survival of heart transplant patients with severe transplant coronary artery
disease in the era or percutaneous coronary intervention and statin therapy. Accepted for
presentation at American Transplant Congress, Washington DC, June 2003.
187.
Ji S, Cesario D, Valderrabano M, Cote S, Hardie M, Boyle NG, Shannon KM, Espejo-Vassilakis M,
Hamilton MA, Hage A, Moriguchi JD, Patel JK, Kobashigawa JA, Wiener I, Shivkumar K, UCLA
Cardiac Arrhythmia Center, Los Angeles, CA. Mechanistic Basis of Supraventricular Arrhythmias
Following Orthotopic Cardiac Transplantation. Accepted for presentation at American Heart
Association Conference 2003, Orlando, FL, November 9-11, 2003.
188.
Cui G, Fonarow G, Kobashigawa JA, Hamilton M, Moriguchi J, Sen L; UCLA Medical
Center/UCLA School of Medicine, Los Angeles, CA. Genotype-Phenotype Correlation of RYR2
Gene Mutations in Inherited Idiopathic Dilated Cardiomyopathy. Accepted for presentation at
American Heart Association Conference 2003, Orlando, FL, November 9-11, 2003.
189.
Deng MC, Columbia University, New York, NY; Mehra MC, Ochsner Clinic, New Orleans, LA;
Eisen HJ, Temple University, Philadelphia, PA; Billingham M, Berry G, Stanford University,
Stanford, CA; Marboe C, Itescu S, Columbia University, New York, NY; Johnson F, Palo Alto VA
Medical Center, Palo Alto, CA; Kobashigawa JA, University of California Los Angeles, Los
Angeles, CA; Wohlgemuth JG, Expression Diagnostics, South San Francisco, CA; Quertermous T,
Hunt S; Stanford University, Stanford, CA. Cardiac Allograft Monitoring Using a Novel Clinical
Algorithm Based on Peripheral Leukocyte Gene Expression Profiling. Accepted for presentation
at American Heart Association Conference 2003, Orlando, FL, November 9-11, 2003.
190.
Mehra MR, Uber PA, Park MH, Scott RL, Ventura HO, Deng MC, Eisen H, Billingham M,
Kobashigawa JA, Zeevi A, Wohlgemuth J, Phillips J, Hunt S. Molecular Pathways of Cardiac
Allograft Dysfunction Independent of Acute Cellular Rejection. Accepted for presentation at
American Heart Association Conference 2003, Orlando, FL, November 9-11, 2003.
191.
Go SE, Almeda NP, Hamilton M, Kobashigawa JA. Success of geriatric heart transplantation
[abstract]. J Investig Med 2004;52(1):S168.
192.
Almeda NP, G Cogert, P Lee, Go SE, Hamilton M, Kobashigawa JA. Concern of corticosteroid
weaning after heart transplantation [abstract]. J Investig Med 2004;52(1):S168-9.
193.
Nakashima J, Marquez A, Oeser BT, Hamilton M, Kobashigawa JA. Early development of
cardiac allograft vasculopahty has poor outcome after heart transplantation [abstract]. J Investig Med
2004;52(1):S169.
194.
Sue E, Marquez A, Kobashigawa E, Hamilton M, Kobashigawa JA. The development of left
ventricular hypertrophy: not a marker for poor outcome after heart transplantation [abstract]. J
Investig Med 2004;52(1):S169.
195.
Marquez A, Sue E, Kobashigawa E, Hamilton M, Kobashigawa JA. The effects of high blood
pressure on outcome after heart transplantation [abstract]. J Investig Med 2004;52(1):S169.
196.
Kobashigawa JA, Patel JK, Marquez A, Oeser BT, Moriguchi JD, Laks H, University of
California, Los Angeles, Los Angeles, CA. The renal benefit of calcinerin inhibitor-free
immunosuppression after heart transplantation: Is it safe? [abstract]. J Am Coll Cardiol 2004;43(5
SupplA):193A.
63
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
197.
Mitropoulos F, Laks H, Neelankavil J, Alejos J, Child JS, Allada V, Drant S, Kobashigawa JA,
Odim J, Fishbein M, Plunkett M. Failing Fontan Circulation Necessitating Transplantation: A
Clinicopathologic Correlation [abstract]. J Am Coll Cardiol 2004;43(5 SupplA):390A.
198.
Mitropoulos F, Laks H, Neelankavil J, Odim J, Alejos J, Kobashigawa JA, Plunkett M.
Orthotopic Heart Transplantation in Patients with Fontan Circulation. Accepted for presentation
at the Annual Society of Thoracic Surgery Conference 2004, San Antonio, TX, January 2004.
199.
Kobashigawa JA, Tobis J, Mentzer RM, Valantine HA, Bourge RC, Smart FW, Miller LW,
Gordon RD. Further analysis of the intravascular ultrasound data from the randomized
mycophenolate mofetil (MMF) trial in heart transplant recipients [abstract]. J Heart Lung Transplant
2004;23(2 Suppl 1):S42.
200.
Kobashigawa JA, Davis SF, Renlund DG, Hummel M, Gerosa G, Brambilla R. Enteric-coated
mycophenolate sodium (EC-MPS) vs. mycophenolate mofetil (MMF) in de novo heart transplant
patients: 6 month efficacy and safety results [abstract]. J Heart Lung Transplant 2004;23(2 Suppl
1):S44-S45.
201.
Eisen H, Kobashigawa J, Starling RC, Cretin N, Jaffe JS, Murphy J. 24-month safety results of a
randomized multicenter, double-blind study of everolimus vs. azathioprine in de novo heart
transplant recipients [abstract]. J Heart Lung Transplant 2004;23(2 Suppl 1):S45.
202.
Kobashigawa JA, Moriguchi JD, Patel J, Shaw J, Oeser BT, and Laks H. Five-year results of a
randomized single center study of tacrolimus (TAC) vs. neoral cyclosporine (CYA) [abstract]. J
Heart Lung Transplant 2004;23(2 Suppl 1):S46.
203.
Kobashigawa JA, Tobis JM, Starling RC, Tuzcu ME, Mehra MR, Yeung A, Valantine H, Smith A,
Anzai H, Oeser BT, Abeywickrama K, Murphy J, Cretin N. Multi-center intravascular ultrasound
validation study among heart transplant recipients: Outcomes after 5 years [abstract]. J Heart Lung
Transplant 2004;23(2 Suppl 1):S51.
204.
Tuzcu EM, Kobashigawa JA, Eisen HJ, Starling RC, Crowe T, Abeywickrama K, Jaffe JS.
Favorable effect of everolimus on cardiac allograft vasculopathy is maintained through 24 months
[abstract]. J Heart Lung Transplant 2004;23(2 Suppl 1):S51.
205.
Takemoto SK, Zhang J, Chang E, Shaw J, Ayele PA, Oeser BT, Gjertson DW, Fishbein MC, Reed
ER, Kobashigawa JA. Significance of persistent post-transplant antibody after cardiac
transplantation [abstract]. J Heart Lung Transplant 2004;23(2 Suppl 1):S60.
206.
Kobashigawa JA, Cogert G, Moriguchi JD, Patel JK, Laks H. The highly sensitized patient
awaiting heart transplantation: success with combination therapy of plasmapheresis and
intravenous gamma globulin [abstract]. J Heart Lung Transplant 2004;23(2 Suppl 1):S61.
207.
Takemoto SK, Cogert G, Oeser BT, Ayele PA, Gjertson DW, Fishbein MC, Reed ER,
Kobashigawa JA. Outcome after pre-transplant plasmapheresis for sensitized recipients awaiting
heart transplantation [abstract]. J Heart Lung Transplant 2004;23(2 Suppl 1):S61.
208.
Grady KL, Naftel DC, Kirklin JK, White-Williams C, Kobashigawa J, Chait J, Young JB, Pelegrin
D, Patton-Schroeder K, Rybarczyk B, Daily J, Piccione W, Heroux A. Predictors of physical
functional disability at 5-6 years after heart transplantation [abstract]. J Heart Lung Transplant
2004;23(2 Suppl 1):S66.
209.
Patel JK, Oeser BT, Go S, Rivera BJ, Plesa ML, Moriguchi JD, Kobashigawa JA.
Retransplantation – never too old for one? [abstract]. J Heart Lung Transplant 2004;23(2 Suppl
1):S72.
210.
Srikanthan P, Hsueh WA, Kobashigawa JA. The use of thiazolidinedione agents in post cardiac
transplant diabetic patients [abstract]. J Heart Lung Transplant 2004;23(2 Suppl 1):S90.
211.
Cui G, Kobashigawa J, Sen L. Etiology of low voltage of QRS complex after heart transplantation
[abstract]. J Heart Lung Transplant 2004;23(2 Suppl 1):S98-S99.
64
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
212.
Kobashigawa JA, Miller L, Russell S, Ewald G, Zucker M, Goldberg L, Eisen H, Tolzman D,
Fitzsimmons WE.
A randomized, prospective, multi-center comparison of tacrolimus,
mycophenolate mofetil (MMF) and steroids vs. cyclosporine (modified usp) MMF and steroids vs.
tacrolimus, sirolimus and steroids in de novo cardiac transplant recipients – 6 month report
[abstract]. J Heart Lung Transplant 2004;23(2 Suppl 1):S106.
213.
Mehra MR, Kobashigawa J, Hunt S, Eisen HJ, Starling R, Johnson FL, Murali S, Pauly D,
Wohlgemuth JG, Morris MS, Woodward R, Deng MC. Molecular testing and prediction of clinical
outcome in heart transplantation: a prospective multicenter trial [abstract]. J Heart Lung Transplant
2004;23(2 Suppl 1):S106.
214.
Kobashigawa JA, Moriguchi JD, Cogert G, Hage A, Hamilton MA, Vassilakis ME, Marquez A,
Yeatman L, Patel J, Laks H. 10-year results of the pravastatin randomized trial in heart transplant
recipients [abstract]. J Heart Lung Transplant 2004;23(2 Suppl 1):S115.
215.
Starling RC, Kobashigawa J, Eisen H, Jaffe J, Li Y. Risk factors for acute rejection and
casculopathy among 634 patients treated with everolimus or azathioprine [abstract]. J Heart Lung
Transplant 2004;23(2 Suppl 1):S138-S139.
216.
Kobashigawa JA, Patel JK, Cogert G, Almeda NP, Go S, Lee P, Camara R, Velleca A, Laks H.
The dark side of corticosteroid weaning after heart transplantation: Is it worth it? Am J Transplant
2004;4(8):174
217.
Kobashigawa JA, Tobis JM, Mentzer RM, Valantine HA, Bourge RC, Smart FW, Miller LW,
Gordon RD. Further analysis of the intravascular ultrasound data from the randomized
mycophenolate mofetil (MMF) trial in heart transplant recipients. Accepted for presentation at the
American Transplant Congress Annual Meeting 2004, Boston, MA, May 15-19, 2004.
218.
Kobashigawa JA, Patel JK, Cogert G, Almeda NP, Go S, Lee P, Camara R, Velleca A, Laks H.
The dark side of corticosteroid weaning after heart transplantation: Is it worth it? Accepted for
presentation at the American Transplant Congress Annual Meeting 2004, Boston, MA, May 15-19, 2004.
219.
Patel JK, Marquez A, Sue E, Kobashigawa E, Laks H, Kobashigawa JA. The development of left
ventricular hypertrophy after heart transplantation: Is this a marker for poor outcome. Accepted
for presentation at the American Transplant Congress Annual Meeting 2004, Boston, MA, May 15-19,
2004.
220.
Patel JK, Go S, Fonarow G, Oeser BT, Laks H, Kobashigawa JA. Heart transplantation for
patients greater than 65 years: Are we expecting too much? Accepted for presentation at the
American Transplant Congress Annual Meeting 2004, Boston, MA, May 15-19, 2004.
221.
Patel JK, Nakashima J, Moriguchi JD, Oeser BT, Marquez A, Laks H, Kobashigawa JA. Poor
outcome of early development of cardiac allograft vasculopathy after cardiac transplantation.
Accepted for presentation at the American Transplant Congress Annual Meeting 2004, Boston, MA,
May 15-19, 2004.
222.
Srikanthan P, Hsueh WA, Kobashigawa JA.
Novel immunosuppressive effects of
thiazolidinedione agents in post cardiac transplant diabetic patients. Accepted for presentation at
the American Transplant Congress Annual Meeting 2004, Boston, MA, May 15-19, 2004.
223.
Mitropoulos FA, Laks H, Kermani R, Marelli D, Ardehali A, Plunkett M, Esmailian F, Odim J,
Moriguchi J, Hamilton M, Patel J, Kobashigawa J. Use of donor hearts with left ventricular
ejection fraction 50% for transplantation. Accepted for presentation at the American Transplant
Congress Annual Meeting 2004, Boston, MA, May 15-19, 2004.
224.
Kobashigawa JA, David K, Chu A, Morris J, Steffen B, Gordon R. Daclizumab versus no
induction therapy, in combination with cyclosporine microemulsion, mycophenolate mofetil, and
corticosteroids, is associated with decreased acute rejection in cardiac transplant recipients and no
observed increase in mortality. Accepted for presentation at the XX International Congress of The
Transplantation Society, Vienna, Austria, September 5-10, 2004.
65
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
225.
Kobashigawa JA, Morris JA, David KM, Chu AH, Steffen BJ, Gordon RD. Daclizumab versus
no inductions therapy, in combinations with cyclosporine microemulsion, mycophenolate mofetil,
and corticosteroids, is associated with decreased acute rejection in cardiac transplant recipients and
no observed increase in mortality. The American Heart Association, Nov 7-10, 2004.
226.
White-Williams C, Grady K, Naftel DC, Kobashigawa J, Chait J, Kirklin JK, Young JB, Pelegrin
D, Patton-Schroeder K, Piccione W, M McLeod, Rybarezyk B, Marenda R, Heroux A. Working at
five to six years after heart transplantation. Circulation 2004;110(17):III-700.
227.
Nakashima JK, Kobashigawa JA, Patel JK, Yamada C, Hamilton M. Patients with refractory
hypercholesterolemia have poor outcome after heart transplantation [abstract]. J Investig Med
2005;53(1):S83.
228.
Seid A, Kobashigawa JA, Patel JK, Yamada B, Hamilton M. A multidisciplinary network of social
support can positively affect outcome in lower socioeconomic patients (medical/Medicaid
insurance) after heart transplantation [abstract]. J Investig Med 2005;53(1):S96.
229.
Alison-Mayne S, Patel JK, Kobashigawa JA, Laks H, Hamilton M. The use of marginal donor
hearts in heart transplant patients [abstract]. J Investig Med 2005;53(1):S96.
230.
Almeda NP, Odim J, Laks H, Patel JK, Hamilton M, Kobashigawa JA. Bypassed donor hearts:
the long term outcome after heart transplantation [abstract]. J Investig Med 2005;53(1):S121-2.
231.
Go SE, Kobashigawa JA, Patel JK, Hamilton M. Asymptomatic humoral rejection diagnosed on
endomyocardial biopsy after heart transplant appears to have clinical significance [abstract]. J
Investig Med 2005;53(1):S122.
232.
Plesa M, Patel JK, Marquez A, Nakashima J, Kobashigawa JA.
Ezetimibe for
hypercholesterolemia in patients after heart transplant [abstract]. J Investig Med 2005;53(1):S145.
233.
Li H, Tanaka K, Chhabra A, Vadnais D, Kobashigawa J, Tobis J. Vascular remodeling patterns
one year after cardiac transplantation [abstract]. J Am Coll Cardiol 2005 Feb;45(Suppl 1):150A.
234.
Li H, Tanaka K, Hitoshi A, Oeser B, Kobashigawa J, Tobis JM. Influence of donor transmitted
atherosclerosis on the development of cardiac allograft vasculopathy [abstract]. J Am Coll Cardiol
2005 Feb;45(Suppl 1):155A-156A.
235.
Busuttil AA, Horwich TB, Fonarow GC, Patel J, Kobashigawa JA. Anemica is associated with a
significant increase in mortality in the orthotopic heart transplant population [abstract]. J Am Coll
Cardiol 2005 Feb;45(Suppl 1):156A.
236.
Kobashigawa JA, Patel JK, Marquez A, Oeser BT, Velleca A, Camara R, Laks H. Calcineurin
inhibitor-free renal sparing protocol for patients with renal insufficiency after heart transplantation:
trouble on the horizon? [abstract]. J Am Coll Cardiol 2005 Feb;45(Suppl 1):157A.
237.
Kobashigawa JA, Ro Thomas, Fishbein MC, Patel JK, Oeser BT, Laks H. Biopsy-proven ISHLT
grades 1A, 1B, and 2 rejection in heart transplant patients: should we re-classify them into one mild
rejection grade? [abstract]. J Am Coll Cardiol 2005 Feb;45(Suppl 1):157A.
238.
Kobashigawa JA, Miller LW, Russell SD. A randomized, prospective, multicenter comparison of
Tacrolimus, Mycophenolate Mofetil (MMF) and steroids vs. Cyclosporine Microemulsion, MMF
and steroids vs. Tacrolimus, Sirolimus and steroids in de novo cardiac transplant recipients – 6
month report. Presented at 3rd International Congress on Immunosuppression, San Diego, CA, Dec 8-11,
2004.
239.
Kobashigawa JA, Tobis J, Mentzer RM, Valantine HA, Bourge RC, Mehra MR, Smart FW, Miller
LW, and Gordon RD. Further analysis of the intravascular ultrasound data from the randomized
Mycophenolate Mofetil (MMF) trial in heart transplant recipients. Presented at 3rd International
Congress on Immunosuppression, San Diego, CA, Dec 8-11, 2004.
240.
Kobashigawa JA, Keogh AM, Aaronson K, Perrone S, Brambilla R.
Enteric-coated
mMycophenolate sodium (EC-MPS) in de novo heart transplant patients: 12-month efficacy and
66
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
safety data. Presented at 3rd International Congress on Immunosuppression, San Diego, CA, Dec 8-11,
2004.
241.
Kobashigawa JA, Patel JK, Furukawa H, Marquez A, Oeser BT, Laks H. Five-year results of a
randomized single center study of Tacrolimus vs. Microemulsion Cyclosporine in heart transplant
patients. Presented at 3rd International Congress on Immunosuppression, San Diego, CA, Dec 8-11, 2004.
242.
Almeda NP, Kobashigawa JA, Patel JK, Camara R, Velleca A, and Laks H. Corticosteroid
weaning after heart transplantation: A five-year risk assessment. Presented at 3rd International
Congress on Immunosuppression, San Diego, CA, Dec 8-11, 2004.
243.
Marquez A, Kobashigawa JA, Patel JK, Oeser BT, Velleca A, Camara R, Laks H.
Cyclosporine/Tacrolimus-free renal sparing protocol for patients with renal insufficiency after
heart transplantation: is it safe? Presented at 3rd International Congress on Immunosuppression, San
Diego, CA, Dec 8-11, 2004.
244.
Grady KL, Rybarcyzk B Naftel DC, Kirklin JK, White-Williams C, Kobashigawa J, Chait J,
Young JB, Pelegrin D, Czerr J, Higgins R, McLeod M, Rissinger J, Heroux A. Predictors of
negative affect at 5-6 years after heart transplantation [abstract]. J Heart Lung Transplant 2005
Feb;24(2S):S45.
245.
Hare JM, Perrone S, Eisen H, McChurry K, Hauptman P, Simonsen S, Crespo M, Arizon J,
Kobashigawa J, Jarcho J. Everolimus in de novo cardiac transplant recipients: 48-month (M)
follow-up [abstract]. J Heart Lung Transplant 2005 Feb;24(2S):S61.
246.
Kobashigawa JA, Miller LW, Felker GM, Russel SD, Ewald GA, Zucker M, Goldberg L, Eisen
HJ, Rayburn BK, Wagoner LE, Philbin E, Pereira N, Czerska B, Kormos RL, Weston M, Conte J,
Hosenpud J, Aaronson K, Hill J, Copeland JG, Czer L, Anderson A, Dec, GW, Torre-Amione G,
Yancy CW, Vega JD, Jarcho JA, Mancini D, Bhat G, First, R, Fitzsimmons W, Tolzman D, Salm
K, Gao J. 12 month report of a 3 arm multicenter comparison of tacrolimus (tac), mmf or
tac/siolimus(srl) and steroids vs cyclosporine microemulsion(cya), mmf, and steroids in de novo
cardiac transplant recipients [abstract]. J Heart Lung Transplant 2005 Feb;24(2S):S61-2.
247.
Starling RC, Deng MC, Kobashigawa JA, Walther D, Wohlgemuth J, Rosenberg S, Mehra MR..
The influence of corticosteroids on the alloimmune molecular signature for cardiac allograft
rejection [abstract]. J Heart Lung Transplant 2005 Feb;24(2S):S65-6.
248.
Patel JK, Ro T, Fishbein MC, Oeser BT, Marquez A, Laks H, Kobashigawa JA. Justification of
the newly proposed ISHLT biopsy grading scale by combining grades 1A, 1B, and 2 into one mild
rejection grade [abstract]. J Heart Lung Transplant 2005 Feb;24(2S):S66.
249.
Laks H, Mitropoulos F, Odim J, Patel JK, Marquez A, Plesa M, Oeser BT, Kobashigawa JA.
Long-term outcome of alternate list heart transplant patients [abstract]. J Heart Lung Transplant
2005 Feb;24(2S):S70.
250.
Odim J, Laks H, Almeda NP, Patel JK, Kobashigawa JA. CABG-patched donor hearts: the long
term outcome [abstract]. J Heart Lung Transplant 2005 Feb;24(2S):S71.
251.
Eisen HJ, Mancini D, Vigano M, Kobashigawa J. Evaluation of cyclosporine (CsA) profiles
month 2 to 6 in an international phase III randomized, multicenter, double-blind study of
everolimus in de novo heart transplant recipients [abstract]. J Heart Lung Transplant 2005
Feb;24(2S):S89.
252.
Li H, Tanaka K, Anzai H, Oeser B, Kobashigawa J, Tobis JM. Influence of donor transmitted
atherosclerosis on the development of cardiac allograft vasculopathy [abstract]. J Heart Lung
Transplant 2005 Feb;24(2S):S90-1.
253.
Lepin EJ, Hong L, Zhang QJ, Gjertson DW, Kobashigawa JA, Fishbein MC, Reed EF.
Phosphorylation of S6 ribosomal protein at serine 235/236 is a marker of human heart
transplantation [abstract]. J Heart Lung Transplant 2005 Feb;24(2S):S97.
67
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
254.
Kobashigawa JA, Fishbein MC, Patel JK, Oeser BT, Almeda NP, Alison-Mayne S, Seid A, Laks
H. Should humoral rejection be included in the new ISHLT biopsy grading scale [abstract]. J Heart
Lung Transplant 2005 Feb;24(2S):S144.
255.
Patel JK, Kobashigawa JA, Marquez A, Oeser BT, Velleca A, Camara R, Laks H. Caution using a
calcineurin inhibitor-free renal sparing protocol for heart transplant patients with renal dysfunction
[abstract]. J Heart Lung Transplant 2005 Feb;24(2S):S160.
256.
Kobashigawa JA, Renlund DG, Gerosa G, Caforio A, Ross H, Lehmkuhl HB, Eisen HJ, Segovia
J, Brambilla, R. Twelve months results of enteric-coated mycophenoalte sodium (EC-MPS) in de
novo heart transplant patients showed excellent efficacy and safety [abstract]. J Heart Lung
Transplant 2005 Feb;24(2S):S380.
257.
Patel JK, Mitropoulos F, Laks H, Moriguchi JD, Wang EZ, Oeser BT, Kobashigawa JA.
Nesiritide immediately after heart transplantation: a pilot study [abstract]. Am J Transplant
2005;5(Suppl 11):169.
258.
Odim J, Yao W, Laks H, Saran M, Kobashigawa J, Gjertson D. The influence of adverse donor
factors on outcome of pediatric heart transplantation – the marginal donor allograft [abstract]. Am
J Transplant 2005;5(Suppl 11):220.
259.
Lepin EJ, Jindra PT, Zhang Q, Jin YP, Kobashigawa JA, Fishbein MC, Reed EF. S6 ribosomal
protein is a novel biomarker of heart allograft rejection [abstract]. Am J Transplant 2005;5(Suppl
11):238.
260.
Kobashigawa JA, Gerosa G, Caforio A, Renlund DG, Ross H, Yonan N, Hummel M, Segovia J,
Almenar L, Brambilla R. Enteric Coated mycophenolate sodium (EC-MPS) is comparable to
mycophenolate mofetil in de novo heart transplant patients. Twelve month efficacy and safety
results [abstract]. Am J Transplant 2005;5(Suppl 11):244.
261.
Eisen JH, Mancini D, Vigano M, Kobashigawa J, Preiss M. Cyclosporin (CsA) profiles at months
(M) 2 to 6 in a randomized, multicenter, double-blind study of everolimus vs. azathioprine in de
novo heart transplant recipients [abstract]. Am J Transplant 2005;5(Suppl 11):244.
262.
Kobahisgawa JA, Miller LW, Russell SD, Ewald GA, Zucker M, First R, Fitzsimmons W, Salm K.
A randomized, prospective, multicenter comparison of tacrolimus (TAC), mycophenolate mofetil
(MMF) and steroids vs cyclosporine microemulsion, MMF and steroids vs TAC, sirolimus and
steroids in de novo cardiac transplant recipients 12 month report [abstract]. Am J Transplant
2005;5(Suppl 11):250.
263.
Kobashigawa J, Hare J, Eisen H, McCurry K, Hauptman P, Simonsen S, Arizon J, Perrone S,
Jarcho J, Moeller V. Everolimus in cardiac transplantation: 48 month results [abstract]. Am J
Transplant 2005;5(Suppl 11):251.
264.
Eisen H, Starling R, Yang L, Ricci F, Kobashigawa J. 4-year incidence of MACE and economic
burden in de novo heart transplant patients: a comparison of everolimus and azathioprine
[abstract]. Am J Transplant 2005;5(Suppl 11):251.
265.
Odim J, Saran M, Yao W, Kobashigawa J, Laks H. The fate of older cardiac allografts in
adolescents [abstract]. Am J Transplant 2005;5(Suppl 11):285.
266.
Laks H, Almeda P, Kobashigawa J, Odim J. Twenty-year single institution experience with 1460
heart transplants. Accepted for presentation at the 15th World congress 2005, WSCTS - World Society of
Cardio-Thoracic Surgeons, Le Meridien Villon Resort & Convention Centre, Vilnius, Lithuania,
Vienna, Austria, June 19-23, 2005.
267.
Miller S, Patel JK, Lee P, Wu GW, Chi L, Fishbein M, Laks H, Kobashigawa JA. Hemodynamic
Compromise Predicts Future Cardiac Allograft Vasculopathy and Nonfatal Major Ad verse Cardiac
Events. J Investig Med 2006;54(1):S120.
68
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
268.
Mansukhani A, Smooke S, Wu GW, Hamilton MA, Kobashigawa JA. The High Incidence of
Glucose Intolerance and New-Onset Diabetes after Cardiac Transplantation is not Affected by
Choice of Calcineurin Inhibitor. J Investig Med 2006;54(1):S120.
269.
Sarkissian S, Ro T, Patel JK, Wu GW, Hamilton MA, Kobashigawa JA. What is the Outcome of
International Society for Heart & Lung Transplantation Grade 1A/1B Rejections under Various
Immunosuppressive Regimens? J Investig Med 2006;54(1):S120.
270.
Kawano J, Cruz D, Wu GW, Patel JK, Sarkissian S, Vaidya V, Laks H, Kobashigawa JA. Average
First-Year Brain Natriuretic Peptide Predicts Poor Outcome after Heart Transplantation. J Investig
Med 2006;54(1):S149.
271.
Wu GW, Patel JK, Reed E, Gjertson D, Hamilton MA, Kobashigawa JA. Flow CytometryPositive, Cytotoxicity-Negative Donor-Specific Crossmatch: To Transplant or Not to Transplant,
That is the Question. J Investig Med 2006;54(1):S150.
272.
Seid A, Mansukhani A, Wu GWW, Hamilton MA, Kobashigawa JA. When to List for Redo Heart
Transplant in Patients with Severe Cardiac Allograft Vasculopathy. J Investig Med 2006;54(1):S150.
273.
Parikh A, Patel JK, Kubak B, Thompson OM, Patel JP, Hamilton MA, Kobashigawa JA.
Hepatitis C Donor Hearts in Noninduction Immunosuppressive Regimens Portend Poor Outcome
after Heart Transplantation. J Investig Med 2006;54(1):S150.
274.
Eisen H, Starling R, Kobashigawa J. 4-year incidence of MACE and economic burden in de novo
heart transplant patients: A comparison of everolimus and azathioprine (AZA). J Heart Lung
Transplant. 2006; 25(2S):59.
275.
Deng MC, Cadeiras M, Baron HM, Marboe HM, Starling RC, Eisen H, Valantine H, Hunt SA,
Kobashigawa J, Mehra MR, Pauly DF, Murali S, Mital S, Berry G, Billingham M, Wohlgemuth J,
Dedrick R. Early detection of cardiac allograft vasculopathy through gene expression profiling –
insights of the CARGO study. J Heart Lung Transplant. 2006; 25(2S):98.
276.
Patel JK, Seid A, Mansukhani A, Thompson OM, Wu GW, Laks H, Kobashigawa JA. When To
list for re-do heart transplant in patients with severe cardiac allograft vasculopathy. J Heart Lung
Transplant. 2006; 25(2S):100-101.
277.
Patel JK, Reed E, Gjertson D, Wu GW, Laks H, Kobashigawa JA. Flow-cytometry positive,
cytotoxicity-negative donor-specific crossmatch: To transplant or not to transplant, that is the
question. J Heart Lung Transplant. 2006; 25(2S):108.
278.
Patel JK, Lai C, Fishbein MC, Go SE, Wu GW, Laks H, Kobashigawa JA. Asymptomatic
humoral rejection after heart transplantation: Does it require therapy? J Heart Lung Transplant. 2006;
25(2S):109.
279.
Mehra MR, Kobashigawa JA, Deng MC, Johnson FL, Baron HM, Uber PA, Lal P, Klingler T,
Rosenberg S, Eisen HJ. The clinical role of gene expression testing in anticipating the future
development of acute cardiac allograft rejection. J Heart Lung Transplant. 2006; 25(2S):110.
280.
Kobashigawa J, Renlund DG, Lehmkuhl HB, Segovia J. Adequate cyclosporine (CsA)
microemulsion (Neoral®) C2-levels critical within the first 30 days to prevent rejection after
cardiac transplant. J Heart Lung Transplant. 2006; 25(2S):111.
281.
Patel JK, Parikh A, Kubak B, Thompson OM, Patel JP, Laks H, Kobashigawa JA. Hepatitis C
donor hearts in non-induction immunosuppressive regimens portend poor outcome after heart
transplantation. J Heart Lung Transplant. 2006; 25(2S):114.
282.
Grady KL, Naftel DC, Kobashigawa J, Chait J, Young JB, Pelegrin D, Czerr J, McLeod M,
Heroux A, Higgins R, White-Williams C, Kirklin JK. Patterns and predictors of quality of life at 5–
10 years after heart transplantation. J Heart Lung Transplant. 2006; 25(2S):131.
69
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
283.
Cruz D, Wu GW, Patel JK, Kawano J, Sarkissian S, Thompson OM, Vaidya V, Laks H,
Kobashigawa JA. Average first-year BNP predicts poor outcome after heart transplantation. J
Heart Lung Transplant. 2006; 25(2S):132.
284.
Ro T, Patel JK, Sarkissian S, Wu GW, Laks H, Kobashigawa JA. What is the outcome of ISHLT
grade 1A/1B rejections under various immunosuppressive regimens? J Heart Lung Transplant. 2006;
25(2S):134.
285.
Smooke S, Dev S, Patel JK, Kawano J, Almeda NP, Thompson OM, Wu GW, Laks H,
Kobashigawa JA. Pre-transplant glucose intolerance and not diabetes predicts non-fatal major
adverse cardiac events after cardiac transplantation. J Heart Lung Transplant. 2006; 25(2S):138.
286.
Lai CK, Reed EF, Zhang Q, Gjertson D, Cecka M, Kobashigawa JA, Wallace WD, Fishbein MC.
HLA Antibodies with C4d Staining and Pathologic Diagnosis of Humoral Rejection. Am J
Transplant. 2006; 6(2S):70.
287.
Odim O, Gleason C, Kobashigawa JA, Laks H, Gjertson D. The Impact of Gender Matching on
Mortality and Rejection after Heart Transplantation. Am J Transplant. 2006; 6(2S):551.
288.
Vaidya VS, Cruz D, Wu GW, Patel JK, Sarkissian S, Kawano J, Laks H, Kobashigawa JA.
Persistently Elevated B-Type Natriuretic Peptide (BNP) Levels after Acute Allograft Rejection in
Heart Transplant Recipients Predict Poor Outcomes. Am J Transplant. 2006; 6(2S):558.
289.
Patel JK, Kawano J, Wu GW, Laks H, Kobashigawa JA. Efficacy of Photopheresis for
Recurrent/Refractory Humoral and Cellular Rejections in Heart Transplant Patients. Am J
Transplant. 2006; 6(2S):146-7.
290.
Patel JK, Miller S, Kawano J, Sarkissian S, Seid A, Wu GW, Laks H, Kobashigawa JA.
Intravenous Immunoglobulin as Part of Combined Immunotherapy Appears Effective for Late
(>30 Days) Complex Rejection after Cardiac Transplantation. Am J Transplant. 2006; 6(2S):147.
291.
Zhang Q, Kobashigawa JA, Ge P, Wu G, William WD, Fishbein MC, Reed EF. HLA and MICA:
Targets of Antibody Mediated Rejection in Heart Transplantation. Am J Transplant. 2006;
6(2S):244.
292.
Patel JK, Reed E, Gjertson G, Wu GW, Laks H, Kobashigawa JA. Flow-Cytometry Positive,
Cytotoxicity-Negative Donor-Specific Crossmatch is Associated with Good Outcome Following
Cardiac Transplantation Using Non-Induction Immunosuppressive Regimen. Am J Transplant.
2006; 6(2S):775.
293.
Patel JK, Lai C, Fishbein MC, Go SE, Wu GW, Laks H, Kobashigawa JA. Asymptomatic
Humoral Rejection after Heart Transplantation is Associated with the Development of Cardiac
Allograft Vasculopathy. Am J Transplant. 2006; 6(2S):379-80.
294.
Lai CK, Reed EF, Kobashigawa JA, Hong L, Chen L, Gan JJ, Fishbein MC. Does C4d
Deposition Alone in Cardiac Allografts Predict the Future Occurrence of Antibody-Mediated
Rejection? Am J Transplant. 2006; 6(2S):380.
295.
Patel JK, Lee P, Miller S, Lai C, Fishbein M, Wu GW, Laks H, Kobashigawa JA. Hemodynamic
Compromise Rejection Predicts Future Cardiac Allograft Vasculopathy and Non-Fatal Major
Adverse Cardiac Events. Am J Transplant. 2006; 6(2S):381-2.
296.
Patel JK, Parikh A, Kubak B, Patel JP, Laks H, Kobashigawa JA. Poor Outcome after Heart
Transplantation with Hepatitis C Donor Hearts and Non-Induction Immunosuppressive
Regimens. Am J Transplant. 2006; 6(2S):382-3.
297.
Deng MC, Cadeiras M, Lim WK, Baron HM, Marboe CB, Starling R, Eisen H, Hunt SA,
Kobashigawa J, Mehra MR, Pauli D, Murali S, Wohlgemuth J, Klingler T, Dedrick R, Califano A.
Reconstructing the Creb-Network from 285 Leukocyte-Arrays in CARGO Yields Insight into
Transcription Factor Function during Quiescence and Rejection. Am J Transplant. 2006; 6(2S):423.
70
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
298.
Patel JK, Smooke SJ, Kawano J, Almeda NP, Wu GW, Laks H, Kobashigawa JA. The High
Incidence of Glucose Intolerance and New-Onset Diabetes after Heart Transplantation is not
Affected by Choice of Calcineurin Inhibitor. Am J Transplant. 2006; 6(2S):556.
299.
Yajnik M, Vaidya VS, Patel JK, Cruz D, Wu GW, Kittleson MM, Hamilton MA Kobashigawa JA.
The Validity of B-Type Natriuretic Peptide Blood Levels to Detect Heart Failure in Heart
Transplant Patients. J Investig Med 2007;55(1):S136.
300.
Kawano MA, Patel JK, Kittleson MM, Hamilton MA, and Kobashigawa JA. Pharmacologic
Myocardial Perfusion Stress Testing to Detect Significant Cardiac Allograft Vasculopathy-Is It
Worthwhile? J Investig Med 2007;55(1):S137.
301.
Seid A, Aye O, Patel JK, Chinakarn L, Kittleson MM, Hamilton MA, Kobashigawa JA. Increased
Infection Risk of Non-Cardiac Surgeries after Heart Transplantation. J Investig Med 2007;55(1):S137.
302.
Gokanapudy L, Itagaki BK, Kobashigawa JA, Wu GW, Brubaker W D, Kawano MA, Kittleson
MM, Hamilton MA, and Patel JK. Re-Transplantation for Heart Failure with Preserved Systolic
Function. J Investig Med 2007;55(1):S137.
303.
Brubaker WD, Itagaki BK, Kobashigawa JA, Wu GW, Kawano MA, Kittleson MM, Hamilton
MA, and Patel JK. The Stiffer the Heart, the Worse the Outcome after Heart Transplantation. J
Investig Med 2007;55(1):S137.
304.
Chinakarn L, Kawano MA, Song H, Patel JK, Hamilton MA, and Kobashigawa JA .Outcome of
Combined Kidney and Redo Heart Transplant Recipients from a Single Center. J Investig Med
2007;55(1):S137.
305.
Itagaki BK, Kobashigawa JA, Wu GW, Patel JK, Kawano MA, Kittleson MM, Hamilton MA, and
Fishbein MC. Widespread Fibrosis of Myocardial and Adjacent Tissues Causing Restrictive Cardiac
Physiology in Patients Needing Re-do Heart Transplant. J Investig Med 2007;55(1):S137.
306.
Song H, Kittleson MM, Yajnik M, Wu GW, Kobashigawa BI, Patel JK, Hamilton MA, and
Kobashigawa JA. Naturally Occurring Leukopenia as a Marker for Good Outcome after Cardiac
Transplantation. J Investig Med 2007;55(1):S158.
307.
Patel JK, Kawano MA, Wu GW, Kawano JC, Yajnik M, Kittleson MM, Kobashigawa JA.
Practically Speaking: The initiation of lower dose mycophenolate mofetil (MMF) 1000 mg bid
appears to have similar outcome to 1500 mg bid after heart transplantation. J Heart Lung Transplant
2007; 26(2S):S70.
308.
Vaidya VA, Yajnik M, Patel JK, Cruz D, Wu GW, Kittleson MM, Kobashigawa JA. The validity
of BNP blood levels to detect heart failure in heart transplant patients. J Heart Lung Transplant
2007;26(2S):S120-1.
309.
Itagaki BK, Kobashigawa JA, Wu GW, Patel JK, Kawano MA, Kittleson MM, Fishbein MC.
Widespread fibrosis of myocardial and adjacent tissues causing restrictive cardiac physiology in
patients needing re-do heart transplant. J Heart Lung Transplant 2007;26(2S):S138.
310.
Itagaki BK, Kobashigawa JA, Wu GW, Brubaker W, Kawano MA, Gokanapudy L, Kittleson
MM, Patel JK. The stiffer the heart, the worse the outcome after heart transplantation. J Heart
Lung Transplant 2007;26(2S):S183.
311.
Patel JK, Kawano JC, Wu GW, Chinakarn L, Kawano MA, Kobashigawa BI, Kittleson MM,
Gordon AL, Kagimoto SM, Kobashigawa JA. Recurrent mild rejection in the first year after heart
transplantation does not affect outcomes: validation of the revised ISHLT grading system. J Heart
Lung Transplant 2007;26(2S):S226.
312.
Zhang Q, Si K, Ge P, Wu GW, Patel JK, Kobashigawa J, Fishbein MC, Reed EF. HLA and
MICA: Targets of antibody mediated rejection in heart transplantation. J Heart Lung Transplant
2007;26(2S):S106.
71
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
313.
Shao ES, Chen TE, Wu GW, Patel JK, Kobashigawa JA. Cardiac transplantation for giant cell
myocarditis: A single center experience. J Heart Lung Transplant 2007;26(2S):S154.
314.
Kobashigawa JA, Kawano MA, Wu GW, Kawano JC, Yajnik M, Kittleson MM, Patel JK. Firstyear mycophenolate mofetil does reductions: Do they portend poor outcome? J Heart Lung
Transplant 2007;26(2S):S228.
315.
Aye O, Patel JK, Seid A, Chinakarn L, Kittleson MM, Kobashigawa JA. Increased infection risk
of non-cardiac surgeries after heart transplantation. J Heart Lung Transplant 2007;26(2S):S236.
316.
Patel JK, Kawano MA, Kittleson MM, Kobashigawa JA. Pharmacological myocardial perfusion
stress testing to detect significant cardiac allograft vasculopathy- is it worthwhile? J Heart Lung
Transplant 2007;26(2S): S236-7.
317.
Miller SJ, Kobashigawa JA, Kittleson MM, Patel JK, Kawano MA, Ardehali A. The use of
ECMO/Intra-aortic balloon pump to support hemodynamics in patients with cardiogenic shock
due to severe rejection. J Heart Lung Transplant 2007;26(2S):S237.
318.
Itagaki BK, Kobashigawa JA, Wu GW, Brubaker W, Kawano MA, Gokanapudy L, Kittleson
MM, Patel JK. Re-transplantation for heart failure with preserved systolic function. J Heart Lung
Transplant 2007;26(2S):S237-8.
319.
Kittleson MM, Song H, Yajnik M, Wu GW, Kobashigawa BI, Patel JK, Kobashigawa JA.
Naturally occurring leucopenia as a marker for good outcome after cardiac transplantation. J Heart
Lung Transplant 2007;26(2S):S254-5.
320.
Bernstein D, Berry G, Billingham M, Marboe CC, Deng MC, Mital S, Eisen H, Williams GE,
Baron H, Klinger TM, Wohlgemuth, Kobashigawa J. Gene expression profiling distinguishes
moderate to severe from mild acute cellular rejection in cardiac allograft recipients. J Heart Lung
Transplant 2007;26(2S):S121.
321.
Grady KL, Naftel DC, Young JB, Pelegrin D, Czerr J, Higgins R, Heroux A, McLeod M,
Rybarczyk B, Kobashigawa J, Chait J, White-Williams C, Myers S, Kirklin JK. Patterns and
predictors of physical functional disability at 5-10 years after heart transplantation. J Heart Lung
Transplant 2007;26(2S):S191.
322.
Hunt J, Bedanova H, Starling RC, Rabago G, Banner NR, Kobashigawa J, Keogh A, Kormos R,
Mehra M, Wahlers T, Noeldeke J. Premature termination of a prospective, open label,
randomized, multicenter study of sirolimus to replace calcineurin inhibitors (CNI) in a standard
care regimen of CNI, MMF, and corticosteroids early after heart transplantation. J Heart Lung
Transplant 2007;26(2S):S203.
323.
Patel JK, Kawano MA, Wu GW, Chinakarn L, Song H, Kittleson MM, Kobashigawa JA. Heart
Transplantation in Septagenarians: Is It Worth It? Am J Transplant 2007;7(S2):406.
324.
Kobashigawa J, Kiyosaki K, Kubak B, Patel J, Kittleson M, Ardehali A. Surgical Treatment of
Heart Failure Transplantation and Arrhythmias I. “Successful Use of Immune Monitoring (Cylex)
In Heart Transplantation for Rejection and Infection Risk. Scientific Sessions 2007, Orlando, FL,
November 4-7, 2007. Circulation Oct 2007;116: II-572.
325.
Kobashigawa J, Patel J, Kawano M, Wu G, Kittleson M, Kiyosaki K, Moriguchi J, Ardehali A.
Surgical Treatment of Heart Failure Transplantation and Arrhythmias II. “The Long Term
Outcome of Treated Presensitized Patients who Undergo Heart Transplantation: Is It Successful?”
Scientific Sessions 2007, Orlando FL, November 4-7, 2007. Circulation Oct 2007;116: II-644.
326.
A. Vaidya, M. Kawano, M. Hamilton and J. Kobashigawa. Long Term Risks of Steroid Weaning
After Heart Transplantation. J Investig Med 2008; 56(1):212.
327.
A. Ankrom, M. Hamilton and J. Kobashigawa. The Use of Aliskiren, a New Blood Pressure
Medication, in Heart Transplant Patients. J Investig Med 2008; 56(1):213.
72
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
328.
D. Patel, K. Kiyosaki, M. Kawano, M. Hamilton, and J. Kobashigawa. The Outcome of Lower
Social Economic Status After Heart Transplantation. J Investig Med 2008; 56(1):213.
329.
A. Brown, J. Kawano, M. Kawano, M. Hamilton, and J. Kobashigawa. Reduction in Malignancy
with Use of Newer Immunosuppressive Regimens in Heart Transplant Patients. J Investig Med 2008;
56(1):213.
330.
E. Sue, M. Kawano, M. Hamilton, and J. Kobashigawa. The Outcome of Successfully Treated
Pre-Transplant Sensitized Patients After Heart Transplantation. J Investig Med 2008; 56(1):214.
331.
H. Song, M. Kawano, K. Kiyosaki, D. Patel, M. Hamilton, and J. Kobashigawa. Kidney
Transplant Prolongs Survival in Patients with End Stage Kidney Disease After Heart
Transplantation. J Investig Med 2008; 56(1):214.
332.
M. Kawano, J. Kawano, M. Hamilton, and J. Kobashigawa. Hypercholesterolemia Resistant to
Statin Therapy in First Year After Transplant is High Risk for Future Complications. J Investig Med
2008; 56(1):214.
333.
S. Carr, K. Kiyosaki, A. Ankrom, M. Kawano, M. Hamilton, and J. Kobashigawa. Adverse Effects
of Sirolimus Versus Everolimus After Heart Transplantation. J Investig Med 2008; 56(1):215.
334.
M. Yajnik, V. Vaidya, M. Kawano, A. Ankrom, M. Hamilton, and J. Kobashigawa. The Economic
Outcome of Heart Transplantation Versus Medical Therapy of Advanced Heart Failure Patients. J
Investig Med 2008; 56(1):215.
335.
B. Simenhoff, M. Kawano, M. Hamilton, and J. Kobashigawa. Reduced Immune Response in the
Older Heart Transplant Patient. J Investig Med 2008; 56(1):215.
336.
K. Kiyosaki and J. Kobashigawa. A Simple Blood Test to Assess Risk for Rejection/Infection in
Heart Transplant Patients. J Investig Med 2008; 56(1):216.
337.
E. Kobashigawa, K. Kiyosaki, U. Duong, M. Hamilton, and J. Kobashigawa. Employment After
Heart Transplantation and the Effects of Governmental Health Insurance Policies. J Investig Med
2008; 56(1):256.
338.
B. Itagaki, M. Kawano, M. Hamilton and J. Kobashigawa. Coronary Spasm After Heart
Transplantation. J Investig Med 2008; 56(1):263.
339.
Kobashigawa JA, Reed E, Sue E, Patel JK, Kittleson MM, Kawano MA, Kiyosaki KK, Ardehali
A. Successfully Treated Pre-transplant Sensitized Patients Have Favorable Post-Transplant
Outcomes. J Heart Lung Transplant 2008;27(2S):S19.
340.
Itagaki B, Patel JK, Kittleson MM, Kawano MA, Ardehali A, Kobashigawa JA. The Innocence of
Coronary Spasm after Heart Transplantation. J Heart Lung Transplant 2008;27(2S):S23.
341.
Patel JK, Simenhoff B, Kittleson MM, Kawano MA, Ardehali A, Kobashigawa JA. Making Sense
of Immunosenescence in Older Heart Transplant Recipients. J Heart Lung Transplant
2008;27(2S):S33.
342.
Kittleson MM, Song HS, Patel JK, Kawano MA, Patel D, Kiyosaki KK, Ardehali A, Kobashigawa
JA. End-stage Renal Disease after Heart Transplantation The Benefits of Kidney Transplantation.
J Heart Lung Transplant 2008;27(2S):S23.
343.
Patel JK, Kawano JC, Kittleson MM, Duong U, Ardehali A, Kobashigawa JA. First-Year Statin
Resistant Hypercholesterolemia: A Cause for Concern in the Development of Cardiac Allograft
Vasculopathy. J Heart Lung Transplant 2008;27(2S):S45.
344.
Kittleson MM, Carr SA, Patel JK, Kawano MA, Kiyosaki KK, Ankrom AK, Ardehali A,
Kobashigawa JA. Everolimus May Have Lower Adverse Effect Profile Compared to Sirolimus in
Heart Transplant Patients. J Heart Lung Transplant 2008;27(2S):S30.
73
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
345.
Patel JK, Brown A, Kittleson MM, Kawano JC, Kawano MA, Kiyosaki KK, Ardehali A,
Kobashigawa JA. Malignancy Risk in 2007 with Current Immunosuppression Regimens. J Heart
Lung Transplant 2008;27(2S):S23.
346.
Kobashigawa JA, Kiyosaki KK, Patel JK, Kittleson MM, Ardehali A. Success of Immune
Monitoring with ImmuKnow (Cylex) to Assess Rejection/Infectious Risk in Heart
Transplantation. J Heart Lung Transplant 2008;27(2S):S41.
347.
Patel JK, Itagaki B, Ankrom A, Kawano MA, Kiyosaki KK, Yajnik M, Abbas A, Kobashigawa JA.
Hemodynamic Compromise Rejection: Diagnose and Treat Cardiac Rejection and Vasculopathy
Before it is Too Late. J Heart Lung Transplant 2008;27(2S):S41.
348.
Kittleson MM, Vaidya AS, Patel JK, Kawano MA, Ardehali A, Kobashigawa JA. Long-Term
Risks Post Steroid Weaning: Not so Rosy After All. J Heart Lung Transplant 2008;27(2S):S23.
349.
Kittleson MM, Kawano JC, Patel JK, Kawano MA, Yajnik MV, Kiyosaki KK, Ardehali A,
Kobashigawa JA. Hypercholesterolemia in Heart Transplant Patients on Proliferation-Signal
Inhibitors: Is Statin Therapy Effective? J Heart Lung Transplant 2008;27(2S):S29.
350.
Vaidya VS, Yajnik M, Heidenreich P, Kawano MA, Vaidya AS, Patel JK, Kittleson MM, Ankrom
AK, Ardehali A, Kobashigawa JA. Comparison of Survival and Costs Between Transplantation
and Medical Treatment of End Stage Heart Failure. J Heart Lung Transplant 2008;27(2S):S34.
351.
Moriguchi J, Kwon M, Punkett M, Esmailian F, Jocson R, Laks H, Marelli D, Beygui R, Davis S,
Ardehali A, Patel J, Kobashigawa J. Improved Clinical Outcomes Using Bi-Ventricular Assist
Devices as Bridges to Transplant in Critically Ill Patients. J Heart Lung Transplant 2008;27(2S):S38.
352.
Kittleson MM, Ankrom AK, Patel JK, Kawano MA Ardehali A, Kobashigawa JA. Aliskiren: A
New Anti-Renin Blood Pressure medication Appears Safe and Effective in Heart Transplant
Recipients. J Heart Lung Transplant 2008;27(2S):S23.
353.
Grady KL, Wang E, Higgins R, Heroux A, Rybarczyk B, Young JB, Pelegrin D, Czerr J,
Kobashigawa J, Chait J, Naftel DC, White-Williams C, Myers S, Kirklin JK. Symptom Frequency
and Distress from 5 to 10 years after Heart Transplantation. J Heart Lung Transplant
2008;27(2S):S29.
354.
Marelli D, Kobashigawa JA, Hamilton MA, Noguchi E, Moriguchi JD, Patel JK, Laks H,
Esmailian F, Beygui R, Plunkett MD, Ardehali A. Long Term Outcome of Heart Transplant in the
Elderly. J Heart Lung Transplant 2008;27(2S):S33.
355.
Marelli D, Kobashigawa J, Beygui R, Esmailian F, Laks H, Plunkett M, Ardehali A. Tricuspid
Valve Regurgitation (TR) after Heart Transplantation Using the Bicaval Anastomosis Technique. J
Heart Lung Transplant 2008;27(2S):S36.
356.
Marelli D, Kobashigawa JA, Moriguchi JD, Shuvayev I, Wong SY, Kahn T, Patel JK, Beygui R,
Esmailian F, Laks H, Plunkett MD, Ardehali A. ECMO to Salvage Severe Cardiogenic Shock in
Advanced Heart Failure and Transplantation. J Heart Lung Transplant 2008; 27(2S):S37.
357.
Grady KL, Wang E, Young JB, Pelegrin D, Czerr J, Kobashigawa J, Chait J, Heroux A, Higgins
R, Rybarczyk B, McLeod M, Naftel DC, Myers S, Kirklin JK. Are Patients Working at 5 to 10
Years after Heart Transplantation? J Heart Lung Transplant 2008;27(2S):S54.
358.
Kittleson MM, Patel JK, Kawano, MA Kubak, Ardehali A, Kobashigawa JA. Aggressive
Antimicrobial Prophylaxis Decreases Infectious Risk Despite Rejection Therapy after Heart
Transplantation. Am J Transpl 2008;8(S2):348.
359.
Wei JP, Lu WH, Lai C, Gjertson DW, Zhang Q, Kiyosaki KK, Kobashigawa JA, Fishbein MC,
Reed EF. Phosphorylated S5 Kinase and S6 Ribosomal Protein are Biomarkers of Antibody
Mediated Rejection in Heart Allografts. Am J Transpl 2008;8(S2):569.
360.
Carr S, Hamilton M, Kobashigawa J, Obesity and cardiac allograft vasculopathy after heart
transplantation. J Investig Med 2009;57(1):158.
74
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
361.
Lo K, Hamilton M, Kobashigawa J, The predictive value of cardiopulmonary stress testing after
heart transplantation. J Investig Med 2009;57(1):158-159.
362.
Kiyosaki K, Hamilton M, Kobashigawa J, A non-invasive means to detect risk for rejection and
infection in heart transplant patients in a large cohort of patients. J Investig Med 2009;57(1):159.
363.
Moradzadeh N, Hamilton M, Kobashigawa J, Right ventricular dysfunction in heart transplant
recipients. J Investig Med 2009;57(1):159.
364.
Kawano M, Hamilton M, Kobashigawa J, the outcome of heart transplant patients with positive
donor specific crossmatch. J Investig Med 2009;57(1):159-160.
365.
Ankrom A, Hamilton M, Kobashigawa J, Cardiac allograft sizing in heart transplant candidates
with pulmonary hypertension. J Investig Med 2009;57(1):160.
366.
Arbit A, Hamilton M, Kobashigawa J, First year heart rate and outcome after heart
transplantation. J Investig Med 2009;57(1):160.
367.
Sohrabian S, Hamilton M, Kobashigawa J, The outcome of renal sparing protocols after heart
transplantation. J Investig Med 2009;57(1):160.
368.
Wong S, Hamilton M, Kobashigawa J, The value of social worker and psychiatric pre-heart
transplant evaluation. J Investig Med 2009;57(1):161.
369.
Patel J, Hamilton M, Kobashigawa J, Pulmonary function testing pre-heart transplant can predict
outcome. J Investig Med 2009;57(1):186.
370.
Yajnik M, Hamilton M, Kobashigawa J, Outcome of older redo heart transplant patients. J Investig
Med 2009;57(1):186-187.
371.
Kim B, Hamilton M, Kobashigawa J, Permanent pacemakers in heart transplant patients. J Investig
Med 2009;57(1):240.
372.
K Kiyosaki, J Kobashigawa, J Patel, J Patel, A Ankrom, M Kittleson, M Kawano, J Moriguchi, E
Shao, A Ardehali. The Benefit of Immune Monitoring (Cylex): A Review of 864 Immune
Monitoring Assays in Heart Transplantation. J Heart Lung Transplant 2009.
373.
K Kiyosaki, J Kobashigawa, E Reed, J Moriguchi, M Kawano, A Ankrom, J Patel, M Kittleson, E
Shao, A Ardehali. The Outcome of Treatment of 100% PRAs in Heart Failure Patients Awaiting
Heart Transplantation. J Heart Lung Transplant 2009.
374.
K Lo, K Kiyosaki, J Kobashigawa, M Kawano, A Ankrom, M Kittleson, E Shao, J Moriguchi, J
Patel, A Ardehali. Low Peak Oxygen Consumption by Cardiopulmonary Stress Testing After Heart
Transplantation Predicts Poor Outcome. J Heart Lung Transplant 2009.
375.
B Kim, K Kiyosaki, E Shao, J Patel, M Kittleson, M Kawano, A Ankrom, J Moriguchi, A Ardehali,
J Kobashigawa. Early Permanent Pacemaker After Heart Transplantation is a Surrogate Marker
for Poor Outcome: Possible Immune Mechanisms. J Heart Lung Transplant 2009.
376.
J Patel, K Kiyosaki, B Kubak, M Kawano, A Ankrom, M Kittleson, E Shao, J Moriguchi, A
Ardehali, J Kobashigawa. Surreptitious Aspergillus Colonization is Not Associated with Poor
Outcome While on Suppressive Azole Therapy. J Heart Lung Transplant 2009.
377.
E Shao, M Kawano, K Kiyosaki, J Patel, M Kittleson, J Moriguchi, A Ardehali, J Kobashigawa.
Late Rapidly Progressive Cardiac Allograft Vasculopathy is Associated with Poor Outcome. J Heart
Lung Transplant 2009.
378.
J Patel, M Kawano, K Kiyosaki, A Ankrom, M Kittleson, J Moriguchi, A Ardehali, J
Kobashigawa. When is Too Old, Too Old for Redo Heart Transplantation? J Heart Lung
Transplant 2009.
75
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
379.
S Sohrabian, M Kawano, K Kiyosaki, A Ankrom, J Patel, J Moriguchi, M Kittleson, A Ardehali, J
Kobashigawa. Spare Me the Renal Sparing Protocol - Poor Long Term Outcomes. J Heart Lung
Transplant 2009.
380.
M Kawano, J Kobashigawa, K Kiyosaki, A Ankrom, J Patel, M Kittleson, E Reed, A Ardehali.
Outcome of Retrospective Positive Donor Specific Crossmatch After Heart Transplantation - Are
They Doomed? J Heart Lung Transplant 2009.
381.
J Patel, M Kawano, K Kiyosaki, E Shao, A Ankrom, M Kittleson, J Moriguchi, A Ardehali, J
Kobashigawa. Addressing the Myth of Elevated Bilirubin as a Contraindication to Heart
Transplantation. J Heart Lung Transplant 2009.
382.
E Moreno, A Velleca, M Kawano, K Kiyosaki, S Wong, A Ankrom, J Patel, M Kittleson, L
Ventura, J Moriguchi, A Ardehali, J Kobashigawa. Does High Risk Status Identified by PreTransplant Social Worker and Psychiatric Evaluation Predict Outcome After Heart Transplant? J
Heart Lung Transplant 2009.
383.
A Ankrom, J Patel, E Shao, S Carr, M Kawano, M Kittleson, K Kiyosaki, J Moriguchi, A Ardehali,
J Kobashigawa. Obesity Confers Protection from Cardiac Allograft Vasculopathy. J Heart Lung
Transplant 2009.
384.
E Shao, M Kawano, N Moradzadeh, A Ankrom, K Kiyosaki, J Patel, M Kittleson, J Moriguchi, A
Ardehali, J Kobashigawa. Right Ventricular Dysfunction Immediately Post Transplant - A Marker
for Poor Outcome? J Heart Lung Transplant 2009.
385.
E Shao, M Kawano, J Patel, M Kittleson, A Ankrom, K Kiyosaki, J Moriguchi, A Ardehali, J
Kobashigawa. The Problem of Rejection in Redo Heart Transplant Recipients. J Heart Lung
Transplant 2009.
386.
J Patel, E Shao, J Patel, M Kawano, K Kiyosaki, A Ankrom, M Kittleson, J Moriguchi, A Ardehali,
J Kobashigawa. Pre-Transplant FEV1/FVC but not FEV1 alone by Pulmonary Function Testing
Predicts Poor Outcome After Heart Transplantation: The Bane of COPD. J Heart Lung Transplant
2009.
387.
J Patel, B Kubak, M Kawano, A Ankrom, M Yajnik, K Kiyosaki, M Kittleson, J Moriguchi, A
Ardehali, J Kobashigawa. The Efficacy of Shorter Duration CMV Prophylaxis After Heart
Transplantation. J Heart Lung Transplant 2009.
388.
M Kwon, A Ankrom, A Ardehali, M Kawano, K Kiyosaki, J Kobashigawa. Oversizing Donor
Cardiac Allografts for Patients with Pulmonary Hypertension May Not Be Necessary. J Heart Lung
Transplant 2009.
389.
Sasaoka T, Kato T, Kobashigawa J, Patel J et al. Retrospective Review of Japanese Heart
Transplant Recipients Transplanted in Japan and Transplanted at UCLA in the U.S. J Heart Lung
Transplant 2009.
390.
Zuckerman A, Kobashigawa J, Arizon JM, Wang SS, Vigano M, Lehmkuhl H, Ross H, Dong G,
Eisen H. Incidences of Incisional Complications after De Novo Cardiac Transplantation in AZA-,
MMF- or Everolimus-Based Regimens: A Cross-Study Analysis on 1008 Patients. J Heart Lung
Transplant 2009.
391.
White M, Cantin B, Haddad H, Kobashigawa J, Ross H, Carrier M, Whittom L, Ali I, Isaac D,
Wang S. Subclinical Inflammation and Oxidative Stress Following De Novo Cardiac
Transplantation: Similar Impact of Tacrolimus vs. Cyclosporine Microemulsion. Accepted for
presentation at the Canadian Cardiovascular Congress, Edmonton, October 25, 2009.
392.
Davis S, Hamilton M, Kobashigawa J, Asymptomatic positive CMV serology is associated with
increased risk for the development of cardiac allograft vasculopathy (CAV) after heart
transplantation. J Investig Med 2010;58(1):113.
393.
Kawano M, Hamilton M, Kobashigawa J, Accommodation after heart transplantation. J Investig
Med 2010;58(1):113.
76
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
394.
Share M, Hamilton M, Kobashigawa J, C4D or C3D positivity in heart transplant biopsies is not a
marker for poor outcome. J Investig Med 2010;58(1):113.
395.
Moradzadeh A, Hamilton M, Kobashigawa J, Donor to recipient height match in addition to
weight match is important for good outcome after heart transplantation. J Investig Med
2010;58(1):115.
396.
Goldstein Z, Hamilton M, Kobashigawa J, Safe transition of pediatric heart transplant patients to
the adult heart transplant program. J Investig Med 2010;58(1):169.
397.
Patel J, Kittleson M, Reed E, Aguas G, Kawano M, Davis S, Burch C, Velleca A, Stimpson E,
Moriguchi J, Ardehali A, Kobashigawa J. The Importance of Anti-HLA DQ Antibodies as a Risk
Factor for the Development of Transplant Coronary Artery Disease (TCAD) After Heart
Transplantation. J Heart Lung Transplant. 2010; 29(2): S73-S74.
398.
Kittleson M, Patel J, Reed E, Gjertson D, Kawano M, Davis S, Burch C, Velleca A, Stimpson E,
Moriguchi J, Ardehali A, Kobashigawa J. Accommodation after Heart Transplantation: Does it
Exist? J Heart Lung Transplant. 2010; 29(2): S63.
399.
Lai C, Patel J, Fishbein M, Kittleson M, Share M, Davis S, Kawano M, Moriguchi J, Ardehali A,
Kobashigawa J. C4d in Heart Transplant Biopsies Does Not Appear to Represent Poor
Outcome. J Heart Lung Transplant. 2010; 29(2): S38.
400.
Moreno E, Velleca A, Burch C, Patel J, Kittleson M, Kawano M, Davis S, Moriguchi J, Ardehali A,
Kobashigawa J. Pre-Transplant Smoking in Heart Transplant Patients: A Marker for Long Term
Outcome? J Heart Lung Transplant. 2010; (29)2: S60.
401.
Kittleson M, Patel J, Moriguchi J, Kawano M, Patel K, Davis S, Hage A, Hamilton M, Ardehali A,
Kobashigawa J. Heart Transplant Rejection with Cardiogenic Shock Supported with
Extracorporeal Membrane Oxygenation (ECMO): Outcome from a Single Center Experience. J
Heart Lung Transplant. 2010; 29(2): S91.
402.
Velleca A, Burch C, Montgomery S, Lockhart D, Patel J, Kittleson M, Kawano M, Davis S,
Moriguchi J, Ardehali A, Kobashigawa J. The Threat of Medication Miscommunication in NonEnglish Speaking Heart Transplant Recipients. J Heart Lung Transplant. 2010; 29(2): S125.
403.
Kawano M, Kittleson M, Fishbein M, Patel J, Davis S, Moriguchi J, Ardehali A, Kobashigawa J.
Review of 12,703 Endomyocardial Biopsies: The Truth of Quality Lesions in the Cyclosporine and
Tacrolimus Era. J Heart Lung Transplant. 2010; 29(2): S73.
404.
Kawano M, Patel J, Kittleson M, Reed E, Gjertson D, Cecka M, Velleca A, Stimpson E, Burch C,
Davis S, Moriguchi J, Ardehali A, Kobashigawa J. The Incidence and Outcome of Sensitization in
Patients Awaiting Re-do Heart Transplantation. J Heart Lung Transplant. 2010; 29(2): S123-S124.
405.
Patel J, Kittleson M, Reed E, Zhang Q, Rajalingam R, Velleca A, Stimpson E, Burch C, Kawano
M, Davis S, Moriguchi J, Ardehali A, Kobashigawa J. The Effectiveness of a Standardized
Desensitization Protocol in Reducing Calculated Panel Reactive Antibodies (cPRA) in Sensitized
Heart Transplant Candidates: Does it Make Sense to Desensitize? J Heart Lung Transplant. 2010;
29(2): S103-S104.
406.
Kittleson M, Patel J, Azarbal B, Moriguchi J, Kawano M, Davis S, Hage A, Ardehali A,
Kobashigawa J. First Angioplasty Does Not Appear to Alter Outcome in Heart Transplant
Patients with Newly Diagnosed Transplant Coronary Artery Disease. J Heart Lung Transplant. 2010;
29(2): S124.
407.
Patel J, Kittleson M, Zhang Q, Reed E, Kawano M, Davis S, Cecka M, Burch C, Velleca A,
Stimpson E, Moriguchi J, Ardehali A, Kobashigawa J. Are Circulating Antibodies Necessary To
Make A Diagnosis Of Antibody-Mediated Rejection? J Heart Lung Transplant. 2010; 29(2): S54.
77
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
408.
Kittleson M, Patel J, Reed E, Zhang Q, Cecka M, Stimpson E, Velleca A, Burch C, Kawano M,
Davis S, Moriguchi J, Ardehali A, Kobashigawa J. Does MFI Quantitation Of Circulating
Antibodies Correlate With Positive Cytotoxicity? J Heart Lung Transplant. 2010; 29(2): S152.
409.
Kittleson M, Patel J, Moriguchi J, Moradzadeh A, Kawano M, Davis S, Ardehali A, Kobashigawa
J. The Adverse Effects of Sirolimus in Heart Transplant Patients: Is it Worth it? J Heart Lung
Transplant. 2010; 29(2): S22.
410.
Patel J, Kittleson M, Share M, Kawano M, Davis S, Fishbein M, Lai C, Moriguchi J, Ardehali A,
Kobashigawa J. Persistent Pulmonary Hypertension In Heart Transplant Patients: Is This A
Recipe For Long-Term Failure? J Heart Lung Transplant. 2010; 29(2): S92.
411.
Patel J, Kittleson M, Kubak B, Kawano M, Davis S, Moriguchi J, Ardehali A, Kobashigawa J.
Asymptomatic Positive CMV Serology is Associated with Increased Risk for the Development of
Transplant Coronary Artery Disease (TCAD): Who Needs Symptoms? J Heart Lung Transplant.
2010; 29(2): S124.
412.
Patel J, Kittleson M, Kubak B, Kawano M, Davis S, Moriguchi J, Ardehali A, Kobashigawa J.
Development Of Cytomegalovirus (CMV) Infection During Ongoing Valganciclovir Therapy. J
Heart Lung Transplant. 2010; (29)2: S66-S67.
413.
Shemin R, Patel J, Ardehali A, Kittleson M, Kawano M, Davis S, Moriguchi J, Kobashigawa J.
Gender Mismatch in Non-induction/Triple-Drug Regimens: Poor 10-Year Outcomes. J Heart Lung
Transplant. 2010; 29(2): S102.
414.
Montgomery S, Kawano M, Lockhart D, Velleca A, Burch C, Patel J, Davis S, Kittleson M,
Moriguchi J, Ardehali A, Kobashigawa J. Does Race Mismatch Have An Impact On Outcome
After Heart Transplantation? J Heart Lung Transplant. 2010; 29(2): S124-S125.
415.
Patel J, Kittleson M, Azarbal B, Hage A, Kawano M, Davis S, Moriguchi J, Ardehali A,
Kobashigawa J. Does A Normal Angiogram Further From Heart Transplantation Confer Less
Chance To Develop CAV?; Should We Still Do Annual Angiograms Late After Transplantation? J
Heart Lung Transplant. 2010; 29(2): S53.
416.
Burch C, Amegatcher A, Patel J, Kittleson M, Kawano M, Davis S, Goldstein Z, Moriguchi J,
Ardehali A, Kobashigawa J. Transition Of Pediatric Heart Transplant Patients To The Adult
Heart Transplant Program: Are They Doomed To Be Rejected? J Heart Lung Transplant. 2010;
29(2): S33.
417.
Kittleson M, Moriguchi J, Kwon M, Reed E, Davis S, Kawano M, Burch C, Velleca A, Stimpson E,
Patel J, Ardehali A, Kobashigawa J. Highly Sensitized Patients on VAD Support awaiting Heart
Transplant on a Ventricular Assist Device (VAD) Appear to have a Less Robust Immune
Response Compared to Non-VAD Patients. J Heart Lung Transplant. 2010; 29(2): S120.
418.
Lockhart D, Doering L, Burch C, Montgomery S, Velleca A, Patel J, Kittleson M, Davis S, Kawano
M, Goldstein Z, Moradzadeh A, Moriguchi J, Ardehali A, Kobashigawa J. Are Recipients From
Heart Donors Listed as Homeless at Increased Risk for Poor Outcome After Heart
Transplantation? J Heart Lung Transplant. 2010; 29(2): S39.
419.
Kwon M, Moriguchi J, Kittleson M, Patel J, Kawano M, Davis S, Reed E, Burch C, Velleca A,
Stimpson E, Ardehali A, Kobashigawa J. Lack of Sensitization In Patients Awaiting Heart
Transplantation On Heartmate II Axial Flow Assist Devices. J Heart Lung Transplant. 2010; 29(2):
S183.
420.
Davis S, Patel J, Kittleson M, Kawano M, Moriguchi J, Hamilton M, Ardehali A, Kobashigawa J.
Potential Immunomodulatory Effects of Granulocyte Colony Stimulating Factor (GCSF) in Heart
Transplant Patients. Am J Transplant. 2010;10(S4):407.
421.
Kawano M, Patel J, Kittleson M, Hamilton M, Hage A, Moradzadeh A, Davis S, Moriguchi J,
Ardehali A, Kobashigawa J. The Effects of Donor Height in Heart Transplant Patients on Triple
Drug Immunosuppression. Am J Transplant. 2010;10(S4):310.
78
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
422.
Kittleson M, Patel J, Moriguchi J, Moradzadeh A, Kawano M, Davis S, Ardehali A, Kobashigawa
J. Splenectomy Prior to Heart Transplantation Does Not Affect Risk for Rejection and/or
Infection after Heart Transplantation in Patients on Triple Drug Immunosuppression. Am J
Transplant. 2010;10(S4):407.
423.
Kittleson M, Patel J, Kawano M, Davis S, Share M, Moriguchi J, Hamilton M, Ardehali A,
Kobashigawa J. Safety and Efficacy of Sildenafil in the 1st Year after Heart Transplantation for
Pulmonary Hypertension. Am J Transplant. 2010;10(S4):307.
424.
Azarbal B, Patel J, Kittleson M, Davis S, Kawano M, Moradzadeh A, Goldstein Z, Moriguchi J,
Ardehali A, Kobashigawa J. Treadmill Nuclear Stress Testing Appears Effective to Detect
Coronary Ischemia in Heart Transplant Patients with Established Transplant Coronary Artery
Disease. Am J Transplant. 2010;10(S4):309.
425.
Patel J, Kittleson M, Davis S, Kawano M, Moriguchi J, Ardehali A, Kobashigawa J. 10-Year
Follow-up of Hepatitis C Donor Hearts in Triple-Drug Immunosuppression: The Final Nail in the
Coffin. Am J Transplant. 2010;10(S4):120.
426.
Patel J, Kittleson M, Kawano M, Davis S, Moriguchi J, Ardehali A, Kobashigawa J. Are Quality B
Lesions in Heart Transplant Biopsies in Patients on Tacrolimus Immunosuppression Harbingers of
Rejection? A Review of 3651 Endomyocardial Biopsies. Am J Transplant. 2010;10(S4):404.
427.
Tatishchey S, Czer L, Kobashigawa J, Luthringer D. Utility of CD68/CD31 Dual
Immunostaining Techniques to Detect Antibody-Mediated Rejection in Post-Transplant Cardiac
Biopsies. Laboratory Investig. 2011; 91(1): 79A.
428.
Tatishchey S, Czer L, Kobashigawa J, Luthringer D. Utility of CD68/CD31 Dual
Immunostaining Techniques to Detect Antibody-Mediated Rejection in Post-Transplant Cardiac
Biopsies. Modern Pathology. 2011; 24(1): 79A.
429.
Cao K, Lai C, Ong G, Naim M, Wang Q, Kobashigawa J, Reinsmoen N. Role of Anti-HLA
Assessment and Risk Stratification in Heart Transplantation. Human Immunology. 2011; 72(1): S5.
430.
Lai C, Masukawa R, Paredes D, Ong G, Wang Q, Nain M, Cao K, Kobashigawa J, Reinsmoen N.
C4D + Antibody Mediated Rejection in Absence of Complement Fixing Donor Specific Antibody
for a Heart Transplant Patient. Human Immunology. 2011; 72(1): S90.
431.
Kawano M, Goldstein Z Hamilton M, Kobashigawa J. Induction vs. non-induction: The saga
continues. J Investig Med 2011;59(1):98.
432.
Davidoff J, Kawano M, Goldstein Z Hamilton M, Kobashigawa J. Pre-transplant blood
transfusion causing sensitization in patients awaiting heart transplantation. J Investig Med
2011;59(1):98-99.
433.
Dyo J, Kawano M, Goldstein Z Hamilton M, Kobashigawa J. The long-term benefit of renal
sparing protocols demonstrate the lack of need for calcineurin inhibitors. J Investig Med
2011;59(1):99.
434.
Geskin A, Kawano M, Goldstein Z Hamilton M, Kobashigawa J. The outcome of African
American heart transplant recipients: are they truly at risk. J Investig Med 2011;59(1):99.
435.
Moradzadeh N, Kawano M, Goldstein Z Hamilton M, Kobashigawa J. The impact of blood
pressure control toward the outcome of heart transplant recipients. J Investig Med 2011;59(1):99.
436.
Barry O, Kawano M, Goldstein Z Hamilton M, Kobashigawa J. Does gender mismatch increase
the risk of antibody-mediated rejection?. J Investig Med 2011;59(1):99-100.
437.
Goldstein Z, Kawano M, Hamilton M, Kobashigawa J. The development of late onset AMR:
Does it exist? J Investig Med 2011;59(1):100.
79
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
438.
Moradzadeh A, Kawano M, Goldstein Z Hamilton M, Kobashigawa J. Low cardiac index in
asymptomatic heart transplant patients at one year post transplant does not lead to poor long term
outcome. J Investig Med 2011;59(1):211-212.
439.
Patel J, Azarbal B, Kittleson M, Kawano M, Goldstein Z, Rafiei M, Moradzadeh A, Czer L, Kass
R, Kobashigawa J. Coronary Angioplasty/Stents for Cardiac Allograft Vasculopathy Does Not
Alter Outcome for Heart Transplant Patients with ISHLT CAV2 or CAV3 Disease. J Heart Lung
Transplant. 2011; 30(4, Supplement): S11.
440.
Patel J, Kittleson M, Kawano M, Goldstein Z, Rafiei M, Moradzadeh A, Azarbal B, Czer L, Kass
R, Kobashigawa J. Hyperlipidemia from Sirolimus: Adverse Impact on Development of Cardiac
Allograft Vasculopathy. J Heart Lung Transplant. 2011; 30(4, Supplement): S12.
441.
Kittleson M, Kawano M, Goldstein Z, Rafiei M, Azarbal B, Moriguchi J, Hage A, Reinsmoen N,
Reed E, Luthringer D, Esmailian F, Kobashigawa J. Does the Detection of Circulating DonorSpecific Antibody Impact Pathology Diagnosed Antibody-Mediated Rejection after Heart
Transplant? J Heart Lung Transplant. 2011; 30(4, Supplement): S17.
442.
Patel J, Kittleson M, Kawano M, Goldstein Z, Stimpson E, Rush J, Rafiei M, Reinsmoen N, Reed
E, Hamilton M, Trento A, Kobashigawa J. The Effects of Moderate Strength Pre-Transplant
Circulating Antibodies on Outcome after Heart Transplantation. J Heart Lung Transplant. 2011;
30(4, Supplement): S21.
443.
Kittleson M, Patel J, Kawano M, Goldstein Z, Rafiei M, Reinsmoen N, Reed E, Hage A, Schwarz
E, Esmailian, Kobashigawa J. Timing of the Development of Donor Specific Antibody after
Heart Transplantation Impacts Long-Term Outcome. J Heart Lung Transplant. 2011; 30(4,
Supplement): S22.
444.
Kobashigawa J, Pauly D, Ross H, Wang S, Cantin B, Burton J, Keogh A, Eisen H, Lopez P,
Dong G, Jiang H, Cines M, Starling R. Reduction of Cardiac Allograft Vasculopathy with
Everolimus over Mycophenolate Mofetil: Intravascular Ultrasound Results of a Randomized
Multicenter Trial. J Heart Lung Transplant 2011; 30(4, Supplement): S24.
445.
Eisen H, Pauly D, Starling R, Lehmkuhl H, Ross H, Kfoury A, Wang S, Cantin B, Van Bakel A,
Zuckernmann A, Lopez P, Dong G, Panis C, Jiang H, Cornu-Artis C, Kobashigawa J. Everolimus
with Reduced CsA vs MMF with Standard CsA Exposure in De Novo Heart Transplant
Recipients: 12 Month Efficacy and Safety Analysis. J Heart Lung Transplant. 2011; 30(4,
Supplement): S25.
446.
Pauly D, Starling R, Kobashigawa J, Wang S, Cantin B, Keogh A, Lehkuhl H, Hirt S, Lopez P,
Dong G, Cines M, Jiang H, Eisen H. Heart Transplant Recipients Treated with Everolimus Have
Less Increase in Intimal Thickness vs MMF, Irrespective of Lipid Values. J Heart Lung Transplant.
2011; 330(4, Supplement): S26.
447.
Stimpson E, Piponniau L, Patel J, Velleca A, Kawano M, Goldstein Z, Rafiei M, Reinsmoen N,
Czer L, Esmailian F, Kobashigawa J. Sorting Out the Intricacies of Multiparity Risk on Outcomes
after Heart Transplantation. J Heart Lung Transplant. 2011; 30(4, Supplement): S27.
448.
Kao T, Velleca A, Kittleson M, Piponniau L, Rush J, Kawano M, Goldstein Z, Luthringer D, Czer
L, Esmailian F, Kobashigawa J. Myth Buster: Does Homogeneous Racial Donor/Recipient
Match Improve Outcome after Heart Transplantation? J Heart Lung Transplant. 2011; 30(4,
Supplement): S27.
449.
Lockhart D, Piponniau L, Velleca A, Patel J, Kittleson M, Kearney B, Kao T, Johnson M, Kawano
M, Goldstein Z, Rafiei M, Kobashigawa J. The Life of the Octogenarian Heart Transplant
Patient. J Heart Lung Transplant. 2011; 30(4, Supplement): S27.
450.
Li F, Lai C, Kobashigawa JA, Fishbein MC, Reed EF. Phosphorylated Signaling Proteins as
Biomarkers of Antibody-Mediated Geart Akkigraft Rejection. J Heart Lung Transplant. 2011; 30(4,
Supplement): S41.
80
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
451.
Kobashigawa J, Patel J, Kittleson M, Velleca A, Kawano M, Moradzadeh A, Goldstein Z, Rafiei
M, Dyo J, Czer L, Esmailian F. Long-Term Benefit of Renal Sparing Protocols Demonstrate the
Lack of Need for Calcineurin Inhibitors. J Heart Lung Transplant. 2011; 30(4, Supplement): S54.
452.
Morrissey RP, Czer L, Kittleson M, Patel J, Schwarz E, Jamero G, Kawano M, Rafiei M, Azarbal B,
Trento A, Kobashigawa J. Induction vs. Non-Induction in Heart Transplantation: The
Controversy Continues. J Heart Lung Transplant. 2011; 30(4, Supplement): S56.
453.
Schwarz ERV, Baraghoush A, Phan A, Hamilton MM, Kobashigawa JA, Bharadwaj. Palliative
Care Involvement in Advanced Heart Failure Pre and Post Cardiac Transplantation. J Heart Lung
Transplant. 2011; 30(4, Supplement): S59.
454.
Zuckermann A, Arizon J, Eisen H, Kobashigawa J, Lehmkuhl H, Pellegrini C, Ross H, Karpov A,
Barten MJ,. Risk Factors for Pericardial and Pleural Effusions in Heart Transplantation. J Heart
Lung Transplant. 2011; 30(4, Supplement): S86.
455.
Zuckermann A, Eisen H, Kobashigawa J, Ross H, Wang S, Lehmkuhl H, Rinaldi M, Torre G,
Yoman N, Arizon J, Pellegrini C, Lopez P, Dong G, Panis C, Hirt S. Wound Healing Events and
Effusions with Everolimus Versus MMF Based Regimens in De Novo Heart Transplant Recipient.
J Heart Lung Transplant. 2011; 30(4, Supplement): S87.
456.
Patel J, Kawano M, Reed E, Goldstein Z, Rafiei M, Reinsmoen N, Azarbal B, Czer L, Trento A,
Kobashigawa J. Circulating Antibody after Heart Transplant and Its Association with Poor
Outcome: A Prospective Assessment. J Heart Lung Transplant. 2011; 30(4, Supplement): S87.
457.
Patel J, Goldstein Z, Kawano M, Rafiei M, Reinsmoen N, Reed E, Luthringer D, Schwarz E,
Trento A, Kobashigawa J. Early Versus Late Antibody-Mediated Rejection: Is There A
Difference? J Heart Lung Transplant. 2011; 30(4, Supplement): S87.
458.
Velleca A, Piponniau L, Kittleson M, Lockhart D, Kao T, Kearney B, Johnson M, Stimpson E,
Rush J, Kawano M, Moreno E, Kobashigawa J. Add to the Cigarette Warning Label: History of
Donor Smoking Leads To Increase in Cardiac Allograft Vasculopathy. J Heart Lung Transplant.
2011; 30(4, Supplement): S109.
459.
Kittleson M, Patel J, Zakowski P, Czer L, Kobashigawa J. Managing the Threat of DonorTransmitted Amoebic Encephalitis in a Heart Transplant Recipient. J Heart Lung Transplant. 2011;
30(4, Supplement): S132.
460.
Yanagida R, Czer LSC, Ruzza A, Vespignani R, Simsir SA, Schwarz ER, De Robertis M, Mirocha J,
Coleman B, Runyon C, Jocson R, Olay C, Kass RM, Kobashigawa J, Trento A. Ventricular Assist
Device Implantation Provides Opportunity for Significant Weight Loss in Obese Patients with
Advanced Heart Failure. J Heart Lung Transplant. 2011; 30(4, Supplement): S162.
461.
Piponniau L, Velleca A, Kittleson M, Lockhart D, Kearney B, Kao T, Johnson M, Kawano M,
Goldstein Z, Rafiei M, Esmailian F, Kobashigawa J. Seasonal Variations in Cardiac Transplant
Antibody-Mediated Rejection. J Heart Lung Transplant. 2011; 30(4, Supplement): S174.
462.
Kittleson M, Patel J, Kawano M, Goldstein Z, Rafiei M, Moriguchi J, Reinsmoen N, Reed E, Hage
A, Trento A, Kobashigawa J. Pre-Transplant Strength of Circulating Antibody as Expressed in
the Calculated Panel Reactive Antibody Score Predicts Antibody-Mediated Rejection after Heart
Transplant. J Heart Lung Transplant. 2011; 30(4, Supplement): S175.
463.
Patel J, Moriguchi J, Stimpson E, Reinsmoen N, Reed E, Kawano M, Goldstein Z, Rafiei M,
Hamilton M, Schwarz E, Kobashigawa J. Success of Desensitization Protocol in Reducing
Calculated Panel Reactive Antibodies in a Large Cohort of Sensitized Heart Transplant Candidates.
J Heart Lung Transplant. 2011; 30(4, Supplement): S175.
464.
Patel J, Kittleson M, Kawano M, Goldstein Z, Rafiei M, Barry O, Hamilton M, Schwarz E,
Esmailian F, Kobashigawa J. Does Gender Mismatch Increase the Risk of Antibody-Mediated
Rejection (AMR) after Heart Transplantation? J Heart Lung Transplant. 2011; 30(4, Supplement):
S178.
81
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
465.
Kobashigawa J, Patel J, Kittleson M, Kawano M, Hage A, Moradzadeh A, Goldstein Z, Rafiei M,
Luthringer D, Schwarz E, Esmailian F. Biopsy-Negative Rejection: An Official New ISHLT
Rejection Category? J Heart Lung Transplant. 2011; 30(4, Supplement): S178.
466.
Zhang Q, Michael CJ, Gjertson DW, Kobashigawa J, Abbas A, Hickey A, Baas AS, Cruz D, Reed
EF. Virtual Crossmatch Significantly Increases Sensitized Patients to Heart Transplantation. J Heart
Lung Transplant. 2011; 30(4, Supplement): S180.
467.
Patel J, Kittleson M, Kawano M, Goldstein Z, Rafiei M, Davidoff J, Hage Am Reinsmoen N,
Schwarz E, Kass R, Kobashigawa J. Contrary to Popular Belief, Pre-Transplant Blood
Transfusions Are Uncommon Sensitizing Events in Patients Awaiting Heart Transplantation. J
Heart Lung Transplant. 2011; 30(4, Supplement): S181.
468.
Kittleson M, Patel J, Kawano M, Goldstein Z, Rafiei M, Moradzadeh A, Moriguchi J, Czer L,
Esmailian F, Kobashigawa J. Challenging the ISHLT Guideline Regarding Switch from
Mycophenolate to Sirolimus with Standard Dose Calcineurin Inhibitor. J Heart Lung Transplant.
2011; 30(4, Supplement): S182.
469.
Kittleson M, Patel J, Esmailian F, Trento A, Kass R, Kawano M, Goldstein Z, Rafiei M, Czer L,
Hamilton M, Kobashigawa J. Primary Graft Dysfunction: Autopsy Data Sheds Light on
Pathogenesis. J Heart Lung Transplant. 2011; 30(4, Supplement): S194.
470.
Kawano M, Kittleson M, Patel J, Goldstein Z, Rafiei M, Moradzadeh N, Moradzadeh A, Hage A,
Kobashigawa J. Impact of the Number of Blood Pressure Medications on the Outcome of Heart
Transplant Recipients. J Heart Lung Transplant. 2011; 30(4, Supplement): S197.
471.
Coleman B, Piponniau L, Patel J, Velleca A, Kawano M, Goldstein Z, Moradzadeh A, Rafiei M,
Geskin A, Azarbal B, Kass R, Kobashigawa J. To Be Immunosuppressed, Transplanted, and
Black: High Risk for Heart Transplantation. J Heart Lung Transplant. 2011; 30(4, Supplement): S219.
472.
Kittleson M, Patel J, Kawano M, Goldstein Z, Barry O, Schwarz E, Czer L, Kobashigawa J. Does
Gender Mismatch Increase the Risk of Antibody-Mediated Rejection? J Am Coll Cardiol. 2011; 57:
E315
473.
White M, Kobashigawa J, Cantin B, Haddad H, Ross H, Carrier M, Pflugfelder P, Isaac D, Cecere
R, Whittom L, Ali I, Wang S, Touyz R. Temporal Changes in Cardiac Molecular Events and
Biomarkers Following De Novo Cardiac Transplantation. J Am Coll Cardiol. 2011; 57: E318.
474.
Eisen HJ, Pauly D, Starling R, Kfoury A, Ross H, Wang S, Cantin B, Hirt S, Lehmkuhl H, Ewald
F, Van Bakel A, Zuckermann A, Lopez P, Dong G, Panis C, Jiang H, Cornu-Artis C,
Kobashigawa J. Efficacy and Renal Function in De Novo Heart Transplant Recipients Receiving
Everolimus with Reduced CsA Compared to MMF with Standard CsA: The A2310 Study. Am J
Transplant. 2011; 11(2, Supplement): 129.
475.
Bara C, Eisen H, Hirt S, Costard-Jaeckle A, Shulz U, Lopez P, Kobashigawa J, Lehmkul HB.
Efficacy and Renal Function in De Novo Heart Transplant Recipients Receiving Everolimus with
Reduced CsA Compared to MMF with Standard CsA: The A2310 Study. Transplant International.
2011; 24(3, Supplement): 22.
476.
Shulz U, Kobashigawa J, Bara C, Hirt S, Lehmkul HB, Lopez P, Costard-Jaeckle A. CMV
Infections are Less Frequent in De Novo Heart Transplant Recipients Receiving
Immunosuppression with Everolimus Plus Reduced CsA Compared to MMF and Standard CsA.
Transplant International. 2011; 24(3, Supplement): 22.
477.
Lehmkuhl H, Kobashigawa J, Bara C, Costard-Jaeckle A, Schulz U, Lopez P, Starling R, Hirt S.
Reduction of Cardiac Allograft Vasculopathy with Everolimus Over Mycophenolate Mofetil:
Intravascular Ultrasound Results of a Randomized Multicenter Trial. Transplant International. 2011;
24(3, Supplement): 49-50.
478.
Hirt S, Wang S, Kobashigawa J, Lehmkuhl H, Rinaldi M, Eisen HJ, Torre Gm Yonan N, Arizon
JM, Lopez P, Dong G, Panis C, Zuckermann A. Comparison of Wound Healing Events and
82
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
Effusions in De Novo Heart Transplant Recipients Treated with Everolimus Versus MMF Based
Regimens. Am J Transplant. 2011; 11(2, Supplement): 131.
479.
Kobashigawa J, Ross H, Kfoury AG, Van Bakel A, Ewald G, Burton J, Andreassen A, Banchs
HL, Segovia J, Lopeszs P, Cines M, Dong G, Potena L. CMV Infections Are Less Frequent in De
Novo Heart Transplant Recipients Receiving Immunosuppression with Everolimus Plus Reduced
CsA Compared to MMF and Standard CsA. Am J Transplant. 2011; 11(2, Supplement): 131.
480.
Starling R, Pauly Dm Wang Sm Cantin B, Ross H, Burton J, Eisen HJ, Keogh A, Dong G, Jiang H,
Cines M, Lopez P, Kobashigawa J. De Novo Heart Transplant Recipients at Increased Risk of
Cardiac Allograft Vasculopathy: IVUS Analysis of Specific Subpopulations Treated with
Everolimus Versus MMF. Am J Transplant. 2011; 11(2, Supplement): 132.
481.
Patel J, Kittleson M, Kawano M, Goldstein Z, Rafiei M, Barry O, Hamilton M, Schwarz E,
Esmailian F, Kobashigawa J. Male Donor to Female Recipient in Heart Transplantation Increases
the Risk of Antibody-Mediated Rejection. Am J Transplant. 2011; 11(2, Supplement): 237.
482.
Patel J, Kittleson M, Goldstein Z, Kawano M, Rafiei M, Reed E, Reinsmoen N, Schwarz E, Kass
R, Kobashigawa J. Virtual Crossmatch and Desensitization Therapy Has Reduced Time to
Transplant for Sensitized Patients. Am J Transplant. 2011; 11(2, Supplement): 237.
483.
Kobashigawa J, Patel J, Kittleson M, Kawano M, Hage A, Moradzadeh A, Goldstein Z, Rafiei M,
Luthringer D, Schwarz E, Esmailian F. The Category of Biopsy-Negative Rejection in Heart
Transplantation. Am J Transplant. 2011; 11(2, Supplement): 238.
484.
Kittleson M, Patel J, Esmailian F, Trento A, Kass R, Kawano M, Goldstein Z, Rafiei M, Czer L,
Hamilton M, Kobashigawa J. Primary Graft Dysfunction and Autopsy Findings. Am J Transplant.
2011; 11(2, Supplement): 238.
485.
Patel J, Azarbal B, Goldstein Z, Rafiei M, Kawano M, Moradzadeh A, Kittleson M, Czer L, Trento
A, Kobashigawa J. Screening Nuclear Stress Testing as a Prognostic Marker after Heart
Transplantation. Am J Transplant. 2011; 11(2, Supplement): 303.
486.
Junge G, Witte S, Zuckermann A, Lehmkuhl H, Schwende H, Wang Z, Kobashigawa J.
Everolimus, mTORC1 Signaling and Evolution of Body Weight after Cardiac Transplantation. Am
J Transplant. 2011; 11(2, Supplement): 304.
487.
Junge G, Witte S, Zuckermann A, Lehmkuhl H, Schwende H, Wang Z, Kobashigawa J.
Everolimus, mTORC1 Signaling and Evolution of Body Weight after Cardiac Transplantation.
Transplant International. 2011; 24(3, Supplement): 5.
488.
Azarbal B, Wei J, Singh S, Currier J, Patel J, Hage A, Makkar R, Kobashigawa J. Frequency of
coronary artery fistulae and extracardiac neovascularization after orthotopic heart transplantation.
Circulation. 2011 Nov 22; 124 (21) S-A14063.
489.
Rafiei M, Stern LK, Patel N, Hamilton M, Kobashigawa J. Lack of correlation of first-year cylex
scores to the development of cardiac allograft vasculopathy suggests the importance of humoral
factors. J Investig Med. 2012; 60(1): 172.
490.
Shiozaki R, Rafiei M, Stern LK, Hamilton M, Kobashigawa J. First-year brain natriuretic peptide
(BNP) as a biomarker after heart transplant for poor outcome and prediction of the severity of
cardiac allograft vasculopathy (CAV). J Investig Med. 2012; 60(1) 172-173.
491.
Patel N, Rafiei M, Stern LK, Hamilton M, Kobashigawa J. Obesity and protection from cardiac
allograft vasculopathy: Is the myth true? J Investig Med. 2012; 60(1): 173.
492.
Patel DP, Rafiei M, Stern LK, Hamilton M, Kobashigawa J. The policy of placing older donors
into older recipients: Is it worth it? J Investig Med. 2012; 60(1): 173-174.
493.
Merz A, Rafiei M, Stern LK, Hamilton M, Kobashigawa J. Has the virtual crossmatch truly
decreased time on the heart transplant waiting list for sensitized patients? J Investig Med. 2012;
60(1): 174.
83
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
494.
Stern LK, Rafiei M, Patel DP, Hamilton M, Kobashigawa J. Infectious complications of
desensitization therapy: Is the cure worse that the disease? J Investig Med. 2012; 60(1): 174.
495.
Tang Z, Rafiei M, Stern LK, Hamilton M, Kobashigawa J. The natural history of biopsy negative
rejection after heart transplantation. J Investig Med. 2012; 60(1): 174.
496.
Lee D, Rafiei M, Stern LK, Hamilton M, Kobashigawa J. Tricuspid regurgitation in the first year
after heart transplant: Does it mean gloom and doom? J Investig Med. 2012; 60(1): 175.
497.
Kwon M, Zhang Q, Abrahamyan A, Zhang Z, Gjertson D, Ardehali A, Kobashigawa J, Shemin
R, Reed E. Characterization of Ventricular Assist Device Mediated Sensitization in the Bridge to
Heart Transplant Patient. Circ Research. 2012; 109(12): AP122
498.
Kai B, Patel J, Kittleson M, Czer L, Trento A, Esmailian F, Kobashigawa J. Does persistent firstyear low of high cardiac index results in poor outcomes after heart transplantation? J Am Coll
Cardiol 2012; 59(13): E990
499.
Perkel D, Patel J, Kittleson M, Chang D, Czer L, Esmailian F, Kobashigawa J. CMV infection in
the era of tacrolimus/mycophenolate: Is there still an impact to develop cardiac allograft
vasculopathy? J Am Coll Cardiol 2012; 59(13): E923
500.
Tadwalkar R, Patel J, Kittleson M, Czer L, Kobashigawa J. Consequences of first-year rejection
after heart transplantation: Is the worse yet to come? J Am Coll Cardiol 2012; 59(13): E992
501.
Chai W, Patel J, Kittleson M, Czer L, Rafiei M, Stern L, Esmailian F, Kobashigawa J. Risk for
deep vein thrombosis and pulmonary embolism after heart transplantation: Characterization of an
old problem. J Am Coll Cardiol 2012; 59(13): E922
502.
Sue E, Patel J, Kittleson M, Czer L, Trento A, Esmailian F, Kobashigawa J. Does strict diabetic
control after heart transplantation lead to better outcome? J Am Coll Cardiol 2012; 59(13): E930
503.
Kobashigawa J, Patel J, Rafiei M, Stern L, Kittleson M, Czer L, Esmailian F. Late Response to
Desensitization Therapy. J Heart and Lung Transplant. 2012; 31(4): S158
504.
Patel J, Kittleson M, Rafiei M, Stern L, Chang D, Czer L, Trento A, Kobashigawa J.
Desensitization Therapy with Immunoglobulin (IVIG) and Rituximab for Patients Awaiting Heart
Transplantation. J Heart and Lung Transplant. 2012; 31(4): S161
505.
Cao K, Lai CH, Flores S, Rafiei M, Mirocha J, Haas M, Ong G, Naim M, Wang Q, Constanza L,
Patel J, Reinsmoen N, Kobashigawa J. Anti-Angiotensin Type 1 Receptor (AT1R) Antibodies
Together with Anti-HLA Donor Specific Antibodies (HLA-DSA) Identify Patients at Risk for
Immune Complication in Heart Transplant. J Heart and Lung Transplant. 2012; 31(4): S163
506.
Rafiei M, Patel J, Kittleson M, Patel N, Stern L, Azarbal B, Czer L, Trento A, Kobashigawa J.
First-Year Rejection and Cylex Scores Suggest the Importance of Acute Events in the
Development of Cardiac Allograft Vasculopathy. J Heart and Lung Transplant. 2012; 31(4): S168
507.
Stern L, Patel J, Kittleson M, Rafiei M, Dilibero D, Hage A, Czer L, Kobashigawa J. Use of
Generic Immunosuppression: Does it Truly Matter? J Heart and Lung Transplant. 2012; 31(4): S203
508.
Kearney B, Chai W, Patel J, Kittleson M, Rafiei M, Stern L, Czer L, Kobashigawa J. Does Level
of Education Affect Outcome After Heart Transplantation? J Heart and Lung Transplant. 2012;
31(4): S203-S204
509.
Patel J, Shiozaki R, Rafiei M, Stern L, Kittleson M, Chang D, Czer L, Esmailian F, Kobashigawa
J. Application of Immunosuppression Clinical Trial Results in Reducing the Incidence of Heart
Transplant Rejection-Bridging the New Millennium. J Heart and Lung Transplant. 2012; 31(4): S24
510.
Patel J, Kittleson M, Czer L, Rafiei M, Stern L, Patel DP, Hage A, Esmailian F, Kobashigawa J.
The Policy of Placing Older Donors into Older Recipients: Is it Worth it? J Heart and Lung
Transplant. 2012; 31(4): S24-S25
84
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
511.
Czer L, Patel J, Kittleson M, Rafiei M, Stern L, Chang D, Luthringer D, Esmailian F,
Kobashigawa J. Consequences of First-Year Rejection after Heart Transplantation: Is the Worse
yet to Come? J Heart and Lung Transplant. 2012; 31(4): S25
512.
Patel J, Kittleson M, Czer L, Rafiei M, Stern L, Esmailian F, Reinsmoen N, Kobashigawa J. Are
Donor Specific Antibodies Detected after Heart Transplant All Bad? J Heart and Lung Transplant.
2012; 31(4): S35
513.
Patel J, Kittleson M, Rafiei M, Stern L, Patel N, Czer L, Esmailian F, Kobashigawa J. Resurgence
of Photopheresis for Recalcitrant Cellular and Antibody-Mediated Cardiac Allograft Rejection. J
Heart and Lung Transplant. 2012; 31(4): S223
514.
Czer L, Patel J, Kittleson M, Rafiei M, Stern L, Chang D, Trento A, Kobashigawa J. Combined
Heart-Kidney Transplant Compared to Heart Transplant Alone May Reduce Long Term
Development of Cardiac Allograft Vasculopathy. J Heart and Lung Transplant. 2012; 31(4): S229
515.
Moriguchi J, Patel J, Kittleson M, Rafiei M, Stern L, Czer L, Trento A, Kobashigawa J. Older
Patients with Hemodynamic Compromise Rejection: What Happened to Immunosenescence? J
Heart and Lung Transplant. 2012; 31(4): S233
516.
Czer L, Lee D, Patel J, Kittleson M, Rafiei M, Stern L, Hage A, Esmailian F, Trento A,
Kobashigawa J. Tricuspid Regurgitation in the First-Year after Heart Transplant: Does it Lead to
Gloom and Doom? J Heart and Lung Transplant. 2012; 31(4): S233-S234
517.
Patel J, Kittleson M, Rafiei M, Stern L, Tang Z, Chang D, Luthringer D, Czer L, Trento A,
Kobashigawa J. The Natural History of Biopsy Negative Rejection after Heart Transplantation. J
Heart and Lung Transplant. 2012; 31(4): S235
518.
Moriguchi J, Patel J, Kittleson M, Rafiei M, Stern L, Chai W, Chang D, Trento A, Czer L,
Kobashigawa J. Risk for Deep Vein Thrombosis and Pulmonary Embolism after Heart
Transplantation: Characterization of an Old Problem. J Heart and Lung Transplant. 2012; 31(4): S235
519.
Kobashigawa J, Patel J, Kittleson M, Rafiei M, Stern L, Czer L, Reinsmoen N, Esmailian F. AntiHLA DQ Antibodies: Does Strength of Antibody Result in Subsequent Greater Cardiac Allograft
Vasculopathy? J Heart and Lung Transplant. 2012; 31(4): S235-S236
520.
Kansara P, Kransdorf E, Kittleson M, Patel J, Coleman B, Jamero G, Runyan C, Olay C, Jocson R,
Czer L, Trento A, Kass R, Esmailian F, Kobashigawa J, Moriguchi J. Improved Outcomes in
“Crash and Burn” Patients through BiVAD Support. J Heart and Lung Transplant. 2012; 31(4): S267S268
521.
Kobashigawa J, Pauly D, Kfoury A, Ross H, Wang SS, Cantin B, Van Bakel A, Starling R, Hirt S,
Dong G, Panis C, Lopez P, Eisen H. Multicenter Randomized Trial of Everolimus vs.
Mycophenolate Mofetil in Heart Transplantation: Final 24 Month Analysis of Efficacy and Safety. J
Heart and Lung Transplant. 2012; 31(4): S75
522.
Coleman B, Patel J, Czer L, Mirocha J, Kobashigawa J. Use of Thymoglobulin after Heart
Transplantation: Is there a Role in African American Patients? J Heart and Lung Transplant. 2012;
31(4): S92-S93
523.
Czer L, Patel J, Kittleson M, Rafiei M, Stern L, Esmailian F, Kobashigawa J. Infectious
Complications of Desensitization Therapy: Is the Cure Worse Than the Disease? J Heart and Lung
Transplant. 2012; 31(4): S108
524.
Patel J, Kittleson M, Kansara P, Rafiei M, Stern L, Chang D, Azarbal B, Czer L, Esmailian F,
Kobashigawa J. Outcomes Validation of the New ISHLT Cardiac Allograft Vasculopathy
Coronary Angiogram Grading Scale. J Heart and Lung Transplant. 2012; 31(4): S121
525.
Czer L, Patel J, Kittleson M, Rafiei M, Stern L, Chang D, Azarbal B, Trento A, Kobashigawa J.
Distal Pruning as an Important Factor for Outcome in the New ISHLT Cardiac Allograft
Vasculopathy Grading Scale. J Heart and Lung Transplant. 2012; 31(4): S121-S122
85
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
526.
Patel J, Kittleson M, Shiozaki R, Rafiei M, Stern L, Azarbal B, Czer L, Esmailian F, Kobashigawa
J. First-Year Brain Natriuretic Peptide (BNP) as a Biomarker after Heart Transplant to Predict
Severity of Cardiac Allograft Vasculopathy (CAV) as per the new ISHLT CAV Scale. J Heart and
Lung Transplant. 2012; 31(4): S122
527.
Kobashigawa J, Pauly D, Kfoury A, Ross H, Wang SS, Cantin B, vanBakel A, Starling R, Hirt S,
Dong G, Panis C, Lopez P, Eisen H. Effect of Everolimus Based Immunosuppression on De
Novo Heart Transplant Recipients-24 Months Efficacy and Safety Results from A2310 Study. Am
J Transplant. 2012; 12 (Suppl 3): 67-68
528.
Patel J, Kittleson M, Czer L, Rafiei M, Stern L, Reinsmoen N, Kobashigawa J. Maintenance
Immunosuppression and De Novo Antibody Production after Heart Transplantation: Does the
Choice of Drugs Matter? Am J Transplant. 2012; 12 (Suppl 3): 73-74
529.
Patel J, Kittleson M, Czer L, Rafiei M, Stern L, Patel DP, Hage A, Esmailian F, Kobashigawa J.
The Policy of Placing Older Donors into Older Recipients: Is it Worth it? Am J Transplant. 2012; 12
(Suppl 3): 96
530.
Patel J, Kittleson M, Czer L, Rafiei M, Stern L, Reinsmoen N, Kobashigawa J. Are DonorSpecific Antibodies Detected after Heart Transplant All Bad? Am J Transplant. 2012; 12 (Suppl 3):
121
531.
Kobashigawa J, Patel J, Rafiei M, Stern L, Kittleson M, Czer L, Reinsmoen N, Esmailian F. Late
Response to Desensitization Therapy. Am J Transplant. 2012; 12 (Suppl 3): 382
532.
Dilibero D, Patel J, Kittleson M, Rafiei M, Stern L, Hage A, Czer L, Kobashigawa J. Use of
Generic Immunosuppression: Does it Truly Matter? Am J Transplant. 2012; 12 (Suppl 3): 384
533.
Rafiei M, Czer L, Patel J, Kittleson M, Stern L, Chang D, Esmailian F, Kobashigawa J. Combined
Heart-Kidney Transplant Compared to Heart Transplant Alone May Reduce Long Term
Development of Cardiac Allograft Vasculopathy. Am J Transplant. 2012; 12 (Suppl 3): 384
534.
Stern L, Patel J, Kobashigawa L, Rafiei M, Velleca A, Kittleson M, Czer L, Bairey Merz N,
Kobashigawa J. Is Hormone Replacement Therapy (HRT) in Postmenopausal Women Associated
with Poor Outcome after Heart Transplantation? Am J Transplant. 2012; 12 (Suppl 3): 477
535.
Kobashigawa J, Patel J, Kittleson M, Rafiei M, Stern L, Czer L, Reinsmoen N, Esmailian F. AntiHLA DQ Antibodies: Does Strength of Antibody Result in Subsequent Greater Cardiac Allograft
Vasculopathy? Am J Transplant. 2012; 12 (Suppl 3): 382
536.
Moriguchi J, Kittleson M, Patel J, Coleman B, Jamero G, Runyan C, Olay C, Jocson R, Chang D,
Czer L, Trento A, Esmailian F, Kobashigawa J. Are Sensitized VAD Patients Similar to Sensitized
non-VAD Patients in Terms of Outcome? Am J Transplant. 2012; 12 (Suppl 3): 120-121
537.
Kansara P, Czer L, Patel J, Kittleson M, Mirocha J, Moriguchi J, Chang D, De Robertis M, Trento
A, Kass R, and Kobashigawa J. Prior Cardiac Surgery is a Predictor of Mortality in the First-Year
in Heart Transplant Recipients. Am J Transplant. 2012; 12 (Suppl 3): 476
538.
Kransdorf E, Czer L, Patel J, Zakowski P, Gaultier C, Zabner R, Chang D, Kittleson M,
Kobashigawa J. High Prevalence and Reactivation of Chagas Disease in Heart Transplant
Recipients. Am J Transplant. 2012; 12 (Suppl 3): 477-478
539.
Reinsmoen NL, Law C-H, Ong GD, Naim M, Wang Q, Masukawa R, Duong H, Patel J,
Kobashigawa J. Optimizing Transplantation of Broadly Sensitized Heart Patients: Three Antibody
Profiling Strategies and Therapeutic Intervention. 24th International Congress of the
Transplantation Society. Berlin, Germany. July 15th-19th 2012
540.
Epailly E, Eisen H, Hirt S, Lehmkuhl H, Andreassen A, Rinaldi M, Yonan N, Potenta L,
Zuckermann A, Dong G, Panis C, Lopez P, Kobashigawa, J. 24-Month Safety and Efficacy of
Concentration Controlled Everolimus with Reduced Cyclosporine Versus Mycophenolate Mofetil
86
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
in 721 De Novo Heart Transplant Recipients: Results from the A2310 Study. 24th International
Congress of the Transplantation Society. Berlin, Germany. July 15th-19th 2012
541.
Tittle M, Rafiei M, Osborne A, Hamilton M, Kobashigawa J. Advances in Heart Transplantation
Across the Millennium. J Investig Med. 2013; 61(1):111.
542.
Kim Y, Rafiei M, Osborne A, Yabuno J, Hamilton M, Kobashigawa J. Long-Term Tacrolimus
Has Significant Renal Benefit Over Cyclosporine in Heart Transplantation. J Investig Med. 2013;
61(1):112.
543.
Ngan A, Rafiei M, Osborne A, Hamilton M, Kobashigawa J. Tacrolimus-Induced Diabetes Leads
to More Diabetic Complications After Heart Transplant. J Investig Med. 2013; 61(1):112.
544.
Osborne A, Rafiei M, Razi R, Hamilton M, Kobashigawa J. New Onset Left Ventricular
Hypertrophy After Heart Transplantation: What is the Meaning? J Investig Med. 2013; 61(1):124.
545.
Yabuno J, Rafiei M, Osborne A, Razi R, Hamilton M, Kobashigawa J. Chronic Anemia After
Heart Transplantation: Is It A Marker For Poor Outcome? J Investig Med. 2013; 61(1):124-125.
546.
Siu M, Rafiei M, Osborne A, Shiozaki R, Hamilton M, Kobashigawa J. Contention: Status 2
Patients Do Not Need To Undergo Heart Transplantation. J Investig Med. 2013; 61(1):162.
547.
Rafiei M, Osborne A, Patel N, Hamilton M, Kobashigawa J. Prevention of Antibody Production
in Heart Transplant Patients Receiving ATG Induction Therapy. J Investig Med. 2013; 61(1):222-223.
548.
Cohen B, Rafiei M, Osborne A, Hamilton M, Kobashigawa J. Characteristics of Primary Graft
Dysfunction- A Single Center Experience. J Investig Med. 2013; 61(1):223-224.
549.
Lee F, Rafiei M, Osborne A, Hamilton M, Kobashigawa J. The Obesity Paradox- Does It Apply
After Heart Transplantation? J Investig Med. 2013; 61(1):223.
550.
Murray-Bruce N, Rafiei M, Osborne A, Hamilton M, Kobashigawa J. Does the Renal Sparing
Protocol with Cessation of Calcineurin Inhibitors Result in Metabolic Improvement? J Investig Med.
2013; 61(1):223.
551.
Dhiantravan V, Patel J, Kittleson M, Rafiei M, Osborne A, Chang D, Czer L, Kobashigawa J.
Mycophenolate not Azathioprine with Increased Risk for Skin Cancer after Heart Transplant. J Am
College of Cardiology. 2013; 61(10) Suppl A: 195
552.
Geft D, Patel J, Kittleson M, Chang D, Rafiei M, Osborne A, Czer L, Esmailian F, Kobashigawa
J. Use of Cylex Immune Monitoring Score to Guide Immunosuppression After Heart
Transplantation Reduces Infection Risk. J Am College of Cardiology. 2013; 61(10) Suppl A: 196
553.
Kansara P, Czer L, Patel J, Mirocha J, Kittleson M, De Robertis M, Moriguchi J, Chang D, Ramzy
D, Kass R, Esmailian F, Trento A, Kobashigawa J. Early Mortality and Morbidity in Heart
Transplant Recipients with Prior History of Cardiac Surgery: Analysis of United Network for
Organ Sharing Database. J Am College of Cardiology. 2013; 61(10) Suppl A: 196
554.
Tadwalkar R, Kittleson M, Patel J, Moriguchi J, Rafiei M, Osborne A, Chang D, Czer L, Esmailian
F, Reinsmoen N, Kobashigawa J. Establishing a PRA Threshold to Treat Sensitized Patients
Awaiting Heart Transplant in the Era of the Virtual Crossmatch. J Am College of Cardiology. 2013;
61(10) Suppl A: 163
555.
Song H, Kittleson M, Patel J, Rafiei M, Osborne A, Chang D, Ramzy D, Hage A, Czer L,
Kobashigawa J. Change in Cylex Scores Predicts Risk for Infection in the First-Year following
Heart Transplantation. J Am College of Cardiology. 2013; 61(10) Suppl A: 196
556.
Moradzadeh A, Kittleson M, Patel J, Rafiei M, Osborne A, Chang D, Czer L, Kobashigawa J. The
Risk of Clostridium Difficile in Heart Transplant Patients on Different Immunosuppression
Regimens. J Am College of Cardiology. 2013; 61(10) Suppl A: 195
87
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
557.
Aaronson A, Kittleson M, Patel J, Rafiei M, Osborne A, Chang D, Czer L, Kobashigawa J.
Benefit of Tacrolimus/Mycophenolate to Reduce Cardiac Allograft Vasculopathy after Heart
Transplantation. J Am College of Cardiology. 2013; 61(10) Suppl A: 195
558.
Rafiei M, Kittleson M, Patel J, Osborne A, Chang D, Czer L, Reinsmoen N, Kobashigawa J. Antithymocyte Gammaglobulin May Prevent Antibody Production after Heart Transplantation. J Am
College of Cardiology. 2013; 61(10) Suppl A: 196
559.
Patel J, Reinsmoen N, Kobashigawa J. Maintenance Immunosuppression and de novo Antibody
Production after Heart Transplantation- Does the Choice of Drugs Matter? Am Society of Transplant:
Cutting Edge of Transplantation. 2013
560.
Patel J, Reinsmoen N, Kobashigawa J. The Incidence of Circulating Antibodies at the Time of
Pathology Defined Antibody-Mediated Rejection after Heart Transplantation. Am Society of
Transplant: Cutting Edge of Transplantation. 2013
561.
Patel J, Reinsmoen N, Kobashigawa J. Pre-Transplant PRA and Risk for Antibody-Mediated
Rejection after Heart Transplantation. Am Society of Transplant: Cutting Edge of Transplantation. 2013
562.
Kobashigawa J, Patel J, Reinsmoen N. The Development and Impact of Circulating Antibodies in
Non-Sensitized Patients after Heart Transplantation. Am Society of Transplant: Cutting Edge of
Transplantation. 2013
563.
Kobashigawa J, Patel J, Reinsmoen N. ATG Induction Improves Outcome for Sensitized Patients
Who Have Undergone Heart Transplantation. Am Society of Transplant: Cutting Edge of Transplantation.
2013
564.
Daun T, Patel J, Kittleson M, Rafiei M, Osborne A, Velleca A, Piponniau L, Chang D, Czer L,
Hamilton M, Kobashigawa J. Does Regular exercise after heart transplantation have any benefit?
Real life experience. J Heart and Lung Transplant. 2013; 32(4): S198
565.
Kansara P, Patel J, Kittleson M, Rafiei M, Osborne A, Chang D, Czer L, Esmailian F, Trento A,
Kobashigawa J. Early Mortality and Morbidity in First 60 Days in Adult Heart Transplant
Recipients with Prior History of Cardiac Surgery: Analysis of United Network for Organ Sharing
database. J Heart and Lung Transplant. 2013; 32(4): S162
566.
Kittleson M, Stewart F, Cowger J, Patel C, Rame E, Testani J, Mountis M, Patel P, Johnson F,
Guglin M, Teuteberg J, Kobashigawa J, Stevenson L, Hamilton M. Triage for Advanced Heart
Failure: Effect of Regional Wait Time Disparity. J Heart and Lung Transplant. 2013; 32(4): S166-S167
567.
Patel J, Kittleson M, Rafiei M, Osborne A, Aaronson A, Chang D, Azarbal B, Czer L, Moriguchi J,
Kobashigawa J. Benefit of Tacrolimus/Myocophenolate to Reduce Cardiac Allograft
Vasculopathy after Heart Transplantation. J Heart and Lung Transplant. 2013; 32(4): S50
568.
Kobashigawa J, Tadwalkar R, Kittleson M, Patel J, Moriguchi J, Rafiei M, Osborne A, Chang D,
Czer L, Esmailian F, Reinsmoen N. Establishing a PRA Threshold to treat Sensitized Patients
Awaiting Heart Transplant in the Era of the Virtual Crossmatch. J Heart and Lung Transplant. 2013;
32(4): S53
569.
Patel J, Kittleson M, Rafiei M, Osborne A, Chang D, Czer L, Kobashigawa J. Proliferation Signal
Inhibitors Reduce Severity of Cardiac Allograft Vasculopathy after Heart Transplantation. J Heart
and Lung Transplant. 2013; 32(4): S50
570.
Kobashigawa J, Starling R, Dong G, Lopez P, Eisen H. Change in Maximum Intimal Thickness
with Everolimus-based Immunosuppression after Heart Transplantation in Patients at Increased
Risk of Cardiac Allograft Vasculopathy. J Heart and Lung Transplant. 2013; 32(4): S25-S26
571.
Kittleson M, Patel J, Rafiei M, Osborne A, Jamero G, Chang D, Azarbal B, Czer L, Kobashigawa
J. Even Mild Renal Insufficiency is a Risk for Mortality after Heart Transplant. J Heart and Lung
Transplant. 2013; 32(4): S40
88
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
572.
Patel J, Kittleson M, Rafiei M, Osborne A, Chang D, Czer L, Esmailian F, Reinsmoen N,
Kobashigawa J. The incidence of circulating antibodies at the time of Pathology Defined
Antibody-Mediated Rejection after Heart Transplantation. J Heart and Lung Transplant. 2013; 32(4):
S20-2S21
573.
Phan A, Kittleson M, Patel J, Rafiei M, Osborne A, Chang D, Czer L, Ramzy D, Esmailian F,
Kobashigawa J. ATG Induction Improves Outcome for Sensitized Patients Who Have
Undergone Heart Transplantation. J Heart and Lung Transplant. 2013; 32(4): S200
574.
Wei J, Azarbal B, Cheng R, Geft D, Rafiei M, Patel J, Czer L, Kobashigawa J. Cardiac Allograft
Vasculopathy is Less Frequent in Contemporary Heart Transplant Population. J Heart and Lung
Transplant. 2013; 32(4): S209-S210
575.
Morlend R, Kittleson M, Patel J, Rafiei M, Osborne A, Hage A, Chang D, Czer L, Moriguchi J,
Trento A, Kobashigawa J. Complications on the Heart Transplant Waiting List is Common:
Reducing Wait List Time for Sensitized Patients May Avoid Complications. J Heart and Lung
Transplant. 2013; 32(4): S208
576.
Wei J, Singh S, Young A, Rafiei M, Hage A, Patel J, Esmailian F, Currier J, Kobashigawa J,
Azarbal B. Coronary Artery Fistulae after Orthotopic Heart Transplantation are Associated with
Decreased Prevalence of Transplant Coronary Artery Disease. J Heart and Lung Transplant. 2013;
32(4): S210-211
577.
Kittleson M, Patel J, Rafiei M, Osborne A, Shiozaki R, Chang D, Moriguchi J, Czer L,
Kobashigawa J. Failed Prednisone Taper Off after heart transplant: Is there a price to be paid? J
Heart and Lung Transplant. 2013; 32(4): S200
578.
Rush J, Kittleson M, Patel J, Rafiei M, Osborne A, Velleca A, Piponniau L, Chang D, Czer L,
Kobashigawa J. Men Versus Women: Outcome Differences on Cyclosporine and Tacrolimus. J
Heart and Lung Transplant. 2013; 32(4): S201
579.
Piponniau L, Kittleson M, Patel J, Rafiei M, Osborne A, Dhiantravan V, Chang D, Czer L, Hage A,
Hamilton M, Moriguchi J, Kobashigawa J. Mycophenolate not Azathioprine is Associated with
Increased Risk for Skin Cancer after Heart Transplant. J Heart and Lung Transplant. 2013; 32(4):
S199
580.
Kobashigawa J, Pauly D, Ross H, Kfoury A, Van Bakel A, Patel D, Wiland A, Lopez P, Balfour
A, Starling R, Eisen H. North American Results from the Multicenter Randomized Trial of
Everolimus vs. Mycophenolate Mofetil in Heart Transplantation. J Heart and Lung Transplant. 2013;
32(4): S201
581.
Kobashigawa J, Patel J, Kittleson M, Chang D, Czer L, Daun T, Trento A, Esmailian F. Results
of a Randomized Trial of Allomap vs. Heart Biopsy in the first year after Heart Transplant: Early
Invasive Monitoring Attenuation through Gene Expression Trial. J Heart and Lung Transplant. 2013;
32(4): S203
582.
Velleca A, Kittleson M, Patel J, Rafiei M, Osborne A, Ngan A, Hage A, Chang D, Czer L,
Kobashigawa J. Tacrolimus- versus Cyclosporine-induced Diabetes Leads to More Diabetic
Complications after Heart Transplantation. J Heart and Lung Transplant. 2013; 32(4): S202
583.
Stimpson E, Patel J, Kittleson M, Rafiei M, Osborne A, Lee F, Chang D, Hage A, Ramzy D, Czer
L, Hamilton M, Kobashigawa J. The Obesity Paradox. J Heart and Lung Transplant. 2013; 32(4):
S212
584.
Reinsmoen N, Lai C, Mirocha J, Cao K, Ong G, Naim M, Wang Q, Riega S, Rafiei M, Patel J,
Kobashigawa J. Increased Negative Impact of Anti-Angiotensin Type 1 Receptor Antibodies
Together with de novo Donor HLA Specific Antibodies on Graft Outcome in Heart Transplant
Recipients. J Heart and Lung Transplant. 2013; 32(4): S113
585.
Kransdorf E, Kittleson M, Patel J, Rafiei M, Osborne A, Chang D, Czer L, Hage A, Zakowski P,
Kobashigawa J. High Rate of Reactivation of Chagas Disease After Heart Transplantation in the
United States. J Heart and Lung Transplant. 2013; 32(4): S130
89
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
586.
Kittleson M, Patel J, Rafiei M, Osborne A, Moradzadeh A, Chang D, Czer L, Zakowski P,
Kobashigawa J. The Development of Clostridium Difficile in Heart Transplant Patients on
Different Immunosuppression Regimens. J Heart and Lung Transplant. 2013; 32(4): S131
587.
Esmailian F, Kobashigawa JA, Naka Y, Mancini D, Soltesz E, Hsich E, Camacho M, Baran D,
Madsen J, LePrince P, Deng M, Ardehali A. The Proceed II International Heart Transplant Trial
with The Organ Care System Technology (OCS). J Heart and Lung Transplant. 2013; 32(4): S95-S96
588.
Kobashigawa J, Kittleson M, Rafiei M, Osborne A, Chang D, Czer L, Ramzy D, Esmailian F,
Patel J. Cylex Scores May Predict Risk for Infection in the First Year Following Heart
Transplantation. J Heart and Lung Transplant. 2013; 32(4): S74
589.
Geft D, Patel J, Kittleson M, Chang D, Rafiei M, Osborne A, Hage A, Czer L, Esmailian F,
Kobashigawa J. Use of Cylex Immune Monitoring Score to Guide Immunosuppression after
Heart Transplantation Reduces Infection Risk. J Heart and Lung Transplant. 2013; 32(4): S73
590.
Kittleson M, Patel J, Rafiei M, Osborne A, Chang D, Ramzy D, Czer L, Reinsmoen N,
Kobashigawa J. Pre-Transplant Circulating Antibodies Predict Antibody-Mediated Rejection after
Heart Transplant Using the New ISHLT Grading Scale. J Heart and Lung Transplant. 2013; 32(4):
S87-S88
591.
Patel J, Kittleson M, Rafiei M, Osborne A, Chang D, Czer L, Reinsmoen N, Trento A,
Kobashigawa J. The Development and Impact of de novo Circulating Antibodies in NonSensitized Patients after Heart Transplantation. J Heart and Lung Transplant. 2013; 32(4): S86
592.
Thottam M, Patel J, Kittleson M, Rafiei M, Osborne A, Velleca A, Piponniau L, Chang D, Czer L,
Hamilton M, Kobashigawa J. Cardiac Rehabilitation after Heart Transplantation Reduces
Development of Cardiac Allograft Vasculopathy. J Heart and Lung Transplant. 2013; 32(4): S80
593.
Kittleson M, Patel J, Rafiei M, Osborne A, Yabuno J, Chang D, Azarbal B, Czer L, Hamilton M,
Kobashigawa J. Chronic Anemia is Not a Predictor for Poor Outcome after Heart
Transplantation. J Heart and Lung Transplant. 2013; 32(4): S254-S255
594.
Kittleson M, Patel J, Rafiei M, Osborne A, Tittle M, Chang D, Czer L, Esmailian F, Trento A,
Kobashigawa J. Longer and Shorter Hospital Stay after Heart Transplant Both Risk Factors for
Suboptimal Outcome. J Heart and Lung Transplant. 2013; 32(4): S263
595.
Coleman B, Patel J, Mirocha J, Czer L, Kobashigawa J. Induction Therapy in African American
Heart Transplant Recipients: Analysis of the UNOS Database. J Heart and Lung Transplant. 2013;
32(4): S134-S135
596.
Eisen H, Ross H, Pauly D, Kfoury A, Van Bakel A, Starling R, Patel D, Wiland A, Lopez P,
Balfour A, Kobashigawa J. Adverse Events (AEs) Associated with Everolimus (EVR) or
Mycophenolate Mofetil (MMF) in De Novo Heart Transplant (HTx) Recipients: Results from the
North American (NA) Subpopulation of Study A2310. J Heart and Lung Transplant. 2013; 32(4):
S200-S201
597.
Deng M, Soltesz E, Hsich E, Naka Y, Mancini D, Esmailian F, Kobashigawa J, Camacho M,
Baran D, Madsen J, LePrince P, Ardehali A. Ex-Vivo Perfusion of Human Donor Hearts Reduces
Cold Ischemia Time. J Heart and Lung Transplant. 2013; 32(4): S156
598.
Deng M, Soltesz E, Hsich E, Naka Y, Mancini D, Esmailian F, Kobashigawa J, Camacho M,
Baran D, Madsen J, LePrince P, Ardehali A. Is Lactate Level during Warm Perfusion a Predictor
for Post Transplant Outcomes? J Heart and Lung Transplant. 2013; 32(4): S156-S157
599.
Kobashigawa J, Pauly D, Ross H, Kfoury A, Van Bakel A, Patel D, Wiland A, Lopez P, Balfour
A, Starling R, Eisen H. North American Results from the Multicenter Randomized Trial of
Everolimus vs Mycophenolate Mofetil in Heart Transplantation. Am J Transplant. 2013; 13 (suppl
5): 93
90
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
600.
Kobashigawa J, Kittleson M, Rafiei M, Osborne A, Chang D, Czer L, Reinsmoen N, Patel J.
Comparable Waiting Time for Highly Sensitized Patients Awaiting Heart Transplant Using
Desensitization Therapy and the Virtual Crossmatch. Am J Transplant. 2013; 13 (suppl 5): 455
601.
Kobashigawa J, Watanabe J, Shafi H, Patel J, Kittleson M, Jordan S, Klapper E, Toyoda M.
Clinical and Mechanistic Outcomes of Photopheresis after Heart Transplantation. Am J Transplant.
2013; 13 (suppl 5): 453
602.
Patel J, Kittleson M, Rafiei M, Osborne A, Chang D, Czer L, Kobashigawa J. Pathology and
Clinical Progression of Biopsy Proven pAMR1 After Heart Transplantation. Am J Transplant. 2013;
13 (suppl 5): 455
603.
Kobashigawa J, Kittleson M, Rafiei M, Osborne A, Chang D, Czer L, Reinsmoen N, Patel J. Poor
Outcomes In Non-Sensitized Patients Developing de Novo Circulating Antibodies After Heart
Transplantation. Am J Transplant. 2013; 13 (suppl 5): 70-71
604.
Patel J, Kittleson M, Rafiei M, Osborne A, Chang D, Czer L, Kobashigawa J. First Year Mild
Renal Insufficiency Associated With Increased Mortality After Heart Transplant. Am J Transplant.
2013; 13 (suppl 5): 453
605.
Osborne A, Patel J, Kittleson M, Rafiei M, Chang D, Czer L, Kobashigawa J. Kidney Dialysis
After Heart Transplantation: The Short and Long Term Outcomes. Am J Transplant. 2013; 13
(suppl 5): 454
606.
Patel J, Kittleson M, Rafiei M, Osborne A, Chang D, Czer L, Kobashigawa J. Potential Downfall
of Failed Prednisone Wean After Heart Transplant. Am J Transplant. 2013; 13 (suppl 5): 457
607.
Kittleson M, Patel J, Rafiei M, Osborne A, Chang D, Czer L, Kobashigawa J. The Role of Cardiac
Rehabilitation After Heart Transplantation in the Reduction of Cardiac Allograft Vasculopathy.
Am J Transplant. 2013; 13 (suppl 5): 452
608.
Patel J, Kittleson M, Rafiei M, Osborne A, Chang D, Czer L, Reinsmoen N, Kobashigawa J. The
Presence of Circulating Antibodies at The Time of Pathology Defined Antibody-Mediated
Rejection After Heart Transplant: Are They Out There? Am J Transplant. 2013; 13 (suppl 5): 453454
609.
Patel J, Kittleson M, Rafiei M, Osborne A, Chang D, Czer L, Kobashigawa J. Tacrolimus-Induced
Diabetes Compared to Cyclosporine May Lead to More Diabetic Complications Post Heart
Transplant. Am J Transplant. 2013; 13 (suppl 5): 94
610.
Rafiei M, Kittleson M, Patel J, Osborne A, Chang D, Czer L, Kobashigawa J. Persistent
Asymptomatic C4d Staining in the First Year After Heart Transplantation is a Marker for Cardiac
Allograft Vasculopathy. Am J Transplant. 2013; 13 (5): 71
611.
Patel J, Kittleson M, Rafiei M, Osborne A, Chang D, Czer L, Kobashigawa J. ATG Induction for
Sensitized Patients Who Have Undergone Heart Transplant: Is it Beneficial? Am J Transplant. 2013;
13 (5): 457
612.
Patel J, Kittleson M, Rafiei M, Osborne A, Chang D, Czer L, Kobashigawa J. Severity of Cardiac
Allograft Vasculopathy After Heart Transplant Is Reduced With Proliferation Signal Inhibitors.
Am J Transplant. 2013; 13 (5): 454
613.
Reinsmoen N, Lai C, Mirocha J, Cao K, Naim M, Ong G, Duong H, Riega S, Rafiei M, Patel J,
Kobashigawa J. Anti-Angiotensin Type 1 Receptor Antibodies Associated With Rejection in
Donor HLA Antibody Negative Recipients. Am J Transplant. 2013; 13 (suppl 5): 456
614.
Kobashigawa J, Patel J, Kittleson M, Chang D, Czer L, Daun T, Trento A, Esmalian F.
Intravascular Ultrasound (IVUS) Results of a Randomized Trial of Allomap vs. Heart Biopsy in the
1st Year after Heart Transplant. Am J Transplant. 2013; 13 (suppl 5): 549
91
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
615.
Kittleson M, Patel J, Rafiei M, Osborne A, Chang D, Azarbal B, Czer L, Esmailian F, Reinsmoen
N, Kobashigawa J. Comparison of Maintenance Immunosuppression and de novo Antibody
Production in the First-Year After Heart Transplant. Circulation. 2013; 128 (22S): A10549
616.
Elboudwarej O, Patel J, Osborne A, Liou F, Reinsmoen N, Kobashigawa J. Prednisone Wean
After Heart Transplantation – Is There a Risk for Antibody Formation? Circulation. 2013; 128
(22S): A10549
617.
Tang S, Chang D, Kobashigawa J. Acyclovir neurotoxicity in an orthotropic heart transplant
patient on peritoneal dialysis. Annals of Int Med 2013; In Press.
618.
Parikh A, Yu Z, Liou F, Hamilton M, Kobashigawa J. Beta Blockers to Lower Heart Rate After
Heart Transplantation May Not Be Beneficial. J Investig Med. 2014;62(1):273
619.
Liou F, Yu Z, Hamilton M, Kobashigawa J. Does Heart-Kidney Transplant confer Protective
Benefits in Immune Responses? J Investig Med. Jan 2014;62(1):158
620.
Wong D, Yu Z, Liou F, Yabuno J, Hamilton M, Kobashigawa J. Cylex Scores for African
Americans vs. Caucasians: Is There a Difference? J Investig Med. 2014;62(1):274
621.
Yabuno J, Yu Z, Liou F, Hamilton M, Kobashigawa J. Is a Lower Cylex Score Helpful in
Preventing the Development of Circulating Antibodies After Heart Transplant? J Investig Med.
2014;62(1):272
622.
Murayama K, Yu Z, Liou F, Hamilton M, Kobashigawa J. Donor Height vs. Weight: Is One
More Important Than the Other? J Investig Med. 2014;62(1):202
623.
Yu Z, Liou F, Hamilton M, Kobashigawa J. A Natural History of Pericardial Effusion After
Heart Transplantation. J Investig Med. 2014;62(1):272
624.
Aquino A, Yu Z, Liou F, Hamilton M, Kobashigawa J. Do Redo Heart Transplant Patients Have
an Increased Risk of Antibody Development? J Investig Med. 2014;62(1):273
625.
Chehrazi-Raffle A, Yu Z, Liou F, Hamilton M, Kobashigawa J. Toxoplasma Serology and
Outcomes after Heart Transplantation: Contention in the Literature. J Investig Med. 2014;62(1):158
626.
Siu M, Yu Z, Liou F, Hamilton M, Kobashigawa J. Ventricular Assist Device Complications on
the Waiting List and Post-Heart Transplant Outcomes. J Investig Med. 2014;62(1):192,202
627.
Ngan A, Yu Z, Liou F, Hamilton M, Kobashigawa J. Sensitized Ventricular Assist Device Patients
vs. Sensitized Non-Ventricular Assist Device Patients: Is There an Immunological Difference? J
Investig Med. 2014;62(1):202
628.
Kai B, Reinsmoen N, Yu Z, Liou F, Yabuno J, Patel J, Kittleson M, Hamilton M, Chang D, Czer
L, Kobashigawa J. Does Anything Work for the Highly Sensitized Patients Awaiting Heart
Transplant? Am Coll Cardiol. 2014; 63 (12_S)
629.
Cheng R, Azarbal B, Patel J, Chang D, Kobashigawa J. Elevated Immune Monitoring after
Cardiac Transplantation is Associated with Increased Plaque Progression by Intravascular
Ultrasound. Am Coll Cardiol. 2014; 63 (12_S)
630.
Grigorian-Shamajan L, Yu Z, Liou F, Patel J, Kittleson M, Azarbal B, Chang D, Czer L,
Kobashigawa J. Percutaneous Coronary Intervention versus Medical Therapy for Moderate
Coronary Lesions after heart Transplantation: What to do? Am Coll Cardiol. 2014; 63 (12_S)
631.
Gurudevan S, Arabia F, Esmailian, Ramzy D, Czer L, Kobashigawa J, Moriguchi J. The Total
Artificial Heart: An Effective Bridge to Transplantation in Patients with Advanced Heart Failure.
Am Coll Cardiol. 2014; 63 (12_S)
632.
Kafi A, Patel J, Kittleson M, Yu Z, Liou F, Yabuno J, Kao T, Czer L, Chang DH, Hage A, Ramzy
D, Kobashigawa J. Abnormal Pulmonary Function Tests Contraindicate Heart Transplant. J
Heart Lung Transplant. 2014; 33(4): S141-142
92
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
633.
Kittleson M, Patel J, Yu Z, Liou F, Aquino A, Velleca A, Czer L, Chang DH, Hamilton M, Trento
A, Reinsmoen N, Kobashigawa J. Do Redo Heart Transplant Patients Have an Increased Risk of
Antibody Development? J Heart Lung Transplant. 2014; 33(4): S284
634.
Lipson-Altman N, Reinsmoen N, Kittleson M, Luthringer D, Patel J, Liou F, Yu Z, Kearny B,
Czer L, Chang DH, Ramzy D, Kobashigawa J. Does the Ability for Donor Specific Antibodies
to Bind Complement Always Result in C4d Staining in the Endomyocardial Biopsy After Heart
Transplant? J Heart Lung Transplant. 2014; 33(4): S83
635.
Moriguchi J, Arabia F, Patel J, Kittleson M, Yu Z, Liou F, Yabuno J, Chang DH, Czer L, Hage A,
Ramzy D, Kobashigawa J. Does VAD Placement Reduce Weight in Obese Severe Heart Failure
Patients? J Heart Lung Transplant. 2014; 33(4): S209
636.
Moriguchi J, Arabia F, Jocson R, Patel J, Kittleson M, Liou F, Yu Z, Ernst W, Hamilton M, Chang
DH, Czer L, Kobashigawa J. Extracorporeal membrane Oxygenation as a Bridge to Decision for
INTERMACS 1 Patients. J Heart Lung Transplant. 2014; 33(4): S250-251
637.
Stimpson E, Dilibero D, Kittleson M, Patel J, Yu Z, Liou F, Yabuno J, Zakowski P, Czer L, Trento
A, Esmailian F, Kobashigawa J. Hepatitis B Vaccination Confers an Increased Rate of Transplant
for Patients on the Heart Transplant Waiting List. J Heart Lung Transplant. 2014; 33(4): S268
638.
Sasevich MJ, Esmailian F, Rihbany K, Pouldar T, Yu Z, Liou F, Ramzy D, Arabia F, Trento A,
Czer L, Hamilton M, Kobashigawa J. Is Pre-Existing Liver Cirrhosis and Fibrosis a
Contraindication to Heart Transplantation? J Heart Lung Transplant. 2014; 33(4): S157
639.
Kobashigawa J, Moriguchi J, Reinsmoen N, Kittleson M, Yu Z, Liou F, Ngan A, Runyan M,
Henry H, Chang DH, Czer L, Arabia F. Sensitized VADs vs. Sensitized Non-VADs: Is There an
Immunological Difference? J Heart Lung Transplant. 2014; 33(4): S305
640.
Yu Z, Patel J, Kittleson M, Liou F, Yabuno J, Jamero G, Chang DH, Czer L, Azarbal B, Trento A,
Esmailian F, Kobashigawa J. The Risk of Prior Chest Radiation Therapy in Patients Who
Undergo Heart Transplantation. J Heart Lung Transplant. 2014; 33(4): S170-171
641.
Kittleson M, Chehrazi-Raffle A, Patel J, Yu Z, Liou F, Johnson M, Stimpson E, Hage A, Chang
DH, Czer L, Zakowski P, Kobashigawa J. Toxoplasma Serology Mismatch with Increased
Mortality? Clarifying the Literature. J Heart Lung Transplant. 2014; 33(4): S179-180
642.
Reinsmoen N, Haas M, Patel J, Lai C, Naim M, Ong G, Wang Q, Mirocha J, Yu Z, Liou F,
Kobashigawa J. Does the Presence of Complement Binding De Novo DSA Distinguish
Different Pathology Defined Rejection Patterns in Heart Transplant Recipients? J Heart Lung
Transplant. 2014; 33(4): S283
643.
Patel J, Kittleson M, Yu Z, Liou F, Yabuno J, Aggarwal C, Kearny B, Chang DH, Czer L,
Esmailian F, Kobashigawa J. Proliferative Signal Inhibitors and Deep Vein Thrombosis: Is There
a Connection? J Heart Lung Transplant. 2014; 33(4): S276-277
644.
Balasubramanya S, Arabia F, Trento A, Ramzy D, Chang DH, Kittleson M, Czer L, Moriguchi J,
Kobashigawa J. Extracorporeal Membrane Oxygenation as a Bridge to Recovery, Bridge to
Ventricular Assist Device and Bridge to Heart Transplantation: A Retrospective Review of Data
from a Single Tertiary Care Institution. J Heart Lung Transplant. 2014; 33(4): S78
645.
Coleman B, Phillips A, Mirocha J, Patel J, Arabia F, Kobashigawa J. Antithymocyte Globulin But
Not Basiliximab Is Beneficial After Infant Heart Transplantation – Analysis of the UNOS
Database. J Heart Lung Transplant. 2014; 33(4): S123
646.
Coleman B, Phillips A, Mirocha J, Patel J, Arabia F, Kobashigawa J. Induction Therapy in
African American Infant Heart Transplants: Is There a Benefit? J Heart Lung Transplant. 2014;
33(4): S43
93
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
647.
Kransdorf E, Kittleson M, Coleman B, Hoffman D, Berkman S, Ramzy D, Steidley DE,
Kobashigawa J. Atypical Hemolytic-Uremic Syndrome Immediately Following Heart
Transplantation. J Heart Lung Transplant. 2014; 33(6): 664-665
648.
Cheng R, Azarbal B, Patel J, Kittleson M, Kobashigawa J. Early Immune Monitoring After
Cardiac Transplantation Predicts Progression of Maximal Intimal Thickness by Intravascular
Ultrasound. J Heart Lung Transplant. 2014; 33(4): S24
649.
Cheng R, Azarbal B, Patel J, Wei J, Kobashigawa J. Presence of Coronary Artery Fistulae after
Cardiac Transplantation Is Associated with Increased Plaque Progression by Intravascular
Ultrasound. J Heart Lung Transplant. 2014; 33(4): S284
650.
Ardehali A, Esmailian F, Deng M, Soltesz E, Hsich E, Naka Y, Mancini D, Camacho M, Baran D,
Zucker, Leprince P, Madsen J, Tsui S, Simon A, Livi U, Guzzi G, Kobashigawa J. The Proceed
II International Heart Transplant Trial with the Organ Care System (OCS™) Technology. J Heart
Lung Transplant. 2014; 33(4): S118
651.
Ardehali A, Mancini D, Naka Y, Kobashigawa J, Esmailian F, Hsich E, Soltesz E, Deng M.
Heart Transplantation After Ex-Vivo Perfusion of the Donor Hearts: Does it Affect Inotropic Use
and Hospital Stay? J Heart Lung Transplant. 2014; 33(4): S117
652.
Doering L, Hickey K, Chen B, Idemundia F, Carter E, Pickham D, Castillo C, Mancini D, Deng
M, Kobashigawa J. Perceived Control: A Target for Improving Psychosocial Outcomes Early
After Heart Transplant. J Heart Lung Transplant. 2014; 33(4): S32-33
653.
Kobashigawa J, Grskovic M, Dedrick R, Gundel K, Woodward R, Vanhaecke J, Crespo-Leiro
MG, Stypmann J, Deng MC, Starling R. Increased Plasma Levels of Graft-Derived Cell-Free DNA
Correlate with Rejection in Heart Transplant Recipients. J Heart Lung Transplant. 2014; 33(4): S14
654.
Selby VN, Mundayat R, Maurer M, Stern L, Klein L, Janmohamed M, Kobashigawa J, Kobes RD,
De Marco T. Survival Following Heart Transplantation in Patients with Transthyretin Amyloid
Cardiomyopathy. J Heart Lung Transplant. 2014; 33(4): S177-178
655.
Moriguchi J, Arabia F, Kittleson M, Patel J, Yu Z, Liou F, Ernst W, Huie N, Hage A, Chang D,
Czer L, Kobashigawa J. Heart Transplantation vs. Ventricular Assist Device as Destination
Therapy in Older Patients: Are They Comparable? Am J Transplant. 2014; 14(S3): 52
656.
Arabia F, Moriguchi , Jocson R, Kittleson M, Patel J, Yu Z, Liou F, Chang D, Czer L, Ramzy D,
Esmailian F, Kobashigawa J. Single Center Experience of Total Artificial Heart as a Bridge to
Heart Transplantation. Am J Transplant. 2014; 14(S3): 52
657.
Kittleson M, Reinsmoen N, Patel J, Liou F, Yu Z, Luu M, Hamilton M, Hage A, Azarbal A,
Kobashigawa J. Heart Transplantation across Low Level Donor Specific c Antibodies: Is It Bad?
Am J Transplant. 2014; 14(S3): 53
658.
Watanabe J, Shafi H, Patel J, Klapper E, Yu Z, Krivitskiy I, Liou F, Kittleson M, Jordan S,
Kobashigawa J, Toyoda M. Extracorporeal Photopheresis (ECP) Improved Allograft Function
and Significantly Reduced Inflammatory Cytokines in Patients (Pts) With Refractory Heart
Allograft Dysfunction. Am J Transplant. 2014; 14(S3): 56
659.
Kittleson M, Patel J, Hamilton M, Yu Z, Liou F, Yabuno J, Azarbal B, Chang D, Geft D,
Kobashigawa J. Anti-Thymocyte Globulin Induction to Prevent Renal Dysfunction: Is It
Necessary Today? Am J Transplant. 2014; 14(S3): 56
660.
Coleman B, Phililps A, Mirocha J, Patel J, Kobashgawa J. Induction Therapy in Pediatric Heart
Transplantation: Is There a Benefit? Globulin Induction to Prevent Renal Dysfunction: Is It
Necessary Today? Am J Transplant. 2014; 14(S3): 57
661.
Esmailian F, Kobashigawa J, Thottam M, Yu Z, Liou F, Patel J, Kittleson M, Czer L, Trento A.
Heart in the Box With Good 1-Year Outcome Post Heart Transplantation. Am J Transplant. 2014;
14(S3): 58
94
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
662.
Patel J, Kittleson M, Ramzy D, Yu Z, Liou F, Yabuno J, Arabia F, Moriguchi J, Czer L,
Kobashigawa J. Perioperative Bleeding Risk of Anti-Platelet Therapy Prior to Heart Transplant.
Am J Transplant. 2014; 14(S3): 59
663.
Azarbal B, Chang D, Esmailian F, Arabia F, Moriguchi J, Kobashigawa J, Makkar R. No Survival
Benefit with Use of Intra-Aortic Balloon Pump in Extracorporeal Membrane Oxygenation: A
Pooled Experience of 1,517 Patients. J Am Coll Cardiol. 2014;64(11_S)
664.
Arbit B, Azarbal B, Vanichsarn C, Chang D, Patel J, Kobashigawa J, Makkar R. Long Term
Clinical and Angiographic Outcomes with Everolimus-Eluting Stents for Cardiac Allograft
Vasculopathy. J Am Coll Cardiol. 2014;64(11_S)
665.
Chang R, Yung A, Azarbal B, Patel J, Kobashigawa J. Early Stenosis on Intravascular Ultrasound
Immediately After Cardiac Transplantation Predicts Downstream Development of Transplant
Coronary Artery Disease. J Am Coll Cardiol. 2014;64(11_S)
666.
Rush J, Johnson M, Kao T, Patel J, Liou F, Yu Z, Luu M, Chang M, Czer L, Trento A, Esmailian
F, Kobashigawa J. Risk of High Risk Donors in Heart Transplantation Am J Transplant. 2014;
14(S3): 424
667.
Reich H, Awad M, Sasevich M, Nissen N, Colquhoun S, Esmailian F, Trento A, Kobashigawa J,
L Czer. Combined Heart and Liver Transplantation in a High-Volume Transplant Center: The
Cedars-Sinai Experience. Am J Transplant. 2014; 14(S3): 424
668.
Liou F, Patel J, M. Kittleson, Yu Z, Luu M, Piponniau L, Luthringer D, Czer L, Chang D,
Hamilton M, Esmailian F, Kobashigawa J. Does Heart-Kidney Transplant Truly Confer
Protective Benefit Against Rejection? Am J Transplant. 2014; 14(S3): 424
669.
Kobashigawa J, Kittleson M, Moriguchi J, Yu Z, Liou F, Luu M, Hamilton M, Chang M, Geft D,
Esmailian F. How Old Is Too Old for Simultaneous Heart Kidney Donation? Am J Transplant.
2014; 14(S3): 425
670.
Kobashigawa J, Patel J, Kittleson M, F Liou, Yu Z, Rush Z, Stimpson E, Hage A, Czer L,
Esmailian F. Impact of the 2006 Donor Heart Allocation UNOS Policy Using Median Waitlist
Times for Patients Awaiting Heart Transplant. Am J Transplant. 2014; 14(S3): 426
671.
Kittleson M, Patel J, Liou F, Yu Z, Lipson-Altman N, Parikh A, Velleca A, Chang D, Czer L,
Hamilton M, Esmailian F, Kobashigawa J. Beta Blockers to Slow Heart Rate for Sinus
Tachycardia After Heart Transplantation: Is It Helpful? Am J Transplant. 2014; 14(S3): 429
672.
Aggarwal C, Patel J, Kittleson M, Yu Z, Liou F, Murayama K, Rush J, Chang D, Hage A, Trento A,
Kobashigawa J. Smaller Donor By Weight May Lead to More Cardiac Allograft Vasculopathy
After Heart Transplantation. Am J Transplant. 2014; 14(S3): 429
673.
Patel J, Kittleson M, Moriguchi J, Liou F, Yu Z, Yabuno J, Azarbal B, Chang D, Czer L,
Kobashigawa J. Cyclosporine vs. Tacrolimus: Which Is a Better Match With Everolimus? Am J
Transplant. 2014; 14(S3): 430
674.
G. Jamero, M. Kittleson, J. Patel, F. Liou, Z. Yu, D. Dilibergo, N. Perry, D. Chang, L. Czer, A.
Hage, F. Esmailian, Kobashigawa J. Are First Year Mycophenolate Trough Levels Associated
With the Subsequent Outcomes After Heart Transplant? Am J Transplant. 2014; 14(S3): 432
675.
Yabuno J, Patel J, Kittleson M, Yu Z, Liou F, Chang D, Czer L, Hamilton M, Trento A,
Reinsmoen N, Esmailian F, Kobashigawa J. A Lower Cylex Score May Be a Useful Tool to
Prevent the Development of Circulating Antibodies After Heart Transplantation? Am J Transplant.
2014; 14(S3): 432
676.
Choi S, Grein J, Kobashigawa J, Jordan S, Zakowski, P. Late-Onset Pneumocystis Pneumonia in
Kidney and Heart Transplant Recipients. Am J Transplant. 2014; 14(S3): 628
95
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
677.
Fong A, Liou F, Siddiqui S, Hamilton M, Kobashigawa J. The Prevolance of Donor Specific
Anti-HLA Antibodies Late after Heart Transplant. J Investig Med. 2015; 63(1):87
678.
Assad N, Liou F, Siddiqui S, Hamilton M, Kobashigawa J. Does the Development of Bw4 and
Bw6 Antibodies Confer Poorer Outcomes in Heart Transplant Patients? J Investig Med. 2015;
63(1):87
679.
Luu M, Aintablian T, Liou F, Hamilton M, Kobashigawa J. Cylex Fails to Improve Predictive
Value of Allomap for Cardiac Allograft Rejection. J Investig Med. 2015; 63(1):88
680.
Aintablian T, Liou F, Luu M, Hamilton M, Kobashigawa J. Antibody Production does Not
Appear to be Important in TAH Patients Despite More Blood Transfusions. J Investig Med. 2015;
63(1):112
681.
Patel P, Liou F, Siddiqui S, Hamilton M, Kobashigawa J. Benefit of Renal Sparing Protocol
Across Time Post Heart Transplantation. J Investig Med. 2015; 63(1):113
682.
Shiozaki R, Liou F, Siddiqui S, Hamilton M, Kobashigawa J. The Time Course of Anti-HLA
Antibody Development Following Heart Transplantation. J Investig Med. 2015; 63(1):113-114
683.
Merchant M, Liou F, Siddiqui S, Hamilton M, Kobashigawa J. Does Switching to Proliferation
Signal Inhibitors Decrease the Risk of Developing Subsequent Malignancies in Heart Transplant
Patients? J Investig Med. 2015; 63(1):139-140
684.
Wong D, Liou F, Siddiqui S, Hamilton M, Kobashigawa J. Do Abnormal Regadenoson Scans
Predict Subsequent Poor Outcome? J Investig Med. 2015; 63(1):140
685.
Yabuno J, Luu M, Liou F, Hamilton M, Kobashigawa J. Patients with Autoimmune Disease: Not
a Contraindication for Heart Transplantation. J Investig Med. 2015; 63(1):141
686.
Arman D, Liou F, Siddiqui S, Hamilton M, Kobashigawa J. Do Prior Driveline Infections
Increase the Risk of Infection in Heart Transplant Patients Treated with ATG Induction Therapy?
J Investig Med. 2015; 63(1):206
687.
Liou F, Shiozaki R, Siddiqui S, Hamilton M, Kobashigawa J. HLA Antibody Class Affects
Outcomes after Heart Transplant. J Investig Med. 2015; 63(1):207
688.
Murayama K, Liou F, Yabuno J, Hamilton M, Kobashigawa J. Shorter Cold Ischemic Time in
Older Donors Post-Heart Transplant Appears to be Protective. J Investig Med. 2015; 63(1):207
689.
Kawano J, Patel J, Kittleson M, Liou F, Wong D, Jamero G, Azarbal B, Chang DH, Czer L, Trento
A, Kobashigawa J. Rubidium Positron Emission Tomography and Coronary Flow Reserve
Predicts Graft Function after Heart Transplant. J Heart Lung Transplant. 2015; 34(4):S48-S49
690.
Kawano J, Kittleson M, Patel J, Azarbal B, Liou F, Siddiqui S, Wong D, Chang DH, Ramzy D,
Czer L, Kobashigawa J. Do Abnormal Regadenoson Scans Predict Subsequent Poor Outcome? J
Heart Lung Transplant. 2015; 34(4): S49
691.
Kobashigawa J, Kittleson M, Liou F, Shiozaki R, Siddiqui S, Piponniau L, Geft D, Hamilton M,
Czer L, Reinsmoen, Patel J. The Time Course of Development of Anti-HLA Antibodies
Following Heart Transplantation. J Heart Lung Transplant. 2015; In Press
692.
Patel J, Reinsmoen N, Kittleson M, Dilibero D, Liou F, Chang DH, Hamilton M, Czer L,
Esmailian, Kobashigawa J. Plasmapheresis and Bortezomib for Sensitized Patients Awaiting
Heart Transplantation – Worth the Effort? J Heart Lung Transplant. 2015; 34(4): S30-S31
693.
Patel J, Dilibero D, Kittleson M, Sana S, Liou F, Chang DH, Hage A, Czer L, Trento A,
Reinsmoen N, Kobashigawa J. Terminal Complement Inhibition for Complement Inhibition for
Highly Sensitized Patients Undergoing Heart Transplantation – Doable? J Heart Lung Transplant.
2015; 34(4):S31
96
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
694.
Esmailian F, Patel J, Kittleson M, Kao T, Liou F, Siddiqui S, Azarbal B, Chang DH, Czer L, Trento
A, Kobashigawa J. Shorter Cold Ischemic Time in Older Donors Post-Heart Transplant Appears
to be Protective. J Heart Lung Transplant. 2015; 34(4):S17
695.
Cheng R, Azarbal B, Herr J, Ramzy D, Kobashigawa J, Arabia F, Moriguchi F. Early Crossover
from Extracorporeal Membrane Oxygenation to More Durable Mechanical Circulatory Support
Increases Survival to Transplant or Recovery. J Heart Lung Transplant. 2015; 34(4):S1-S368
696.
Coleman B, Guo X, Patel J, Reinsmoen N, Jia Y, Kobashigawa J. Genetic Risk Score (GRS)
Predicts Worse Survival in African American Heart Transplant. J Heart Lung Transplant. 2015;
34(4):S114-S115
697.
Arabia F, Kittleson M, Czer L, Hajj J, Passano E, Liou F, Siddiqui S, Chang DH, Kobashigawa J,
Moriguchi J. The Risk of Hospital Readmissions Following Mechanical Circulatory Support
Placement. J Heart Lung Transplant. 2015; 34(4):S126
698.
Patel J, Vescio R, Kittleson M, Siddiqui S, Liou F, Yabuno J, Piponniau L, Kearney B, Hamilton M,
Czer L, Kobashigawa J. Single Center Experience with Amyloid Patients in the Current Era of
Disease Specific Medications. J Heart Lung Transplant. 2015; 34(4):S148
699.
Kittleson M, Patel J, Liou F, Siddiqui S, Chang DH, Hage A, Hamilton M, Czer L, Trento A,
Esmailian F, Kobashigawa J. Combined Kidney Transplant in Patients Needing Redo Heart
Transplant: Viable Option? J Heart Lung Transplant. 2015; 34(4):S187
700.
Kittleson M, Patel J, Liou F, Siddiqui, Yabuno J, Chang DH, Ramzy D, Czer L, Esmailian F,
Reinsmoen N, Kobashigawa J. Low Level Donor Specific Antibodies at Transplant does not
Appear to be Associated with the Development of Cardiac Allograft Vasculopathy after Heart
Transplantation. J Heart Lung Transplant. 2015; 34(4):S286-287
701.
Siddiqui S, Kittleson M, Patel J, Liou F, Aintablian T, Chang DH, Hage A, Czer L, Esmailian F,
Kobashigawa J. Risk Factors for Hospital Admissions for Rejection Following Heart
Transplantation: The Real Story. J Heart Lung Transplant. 2015; 34(4):S299-S300
702.
Runyan C, Arabia F, Czer L, Kittleson M, Passano E, Liou F, Yabuno J, Henry H, Chang DH,
Kobashigawa J, Moriguchi J. Left Ventricular Assist Devices vs. Total Artificial Hearts: Which
Causes More Cerebrovascular Accidents. J Heart Lung Transplant. 2015; 34(4):S213
703.
Ghafourian K, Moriguchi J, Kittleson, Czer L, Passano E, Liou F, Huie N, Chang DH, Trento A,
Arabia F, Kobashigawa J. Drop in Estimated Glomerular Filtration Rate at 1 Year after Heart
Transplantation – Concern for Poor Outcome. J Heart Lung Transplant. 2015; 34(4):S92
704.
Rush J, Kittleson M, Patel J, Stimpson E, Kao T, Liou F, Aintablian, Siddiqui S, Chang DH, Czer
L, Esmailian F, Kobashigawa J. Is There a Risk of Cocaine and Methamphetamine Use in Heart
Donors? J Heart Lung Transplant. 2015; 34(4):S213
705.
Runyan C, Moriguchi J, Kittleson M, Czer L, Passano E, Liou F, Chang DH, Ramzy, Esmailian F,
Kobashigawa J, Arabia F. Reliability of the Freedom Driver after Total Artificial Heart
Implantation. J Heart Lung Transplant. 2015; 34(4):S276–S277
706.
Stimpson, Kao T, Kim L, Morrison S, Patel J, Kittleson M, Liou F, Siddiqui S, Yabuno J, Czer L,
Kobashigawa J. Care after Heart Transplant, No One Better Than Family: Wrong. J Heart Lung
Transplant. 2015; 34(4):S236
707.
Henry H, Arabia F, Kittleson M, Czer L, Passano E, Yabuno J, Siddiqui S, Antifantis E, Chang
DH, Kobashigawa J, Moriguchi J. Does the Specific Type of Caregiver Impact Readmission after
Mechanical Circulatory Support Device Placement? J Heart Lung Transplant. 2015; 34(4):S230
708.
McMenamy M, Arabia F, Czer L, Kittleson M, Passano E, Liou F, Yabuno J, Chang DH,
Esmailian F, Kobashigawa J, Moriguchi J. Breaking the Myth of Obesity as a Contraindication to
Continuous Flow Left Ventricular Assist Devices. J Heart Lung Transplant. 2015; 34(4):S193
97
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
709.
Ghafourian K, Patel J, Kittleson M, Passano E, Liou F, Siddiqui S, Yabuno J, Geft D, Chang DH,
Czer L, Trento A, Kobashigawa J. Does Time on Ventricular Assist Device Compromise PostTransplant Outcome? J Heart Lung Transplant. 2015; 34(4):S178-179
710.
Arabia F, Czer L, Kittleson M, Passano E, Yabuno J, Liou F, Siddiqui S, Chang DH, Ramzy D,
Kobashigawa J, Moriguchi J. Does Gender Make a Difference after Total Artificial Heart
Implantation? J Heart Lung Transplant. 2015; 34(4):S219-S220
711.
Kumar P, Liou F, Patel J, Czer L, Kobashigawa J, Luthringer D. Recurrence of Amyloid in
Endomyocardial Biopsies Following Orthotropic Heart Transplantation. J Heart Lung Transplant.
2015; In Press
712.
Liou F, Kittleson M, Patel J, Siddiqui S, Luu M, Kearney B, Ramzy D, Chang DH, Czer L,
Reinsmoen N, Kobashigawa J. Anti-Human Leukocyte Antigen Antibody Class Affects
Outcomes after Heart Transplant. J Heart Lung Transplant. 2015; 34(4):S298–S299
713.
Cheng R, Azarbal B, Esmailian F, Trento A, Kobashigawa J, Arabia F, Moriguchi J. Initial
Implant of Ventricular Assist Devices in INTERMACS Profiles 1 and 2 Patients in Refractory
Cardiogenic Shock Improves Survival to Transplant Recovery. J Heart Lung Transplant. 2015; 34(4)
714. Cheng R, Vanichsarn C, Azarbal B, Czer L, Kittleson M, Patel J, Kobashigawa J. Rapid
Progression of Allograft Coronary Artery Stenosis is Decreased in Patients Who Received
Antithymocyte Globulin Induction at the Time of Transplant. J Heart Lung Transplant. 2015;
34(4):S290
715.
Koomalsingh K, Kiankhooy A, Ramzy D, Esmailian F, Trento A, Moriguchi J, Kobashigawa J,
Arabia F. The Total Artificial Heart (TAH) Experience at Cedars Sinai Medical Center. J Heart Lung
Transplant. 2015; In Press
716.
Arabia F, L Czer, Kittleson M, Passano E, Liou F, Yabuno J, Henry H, Chang DH, Esmailian,
Kobashigawa J, Moriguchi J. The Selection Process for the Total Artificial Heart. Am J
Transplant. 2015; In Press
717.
Patel J, Vescio R, Kittleson M, Siddiqui S, Liou F, Yabuno J, Piponniau L, Kearney B, Hamilton M,
Czer L, Kobashigawa J. Heart Transplant for Amyloid Patients in the Current Era of
Bortezomib. Am J Transplant. 2015; In Press
718.
Velleca A, Kittleson M, Perry N, Patel J, Liou F, Siddiqui S, Rush J, Ramzy D, Czer L, Chang DH,
Kobashigawa J. Increased Length of Stay after Heart Transplant: What are the Risk Factors? Am
J Transplant. 2015; In Press
719.
Kobashigawa J, Kittleson M, Patel P, Liou F, Siddiqui S, Chang DH, Azarbal B, Ramzy D, Czer
L, Patel J. Outcome of Renal Sparing Protocol in a Cross-Sectional Analysis after Heart
Transplant. Am J Transplant. 2015; In Press
720.
Stimpson E, Kao T, Kim L, Morrison S, Patel J, Kittleson M, Liou F, Siddiqui S, Yabuno J, Czer L,
Kobashigawa J. Social Support after Heart Transplant. Am J Transplant. 2015; In Press
721.
Kawano J, Kittleson M, Patel J, Azarbal B, Liou F, Siddiqui S, Wong D, Chang DH, Ramzy L,
Czer L, Kobashigawa J. Predictive Value of Regadenoson Scans after Heart Transplant. Am J
Transplant. 2015; In Press
722.
Kobashigawa J, Kittleson M, Liou F, Shiozaki R, Siddiqui S, Piponniau L, Geft D, Hamilton M,
Czer L, Reinsmoen N, Patel J. Natural History of Anti-Human Leukocyte Antigen Antibodies
after Heart Transplant. Am J Transplant. 2015; In Press
723.
Patel J, Reinsmoen N, Kittleson M, Dilibero D, Liou F, Chang DH, Hamilton M, Czer L,
Esmailian, Kobashigawa J. Outcome of Bortezomib/Plasmaperesis for the Sensitized Patient
Awaiting Heart Transplant. Am J Transplant. 2015; In Press
724.
Kobashigawa J. The Changing Face of First-Year Intravascular Ultrasonography in Heart
Transplantation.
98
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
725.
Patel J, Reinsmoen N, Kittleson M, Velleca A, Dilibero D, Liou F, Chang DH, Hage A, Czer L,
Esmailian F, Kobashigawa J. Rituximab with Intravenous Immune Globulin in Sensitized
Patients Awaiting Heart Transplant: Does it Work? Am J Transplant. 2015; In Press
726.
Jamero G, Moriguchi J, Czer L, Kittleson M, Siddiqui S, Liou F, Arman D, Lam L, Chang DH,
Zakowski P, Kobashigawa J, Arabia F. Anti-Thymocyte Globulin Induction in Infected
Mechanical Circulatory Support Patients: Is it Safe? Am J Transplant. 2015; In Press
727.
Arabia F, Kittleson M, Czer L, Hajj J, Passano E, Liou F, Siddiqui S, Chang DH, Kobashigawa J,
Moriguchi J. Assessment of Hospital Readmissions after Mechanical Circulatory Support. Am J
Transplant. 2015; In Press
728.
Henry H, Arabia F, Kittleson M, Czer L, Passano E, Yabuno J, Siddiqui, Antifantis E, Chang DH,
Kobashigawa J. Type of Caregiver and Outcome after Mechanical Circulatory Support Placement.
Am J Transplant. 2015; In Press
729.
Luu M, Kittleson M, Patel J, Liou F, Siddiqui S, Pipponiau L, Hage A, Chang DH, Czer L, Trento
A, Kobashigawa J. T-Cell Immune Function vs. Gene Expression Profiling for Heart Transplant
Rejection. Am J Transplant. 2015; In Press
730.
Kittleson M, Patel J, Liou F, Siddiqui S, Fong A, Johnson M, Chang DH, Czer L, Esmailian F,
Reinsmoen N, Kobashigawa J. The Effects of Donor Specific Anti-Human Leukocyte Antigen
Antibodies Late after Heart Transplantation. Am J Transplant. 2015; In Press
731.
Kittleson M, Patel J, Liou F, Siddiqui S, Yabuno J, Chang DH, Ramzy D, Czer L, Esmailian F,
Reinsmoen N, Kobashigawa J. Is There a Protective Value for Low Level Donor Specific
Antibodies to Prevent Cardiac Allograft Vasculopathy after Heart Transplant? Am J Transplant.
2015; In Press
732.
Kobashigawa J, Ghafourian K. Slowing Sinus tachycardia in Heart Transplant Recipients: Is It
Time? Revista Espanola de Cardiologa. 2015; In Press.
733.
Chang DH, Kobashigawa J. Novel Diagnostic and Treatment Strategies for Allograft
Vasculopathy. Expert Rev Cardiovasc Ther. 2015; In Press.
734.
Cole, RM, Kobashigawa J. Desensitization Strategies Pre-and Post-Cardiac Transplantation.
Current Treatment Options in Cardiovascular Medicine. 2015; In Press.
735.
Kobashigawa J. The Changing Face of First-Year Intravascular Ultrasonography in Heart
Transplantation. JACC: Heart Failure. 2015; In Press
M E N TO R I N G
Summer Research Interns (Undergraduate Students)
Description: Retrospective research projects are developed and assigned to undergraduate student interns.
Responsibilities for interns include conducting literature searches and drafting data collection tools; collecting
demographic and medical information from medical records; entering and managing data in project spreadsheets;
assisting in preparation of results in the form of abstracts and manuscripts; participating in weekly research
meetings; completing training in the protection of human subjects; adhering to HIPAA requirements. All student
interns have the opportunity to submit a research abstract for publication and presentation.
Pamela Alameda, University of California Los Angeles
Tamar Aintablian, University of California, Irvine
Ani Aharonyan, University of California Los Angeles
99
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
Allison Ankrom, University of Washington
Nima Assad, University of California San Diego
Olivia Barry, University of California Berkeley
Ashland Brown, University of California Los Angeles
Erica Brownfield, University of California Los Angeles
Will Brubaker, Brigham Young University
Kristin Bucher, University of California Santa Cruz
Stephanie Carr, University of California Los Angeles
Judith Cassem, University of California Los Angeles
Jennifer Chuang, University of California Los Angeles
Greg Cogert, University of California Los Angeles
Justin Davidoff, University of California Los Angeles
Stephanie Davis, University of California Los Angeles
Jeffrey Dyo, University of California San Diego
Kim Einhorn, University of California Los Angeles
Julie English, University of California Los Angeles
Albert Geskin, University of California Los Angeles
Sheryllene Go, University of California Los Angeles
Lakshmi Gokanapudy, University of California Los Angeles
Zachary Goldstein, University of Califon Los Angeles
Jordan Kawano, CA State Polytechnic University, Pomona
Matt Kawano, University of California Davis
Francine Kim, University of Notre Dame
Ye Seul Kim, University of California Los Angeles
Krista Kiyosaki, Stanford University
Erin Kobashigawa, Stanford University
Brian Kobashigawa, University of Michigan
Laura Kobashigawa, Brown University
Paul Lee, University of California Los Angeles
Bobby Lee, University of California Los Angeles
Frances Lee, Emory University
Allen Lipson, University of California Los Angeles
Peter Lin, University of California Los Angeles
Gaia Magnani, University of California Los Angeles
Tatiana Manayan, Sacramento State University
Asha Mansukhani, University of California Los Angeles
Angela Marquez, University of California Los Angeles
Sam Mayne, University of California Berkeley
Madeleine Merchant, Carelon College
Allison Merz, Amherst College
Shaun Miller, University of California Los Angeles
Ariel Moradzadeh, University of California Los Angeles
Nathan Moradzadeh, University of California Los Angeles
Kellee Murayama, Occidental College
Nicholette Murray-Bruce, University of Southern California
Jonathan Nakashima, University of California, Los Angeles
Alex Ngan, Columbia University
Jay Patel, Drexel University
Dhruv Patel, University of California Los Angeles
Nishil Patel, University of California Los Angeles
Pareena Patel, University of Warwick
Mai Phan, University of California Los Angeles
Monica Plesa, University of California Los Angeles
Matthew Rafiei, University of California Los Angeles
Thomas Ro, University of California Los Angeles
Alex Sabad, University of California Los Angeles
Sarmen Sarkissian, University of California Los Angeles
Andrea Seid, University of California Los Angeles
Rayshma Sharoff, University of California Los Angeles
Jeremy Shaw, University of Texas Southwestern
Brian Shiozaki, University of Southern California
Ryan Shiozaki, University of California, Los Angeles
100
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
Michelle Siu, Loyola Marymount University
Helen Song, University of California Los Angeles
Lily Stern, University of California Los Angeles
Eric Sue, Stanford University
Joy Tang, Washington University
Mia Tittle, University of California Santa Barbara
Ajay Vaidya, University of Oklahoma
Lianne Wener, University of California Los Angeles
Derek Wong, University of California Los Angeles
Samantha Wong, University of California Los Angeles
Grace Wu, Stanford University
Jamie Yabuno, University of California Los Angeles
Meghana Yajnik, University of California Los Angeles
Research Mentor (Medical School Students)
Description: Medical School students are mentored through the research process, including developing concepts,
refining lines of inquiry, literature review, data collection and analysis and abstract submission. Research
mentoring is supplemented by clinical exposures.
Aaron Fong, Baylor College of Medicine, 2017
Darian Arman, Tulane University School of Medicine, 2017
Amanda Aquino, Michigan State University College of Human Medicine, 2016
Alexander Chehrazi-Raffle, Chicago Medical School, 2016
Anup Parikh, University of Medicine and Dentistry of New Jersey, 2016
Brandon Cohen, NYU School of Medicine, 2015
David Lee, University of Nevada Medical School, 2011
Michael Share, Jefferson Medical College, 2010
Eric Sue, USC Medical School, 2010
Keira Lo, Taiwan, 2008-2009
Ohnmar Aye, Taiwan, 2006-2007
Boris Arbit, Dartmouth College Medical School, 2006
Anne Silao, MD - University of the East, Philippines, 2005-2006
Sumeet Subherwal, UC Irvine Medical School, 2002-2003
Greg Cogert, UC Irvine Medical School, 1996-1999
Kengo Soghoyan, UCD School of Medicine, 2018
Evan Norris, George Washington University Medical School, 2018
Clinical Research Mentor (Interns, Residents, Fellows)
Description: Junior investigators/Junior Faculty are mentored through the investigative research process,
including developing and implementing protocols, data collection and analysis, abstract submission and presentation
at major scientific forums and manuscript writing and publication.
Deborah Budge, UCLA Cardiology Fellow
Wanxing Chai, Peking Union Medical College
David Chang, UCLA Cardiology Fellow
Daniel Cruz, UCLA Cardiology Fellow
Sandesh Dev, UCLA Heart Transplant Fellow
Howard Dinh, UCLA Cardiology Fellow
Hiroshi Furukawa, UCLA Research Fellow
Pavel Goyhkman, Cedars-Sinai Cardiology Fellow
Aric Gregson, UCLA Infectious Disease
Reema Hasan, University of Michigan
Eric Hong, UCLA Intern
Helen Huang, Cedars-Sinai Resident
Brandon Itagaki, UCLA Resident
Aarya Kafi, Cedars-Sinai Resident
Brandon Kai, Cedars-Sinai Resident
101
CURRICULUM VITAE
JON KOB ASHIGAWA, MD
Tigran Khachatryan, Cedars-Sinai Resident
Pranav Kansara, Cedars-Sinai Cardiology Fellow
Brian Kim, UCLA Intern
Adva Kornblit, Cedars-Sinai Resident
Evan Kransdorf, Cedars-Sinai Cardiology Fellow
Ryan Morrissey, Cedars-Sinai Cardiology Fellow
Amish Parikh, UCLA Resident
Vishal Parikh, Cedars-Sinai Resident
David Perkel, Cedars-Sinai Resident
Tim Provias, UCLA Intern/Resident
Stuart Russell, UCLA Cardiology Fellow
Esha Sachdev, Cedars-Sinai Resident
Yuji Saito, UC Irvine Cardiology Fellow
Esther Shao, UCLA Cardiology Fellow
Timothy Smith, UCLA Resident
Stephanie Smooke, UCLA Resident
Sahar, Sohrabian, UCLA Resident
Eric Sue, Cedars-Sinai Resident
Rigveg Tadwalker, Cedars-Sinai Resident
Vijay Vaidya, UCLA Resident
Christopher Vanichsarn, Cedars-Sinai Resident
Karolina Juszczynski, Western Town College
Clinical Preceptorships (1 – 4 Week Training):
Description: Clinical training in heart failure, heart transplantation and mechanical circulatory support, designed to
address the specific needs of visiting faculty and include observational training, didactic lectures, and case studies.
Simon Jackson, MD - Queen Elizabeth II Hospital, Halifax, October 2003
Marie Helene Le Blanc, MD - University of Laval, October 2003
Vivek Rao, MD - Toronto General Hospital, October 2003
Alan Menkis, MD - London Health Sciences Center, October 2003
Chih-Hsin Hsu. MD - National Cheng Kung University, September 2005
Waqas Ghumman, MD – Indiana University, October 2008
Tomako Kato, MD – National Cardiovascular Center, Japan, February 2008
Matsuyama, MD – National Cardiovascular Center, Japan, February 2008
Masanobu Yanase, MD – National Cardiovascular Center, Japan, February 2010
Tomoyuki Fujita, MD – National Cardiovascular Center, Japan, February 2010
Michael Dickinson, MD – Spectrum Health, Michigan, November 2011
Osamu Seguchi, MD – National Cardiovascular Center, Japan, March 2011, February 2014
Yoshihiro Murata, MD – National Cardiovascular Center, Japan, March 2011
Yuk “Fai” Lai, MD - ?? August 2012
Lilian Grigorian, MD – University Hospital Complex of Vigo, August 2013
Byung-Chul Chang – Yonsen Medical Center, Seoul, Korea, February 2014
M U LT I - CE N T E R S T U D I E S

RS61443 (Syntex, study 1866) for refractory cardiac allograft rejection, 1991-92, UCLA Principal
Investigator.

Multicenter intravascular ultrasound study in cardiac transplant patients to define the natural progression
of transplant coronary disease, (CVIS, Inc) 1993-present, UCLA Principal Investigator.

Chairman, Executive Steering Committee, for the Multicenter Mycophenolate Mofetil Randomized Primary
Prevention Trial in Cardiac Transplant Patients (Roche, study 1864), 1995-1999.
102
CURRICULUM VITAE
JON KOB ASHIGAWA, MD

Mycophenolate Mofetil (Roche, study 1864) randomized primary prevention trial in cardiac transplant
patients, 1994-1999, UCLA Principal Investigator.

Intravascular ultrasound core laboratory for Mycophenolate Mofetil Study (Roche, study 1864) 1994-1999,
Study Co-Principal Investigator.

Rapamycin (Wyeth Laboratories) randomized study for the treatment of ISHLT grade 2 or 3A rejection
in cardiac transplant patients, 1994-present, UCLA Principal Investigator.

Sandoz multicenter study for the use of cyclosporine in cardiac transplantation. 1994-present, UCLA
Principal Investigator.

RAD (Novartis) randomized trial in primary heart transplant patients, 1998-2007, UCLA Principal
Investigator.

Zenapax (Roche) randomized trial in primary heart transplant patients, 1998-2005, UCLA Principal
Investigator and member of Steering Committee of this Multicenter Study.

Quality of Life Outcomes for Heart Transplant Patients 5-10 years After Transplantation (NIH), 2000present, UCLA Principal Investigator.

Breath Test randomized trial in primary heart transplant patients, 2000-present, UCLA Principal
Investigator.

Valganciclovir and Cardiac Allograft Vasculopathy (VCAV) Multicenter Study, 2001-present, UCLA
Principal Investigator and member of Steering Committee of this Multicenter Study.

A 12-month, Single-blind, Randomized, Parallel Group, Multicenter Study to Investigate the Efficacy and
Safety of ERL080A Compared with MMF in de novo Heart Recipients (Novartis), 2001-2007, UCLA
Principal Investigator and member of Steering Committee.

Multicenter Study of Tacrolimus/MMF vs. Cyclosporine/MMF vs. Tacrolimus/Sirolimus (3-arm,
Fujisawa), 2001-2005, UCLA Principal Investigator and member of the Steering Committee.

A Retrospective Analysis of Cardiovascular and Immunologic Risk Factors Affecting Survival of De
Novo Cardiac Transplant Recipients (Fujisawa), 2002-2003, Principal Investigator.

Non-Invasive Detection of Rejection in Cardiac Allograft Recipients Using Gene Expression Profiling:
CARGO Trial 2002-2007, UCLA Principal Investigator and member of the Steering Committee.

Intravascular Ultrasound (IVUS) Validation Study Among Heart Transplant Recipients: Outcomes After
5 Years (Novartis), 2002-2005, Principal Investigator.

Intravascular Ultrasound (IVUS) Studies among Heart Transplant Recipients Participating in the
Mycophenolate Mofetil Study: Let’s Take Another Look (Roche), 2003-2007, Principal Investigator.

Randomized trial monitoring acute rejection by surveillance biopsy, compared to peripheral blood
leukocyte gene profiling, 2004, Endpoint Committee Member.

A Facilitated Access Program to Provide Everolimus (RAD) for Maintenance Patients Completing
Therapy in RAD Trials in Solid Organ Transplantation (RAD 2401, Novartis), 2004-present, UCLA
Principal Investigator.

A comparison between tacrolimus and cyclosporine in de novo cardiac transplant recipients (FKC-009,
Astellas), 2005-present, UCLA Principal Investigator.

Ultrafiltration versus IV Diuretics for Patients Hospitalized for Acute Decompensated Congestive Heart
Failure: A Prospective Randomized Clinical Trial (UNLOAD, CHF Solutions), 2005-2006, Co-Investigator.

Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting
(IMPROVE HF, Medtronic), 2006-present, Co-Investigator.
103
CURRICULUM VITAE
JON KOB ASHIGAWA, MD

A 24 month, multi-center study Certican with reduced Neoral vs. MMF with standard dose Neoral in de
novo heart transplant recipients (RAD 2310, Novartis), 2006-present, UCLA Principal Investigator, Steering
Committee.

Ability of the PD2i cardiac analyzer to predict the risk of high risk patients developing ventricular
fibrillation or ventricular tachycardia (VITAL, Vicor), 2007-present, Co-Investigator.

Observational Study of Alloimmunity in Cardiac Transplant Recipieints (CTOT-05, NIAID/NHLBI),
2008-present, UCLA Principal Investigator.

Early Invasive Monitoring Attenuation Through Gene Expression Trial (EIMAGE, XDx, Inc.), 2009,
UCLA Principal Investigator.

CTOT 13 -Sensitization Trial (NIAID/NHLBI/NIH), Protocol Chair (2009 – present)

Chairmain, Steering Committee
104
November 29, 2015
AST Nominating Committee,
It is a distinct pleasure to recommend Jon Kobashigawa for the AST’s Senior
Achievement Award in Clinical Transplantation. I am not sure it is possible to
overstate the key role Jon has played in the advancement in the field cardiac
transplantation over the past 30 years. Jon is internationally acclaimed for his work
and has led much of the seminal research in the field of cardiac transplantation
including the effect of statins on coronary vasculopathy, the quantification of
vasculopathy and subsequent risk prediction with intravascular ultrasound, the use
of mycophenolate mofetil, daclizumab and everolimus in heart transplantation,
desensitization therapy, treatments for antibody medicated rejection and molecular
diagnostics for the assessment of the risk of rejection. Jon has hundreds of
impactful publications in every major journal, including many first author
publications in the New England Journal of Medicine.
With his world renowned expertise and collaborative spirit he has served in
innumerable roles in every society related to cardiac transplantation, including many
prominent leadership positions within the AST including both the ATC and WTC
Program Committees, the Clinical Practice Committee, Practice Guidelines
Committee and currently as co-chair of the Thoracic and Critical Care COP. Jon’s
organizational prowess and desire to improve the field has resulted a long history of
organizing the cardiac transplant community to address knowledge gaps, discuss
controversies and develop novel treatment strategies. The most recent example of
which was the Consensus Conference on Donor Heart Selection and Management
prior to the 2015 ATC.
Jon’s impact has been felt throughout the field of cardiac transplantation with his
roles on editorial boards, as a reviewer for dozens of journals, his hundreds of
presentations both nationally and internationally, innumerable abstract
presentations and over 30 book chapters. Jon has not only been productive and
collaborative, but he is a thought leader, if not the thought leader, in the field of
cardiac transplantation. Much of the basis of what is now considered routine clinical
care after cardiac transplantation was established by Jon’s work. He is constantly
ahead of the curve and continues to push the field forward through his keen clinical
acumen and his unmatched vision.
While he has shaped the field of cardiac transplantation through his dedication,
research, and collaboration, he also has an unparalleled record of mentorship of the
next generation of transplant physicians. Jon has nearly 4 pages of students, interns,
residents, fellows and visiting faculty which he has mentored, many of whom have
gone on to become leaders in transplantation. His colleagues also recognize Jon for
his affability, approachability and unmatched effort and enthusiasm for patients and
the field.
Jon is truly remarkable and it is difficult to adequately quantify his impact on cardiac
transplantation. He is universally recognized as a leader in research, clinical care and
mentorship whose impressive body of work has become the basis for the care of
patients and whose energy and forwarding thinking approach will continue to
advance the field. I cannot think of a practicing physician in the field of cardiac
transplantation who is more deserving and emblematic of the AST’s Senior
Achievement Award in Clinical Transplantation.
Sincerely,
Jeffrey Teuteberg, MD